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SUMMARY 
Summary 
DNA single strand breaks (SSBs) are one of the most common lesions to 
genomic DNA, arising from various endogenous and exogenous sources. Single 
strand break repair (SSBR) constitutes a biochemical pathway whereby SSBs 
are detected, enzymatically processed and ligated.  Whilst the general 
mechanisms of SSBR are relatively well described in vitro, there are remaining 
questions concerning how the pathway operates in vivo. For example, an early 
step in SSBR is thought to be the poly(ADP-ribose) polymerase 
(PARP)-dependent modification of SSB-proximal proteins with ADP-ribose, 
which is a signal for the recruitment of downstream repair factors, including the 
central scaffold XRCC1. Yet, the presence of multiple DNA-dependent PARP 
genes (PARP1, PARP2 and PARP3) has caused confusion regarding their 
specific roles in SSBR. This thesis potentially clarifies some contentious aspects 
of PARP function in the repair of SSBs induced by reactive oxygen species (ROS) 
and by Topoisomerase 1 (Top1). By employing PARP1-/-/PARP2-/- cells 
generated herein using CRISPR-Cas9 technology, in combination with pre-
extraction immunofluorescence imaging and high-content analysis, I demonstrate 
that both PARP1 and PARP2 contribute towards ROS-induced ADP-ribosylation 
and XRCC1 chromatin-localization, but that in response to Top1-SSBs, these 
functions are specifically supported by PARP1 alone. Furthermore, using 
TDP1-/- and XRCC1-/-/TDP1-/- cells also generated herein, I characterize a striking 
hyper-ADP-ribosylation phenotype in response to Top1-SSBs. The clinical 
significance of this was confirmed by co-workers, who observed a similar 
phenotype in an XRCC1-deficient patient, where mutations in XRCC1 underlie a 
novel cerebellar neurodegenerative disease. This phenotype could be utilized in 
future to screen for genes with novel functions in SSBR.  Finally, I investigate the 
functional implications of disrupted SSBR genes for rates of repair and cellular 
viability using alkaline single-cell electrophoresis and clonogenic survival assay. 
In doing so, I unexpectedly discovered that deletion of PARP1 suppresses CPT-
induced comet tail moments of WT and XRCC1-/- cells. 
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1.1. General introduction 
Genomic DNA is constantly at threat from a variety of endogenous and 
exogenous chemicals, and from electromagnetic and particle radiation originating 
on Earth, in the Sun, and beyond. Whilst it is true that natural selection relies 
upon the sporadic mutations that may result from genetic lesions or their 
inaccurate repair, life itself would be impossible without near-perfect molecular 
maintenance. It is for this reason that DNA repair pathways have developed in 
complexity throughout Evolution; from the minimal collection of genes found in 
prokaryotes, to the paralogous and often-redundant multitude in multicellular 
eukaryotes.   
By far the most frequently occurring DNA lesions are the substrates of 
base excision repair (BER) and single-strand break repair (SSBR) (Lindahl 1993). 
Collectively, these lesions have been estimated to occur in humans with a 
frequency in the order of 104 to 105 cell-1 day-1, depending on the cell type (Lindahl 
1993, Nakamura and Swenberg 1999, Hegde, Hazra et al. 2008, Swenberg, Lu 
et al. 2011). This introduction will review the various sources and types of 
BER/SSBR substrates (see section 1.2), the pathways that operate to repair them 
in human cells (see section 1.5), and the consequences for our understanding of 
human disease (see section 1.6).  This thesis is particularly focussed on the 
formation and repair of two types of physiologically-relevant DNA single-strand 
breaks (SSBs): those resulting from reactions with reactive oxygen species 
(ROS), and those resulting from the abortive activity of Topoisomerase I. As the 
formation of ROS-induced SSBs can occur indirectly as intermediates within 
BER, this introduction will also provide an overview of the substrates and 
mechanisms of this pathway.  
BER/SSBR comprises a front-line repair system which when perturbed or 
overburdened can lead to the formation of more dangerous lesions, such as 
double strand breaks (DSBs) during replication (see section 1.3). To aid in 
understanding the cellular and physiologically consequences of unrepaired 
SSBs, this chapter will therefore also provide a brief overview of DSB repair 
(DSBR) mechanisms and the DNA Damage Response (DDR) (see section 1.4). 
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1.2. Base Modifications and SSBs 
There are numerous sources of DNA SSBs, including chemical agents, ionising 
radiation, and endogenous enzymes. Some of these agents, such as ROS, can 
cause SSBs both directly, and indirectly as intermediates in the BER of modified 
nucleobases. This section will begin by introducing the various sources of SSBs 
and base modifications, and the chemistry of the resulting lesions (sections 1.2.1 
to 1.2.4).  
 
1.2.1.  Reactive Oxygen Species (ROS) 
ROS is a collective term for a group of molecules containing incompletely reduced 
and therefore highly reactive forms of oxygen. This includes the superoxide 
radical anion (O2•-), hydroxyl radical (OH•), hydrogen peroxide (H2O2), 
hydroperoxyl radical (HO2•), peroxynitrite (ONOO-), Ozone (O3) and singlet 
oxygen (1O2) (Krumova and Cosa 2016), amongst others. Of these, hydroxyl 
radicals, singlet oxygen and peroxynitrite are the most relevant direct DNA 
damage sources (Cooke, Evans et al. 2003). The primary endogenous source of 
hydroxyl radicals and peroxynitrites is superoxide radical anions generated in the 
mitochondria by low levels of electron leakage from the electron transport chain 
(1-3% of electrons; (Valko, Leibfritz et al. 2007)), or at the plasma membrane by 
NADPH oxidases. The anionic nature of the superoxide radical anion restricts 
diffusion across plasma membranes, but it may react to form more freely 
diffusible ROS. One such reaction is with a nitric oxide radical (•NO) to produce 
peroxynitrite (Szabo, Ischiropoulos et al. 2007), which may diffuse to the nucleus 
and damage DNA directly. Another is the dismutation of two superoxide radicals 
into hydrogen peroxide or water, which is catalysed by superoxide dismutase 
(SOD) in a two-step reaction (Hayyan, Hashim et al. 2016). Hydrogen peroxide 
is much more diffusible than superoxide, being comparable to water in this 
respect (Chung, Xia et al. 2007). This allows it to cross plasma membranes and 
permeate into the nucleus. Here it may participate in a Fenton reaction, whereby 
Fe2+ is oxidized to Fe3+, generating the highly reactive hydroxyl radical (OH•) 
(Cooke, Evans et al. 2003).  The third species which is thought to contribute 
appreciably to oxidative DNA damage is singlet oxygen, which can be generated 
 Figure 1.1.  Common products of nucleobase oxidation. The structures of 
the four DNA nucleobases are shown, along with some of the most frequent 
products of their oxidation. The purines guanine and adenine can be oxidized 
in ring opening reactions to form formamidopyrimidine (FaPy) derivatives, or 
oxidized to produce 8-oxo derivatives. Adenine can additionally be oxidized at 
position 2 to form 2-hydroxyadenine. By comparison, the most common 
oxidation products of the pyrimidines thymine and cytosol are glycol 
derivatives. 
guanine                              adenine                     thymine                   cytosine 
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directly by photoexcitation of molecular oxygen in the presence of a 
photosensitizing molecule (Valko, Leibfritz et al. 2007) or by the action of several 
enzymes (Hayaishi and Nozaki 1969, Chan 1971, Kanofsky 1983), often involved 
in host immune responses (Teixeira, Cunha et al. 1999). ROS can react with all 
moieties of DNA; leading to strand breaks and oxidization of bases, in a ratio 
which differs depending on the ROS in question (Kennedy, Moore et al. 1997).  
 
  Whilst all four DNA nucleobases can be oxidized in vivo to produce a 
variety of derivatives (Fig. 1.1.), the low redox potential of guanine makes it 
particularly susceptible (Neeley and Essigmann 2006). Of the many possible 
guanine oxidation products (Neeley and Essigmann 2006), the most common is 
8-oxoguanine (8-oxoG). If not repaired, this lesion is especially deleterious 
because in its syn configuration it can pair with an adenine base (Hsu, Ober et 
al. 2004), bringing the potential for G-to-T transversion mutations during DNA 
replication. Oxidized bases are substrates for BER, which will be discussed in 
section 1.5.1. 
 
In addition to the nucleobases, the deoxyribose-phosphate (dRP) moiety 
of DNA is susceptible to direct attack by ROS. This generally proceeds by 
abstraction of one of the seven available hydrogen atoms on deoxyribose, leaving 
a radical carbon atom which can initiate intramolecular rearrangements and result 
in strand breakage (Pogozelski and Tullius 1998). Notably, strand scission by 
these mechanisms does not produce directly ligatable DNA ends, but rather 
non-canonical 3’-phosphate, 3’-phosphoglycolate, or 3’-phosphoglycolaldehyde 
termini (Bertoncini and Meneghini 1995, Breen and Murphy 1995). A summary of 
DNA SSB end chemistry is provided in Fig. 1.2. ROS can also generate SSBs 
indirectly, as intermediates in the base excision repair (BER) of oxidized bases 
(see section 1.5.1), or by increasing steady-state levels of Top1ccs via multiple 
mechanisms (see section 1.2.3). It should also be noted that ROS are also able 
to generate DSBs directly, but that they do so at a much lower frequency than 
SSBs (in the case of H2O2 treatment, the ratio of SSBs to DSBs is approximately 
2000:1 (Bradley and Kohn 1979)).  
 
Direct Break
(ROS)
Top1
Indirect Break
(BER)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3’-phosphate 
3’-phosphoglycolate 
3’-α,β unsaturated aldehyde 3’-Top1 peptide 
5’-hydroxyl 
5’-aldehyde 
5’-deoxyribose phosphate 
Figure 1.2. The chemistry of non-canonical DNA SSB termini. A summary 
of some common non-canonical DNA SSB termini is provided, showing lesions 
which may arise as a result of direct oxidative strand scission (top circle); as 
intermediates in base excision repair (left circle); or as intermediates in the 
repair of Top1-SSBs (right circle). Chemical structures of these 3’ and 5’ 
termini are shown at the top and bottom of the figure; outlined in blue and 
green, respectively. [Figure adapted from (Caldecott 2008)]. 
3’-phosphoglycolaldehyde 
5 
 
1.2.2.  Ionising Radiation 
Ionising radiation (IR) is a collective term for types of radiation which have enough 
energy to remove electrons from substrates, thereby causing their ionisation 
(WHO 2017). This includes, but is not limited to: alpha (α), beta (β), gamma (γ) 
and x-ray radiation. There are many natural sources of IR, including decay of 
radioactive isotopes on earth, nuclear fusion in the sun, and cosmic rays 
originating outside of the solar system. Different forms of IR are also used for 
diagnostics and cancer radiotherapy. Ionising radiation causes DNA damage 
directly by ionising different moieties of the DNA molecule; or indirectly by ionising 
proximal water molecules, which then react with DNA (Symons 1994), as detailed 
above (see section 1.2.1). 
 
Ionising radiation causes both DNA single- and double-strand breaks, with 
the relative amount of each dependent on the ionization density. For example, 
high ionising density radiation such as α-radiation causes a higher DSB:SSB ratio 
(Scholz, Weidner et al. 1997) than low ionising density radiation, such as 
γ-radiation (Roots, Kraft et al. 1985). Although specific estimates of these ratios 
vary due to the break detection method (Balagurumoorthy, Adelstein et al. 2011), 
it is important to note that all forms of ionising radiation cause a greater DSB:SSB 
ratio than oxidising agents, due to clustering of ionisation events in a small area.  
 
1.2.3.  Topoisomerase I 
The double helical nature of DNA raises a topological problem whenever 
metabolic processes such as transcription or replication occur. In order for a DNA 
or RNA polymerase to read the template DNA, the helix must be unwound and 
denatured. For long or circular molecules, this results in the accumulation of 
positive supercoils ahead of the point of unwinding (Liu and Wang 1987, Giaever 
and Wang 1988, Gilbert and Allan 2014). In the case of transcription by RNA 
polymerase, negative supercoils also accumulate behind the transcription 
elongation complex, whereas in replication, the two daughter strands are in a 
relaxed conformation (Pruss, Manes et al. 1982, Wang 2009, Gilbert and Allan 
2014). Whilst a certain degree of supercoiling might be important for some 
functions, over-accumulation produces topological stress which can impede 
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progression of replication and transcription complexes (Brill, DiNardo et al. 1987, 
Gartenberg and Wang 1992, Bermejo, Doksani et al. 2007, Gilbert and Allan 
2014). Additional topological problems are encountered in mitosis when 
intertwined sister chromatids must be physically separated (Sundin and 
Varshavsky 1980, Baxter 2015). The solution to all of these topological problems 
involves the cleavage of one or both DNA strands, followed by the rotation or 
passage of DNA relative to the cut strand, and finally resealing of the break 
(Wang 2002). The topoisomerases comprise a dedicated family of enzymes 
which perform these essential roles in all domains of life. However, 
topoisomerases have the potential to become abortive, resulting in the 
persistence of topoisomerase-linked single- or double-strand breaks (Pommier, 
Leo et al. 2010). Humans possess six Topoisomerases of three types; type IA, 
type IB and type IIA.  Type I topoisomerases are those that cleave a single strand 
of DNA, including the type IA Topoisomerase III (Top3α and Top3β in humans), 
and the type IB Topoisomerase I (Top1 and Top1mt in humans). Type II 
topoisomerases, by comparison, cleave both strands of DNA and include the type 
IIA Topoisomerase II (Top2α and Top2β in humans). Top1 is of particular 
relevance to this project, because of its roles in facilitating both transcription and 
replication, and its liability to create permanent SSBs (Pommier, Leo et al. 2010). 
 
Eukaryotic Top1 relaxes both negative and positive supercoiled DNA (Brill, 
DiNardo et al. 1987, Pommier, Sun et al. 2016). It does this by cleaving a single 
strand, forming a free 5’-hydroxyl DNA end and a transient 3’-phosphotyrosine 
covalent linkage between the catalytic tyrosine residue in its active site and the 
3’-phosphate group of DNA; this intermediate is termed the Top1-cleavage 
complex (Top1cc) (Fig. 1.3.) (Champoux 1977, Tse, Kirkegaard et al. 1980, Lynn 
and Wang 1989, Redinbo, Stewart et al. 1998, Stewart, Redinbo et al. 1998). 
Rotation of the broken strand can then proceed spontaneously, due to the 
potential energy stored in the supercoiled DNA. This rotation occurs in a 
controlled fashion, due to the presence of two minimal contacts between Top1 
and the DNA helix downstream of the cleavage position (Redinbo, Stewart et al. 
1998, Stewart, Redinbo et al. 1998).  Finally, the break is resealed by nucleophilic 
attack of the DNA 5’-hydroxyl group on the 3’-phosphotyrosine linkage. The 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. The catalytic mechanism and biological roles of vertebrate 
Top1. The enzymatic mechanism of Top1 proceeds via a protein-DNA 
covalent intermediate, involving a DNA 3’-tyrosyl phosphodiester bond (A). 
This Top1 cleavage complex (Top1cc) allows controlled spontaneous rotation 
of DNA downstream of the cleavage site, relieving positive or negative 
supercoils (Sc-/+), prior to religation of the DNA (B). Vertebrates possess two 
TOP1 genes: nuclear (TOP1) and mitochondrial (TOP1mt) (C).  [Figure taken 
from (Pommier, Sun et al. 2016)]. 
A 
B 
C 
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cleavage and ligation steps are catalysed by a pentad of amino acids (Arg488, 
Lys532, Arg590, His632 and Tyr723) in the Top1 active site (Champoux 2001).  
 
 Whilst Top1 does not display strict sequence specificity, cleavage maps 
do reveal favoured sites (Been, Burgess et al. 1984, Francis Stewart, Herrera et 
al. 1990). Furthermore, base frequency analysis has suggested some sequence 
preferences between the -4 and -1 base pairs (relative to Top1cc) (Jaxel, 
Capranico et al. 1991), the most important of which being a T in the -1 position. 
Lesions such as 8-oxoG (Pourquier, Ueng et al. 1999), 5-hydroxyC (Pourquier, 
Ueng et al. 1999) and uracil (Pourquier, Ueng et al. 1997) at the +1 position have 
also been reported to increase Top1cc formation by increasing DNA binding.  
 
 Several factors can prevent ligation, leading to formation of a permanent 
Top1-SSB. One factor is the presence of other proximal lesions. For efficient 
ligation, the 5’-hydroxyl group must be positioned correctly for reaction with the 
3’-phosphotyrosine linkage (Wang 2009). This generally requires that the +1 
nucleobase (relative to the Top1cc) be correctly annealed by hydrogen bonding 
and base stacking with its complementary and neighbouring nucleobases, 
respectively. This is thought to explain the diversity of proximal lesions which can 
trap Top1ccs, including alkylated nucleobases (Pourquier, Bjornsti et al. 1998), 
mismatched nucleobases (Yeh, Liu et al. 1994), ribonucleotides (Pourquier, Ueng 
et al. 1997), abasic sites (Pourquier, Ueng et al. 1997), and UV photoproducts 
(Lanza, Tornaletti et al. 1996). Additionally, trapping of Top1 can occur if there 
are proximal SSBs on the Top1-cleaved strand, leading to formation of gaps; or 
proximal SSBs on the Top1-uncleaved strand, leading to DSB formation 
(Pourquier, Pilon et al. 1997). Finally, Top1ccs can be reversibly stabilized by the 
quinoline alkaloid camptothecin (CPT) and its analogs. These small molecules 
intercalate between the -1 and +1 base pairs (relative to Top1cc), displacing the 
+1 nucleotide and preventing ligation (Redinbo, Stewart et al. 1998, Staker, 
Hjerrild et al. 2002). The extended lifetime of the CPT-stabilized Top1cc renders 
it susceptible to conversion into an irreversible Top1-SSB. It is a common 
misconception that the oxidized bases 8-oxoG and 5-hydroxyC stabilize the 
Top1cc by inhibition of religation; instead, as noted above, these increase the 
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steady-state levels of Top1cc by stimulating the forward cleavage reaction 
(Pourquier, Ueng et al. 1999, Pourquier, Takebayashi et al. 2000). 
 
 A major mechanism by which a Top1cc can become irreversible is by 
collision with the transcription or replication machinery (Wu and Liu 1997) 
(Hsiang, Lihou et al. 1989). Both events are thought to displace the 5’-hydroxyl 
terminus, preventing restoration of the phosphodiester bond (Hsiang, Lihou et al. 
1989, Wu and Liu 1997). The outcomes of the two events are different, both at 
the molecular level and in terms of cytotoxicity. In the case of replication fork 
collision, a Top1cc on the leading strand results in replication run-off, producing 
a blunt DSB with a 5’-hydroxyl terminus, which must be repaired by homologous 
recombination (see section 1.4.2) (Strumberg, Pilon et al. 2000). Lagging strand 
synthesis is likely to proceed past the lesion at least one Okazaki fragment length 
due to uncoupling of DNA synthesis (Pag, xe et al. 2003). The result of a Top1cc 
on the lagging strand is less well defined, but they may not impede progression 
of the replication fork because Okazaki fragment synthesis might initiate beyond 
the lesion. The impediment to DNA replication, coupled with the possible 
formation of large numbers of one-ended DSBs (Furuta, Takemura et al. 2003), 
can explain the significant S-phase selectivity of CPT cell killing (Li, Fraser et al. 
1972, Tobey 1972).  
 
 Collision of the transcription elongation complex with a Top1cc results in 
stalling of RNAPII and the formation of regions of DNA:RNA hybridization known 
as R-loops (Sordet, Redon et al. 2009), which have been implicated in causing 
genomic instability (see section 1.3.1). Cells which rely on high levels of 
transcription, such as neurons, may be particularly sensitive to the depletion of 
essential mRNAs which results from CPT-induced Top1ccs (Morris and Geller 
1996). Additionally, apoptosis may be triggered by several mechanisms, which 
are discussed below (see sections 1.4.3.2 and 1.5.2.1). 
 
1.2.4.  Alkylation, Deamination and AP-site Formation 
In addition to ROS, IR and Top1, there are other damage sources which result in 
the formation of BER/SSBR substrates. One example is DNA alkylating agents, 
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which are found as environmental and dietary contaminants (Hecht and 
Hoffmann 1989, Hotchkiss 1989), as well as endogenously, such as in the gastric 
juice (Pignatelli, Malaveille et al. 1993, Xu and Reed 1993, Kyrtopoulos 1998). 
Probably the most significant examples of these agents are the (predominately 
exogenous) N-nitroso compounds N-nitrosodimethylamine (NMDA) and 
4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (AKA nicotine-derived 
nitrosamine ketone, NNK), and the endogenous methylation cofactor S-Adenosyl 
methionine (SAM). These agents generate methyl adducts on nitrogen and 
oxygen atoms of the nucleobases, particularly N7-methylguanine (7-MeA), 
O6-methylguanine (6-MeG), N3-methyladenine (3-MeA) and O4-methylthymine 
(4-MeT) (Beranek 1990, Kyrtopoulos 1998); and on oxygen atoms of the DNA 
phosphate moiety, giving rise to methylphosphotriesters (Beranek 1990). Of 
these lesions, 7-MeG is the most prevalent, accounting for approximately 70% of 
all adducts formed (Beranek 1990). Whilst not the major lesion, occurring at an 
approximately ~20-fold lower frequency than 7-MeG, 6-MeG is thought to 
contribute heavily to mutagenesis (Swenberg, Bedell et al. 1982, Zaidi, Allay et 
al. 1995, Zaidi, Pretlow et al. 1995, Kyrtopoulos 1998). This has been attributed 
to G-to-A transversion mutations (Saffhill and Hall 1985); which result from an 
increase in the rate of incorporation of thymine opposite 6-MeG, and of the 
immediate subsequent nucleotide (Tan, Swann et al. 1994). Additionally, 
although 3-MeA is thought to occur ~7-fold less frequently than 7-MeG, it is highly 
cytotoxic due to its capacity to block DNA replication (Engelward, Allan et al. 
1998, Plosky, Frank et al. 2008). 
 
Abasic sites (AKA apurinic/apyrimidinic site; AP site) constitute another 
prevalent type of BER substrate (and intermediate). These form when the 
glycosidic bond linking a nucleobase to the deoxyribose moiety of DNA is 
hydrolysed, which can occur spontaneously, or by glycosylase enzyme activity 
operating early within BER (see section 1.5.1) (Lindahl 1993). The rate of 
spontaneous loss of a purine is ~20-fold that of a pyrimidine, occurring with a 
frequency of approximately 10,000 vs 500 cell-1day-1 in humans, respectively 
(Lindahl and Nyberg 1972, Lindahl and Karlstrom 1973, Lindahl 1993). AP sites 
themselves are labile, and can result in strand scission via β-elimination (Lindahl 
1993). In addition, AP sites are potentiators of other types of DNA damage, such 
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as topoisomerase associated strand breaks (see section 1.2.3), and if replicated 
can lead to base substitution or frameshift mutations (Boiteux and Guillet 2004).  
 
In addition to the spontaneous reactions of the DNA backbone, the 
nucleobases themselves are prone to spontaneous deamination (Lindahl 1993). 
The pyrimidines cytosine and 5-methylcytosine are particularly susceptible to 
this, being converted to uracil and thymine, respectively (Lindahl 1993). The rate 
of cytosine deamination has been estimated to be approximately 
60-500 cell-1day-1 in humans (Krokan, Standal et al. 1997), and the rate of 
deamination of 5-methylcytosine is estimated to be ~3-4-fold faster than this 
(Lindahl and Nyberg 1974, Wang, Kuo et al. 1982).  If unrepaired, the resulting 
mismatched bases can lead to C-to-T transition mutations upon DNA replication 
(Duncan and Miller 1980). 
 
1.3.  Blockage of Transcription and Replication by SSBs  
As detailed above, the collision of elongating replication or transcription 
complexes can convert a reversible Top1cc to a Top1-SSB requiring repair, whilst 
simultaneously arresting the progression of the DNA or RNA polymerase. 
Moreover, blockage of replication and transcription is a general consequence 
common to many types of SSB and some base modifications. This section will 
focus on the transcription and replication block imposed by SSBs. 
 
1.3.1. Transcription Blockage 
When SSBs occur in gene bodies they are an impediment to transcription 
elongation (Zhou and Doetsch 1993, Zhou and Doetsch 1994, Kathe, Shen et al. 
2004). This effect is dependent on both end-chemistry and gap length, with 
bulkier groups and longer gaps proving the strongest block to transcription (Neil, 
Belotserkovskii et al. 2012). Transcription blockage may result in the depletion of 
essential mRNAs, which could trigger cell death indirectly (Rulten and Caldecott 
2013). Additionally, stalling of RNAPII at transcription-blocking lesions, including 
SSBs (Roy, Zhang et al. 2010), can cause accumulation of R-loops, which have 
been implicated in causing genomic instability; and of RPA-bound ssDNA 
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regions, which trigger an ATR-p53 apoptotic programme (see section 1.4.3.2) 
(Ljungman and Zhang 1996, Ljungman, Zhang et al. 1999, Vrouwe, Pines et al. 
2011, Rulten and Caldecott 2013).  
In recent years there has been much interest in the mechanisms of 
formation, repair and genotoxicity of R-loops (Aguilera and Garcia-Muse 2012). 
Whilst R-loops have physiological functions, such as in immunoglobulin class 
switch recombination (Skourti-Stathaki and Proudfoot 2014) and the termination 
of transcription (Mischo, Gómez-González et al. 2011, Skourti-Stathaki, 
Proudfoot et al. 2011), their excessive accumulation is believed to have genotoxic 
effects (Aguilera and Garcia-Muse 2012). There are several hypotheses to 
explain R-loop induced genetic instability, such as the increased susceptibility of 
the displaced ssDNA to damage by endogenous enzymes (Petersen-Mahrt, 
Harris et al. 2002, Chaudhuri and Alt 2004) and chemical reactions (Frederico, 
Kunkel et al. 1990). Furthermore, R-loops themselves are a strong impediment 
to replication forks, which is thought to be a significant mechanism in generating 
genetic instability (Tuduri, Crabbe et al. 2009, Alzu, Bermejo et al. 2012, 
Castellano-Pozo, Garcia-Muse et al. 2012).  
 
1.3.2.  Replication Blockage and the Formation of DSBs 
Like CPT exposure, UV irradiation results in the formation of single strand 
interruptions; however, in the case of UV irradiation this occurs indirectly, 
following the excision of a single-stranded DNA tract containing UV 
photoproducts by the nucleotide excision repair pathway (NER) (Marteijn, Lans 
et al. 2014). Early experiments showed that exposure to either CPT or UV 
radiation caused DNA replication arrest and/or S-phase specific cell-killing 
(Hanawalt 1966, Li, Fraser et al. 1972), and subsequently it was revealed that 
these phenotypes were accompanied by the replication-coupled formation of 
DSBs (Tsao, Russo et al. 1993). This mechanism was generalized to other types 
of single strand interruption, after similar observations were made in a study 
utilizing DNA nicks induced by the site-specific single-strand endonuclease gpII 
(Kuzminov 2001). Furthermore, genetic or chemical perturbation of SSBR (see 
section 1.5.2), causes elevated levels of spontaneous S-phase DSBs (Bryant, 
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Schultz et al. 2005, Saleh-Gohari, Bryant et al. 2005), and inhibition of the SSB-
sensing PARP enzymes (see section 1.5.2.1) renders cells heavily reliant on 
functional homologous recombination (HR) (Bryant, Schultz et al. 2005), which 
repairs replication-coupled DSBs (see sections 1.4.2 and 1.6.1) (Arnaudeau, 
Lundin et al. 2001, Saleh-Gohari, Bryant et al. 2005).  
 
1.4. Double Strand Break Repair and the DNA Damage 
Response 
The previous section detailed how persistent SSBs can cause replication fork 
collapse and the generation of DSBs during S-phase. In addition, DSBs can be 
caused directly in all phases of the cell cycle, by clustered oxidative damage, 
such as that resulting from IR (see section 1.2.2). DSBs are extremely dangerous 
for genome integrity, and for this reason multiple pathways have evolved both to 
repair DSBs, and to trigger cell-cycle arrest or apoptotic mechanisms. A brief 
overview of some of these mechanisms will be provided below. 
 
1.4.1.  Non-Homologous End Joining 
Non-homologous end joining (NHEJ) is a collective term for two known molecular 
pathways which join DNA ends directly; without requiring the presence of a 
homologous template, and thus able to occur in all phases of the cell cycle 
(Chang, Pannunzio et al. 2017). The first of these pathways to be identified is 
now termed classical-NHEJ (C-NHEJ), to distinguish it from the more recently 
identified alternative-NHEJ (A-NHEJ) pathway (Chang, Pannunzio et al. 2017). 
 
C-NHEJ constitutes the major repair pathway for the repair of DSBs in 
human cells (Lieber 2010), and is able to be completed very rapidly. The 
recognition system is composed of an abundant ring-like heterodimer of two 
similar proteins, Ku70 and Ku80, which threads over each DNA end, limiting DSB 
mobility (Downs and Jackson 2004) and acting as a scaffold for the recruitment 
of downstream factors (Yang, Guo et al. 2016), which are, similarly to SSBR (see 
section 1.5.2), involved in scaffolding, end-processing, polymerisation, and 
ligation. An early interactor with the DSB-Ku complex is the DNA-dependent 
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protein kinase catalytic subunit (DNA-PKcs), a member of the phosphoinositide 
3 kinase-related kinase (PIKK) family, which includes ataxia-telangiectasia 
mutated (ATM) and ataxia-telangiectasia and Rad3 related (ATR) kinases. DNA-
PKcs is activated upon binding to the C-terminal 12aa of Ku80 (Gell and Jackson 
1999); phosphorylating many protein targets, including itself, to positively 
regulate C-NHEJ. Another interactor to the DSB-Ku complex is the XRCC4-XLF-
Lig4 complex (Nick McElhinny, Snowden et al. 2000), which has been reported 
to tether DNA termini by bridging DSBs (Pang, Yoo et al. 1997, Brouwer, Sitters 
et al. 2016). The processing of complex DNA termini is carried out by several 
proteins, including those shared with SSBR (see section 1.5.2.3), such as 
polynucleotide kinase 3’-phosphatase (PNKP), Aprataxin (APTX) and Aprataxin 
and PNKP-like factor (APLF); and those which are unique to C-NHEJ, such as 
the specialized nucleases Artemis and Werner syndrome protein (WRN), and the 
PolX family polymerases Polλ and Polµ (Davis and Chen 2013). Finally, ligation 
is conducted by Lig4, in complex with XLF and XRCC4 (Grawunder, Wilm et al. 
1997, Schär, Herrmann et al. 1997). 
 
More recently, another mechanism for direct end-joining of DSBs has been 
described; this is termed alternative-NHEJ (A-NHEJ) (Sfeir and Symington 2015). 
Some believe that this is an independent pathway whilst others suggest that it 
performs a backup or rescue function when C-NHEJ stalls. A-NHEJ relies on 
aligning DNA ends using microhomologous regions of 5-25 bp, often leading to 
significant deletions at the repair junctions (McVey and Lee 2008). The 
mechanisms surrounding A-NHEJ are still being elucidated, but are thought to 
involve the actions of PARP1 and the MRN complex (see section 1.4.2) (Wang, 
Wu et al. 2006). 
 
1.4.2.  Homologous Recombination 
The replication of DNA provides a backup of the genome, allowing for potentially 
error-free repair of DSBs arising in S or G2 phases of the cell cycle by utilizing 
the undamaged sister chromatid as a template (Heyer, Ehmsen et al. 2010). This 
process competes with the NHEJ pathways described above, which also function 
in S and G2.  
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Homologous recombination involves the resection of a DSB into a 3’-
overhang by the combined nuclease activities of the MRE11-RAD50-NBS1 
(MRN) complex (Trujillo, Yuan et al. 1998, Williams, Williams et al. 2007), Exo1 
(Moreau, Morgan et al. 2001), DNA2 (Bae, Choi et al. 1998, Zhu, Chung et al. 
2008) and CtIP (Sartori, Lukas et al. 2007); in cooperation with the helicase BLM 
(Gravel, Chapman et al. 2008, Huertas 2010). This 3’- ssDNA tail is bound by the 
single stranded DNA binding protein RPA (Heyer, Rao et al. 1990), which is 
subsequently displaced by the Rad51 recombinase (Sung 1994). This is 
accomplished with the aid of a host of mediator proteins including:  XRCC2, 
XRCC3, RAD51B, RAD51C, RAD51D, RAD52, and BRCA2 (Heyer, Ehmsen et 
al. 2010). Rad51 assembles into a protein-DNA filament, which can carry out an 
active “homology search” throughout the nucleus (Haber 2013). With the aid of 
Rad54, the Rad51-DNA filament can coordinate dsDNA regions of homology, by 
a mechanism which is still unclear (Haber 2013). This results in strand invasion 
to form a region of heteroduplex DNA, with displacement of a D-loop; a process 
which is known as synapsis (Heyer, Ehmsen et al. 2010). The invaded 3’-strand 
then primes DNA synthesis by the replicative polymerase complex, which 
extends the heteroduplex.  
 
There are three main postsynaptic pathways, termed break-induced 
replication (BIR), synthesis-dependent strand annealing (SDSA), and double 
Holliday junction (dHJ) formation (Heyer, Ehmsen et al. 2010). These pathways 
differ in their molecular outcomes, and in the proteins required. If another DNA 
end is not available, such as in the case of replication fork collapse at a single 
strand break (see section 1.3.2), BIR allows polymerisation to occur as far as the 
next replication fork (or to the end of the chromatid) (Heyer, Ehmsen et al. 2010). 
This can result in large losses of heterozygosity. When a second DNA end exists, 
such as for DSBs arising in G2, the predominant mechanism is thought to be 
SDSA, whereby the newly synthesized 3’-overhang is displaced from its intact 
template and anneals with the resected region of the other end (Haber 2013). 
This minimises loss of heterozygosity, as the subsequent gap-filling and ligation 
always results in a non-crossover product. A final possibility for DSB processing 
is the formation of a dHJ. This involves annealing the other resected DNA end to 
the D-loop displaced by the first strand invasion, followed by extension and 
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ligation of both ends (Heyer, Ehmsen et al. 2010). These joint molecules (JM) 
can migrate; prior to resolution by the endonucleases GEN1, SLX1-SLX4 and 
Mus81-Eme1 (Wyatt, Sarbajna et al. 2013), generating crossover or non-
crossover products; or dissolution by the BLM-TopoIIIα-RMI1-RMI2 (BTR) 
complex, generating non-crossover products. In mitotic cells, dissolution by the 
BTR complex is the preferred pathway choice (Heyer, Ehmsen et al. 2010). 
 
1.4.3. The DNA Damage Response 
The serine/threonine kinases ATM and ATR act as molecular sensors of activated 
MRN and RPA-coated ssDNA regions, respectively; both of which are signals of 
DSBs (see section 1.4.2) (Marechal and Zou 2013). Furthermore, RPA-coated 
ssDNA is a structure present in many repair pathways, including nucleotide 
excision repair (NER), mismatch repair (MMR), long-patch base excision repair 
(LP-BER), interstrand crosslink (ICL) repair; and at stalled replication forks and 
transcription complexes, thus allowing ATR to function as a sensor of diverse 
damage and replication stresses (Zou, Liu et al. 2006). ATR and ATM 
phosphorylate diverse protein targets involved in repair, replication, cell cycle, 
and apoptotic mechanisms; promoting cell survival and/or preventing 
oncogenesis (Marechal and Zou 2013). These complex signalling networks are 
collectively known as the DNA damage response (DDR).  
 
1.4.3.1.  ATM 
The MRN complex is thought to be the initial sensor of the DSB, which recruits 
and activates the PIKK ATM (Falck, Coates et al. 2005, Lavin 2007). Activated 
ATM phosphorylates a wide range of protein targets, promoting repair 
mechanisms and the DDR (Marechal and Zou 2013). One important target of 
ATM is the histone variant H2AX, which is phosphorylated on Ser139 in the 
vicinity of a DSB (Rogakou, Pilch et al. 1998). This signal has significant roles in 
promoting chromatin restructuring and DSBR mechanisms, including resection 
(Marechal and Zou 2013).  Other important targets of ATM are BRCA1, 
Checkpoint kinase 2 (Chk2) and P53; which have roles in repair, cell cycle control 
and apoptosis, respectively (Marechal and Zou 2013). The involvement of ATM 
in such diverse cellular signalling programmes explains the complexity and 
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multisystemic-nature of the disease which is associated with its mutation: Ataxia 
telangiectasia (AT) (Savitsky, Barshira et al. 1995). AT patients are sensitive to 
DSB-inducing agents; prone to cancer; and exhibit neurodegeneration, leading 
to early-onset ataxia (Taylor, Harnden et al. 1975, Rothblum-Oviatt, Wright et al. 
2016). 
 
1.4.3.2.  ATR 
ATR is recruited to RPA-coated ssDNA by ATR interacting protein (ATRIP), 
causing its activation (Zou and Elledge 2003). Activated ATR phosphorylates 
Checkpoint kinase 1, which is integral in promoting intra-S and G2/M cell-cycle 
arrest. Additionally, ATR phosphorylates targets involved in modulating origin 
firing and replisome stability, highlighting its role in the tolerance of replication 
stress. These functions are generally unique to ATR, which, unlike ATM and 
DNA-PK, is essential in replicating cells (de Klein, Muijtjens et al. 2000, Nam and 
Cortez 2011). Hypomorphic mutations in ATR cause the extremely rare 
autosomal recessive disease Seckel syndrome, which is characterized by a 
severe growth defect resulting in microcephallic primordial dwarfism (O'Driscoll, 
Gennery et al. 2004). 
 
1.5. DNA Base Excision and Single Strand Break Repair 
The mechanisms of DSBR and the DDR described above are essential to prevent 
the severe genotoxic consequences of DSBs. However, the vast majority of DNA 
breaks which arise in cells are SSBs (see section 1.2). Complex molecular 
mechanisms have evolved to detect and repair these SSBs, and to prevent their 
conversion to DSBs during replication. The focus of this thesis is the detection 
and repair of oxidative and Top1-linked SSBs; therefore, most attention will be 
paid to these topics in the following sections. As discussed above (see section 
1.2.1), both the deoxyribose and nucleobase moieties of DNA are susceptible to 
attack by ROS, resulting in the formation of not only direct SSBs but also oxidized 
bases. Oxidized bases are excised during BER, resulting in the formation of 
intermediate SSBs which are the substrates of SSBR. These processes, which 
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are thought to be tightly coordinated  in vivo (Wilson and Kunkel 2000), will be 
discussed in detail in the following sections. 
 
1.5.1.  Base Excision Repair  
As detailed above, DNA nucleobases can be oxidized (see section 1.2.1), 
alkylated (see section 1.2.4), lost by spontaneous hydrolysis (see section 1.2.4) 
or deaminated to produce non-canonical types (see section 1.2.4). Collectively, 
these lesions constitute a substantial proportion of the total arising in cells every 
day (Lindahl 1993). Consequently, an extremely efficient and degenerate 
pathway has evolved to deal with these lesions: base excision repair (BER). This 
makes up the earliest activities involved in BER/SSBR, DNA glycosylase and AP 
lyase or AP endonuclease.  
 
The first step of BER, recognition and excision of the base by a DNA 
glycosylase, is enzymatically diverse. There are eleven known human DNA 
glycosylases (Hendrich, Hardeland et al. 1999, Hazra, Izumi et al. 2002, Hegde, 
Hazra et al. 2008, Jacobs and Schär 2012, Liu, Doublié et al. 2013). Whilst they 
each tend to have a preferred substrate there is a great deal of functional 
redundancy. The glycosylases involved in excising uracil (U) and its derivatives 
from DNA, as well as thymine (T) mispaired with guanine (G), include the 
monofunctional DNA glycosylases uracil DNA glycosylase, (UNG) (Lindahl 
1993), single-strand selective monofunctional DNA glycosylase (SMUG1) 
(Haushalter, Todd Stukenberg et al. 1999), thymine DNA glycosylase (TDG) 
(Wiebauer and Jiricny 1989), and methyl-CpG-binding domain protein 4 (MBD4) 
(Hendrich, Hardeland et al. 1999). Other monofunctional DNA glycosylases 
include 3-methyladenine DNA glycosylase (MPG) (O'Connor and Laval 1990) 
and MutY DNA glycosylase (MUTYH) (McGoldrick, Yeh et al. 1995), which excise 
alkylated purines and 8-oxoG-paired adenine, respectively (Hegde, Hazra et al. 
2008). Monofunctional glycosylases catalyse the removal of the nucleobase to 
generate an AP site, which is subsequently incised by AP endonuclease (APE1) 
(See section 1.5.2.3.1 for a detailed overview of APE1) (Hegde, Hazra et al. 
2008). 
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 By comparison, glycosylases which recognize oxidized bases, such as 
8-oxoguanine DNA glycosylase (OGG1) (Lu, Nash et al. 1997), endonuclease 
II-like protein 1 (NTH1) (Dizdaroglu, Karahalil et al. 1999); endonuclease VIII-like 
1 (NEIL1) (Hazra, Izumi et al. 2002), endonuclease VIII-like 2 (NEIL2) (Morland, 
Rolseth et al. 2002), and endonuclease VIII-like 3 (NEIL3) (Liu, Bandaru et al. 
2010) are all bifunctional enzymes, meaning that they also possess intrinsic AP 
lyase (AKA AP endonuclease class I) activity (Hazra, Izumi et al. 2002, David, 
O'Shea et al. 2007, Hegde, Hazra et al. 2008, Liu, Doublié et al. 2013). It is 
important to note that there is thought to be considerable redundancy between 
these pathways, such that AP sites generated by the monofunctional 
glycosylases can be substrates for the AP lyase activity of bifunctional 
glycosylases (Wiederhold, Leppard et al. 2004), and AP sites generated by the 
bifunctional glycosylases can be substrates for APE1 (Allinson, Dianova et al. 
2001).  
 
The AP endonuclease catalytic mechanism differs for APE1, 
OGG1/NTH1, and NEIL1/NEIL2, resulting in different product termini (Hegde, 
Hazra et al. 2008). APE1 catalyses cleavage 5’ relative to the AP site, resulting 
in 3’-OH and 5’-dRP termini. This is defined as a class II AP endonuclease activity 
(Levin and Demple 1990). By comparison, the bifunctional glycosylases employ 
a class I AP endonuclease mechanism (Levin and Demple 1990), more 
commonly referred to as an AP lyase mechanism, whereby the cleavage is made 
3’ relative to the AP site. OGG1 and NTH1 use a β-elimination mechanism, which 
opens the deoxyribose ring and results in 3’-phospho α,β-unsaturated aldehyde 
(3’-PUA) and 5’-phosphate termini. By comparison, NEIL1, NEIL2 and NEIL3 
catalyse a βδ elimination mechanism, resulting in 3’ and 5’- phosphate termini. 
APE1 therefore produces canonical 3’ and blocked 5’ termini, whereas for the 
bifunctional glycosylases the opposite is true. The presence of blocked termini 
necessitates an end-processing step to yield substrates suitable for gap filling 
and ligation (Hegde, Hazra et al. 2008). Top1-SSBs and direct SSBs induced by 
ROS also have blocked termini (see section 1.2.1 and 1.2.3), and it is at this stage 
that SSBR converges with BER.  
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1.5.2.  Single Strand Break Repair 
The current consensus model of SSBR can be divided into five major steps: 
recognition of a SSB by a PARP enzyme; PAR-dependent recruitment of the 
XRCC1 scaffolding protein and its interactors; end-processing of damaged DNA 
termini by several XRCC1-interacting enzymes; gap-filling by DNA 
polymerases; and finally, ligation to restore the intact duplex. These simplified 
steps are summarised in Fig. 1.4., and will be discussed in detail below. 
 
1.5.2.1. Break detection and ADP-ribosylation 
DNA single-strand break repair (SSBR) repairs SSBs arising directly from 
oxidative sugar damage (see section 1.2.1), from the excision of non-canonical 
nucleotides and AP-sites in BER (see section 1.5.1), and from the abortive action 
of Top1 (see section 1.2.3). The sum frequency of these SSBs in mammals is 
estimated to be approximately 104 to 105 cell-1 day-1 (Lindahl 1993), necessitating 
an extremely sensitive surveillance system in higher eukaryotes (Caldecott 
2008). This system employs several Diphtheria toxin-like adenosine 
diphosphate-ribosyltransferases (ARTDs) to detect strand interruptions and 
signal their presence. It is important to note that there is evidence that SSBs 
generated as intermediates in BER do not always require this signalling 
mechanism (Allinson, Dianova et al. 2003, Strom, Johansson et al. 2011), as they 
may be passed from one enzyme to the next in a coordinated fashion (Wilson 
and Kunkel 2000). 
 
 Of the eighteen known human ARTDs (Citarelli, Teotia et al. 2010, 
Hottiger, Hassa et al. 2010), three have been shown to be activated by DNA 
strand interruptions; these are ARTD1, ARTD2 and ARTD3 (Okayama, Edson et 
al. 1977, Amé, Rolli et al. 1999, Boehler, Gauthier et al. 2011). These enzymes 
are more commonly known by their previous names: poly(ADP-ribose) 
polymerase 1, 2, and 3 (PARP1, PARP2, and PARP3), which is how they will be 
referred to throughout this thesis. PARP1, PARP2 and PARP3 catalyse the 
post-translational modification of local acceptor proteins with units of adenosine 
diphosphate-ribose (ADP-ribose) (Fig. 1.5.). This reaction involves the transfer of 
  
 
 
 
 
 
 
 
 
 
Figure 1.4. A simplified overview of SSBR pathways. SSBs can arise 
directly, from oxidation of the deoxyribose phosphate backbone; indirectly, as 
BER intermediates; or from abortive activity of Top1. SSBs are primarily 
detected by PARP1, which modifies local proteins, including itself, at the site 
of the lesion. PAR serves as a signal for the recruitment of a complex of 
enzymes involved in end-processing, gap-filling, and ligation; the stabilities 
and activities of which are stimulated by the scaffolding protein XRCC1. End-
processing restores canonical 3’-hydroxl and 5’-phosphate termini from 
diverse blocked-SSBs. Gap-filling of 1 nucleotide is conducted by Polβ (short 
patch); gap-filling of 2-12 nucleotides is conducted by Polδ/ε (long patch), 
displacing a 5’-flap which is removed by FEN1. Finally, ligation of short patch 
and long patch products is conducted by Lig3 and Lig1, respectively. [Figure 
taken from (Caldecott 2008)]. 
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ADP-ribose from the substrate nicotinamide adenine dinucleotide (NAD+), to a 
suitable nucleophilic acceptor. Known acceptor amino acids of the 
damage-responsive PARPs include aspartate (D), glutamate (E), lysine (K), 
arginine (R), and serine (S) (Messner, Altmeyer et al. 2010, Martello, Leutert et 
al. 2016, Bonfiglio, Fontana et al. 2017). Modification with a single unit of 
ADP-ribose is known as mono ADP-ribosylation (MARylation). The subsequent 
polymerisation of ADP-ribose to form oligo and poly ADP-ribose (OAR and PAR, 
respectively), occurs via transfer of another ADP-ribose unit to the 2’ position of 
the preceding adenosine moiety (Hottiger, Hassa et al. 2010). Occasionally an 
ADP-ribose unit may be transferred to the 2’ position of the ribose 5’-phosphate 
moiety, forming a branch point in the chain (Juarez-Salinas, Levi et al. 1982, 
Hottiger, Hassa et al. 2010). The percentage of ADP-ribose moieties with a 
branch point in a PAR chain has been estimated to be between 0.8 and 1.6% 
(Juarez-Salinas, Levi et al. 1982), but further insights into PAR branch structure 
are limited. The various abilities of PARP1, PARP2 and PARP3 to generate MAR, 
OAR and linear/ branched PAR is still being studied; but the consensus is that 
PARP1 and PARP2 generate long and branched PAR, whereas PARP3 
generates predominantly MAR (Vyas, Matic et al. 2014). PARylation of local 
proteins at the site of DNA strand breaks leads to relaxation of chromatin (Poirier, 
de Murcia et al. 1982), allowing repair processes to take place (see section 
1.5.2.1.1). Simultaneously, PAR and MAR serve as molecular signals for the local 
enrichment of numerous DNA repair and DDR proteins (see section 1.5.2.1.4), 
which interact directly and indirectly with this highly-charged molecule.  
 
Similarly to other post translational modifications involved in signalling, 
PAR is removed by a number of “eraser” enzymes, such as poly(ADP-ribose) 
glycohydrolase (PARG) (Miwa and Sugimura 1971), which possesses endo and 
exoglycohydrolase activities (Brochu, Duchaine et al. 1994). This enzyme 
cleaves the bonds between ribose moieties of a PAR chain, but is unable to 
remove the terminal protein-linked MAR (Slade, Dunstan et al. 2011). The 
removal of this terminal moiety has been shown recently to be accomplished by 
the activities of the catalytic macro domain-containing proteins MacroD1, 
MacroD2 and O-acyl-ADP-ribose deacylase 1 (OARD1) (see section 1.5.2.1.4 for 
further discussion) (Jankevicius, Hassler et al. 2013, Rosenthal, Feijs et al. 2013).  
 Figure 1.5. The structure of PAR. A simple representation of a PAR chain, 
showing: ADP-ribose, iso-ADP-ribose and ADP-ribose-adenosine  moieties 
(blue, green and orange ovals, respectively), and the domains which bind 
them; the branch point at the 2’ position of ribose (red circle); the substrate 
coenzyme NAD+, and leaving group nicotinamide; and the position of linkage 
with an amino acid sidechain (X). 
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The balance of PAR generation and removal has important consequences 
for cellular metabolism and programmed cell death. Excessive PARP activity can 
trigger a mechanism of programmed cell death called Parthanatos, which acts 
independently of the caspase axis (Yu, Wang et al. 2002), and is particularly 
prevalent in neurons, where it is associated with several common neurological 
pathologies, such as Parkinson’s (Mandir, Przedborski et al. 1999, Lee, Kang et 
al. 2014), Huntington’s (Vis, Schipper et al. 2005) and Alzheimer’s diseases 
(Love, Barber et al. 1999, Abeti and Duchen 2012, Strosznajder, Czapski et al. 
2012); amyotrophic lateral sclerosis (ALS) (Hivert, Cerruti et al. 1998); cerebral 
ischemia (Eliasson, Sampei et al. 1997, Narne, Pandey et al. 2017); and with the 
recessive ataxias caused by genetic disruption of SSBR (see section 1.6) (Hoch, 
Hanzlikova et al. 2017). This pathway is dependent on the translocation of the 
flavoprotein apoptosis inducing factor (AIF) from the mitochondria to the nucleus 
(Yu, Wang et al. 2002),  the trigger for which was originally thought to be depletion 
of the PARP substrate NAD+, but more recent evidence has cast doubt on this.  
For example, it was recently shown that PARG inactivation leads to PARthanatos 
without depletion of NAD+ (Goto, Xue et al. 2002, Zhou, Feng et al. 2011). This 
has led some to suggest that free PAR or a PARylated protein may mediate AIF 
release directly (Andrabi, Kim et al. 2006, Yu, Andrabi et al. 2006, Fatokun, 
Dawson et al. 2014). Until recently, the mechanism by which AIF mediates 
nuclear DNA fragmentation was similarly unclear. In 2016 Wang et al published 
that in mammals, macrophage migration inhibitory factor (MIF) is an 
endo/exonuclease which associates with AIF and is essential for the DNA 
fragmentation which accompanies PARthanatos (Wang, An et al. 2016).  
 
Elucidating the specific biological roles of the DNA dependent PARPs has 
been the subject of much research in recent years. A summary comparison of 
some key structural and functional features of PARP1, PARP2 and PARP3 is 
provided in Fig. 1.6, and these enzymes will be discussed in detail in the following 
sections. 
 
  
 
 
 
 
 
 
 
 
 
Gene Protein size (aa) 
Primary break 
recognition 
domains 
Break 
termini 
preference 
Type of ADPr 
produced 
PARP1 1014 ZFD1 & ZFD2 None Branched PAR 
PARP2 570 WGR 5’-phosphate Branched PAR 
PARP3 533 WGR 5’-phosphate MAR 
 
 
 
 
 
 
 
 ZFD1    ZFD2    ZFD3            BRCT                   WGR        HD             ART 
   N-terminal Region                                              Catalytic Domain 
                                                                          WGR        HD             ART 
                                                                          WGR        HD             ART 
PARP1 
 
PARP2 
 
PARP3 
 
1         100         215         370                           500                   650         785                    1014 
1       78              220        370                      570 
1    40            180         310                      533 
Figure 1.6. Summary comparison of PARP1, PARP2, and PARP3 
structure and function. The domain structure of PARP1, PARP2 and PARP3 
is shown, including those conserved between all three enzymes: Trp-Gly-Arg 
domain (WGR), helical domain (HD), ADP-ribosyl transferase domain (ART); 
and those unique to PARP1: zinc finger domains 1, 2, and 3 (ZFD1, ZFD2, 
and ZFD3, respectively); and BRCA1 c-terminus domain (BRCT). The 
approximate amino acid positions of the domain boundaries are included 
(Langelier, 2014) (A). A summary of some key features of PARP1, PARP2 and 
PARP3 structure and function are provided in B. 
A 
 
 
 
 
 
 
 
 
B 
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1.5.2.1.1. PARP1  
PARP1 was initially identified in 1971, following its partial purification from rat liver 
nuclei (Yamada, Miwa et al. 1971). In this early study, and in a subsequent 
publication (Okayama, Edson et al. 1977), it was noted that the activity of the 
enzyme in vitro was dependent on the presence of DNA, and was stimulated 
2-3-fold by the addition of purified histones (Yamada, Miwa et al. 1971, Okayama, 
Edson et al. 1977). Subsequent studies of ADP-ribose production in 
x-ray-irradiated or endonuclease-treated mammalian cell “ghosts” 
(detergent-permeabilized cells) revealed the dramatic activation of PARP1 by 
DNA strand breaks (Berger, Weber et al. 1978, Halldorsson, Gray et al. 1978, 
Benjamin and Gill 1980). Then, in 1980, the authors of a seminal study 
demonstrated that inhibition of PARP1 with 3-aminobenzamide reduced the 
repair rate of SSBs induced by the alkylating agent dimethyl sulphide (DMS) 
(Durkacz, Omidiji et al. 1980), indicating a role for PARP1 in DNA repair.  
 
 Subsequent work from the Poirier laboratory used electron microscopy 
(EM) to show that in vitro PARP1-mediated poly(ADP-ribosyl)ation (PARylation) 
of polynucleosomes causes them to adopt a relaxed, “beads-on-a-string 
structure” (Poirier, de Murcia et al. 1982, de Murcia, Huletsky et al. 1986), which 
is characteristic of chromatin depleted of the linker histone H1 (Thoma, Koller et 
al. 1979), and prompted the hypothesis that PARP1 was involved in the relaxation 
of chromatin to allow repair processes to take place. In these reactions, H1 was 
found to be the major PARylated histone, which is supported by recent in vitro 
experiments (Grundy, Polo et al. 2016). Other more recent work has 
demonstrated that PARP1 itself is a ubiquitous component of undamaged 
chromatin (Kraus 2008, Muthurajan, Hepler et al. 2014), competing with H1 for 
overlapping sites on the linker DNA (Kim, Mauro et al. 2004). In a study employing 
reconstituted chromatinized plasmids, it was shown that both PARP1 and H1 
binding could dramatically condense chromatin structures, leading to extension 
of the nucleosome repeat length by 11% and 14%, respectively (Kim, Mauro et 
al. 2004). Furthermore, this effect saturated at a 1:1 ratio of nucleosomes to 
PARP1 or H1, suggesting stoichiometric binding with the linker DNA sites (Kim, 
Mauro et al. 2004). In the same study, it was demonstrated that inclusion of 
PARP1 reduced in vitro transcription of chromatinized plasmids, similar to the 
23 
 
regulation conferred by H1-mediated chromatin condensation; and that in the 
case of PARP1 but not H1, this could be reversed by addition of NAD+ (Kim, 
Mauro et al. 2004, Muthurajan, Hepler et al. 2014). In addition to this in vitro work, 
PAR-mediated decondensation of chromatin has also been reported in vivo (Tulin 
and Spradling 2003, Strickfaden, McDonald et al. 2016), and has become a 
central paradigm of the PARP field.  
 
 PARP1 is a highly active enzyme, accounting for 80-90% of the total 
cellular PARylation in mammalian cells (Shieh, Ame et al. 1998), and is known to 
generate branched chains of up to 200 residues in length, on diverse protein 
targets, including itself.  PARP1 is also an extremely abundant molecule in the 
nucleus, with the PARP1:nucleosome ratio estimated to be approximately 1:20 
(Muthurajan, Hepler et al. 2014). The high abundance of PARP1, coupled with its 
integral association with chromatin, make it perfectly poised to rapidly detect 
proximal strand breaks as they occur in the genomic DNA. To perform this 
sensory role, PARP1 uses its N-terminal zinc finger domains (ZFD) to detect 
strand interruptions (Gradwohl, Menissier de Murcia et al. 1990). This allosteric 
signal is transmitted to the catalytic domain, which stimulates activity up to 
500-fold (Rouleau, Patel et al. 2010). PARP1 is potently stimulated by breaks 
with diverse termini, including: canonical, 3’-phosphate and 5’-hydroxyl termini; 
with gaps and overhangs also being well tolerated (Langelier, Riccio et al. 2014).  
 
How PARP1 achieves such a broad sensitivity as a receptor was unclear, 
until a recent study elucidated the structural basis of SSB recognition by PARP1 
(Eustermann, Wu et al. 2015). In its DNA-free conformation, PARP1 is a highly 
flexible protein, in which the six constituent domains behave like 
beads-on-a-string (Lilyestrom, van der Woerd et al. 2010, Eustermann, Wu et al. 
2015). Strand break-stimulation of PARP1 involves a stepwise multi-domain 
folding pathway (Fig. 1.7.), which begins with ZFD1 and ZFD2 binding to DNA in 
a directional manner (Eustermann, Wu et al. 2015). This deforms the DNA in such 
a way that a cryptic binding interface is exposed for ZFD3, encompassing parts 
of ZFD1 and the DNA 5’-stem. Similarly, ZFD3 association generates a binding 
interface for the WGR domain, encompassing parts of ZFD1, ZFD3 and the DNA. 
The assembly of the three ZFDs with the WGR domain finally creates an interface 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. The structural basis of SSB detection by PARP1. A model of 
the allosteric mechanism by which PARP1 detects a SSB is depicted [figure 
taken from (Eustermann, Wu et al. 2015), in accordance with the Creative 
Commons Attribution Licence (CC BY)]. In this model, initial recognition of 
DNA deformability by the zinc finger domains 1 and 2 (F1 and F2) triggers a 
sequential folding-up of the flexible PARP1 structure; with each association 
creating the binding interface for the next. This cumulates in binding of the 
catalytic (CAT) domain to an interface on the tryptophan-glycine-arginine 
(WGR) and zinc finger 3 (F3) domains, which destabilizes an autoinhibitory 
helical domain (HD) and allows productive catalysis. Note that the BRCT 
domain and proximal linker regions remain flexible, suggesting that they may 
reach the active site, which might explain their elevated automodification.  
1.                                       2.                                    3. 
 
 
 
 
 
 
6.                                       5.                                     4. 
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for the association of the CAT domain, encompassing parts of ZFD3 and the 
WGR domain. Binding of the CAT domain triggers the unfolding of an 
autoinhibitory helical subdomain (HD), resulting in stimulation of PARP1 activity 
(Dawicki-McKenna, Langelier et al. 2015). An elucidating feature of this break 
recognition model is the absence of contacts between the DNA termini and the 
amino acids of ZFDs; detection is instead based on the extreme deformability of 
SSBs compared to intact DNA (Eustermann, Wu et al. 2015).  This explains the 
ability of PARP1 to recognise breaks with diverse termini. Furthermore, the 
flexibility of the ZFD1-ZFD2 linker region allows for a “fly-casting” mechanism; 
whereby initial ZFD2 binding to the 3’ DNA stem tethers PARP1 at the break site, 
allowing for subsequent scanning by ZFD1 for a 5’ DNA stem. This feature 
explains the ability of PARP1 to detect breaks with varying gap length 
(Eustermann, Wu et al. 2015). 
 
The automodification of PARP1 accounts for a large proportion of its 
activity (D'Amours, Desnoyers et al. 1999, Langelier, Planck et al. 2012), and is 
thought to predominately occur at Glu, Asp and Lys residues within an 
automodification domain (373 to 525aa), including: D387, E488, E491 (Tao, Gao 
et al. 2009), K498, K521 and K524 (Altmeyer, Messner et al. 2009) (Kameshita, 
Matsuda et al. 1984). More recent work has revealed that automodification is by 
no means restricted to this region, and appears to occur throughout the protein 
to some degree (Gagne, Ethier et al. 2015). Despite these recent revelations, it 
is clear that the BRCT-WGR linker domain is subject to especially extensive 
automodification (Kameshita, Matsuda et al. 1984). This fits well with the 
structural model of PARP1-SSB interaction proposed by Eustermann et al; in 
which the BRCT-WGR linker remains flexible, and can reach the active site in cis 
(Eustermann, Wu et al. 2015). Previously, a model of PARP1 break detection 
was proposed in which the protein functioned as a homodimer, leading to 
automodification in trans (Ali, Timinszky et al. 2012). However, the work of 
Eustermann et al has shown that trans automodification of PARP1 occurs only 
when the DNA substrate contains proximal termini; such as a short linear dsDNA 
molecule, with breaks at either end. By comparison, no trans modification was 
observed when employing a nicked dumbbell DNA substrate, which mimics an 
isolated SSB (Eustermann, Wu et al. 2015).  
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Besides PARP1 itself, histones constituent the major acceptor of PAR 
modification (Adamietz and Rudolph 1984, Adamietz 1987); as mentioned above, 
this includes primarily the linker histone H1 (Poirier, de Murcia et al. 1982, Aubin, 
Fréchette et al. 1983, Gibson, Zhang et al. 2016, Grundy, Polo et al. 2016), but 
also all core histones (H2A, H2B, H3, and H4) to a lesser extent, which are 
modified on their flexible N-terminal tails (Messner, Altmeyer et al. 2010, Gibson, 
Zhang et al. 2016). Recent work has identified histone PARylation factor 1 
(HPF1), a novel protein involved in attenuating PARP1 and PARP2 
hyper-automodification and promoting their trans modification of histones (Gibbs-
Seymour, Fontana et al. 2016). Subsequent work by the same group has clarified 
the role of HPF1 as a PARP1/PARP2 interactor which is necessary and sufficient 
for the ADP-ribosylation of Ser residues in many target proteins, including both 
histones and itself (Bonfiglio, Fontana et al. 2017). The recent unexpected 
identification of Ser as an acceptor of ADP-ribosylation, indeed a particularly 
prominent one, has dramatically altered our understanding of the 
ADP-ribosylated proteome (Leidecker, Bonfiglio et al. 2016, Bonfiglio, Fontana et 
al. 2017, Leung 2017). Intriguingly, it has been suggested that direction of PARP1 
and PARP2 activity towards Ser by HPF1 may also be accompanied by a shift in 
the polymer chain length; possibly even to MARylation (Bonfiglio, Fontana et al. 
2017, Leung 2017).  
 
Recent work has highlighted a potentially novel function of PARP1-
mediated PARylation: the nuclear generation of adenosine triphosphate (ATP) 
(Wright, Lioutas et al. 2016). The remodelling of chromatin which accompanies 
DNA transcription, replication and repair requires the activities of ATP-consuming 
enzymes. In this study, the authors demonstrated that ATP can be generated by 
the nuclear enzyme NUDIX5 (nucleoside diphosphate linked moiety X hydrolase 
5) from pyrophosphate and free ADP-ribose (the product of PARG-mediated 
hydrolysis of PAR) (Wright, Lioutas et al. 2016). The authors further demonstrate 
than when this mechanism is perturbed by inhibition of PARP1, PARG or 
NUDIX5, there is a reduction in chromatin modelling associated with 
progesterone-induced gene expression. The authors postulate that the nuclear 
ATP generation might also be required for repair processes, and that PAR may 
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therefore serve as a means of concentrating ATP generation at sites of DNA 
damage (Wright, Lioutas et al. 2016). 
 
Independently of its role as a SSB sensor, PARP1 has been implicated in 
the tolerance of replication, following initial immunofluorescence experiments 
which demonstrated colocalization of PARP1 with replication foci in S-phase cells 
stress (Sugimura, Takebayashi et al. 2008, Bryant, Petermann et al. 2009). This 
was followed by observations that inhibition, knockdown or genetic loss of PARP1 
prevents the replication fork restart following Top1 poisoning by CPT (Sugimura, 
Takebayashi et al. 2008, Berti, Ray Chaudhuri et al. 2013) or depletion of the 
dNTP pool by hydroxyurea (HU) (Bryant, Petermann et al. 2009). This effect was 
found to be epistatic with loss of the HR nuclease MRE11, leading the authors to 
propose that PARP1 promotes MRE11 recruitment to stalled replication forks 
which promotes their restart via HR (Bryant, Petermann et al. 2009). Interestingly, 
it was seen that depletion of either PARP1 or PARP2 significantly reduced 
recombination at replication forks stalled by HU or thymidine (dT), and increased 
sensitivity to these agents in a non-additive manner, suggesting that the two 
proteins may collaborate in promoting replication stress tolerance (Bryant, 
Petermann et al. 2009).  
 
1.5.2.1.2. PARP2 
Parp2 (PARP2 in humans) was the second of the PARP/ARTD gene family to be 
identified, following the observation of residual PAR synthesis in Parp1-/- MEFS 
(Amé, Rolli et al. 1999). PARP2 protein shares significant homology (62% 
identical or similar amino acids) with the C-terminal half of PARP1; including the 
WGR domain, HD, and ART domain (NCBI 2016). The homology is even more 
pronounced when considering only the active site region (amino acids 859 to 908 
of PARP1) of the ART domain (92% identical or similar amino acids) (NCBI 2016). 
This explains the strikingly similar products of PARP1 and PARP2 catalytic 
activity: branched, high molecular weight PAR (Amé, Rolli et al. 1999).  
 
 PARP2 lacks the ~500aa N-terminal region (NTR) of PARP1, containing 
the ZFDs (Fig. 1.6.) (NCBI 2016). Instead, it has an NTR of only 78 aa, the 
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function of which is unclear. The lack of the ZFDs means that PARP2 relies more 
than PARP1 on its WGR and CAT domains, in addition to its NTR, for 
DNA-binding (Riccio, Cingolani et al. 2016). The NTR is natively disordered, as 
evidenced by circular dichroism and limited proteolysis experiments (Riccio, 
Cingolani et al. 2016); and contains a bipartite NLS, which has been 
characterized by X-ray crystallography (Riccio, Cingolani et al. 2016). Recently, 
Riccio et al reported that the NTR contributes significantly to DNA binding in vitro, 
especially to nicked SSB substrates (Riccio, Cingolani et al. 2016). This is evident 
from the 358-fold loss of affinity for a nicked dumbbell oligonucleotide of the 
ΔNTR truncation (Kd =13.3 µM) relative to full length (FL) PARP2 (Kd = 37 nM) 
(Riccio, Cingolani et al. 2016). Additionally, the isolated NTR has significantly 
higher affinity for DSB, nicked SSB and gapped SSB substrates than the isolated 
WGR or CAT domain, in vitro (Riccio, Cingolani et al. 2016). However, 
GFP-tagged NTR is unable to be recruited to laser microirradiated sites; unlike 
the ΔNTR truncation, which displays kinetics similar to FL PARP2 (Riccio, 
Cingolani et al. 2016). These discrepancies between in vitro and in vivo 
experiments may reflect differences in break recognition in chromatin vs naked 
DNA, and will require further study.  
 
 Despite the structural differences between PARP1 and PARP2, 
biologically-relevant functional differences remain unclear. It is known that 
Parp1-/- and Parp2-/- mice are viable, but embryonic fibroblasts from both display 
sensitivity to IR and alkylating agents (Ménissier de Murcia, Ricoul et al. 2003). 
Parp1-/-/Parp2-/- mice, by comparison, are not viable, with embryogenesis 
arresting around the onset of gastrulation  (embryonic day 6; E6) (Ménissier de 
Murcia, Ricoul et al. 2003). This result suggests that PARP1 and PARP2 may 
fulfil overlapping or redundant roles during unperturbed embryogenesis. 
 
 Recent work has suggested that whereas PARP1 displays broad 
recognition of strand breaks with diverse termini, PARP2 is preferentially 
activated by 5’-phosphorylated breaks, a property that it shares with PARP3 
(Langelier, Riccio et al. 2014). This led Langelier et al to propose a role for PARP2 
in the late stages of break repair, immediately prior to ligation (Langelier, Riccio 
et al. 2014). It was further suggested that this might involve a final burst of 
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PARylation as a signal to recruit or stimulate ligase complexes for the ligation 
reaction (see section 1.5.2.4). Whilst this is perhaps an appealing hypothesis, 
there are several discrepancies. For example, PARP1 is also highly stimulated 
by 5’-phosphorylated breaks, and would presumably also be able to fulfil the 
proposed role. As noted above, Parp2-/- mice are viable; further suggesting that 
the proposed role is not essential in vivo.  
 
 In addition to differences in break recognition specificity, it has been 
suggested that PARP1 and PARP2 may also differ in terms of protein substrate 
preference (Oliver, Amé et al. 2004) (Messner, Altmeyer et al. 2010). Structural 
evidence for this hypothesis stems from the fact that the PARP2 catalytic domain, 
whilst being largely homologous to that of PARP1, possesses a three-amino acid 
insertion, resulting in an extended six-residue deviation from the backbone 
observed in the PARP1 (Oliver, Ame et al. 2004). Within this loop, Tyr528 points 
directly into the acceptor site. This is not predicted to affect 
ADP-ribosyltransferase activity on ADP-ribose acceptors (e.g 
poly(ADP-ribosyl)ation activity) but it may confer a different protein acceptor 
specificity (Oliver, Ame et al. 2004). Despite these structural predictions, 
biochemical evidence of differing protein substrate specificity for PARP1 and 
PARP2 is lacking. One recent study employed a chemical genetics and 
proteomics strategy to identify the proteins specifically ADP-ribosylated by 
PARP1, PARP2 or PARP3 (Gibson, Zhang et al. 2016). This innovative approach 
enabled the authors to assess the degree of overlap between the protein targets 
of these three enzymes. However, there are a number of caveats to this work. 
Firstly, due to the impermeability of the cell membrane to the NAD analogs 
employed in the technique, the experiments were undertaken in vitro using 
recombinant PARPs and cell extracts. This may limit how accurately the data 
reflect the physiological activity of the enzymes in vivo. Secondly, the technique 
was limited to identifying ADP-ribosylated glutamate and aspartate residues. 
Given the fact that other residues are known to be acceptors of ADP-ribosylation, 
including lysine, arginine, and serine; the ADP-ribosylated proteome identified in 
the study is unlikely to be exhaustive. Future work will be required to fully 
elucidate the protein targets of the DNA-dependent PARPs in vivo.  
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1.5.2.1.3. PARP3 
PARP3 was the third of the DNA break-stimulated ARTD/PARP family to be 
identified, being shown to be stimulated by DSBs in vitro and being implicated in 
promoting XRCC4-Lig4 function in NHEJ (see section 1.4.1) (Rulten, Fisher et al. 
2011). Subsequently it was revealed that PARP3 is even more potently 
stimulated by 5’-phosphorylated SSBs than by DSBs in vitro (Grundy, Polo et al. 
2016). Grundy and Polo et al were able to show that PARP3 specifically 
transmodifies H2B, primarily at Glu2, in response to a restriction 
enzyme-mediated single strand break. Furthermore, they showed that PARP3 
stimulation was dependent on the break being 5’-phosphorylated, supporting the 
findings of Langelier et al (Langelier, Riccio et al. 2014). NMR observations of 
chemical shift perturbations in the WGR domain, upon addition of an 
oligonucleotide harbouring a 5’-phosphorylated nick, allowed a model of binding 
to be proposed (Grundy, Polo et al. 2016). In this model, the DNA resides on one 
face of the WGR domain, interacting with a basic patch that is highly conserved 
amongst PARP3 orthologs. Interestingly, important residues of this basic patch 
(Y83, R103, K127, and K149) are conserved with PARP2 (Grundy, Polo et al. 
2016), suggesting that this may be the DNA-binding interface in both enzymes.  
 
 Based on conservation between PARP1-3 of a triad of residues in the 
active site (H887, Y919 and E988), amongst other structural features, PARP3 
was previously predicted to exhibit poly(ADP-ribose) polymerase activity (Kleine, 
Poreba et al. 2008). It has been subsequently demonstrated that this is not the 
case and that PARP3 functions as a mono(ADP-ribose) transferase in vivo and 
in vitro (Loseva, Jemth et al. 2010, Vyas, Matic et al. 2014, Grundy, Polo et al. 
2016). The functional consequences of this for PARP3-mediated DNA damage 
signalling remain to be fully understood. More generally, the potential role of 
PARP3 in SSBR remains to be fully elucidated. Experiments in chicken DT40 
cells have confirmed that stable depletion of PARP3 slows repair of γ-radiation 
induced SSBs (Grundy, Polo et al. 2016), but as chickens lack a PARP2 gene it 
is unclear to what extent this represents the role of PARP3 in humans. 
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1.5.2.1.4. ADP-ribose binding domains 
In addition to the chromatin decondensation mediated by auto-PARylation and 
PARylation of H1 (see section 1.5.2.1.1), ADP-ribosylation of core histones and 
other local proteins serves as a signal for the recruitment of factors involved in 
chromatin remodelling and DNA repair (Althaus, Kleczkowska et al. 1999). There 
are several types of protein domains which have been reported to bind to 
ADP-ribose PTMs, including: Macro domain, Trp-Trp-Glu (WWE) domain, 
PAR-binding zinc finger (PBZ) motif, PAR-binding motif (PBM), BRCA1 C-
terminal (BRCT) domain, OB-fold, and forkhead-associated (FHA) domain 
(Malanga, Pleschke et al. 1998, Pleschke, Kleczkowska et al. 2000, Karras, 
Kustatscher et al. 2005, Ahel, Ahel et al. 2008, Kang, Lee et al. 2011, Zhang, Liu 
et al. 2011, Barkauskaite, Jankevicius et al. 2013, Li, Lu et al. 2013, Zhang, Chen 
et al. 2014, Breslin, Hornyak et al. 2015). These domains recognize different 
moieties of MAR and/or PAR (Fig. 1.5.), and are contained in effector proteins 
with diverse roles in many signalling pathways. The most well described of these 
domains (PBM, PBZ, Macro domain, and WWE domain), along with the novel 
PAR-binding BRCT domain of the core BER/SSBR scaffolding protein X-ray 
cross-complementing protein 1 (XRCC1), will be discussed below.  
 
The first of the PAR-binding modules to be identified was the PBM 
(Malanga, Pleschke et al. 1998), a domain of 22-25 amino acids which has now 
been identified in many nuclear proteins; including the core and linker histones, 
and proteins involved in BER/SSBR, NER, HR, NHEJ and the DDR (Gagné, 
Isabelle et al. 2008, Teloni and Altmeyer 2016). This flexible motif lacks any strict 
consensus sequence, but has been proposed to generally conform to: 
[HKR][X][X][AIQVY][KR][KR][AILV][FILPV] (Gagné, Isabelle et al. 2008, 
Barkauskaite, Jankevicius et al. 2013). The flexibility of this domain has precluded 
structural work, preventing identification of the PAR moiety to which it binds. By 
comparison, the PBZ, Macro domain, and WWE domain all bind to well defined 
moieties of PAR.  
 
The second of the PAR binding domains to be identified was the macro 
domain, a globular protein domain of 130-190 amino acids, which interacts with 
ADP-ribose in various metabolites, including PAR (Karras, Kustatscher et al. 
31 
 
2005, Teloni and Altmeyer 2016). These domains are found in the macro histone 
variants macroH2A1.1, macroH2A1.2, and macroH2A2, as well as in some 
members of the ARTD family (PARP9, PARP14, and PARP15) (Teloni and 
Altmeyer 2016). Because these domains are modular and contain a ADP-ribose 
binding pocket, some have evolved catalytic activity (Chen, Vollmar et al. 2011). 
This includes Macro domains which can degrade PAR, such as that found in 
MacroD1, MacroD2, and OARD1 (Peterson, Chen et al. 2011). The structure of 
the macroH2A1.1 macrodomain, in complex with ADP-ribose, has been solved 
by x-ray crystallography (Timinszky, Till et al. 2009). Significant interactions were 
observed between the 2-OH’ and 3’-OH of the adenosine ribose with D352 and 
S355; which has led to suggestions that macrodomains cap PAR chains, rather 
than interacting with non-terminal ADP-ribose units (Timinszky, Till et al. 2009). 
This binding mode also allows macrodomains to interact with MAR, making them 
unique amongst the ADP-ribose binding domains, and allowing the catalytic 
macrodomains to remove terminal protein-linked ADP-ribose units (Jankevicius, 
Hassler et al. 2013, Rosenthal, Feijs et al. 2013). 
Three years following the identification of the macro domain as a PAR 
binding domain, the PBZ was identified (Ahel, Ahel et al. 2008). The PBZ is a 
comparable size to the PBM (<30 residues); but with a well-defined structure, 
which has been solved by NMR and X-ray crystallography (Eustermann, 
Brockmann et al. 2010, Isogai, Kanno et al. 2010, Li, McCulloch et al. 2010, 
Oberoi, Richards et al. 2010). The consensus sequence 
([K/R]-X-X-C-X-[F/Y]-G-X-X-C-X-[K/R]-[K/R]- X-X-X-X-H-X-X-X-[F/Y]-X-H) has 
been identified in only three human proteins: Aprataxin and PNKP-like factor 
(APLF), checkpoint with forkhead and ring finger domains (CHFR), and DNA 
crosslink repair protein 1A (DCLRE1A) (Ahel, Ahel et al. 2008). Of these, only the 
APLF and CHFR PBZ motifs have been shown to bind PAR; the DCLRE1A PBZ 
is predicted not to (Oberoi, Richards et al. 2010). The relative rarity of the PBZ is 
notable in comparison to the ubiquitous PBM. The PBZ is also unique in that it 
appears to bind to the ADP-ribose-adenosine moiety of a consecutive residues 
(Eustermann, Brockmann et al. 2010, Li, McCulloch et al. 2010).  
 
Another three years from the discovery of the PBZ, the WWE domain was 
identified as a PAR binding domain (Kang, Lee et al. 2011, Zhang, Liu et al. 
32 
 
2011).This globular domain of ~80 amino acids, has since been identified in 12 
human proteins, in two classes (Kang, Lee et al. 2011, Zhang, Liu et al. 2011, 
Wang, Michaud et al. 2012, Teloni and Altmeyer 2016). The first class is those 
that are present in a subgroup of the ARTD/PARP family (PARP7, PARP11, 
PARP12, and PARP14); notably these are all incapable of generating PAR 
(Wang, Michaud et al. 2012). The second class is made up of nine ubiquitin 
ligases of several types, including the PAR-dependent E3 ligase RNF146/Iduna 
(Wang, Michaud et al. 2012). This protein is particularly notable, as it binds to 
PARP1, PARP2, and XRCC1, amongst other repair proteins and chromatin 
factors (Kang, Lee et al. 2011). The WWE domain has been shown to bind to the 
iso-ADP-ribose moiety of PAR, which contains moieties of consecutive 
ADP-ribose residues (Wang, Michaud et al. 2012). This domain is therefore 
unable to bind MAR.  
 
The identification of not one, but four unique PAR-binding domains, 
appeared to explain the PAR-dependent recruitment kinetics of many DNA repair 
and DDR proteins, including the crucial SSBR factor XRCC1, which possesses a 
putative PBM. However, this was not the case. In the following section, the history 
of XRCC1 research will be reviewed, including the elucidation of its true 
PAR-binding domain.  
 
1.5.2.2. XRCC1  
XRCC1 was originally identified (Thompson, Brookman et al. 1985) and cloned 
(Thompson, Brookman et al. 1990) by complementation of a mutant Chinese 
hamster ovary (CHO) cell line designated EM9. These cells were originally shown 
to be extremely sensitive to alkylating agents, to have attenuated rates of DNA 
strand break repair, and have a dramatically elevated frequency of sister 
chromatid exchanges (SCEs) (Thompson, Brookman et al. 1982). Subsequently, 
they have also been found to be sensitive to many other DNA-damaging agents, 
including: H2O2 (Cantoni, Murray et al. 1987), CPT (Caldecott and Jeggo 1991), 
IR (Thompson, Brookman et al. 1990), amongst others. The XRCC1 locus was 
sequenced in EM9 cells and a point mutation was identified which substitutes 
Gln221 for a stop codon, truncating the protein approximately 1/3rd into the CDS. 
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Figure 1.8. The domain structure and interacting partners of XRCC1. The 
domain structure of XRCC1 is depicted, along with the known regions of 
interaction with other protein partners [adapted from (Hanssen-Bauer, 
Solvang-Garten et al. 2012)] (A). A crystal structure of the central BRCT I 
domain is shown; with highlighted residues comprising the phosphate-binding 
pocket, which mediates interaction with PAR [taken from (Breslin, Hornyak et 
al. 2015)] (B). Crystal structures of the XRCC1-NTD:Polβ-CD and the XRCC1-
BRCTII:Lig3-BRCT interfaces are shown in (C) and (D), respectively [taken 
from (Cuneo and London 2010) and (Cuneo, Gabel et al. 2011), respectively]. 
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This truncated polypeptide is presumably degraded by nonsense-mediated 
decay (NMD), as no XRCC1 is detected by WB. This cell line has been the 
predominant model of XRCC1 deficiency since its original identification thirty-five 
years ago. 
 
XRCC1 is rapidly recruited to sites of SSBs; acting as a scaffolding protein 
which recruits, stabilizes and stimulates enzymes involved in end-processing 
(see section 1.5.2.3), gap-filling and ligation (see section 1.5.2.4) (Fig. 1.8.) 
(Caldecott 2008). The rapid recruitment of XRCC1 to DNA damage sites led to 
hypotheses of PAR-binding. As mentioned above, this was originally ascribed to 
the C-terminal region of the BRCT I domain, which contains a putative PBM 
(Pleschke, Kleczkowska et al. 2000). However, mutation of five of the basic 
residues in the motif to alanine failed to impact on XRCC1 function (C. Breslin, 
unpublished observations). Furthermore, subsequent studies have demonstrated 
the importance of a conserved phosphate-binding pocket upstream of the 
putative PBM, in the centre of the BRCT I domain (Li, Lu et al. 2013, Breslin, 
Hornyak et al. 2015). Mutation of two constituent residues which are predicted to 
be involved in phosphate binding, Arg335 and Lys369, leads to: attenuated 
PAR-binding in vitro, reduced accumulation at sites of UVA laser and 
H2O2-induced damage, and cellular sensitivity to MMS and H2O2 (Breslin, 
Hornyak et al. 2015). Whilst the exact moiety to which this BRCT-domain binds 
has not been identified, it appears to be specific to PAR. This is evidenced by the 
inability of excess MAR to compete with WT XRCC1161-406 binding to adsorbed, 
PARylated PARP1 or H1 (Breslin, Hornyak et al. 2015). By comparison, 
auto-PARylated PARP1 could compete with this binding. Interestingly, mutant 
(R335A, K369A) XRCC1161-406 was still able to bind to adsorbed proteins which 
had been PARylated with an excessive NAD+ concentration (Breslin, Hornyak et 
al. 2015). This may suggest that there are other motifs which contribute to XRCC1 
PAR-binding, perhaps including the putative PBM described above.  
 
XRCC1 is thought to adopt a rod-like structure in solution (Mani, Karimi-
Busheri et al. 2004); which has been proposed to be characteristic of other 
proteins with multiple BRCT domains, often fulfilling scaffolding roles (Williams, 
Green et al. 2001). The proposed rod-like structure is thought to extend the 
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surface area for interaction with other proteins. Many of these protein-protein 
interfaces have been mapped to specific regions of XRCC1 (Fig. 1.8.). One such 
interaction is of the XRCC1 CTD with Lig3α (see section 1.5.2.4). This is a 
constitutive interaction, being unaffected by DNA damage induction; and 
significantly stabilizes Lig3α, such that loss of XRCC1 results in an ~80% 
reduction in Lig3α levels (Caldecott, Tucker et al. 1995). The NTD of XRCC1 
interacts with the nucleotide-binding thumb domain of repair polymerase Polβ, 
facilitating the recruitment of this end-processing (see section 1.5.2.3.4) and 
gap-filling (see section 1.5.2.4) enzyme to DNA breaks. XRCC1 also interacts 
with the end-processing factors Aprataxin (see section 1.5.2.3.5) and PNKP (see 
section 1.5.2.3.2), and the more recently identified partner Aprataxin and 
PNKP-like factor (APLF) (Whitehouse, Taylor et al. 2001, Clements, Breslin et al. 
2004, Loizou, El-Khamisy et al. 2004, Iles, Rulten et al. 2007).  These interactions 
are mediated by the forkhead associated (FHA) domains of Aprataxin, PNKP and 
APLF; which bind to a phosphorylated region of XRCC1 in the linker region 
between the central BRCT I and C-terminal BRCT II domains. This region 
contains eight serine/threonine phosphorylation consensus sites for the 
constitutively-expressed casein kinase 2 (CK2) (Kubota, Nash et al. 1996). The 
phosphorylation marks are independent of DNA-damage, and appear to be 
constitutive (Luo, Chan et al. 2004). The binding of one FHA domain-containing 
partner is thought to preclude interaction with the others; suggesting that XRCC1 
forms distinct complexes in cells (Luo, Chan et al. 2004).  
 
The BRCT I domain of XRCC1 has been previously reported to interact 
with the PARP1 BRCT domain, in a PAR-independent fashion (Masson, 
Niedergang et al. 1998, Beernink, Hwang et al. 2005). However, other reports 
have contradicted this (Loeffler, Cuneo et al. 2011, Kim, Stegeman et al. 2015), 
and the consensus now is that the XRCC1-PARP1 interaction is mediated largely 
or entirely by PAR (London 2015). 
 
XRCC1 has been reported to interact with various glycosylases (Marsin, 
Vidal et al. 2003, Campalans, Marsin et al. 2005, Akbari, Solvang-Garten et al. 
2010, Hegde, Hegde et al. 2012) involved in base excision repair (see section 
1.5.1), and with APE1 (Vidal, Boiteux et al. 2001). Some of these interactions 
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have been suggested to be direct, whilst others are likely to occur via interaction 
with other partners of XRCC1. In this way, products of BER are thought to be 
passed directly to the SSBR system (Wilson and Kunkel 2000). The interaction 
with APE-1 may also serve to recruit this enzyme in its role of end-processing at 
3’-phosphoglyocolate and 3’-phosphoglycolaldehyde SSB termini (see section 
1.2.1). 
 
In addition to promoting the PAR-dependent recruitment of SSBR factors 
at DNA strand breaks, in vitro reconstitution of SSBR reactions has revealed that 
XRCC1 also stimulates the overall reaction (Whitehouse, Taylor et al. 2001). In 
these experiments, the activity of the core SSBR complex containing XRCC1, 
Polβ, PNKP, and Lig3α was investigated using a DNA substrate harbouring 
5’-hydroxyl and 3’-phosphate termini and a one bp gap. As shall be discussed 
below in detail (see section 1.5.2.3), this substrate requires the activities of PNKP, 
Polβ and Lig3α to be successfully repaired. Omission of XRCC1 from these 
reactions significantly slowed the completion of SSBR when the concentrations 
of the other factors were limiting. Intriguingly, this was not the case when 
employing a substrate with canonical termini. As this substrate does not require 
the activity of PNKP, this suggested that XRCC1 predominately stimulates PNKP 
activity, which was confirmed with further experiments (Whitehouse, Taylor et al. 
2001). 
 
 In this section, XRCC1 has been introduced as a scaffolding protein which 
helps to recruit and stimulate the activities of enzymes required for the 
end-processing, gap-filling and ligation of SSBs. In the following sections, these 
enzymes will be discussed in more detail, beginning with the most 
enzymatically-diverse of the three stages: end-processing. 
 
1.5.2.3. End-processing  
As discussed above, single strand breaks from various sources rarely contain 
canonical termini. This necessitates a host of enzymes to process these termini 
prior to gap-filling and ligation steps, many of which are interaction partners of 
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Figure 1.9. Simplified model of the end-processing enzymatic activities 
required for the BER/SSBR of different lesions. SSBs can arise directly or 
indirectly as a result of various agents. Direct SSBs can arise by reaction of 
reactive oxygen species (ROS) with the deoxyribose phosphate moiety of 
DNA, or the through cleavage by Top1. Alternatively, DNA bases are 
susceptible to oxidation, alkylation or deamination, producing non-canonical 
bases which are the substrates of BER (A). ROS-induced direct SSBs often 
have a canonical 5’-phosphate (P) terminus and a non-canonical 3’-
phosphoglycolate (PG), 3’-phosphoglycolaldehyde (PGA) or 3’-phosphate (P) 
terminus. By comparison, Top1-induced direct SSBs have non-canonical 5’-
hydroxyl (OH) and non-canonical 3’-Top1 peptide termini. ROS-induced 
indirect SSBs result from the dual glycosylase and endonuclease activities of 
OGG1, NTH1, NEIL1, NEIL2 or NEIL3 at oxidized bases. These bifunctional 
glycosylases produce a canonical 5’-phosphate terminus and either a non-
canonical 3’-phospho α,β-unsaturated aldehyde (PUA) terminus (OGG1 and 
NTH1), or a non-canonical 3’-phosphate terminus (NEIL1, NEIL2 and NEIL3). 
By comparison, the monofunctional glycosylases (UNG, SMUG1, TDG, 
MBD4, MPG and MUTYH) are variously responsible for excision of alkylated 
bases, deaminated bases, and misincorporated ribonucleotides and 
deoxyribonucleotides. The glycosylation activity of these enzymes produces 
an apurinic/apyrimidinic (AP) site, which is the substrate of the AP 
endonuclease (APE1). APE1 generates a SSB with a non-canonical 5’-
deoxyribose phosphate (dRP) terminus and a canonical 3’-hydroxyl terminus. 
(B). 3’-PG, 3’-PGA and 3’-PUA termini are substrates for APE1 and tyrosyl-
DNA phosphodiesterase 1 (TDP1). The 5’-dRP terminus is a substrate for DNA 
polymerase β (Polβ). 3’-Top1 peptide termini are substrates for TDP1. 5’-OH 
and 3’-P termini are substrates for the dual activities of polynucleotide kinase 
3’-phosphatase (PNKP). Finally, the 5’-adenosine monophosphate (AMP) 
terminus that can result from abortive ligation is a substrate for Aprataxin. 
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XRCC1 (Fig. 1.8.). An overview of the enzymatic activities required for the repair 
of some common damaged termini is shown in (Fig. 1.9.). 
 
Three enzymes are implicated in processing blocked termini which result 
from direct oxidation of the dRP moiety of DNA: APE1, PNKP, and tyrosyl-DNA 
phosphodiesterase 1 (TDP1).  These enzymes are also involved in processing 
blocked termini which result from excision of oxidized bases by the bifunctional 
glycosylases. By comparison, the 5’-dRP terminus which results from base 
excision by the monofunctional glycosylases and the subsequent endonuclease 
activity of APE1 requires processing by DNA polymerase β (Polβ).  The blocked 
terminus which results from abortive Top1 activity is processed by proteolysis 
and the activities of TDP1 and PNKP. Finally, a special type of damaged 
terminus, which result from abortive ligation, is processed by APTX. These end-
processing enzymes, and the reactions they catalyse, will be discussed in more 
detail below. 
 
1.5.2.3.1. APE1 
The first definitive proof of an endonuclease activity specific for AP sites was in 
1972 (Paquette, Crine et al. 1972, Verly and Paquette 1972), following 
observations of this  activity copurifying with E. coli endonuclease II preparations 
(Hadi and Goldthwait 1971).  This AP endonuclease (APE) activity was 
subsequently demonstrated to belong to the previously characterized 
exonuclease III (ExoIII) (Weiss 1976, Lindahl 1979). E. coli xth- mutants, which 
are deficient for ExoIII, retain a residual level of APE activity that was attributed 
to another enzyme: endonuclease IV (EndoIV), encoded by the gene nfo. 
Homologs of ExoIII and EndoIV are now known to make up two types of APEs 
which exist throughout all domains of life. ExoIII-like APEs constitute the major 
APE activity in E. coli and most studied eukaryotes; many of which, including 
mammals, lack an EndoIV-like APE (Hadi and Wilson 2000).  
 
In addition to its APE activity at intact AP sites, ExoIII-like human APE1 
also possesses an ~200-fold lower activity for hydrolysis of 3’-P, 3’-PG, 3’-PGA 
and 3’-PUA termini in vitro (Chen, Herman et al. 1991), and is thus implicated in 
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processing 3’-termini of direct ROS-induced SSBs and those generated by the 
AP lyase activity of the bifunctional glycosylases (Fig. 1.9.) (Wallace 1998, Evans, 
Limp-Foster et al. 2000, Hegde, Hazra et al. 2008).   
 
Human APE1 is a ~35 KDa protein, composed of a 61 aa N-terminal 
extension linked to a globular α/β region composed of two domains (Gorman, 
Morera et al. 1997). The globular region shares structural homology with E. coli 
ExoIII and DNAse I. APE1 and ExoIII share similar loop motifs which are notably 
absent in DNAse I, which led to the hypothesis that these loops were responsible 
for the DNA substrate specificity of APE1 and ExoIII, compared to DNAse I, which 
is highly promiscuous (Gorman, Morera et al. 1997). This hypothesis was 
subsequently proven correct when it was shown that APE1 inserts its loop motifs 
into both the major and minor groove of DNA, coordinating the AP-site in such a 
way as to exclude DNA bases (Mol, Izumi et al. 2000). The absence of APE-1 
leads to early embryonic lethality in mice (Xanthoudakis, Smeyne et al. 1996) and 
induces apoptosis within 24 h at the cellular level (Izumi, Brown et al. 2005), 
highlighting the importance of APE1 in BER and SSBR. 
As noted above, APE1 is able to process a range of 3’-termini, including 
the 3’-phosphate terminus in vitro (Chen, Herman et al. 1991). However, the 
kinetics of APE1 3’-phosphatase activity are very slow, with a turnover number 
(kcat) of ~0.03 min -1  (Wiederhold, Leppard et al. 2004). Indeed, APE1 is not the 
dominant 3’-phosphatase in cells. This is the role of PNKP, which will be 
discussed below. 
 
1.5.2.3.2. PNKP 
The first enzymes to be identified which were capable of phosphorylating RNA 
and DNA 5’-hydroxyl termini were found in the bacteriophages T2 and T4 
(Novogrodsky and Hurwitz 1966), which was followed in quick succession by the 
identification of a comparable activity in rat liver nuclei (Novogrodsky, Tal et al. 
1966). The T4 polynucleotide kinase (PNK) became widely employed in the 
radiolabelling of nucleic acids with 32P for use in downstream applications, 
including early methods for sequencing DNA (Maxam and Gilbert 1977). Over ten 
years after the identification of T4 PNK, it was discovered that the enzyme also 
38 
 
catalysed another reaction: the removal of phosphate from a 3’-phosphate 
terminus (Cameron and Uhlenbeck 1977), which is a feature common to 
mammalian PNK orthologs, including the 57 KDa human enzyme, PNKP (Karimi-
Busheri, Daly et al. 1999). The possession of both 3’-DNA phosphatase and 
5’-DNA kinase activities makes PNKP a critical end-processing enzyme, required 
not only in the repair of direct oxidative SSBs; but also in those arising as 
intermediates in BER and following abortive Top1 activity (Fig. 1.9.).  
 
Mammalian PNKPs are comprised of an N-terminal forkhead-associated 
(FHA) domain joined via a flexible linker to tandem kinase and phosphatase 
domains at the C-terminus (Bernstein, Williams et al. 2005). This bipartite C-
terminal domain shares homology with that of T4 PNK (Wang, Lima et al. 2002), 
although in T4 the phosphatase domain is C-terminal to the kinase domain. The 
kinase domain of mammalian PNKP differs from that of T4 PNK, in that it has a 
wider nucleic acid binding cleft, which is able to accommodate a double-stranded 
DNA substrate (Bernstein, Williams et al. 2005) and therefore prefers to 
phosphorylate 5’-hydroxyl termini at DNA nicks, gaps, and DSBs with 3’- single-
stranded overhangs (Karimi-Busheri and Weinfeld 1997, Bernstein, Hammel et 
al. 2009). The PNKP phosphatase domain is similarly able to act on double-
stranded DNA substrates, but unlike the kinase domain it lacks a substrate cleft 
wide enough to accommodate these substrates without prior DNA denaturation 
and/or protein conformational change (Bernstein, Williams et al. 2005, Havali-
Shahriari, Weinfeld et al. 2017). The N-terminal FHA domain, which is absent in 
T4 PNK, mediates the interaction of mammalian PNKP not only with the 
phosphorylated CK2 sites of XRCC1 (see section 1.5.2.2) (Whitehouse, Taylor 
et al. 2001), but also with the similar sites in the NHEJ protein XRCC4 (Koch, 
Agyei et al. 2004) (see section 1.4.1). This promotes its recruitment to DSBs, 
which also often harbour 5’-hydroxyl and 3’-phosphate termini requiring repair 
(Chappell, Hanakahi et al. 2002). 
 
The ubiquitous role of PNKP in many BER/SSBR sub-pathways (Fig. 1.9.) 
explains how its depletion results in cellular sensitivity to such a wide range of 
genotoxic agents, including: IR, CPT, H2O2, and MMS (Rasouli-Nia, Karimi-
Busheri et al. 2004). Moreover, in unchallenged cells, PNKP depletion results in 
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an approximately seven-fold increased frequency of spontaneous mutation 
(Rasouli-Nia, Karimi-Busheri et al. 2004), highlighting its importance for the 
maintenance of genome integrity. More recently, hypomorphic PNKP mutations 
have been identified in patients with the neurological disease microcephaly, 
seizures, and developmental delay (MCSZ) (Shen, Gilmore et al. 2010), and in 
the neurodegenerative disease ataxia with oculomotor apraxia type 4 (AOA4) 
(Bras, Alonso et al. 2015), which will be discussed in detail in section 1.6.2. 
 
PNKP is unlike APE1 in that it is apparently unable to process a broad 
range of 3’-termini (Wiederhold, Leppard et al. 2004) (Inamdar, Pouliot et al. 
2002). However, there is another human 3’-end processing enzyme with broad 
substrate specificity: TDP1. This enzyme will be discussed in detail below. 
  
1.5.2.3.3. TDP1  
TDP1 was first cloned in 1999 (Pouliot, Yao et al. 1999), three years after 
researchers purified an enzyme capable of hydrolysing DNA 3’-phosphotyrosyl 
bonds in S. cerevisiae (Yang, Burgin et al. 1996). These initial publications 
identified the importance of TDP1 in the repair of abortive Top1-linked SSBs, 
because inactivating mutations in the gene sensitised HR-compromised cells to 
the Top1 poison CPT (Pouliot, Yao et al. 1999). Subsequent work has further 
improved our understanding of the role of TDP1 both in the repair of Top1-SSBs, 
and in the repair of other types of SSBs. 
 
SSBs which arise as a result of abortive Top1 activity (see section 1.2.3) 
possess unique polypeptide-linked 3’-termini. Following Cullin 3-dependent 
polyubiquitylation (Desai, Liu et al. 1997), these Top1 polypeptides are degraded 
by the proteasome (Zhang, Tomida et al. 2004). Both the CPT-induced 
polyubiquitylation and degradation of Top1 seem to be dependent upon 
transcription, rather than replication, as they are blocked by inhibitors of the 
former (DRB and α-amanitin), but not the latter (aphidicolin) (Desai, Liu et al. 
1997, Desai, Zhang et al. 2003, Lin, Ban et al. 2008). Using the expression of 
dominant negative ubiquitin mutants, polyubiquitylation was shown to occur via 
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K48-ubiquitin linkages (Lin, Ban et al. 2008), which are known to serve as a 
molecular signal for degradation by the 26S proteasome (Pickart 1997).  
 
Following degradation of Top1 to an oligopeptide, TDP1 can catalyse 
cleavage of the  3’-tyrosyl phosphodiester bond (Yang, Burgin et al. 1996, Pouliot, 
Yao et al. 1999). In vitro activity assays have shown that TDP1 has very low 
cleavage activity upon the full length Top1cc, instead preferring oligopeptide 
substrates < 13 amino acids in length (Debethune, Kohlhagen et al. 2002). This 
can be rationalised by the inaccessibility of the Top1 active site, and therefore 
the DNA-tyrosyl phosphodiester linkage, in the native Top1cc structure (Redinbo, 
Stewart et al. 1998). TDP1 is a member of the phospholipase D (PLD) 
superfamily, and has been shown to be widely conserved amongst eukaryotic 
organisms (Pouliot, Yao et al. 1999, El-Khamisy and Caldecott 2006), since its 
original discovery in S. cerevisiae. The PLD superfamily catalyse phosphoryl 
transferase reactions, fulfilling diverse roles in all domains of life (Interthal, Pouliot 
et al. 2001). These PLD enzymes typically contain two copies of a 
highly-conserved active site motif: HXK(X)4D(X)6GSXN. Human TDP1, and its 
orthologs, possess unusual “HKD” motifs, in that the aspartate residue is not 
conserved. The histidine and lysine residues are conserved, however, and their 
mutation has been shown to dramatically attenuate TDP1 activity in vitro 
(Interthal, Pouliot et al. 2001). Interestingly, similar to other PLD enzymes, the 
TDP1 catalytic mechanism has been shown to proceed via 
3’-phosphohistidyl-DNA covalent intermediate, which is subsequently hydrolysed 
by nucleophilic attack of an activated water molecule (Interthal, Pouliot et al. 
2001). The histidines of the two HKD motifs are crucial for both steps. H263 is 
the nucleophile which attacks the 3’-phosphotyrosyl linkage in the first step; with 
protonated H493 acting as a general acid catalyst by protonating the tyrosine 
oxygen. Subsequently, H493 acts as a general base in the activation of the 
second nucleophile: water. Interestingly, H493 is the mutated residue in the 
hereditary neurodegenerative disease spinocerebellar ataxia with axonal 
neuropathy (SCAN1) (see section 1.6.2).  
 
The product of TDP1 activity is a 3’-phosphate terminus which, along with 
the 5’-hydroxyl terminus generated initially by Top1 incision, requires the activity 
41 
 
of PNKP to be converted to a canonical terminus. In addition to its tyrosyl 
phosphodiesterase activity, TDP1 is also able to process other 3’-termini in vitro, 
including 3’-phosphoglycolate and 3’-PUA termini (Inamdar, Pouliot et al. 2002, 
Interthal, Chen et al. 2005, Zhou, Akopiants et al. 2009, Lebedeva, Rechkunova 
et al. 2011). This has implicated TDP1 in the repair of SSBs arising directly and 
indirectly from oxidation of DNA (Fig 1.9.) (Interthal, Chen et al. 2005, Zhou, Lee 
et al. 2005). 
 
Human TDP1 possess an N-terminal 140aa domain which is unconserved 
with its orthologs in lower eukaryotes (Interthal, Pouliot et al. 2001, El-Khamisy 
and Caldecott 2006). This domain does not influence catalytic activity, but is 
nonetheless important for TDP1 function in vivo. In lower eukaryotes, the primary 
role of TDP1 appears to be in repairing replication induced Top1-DSBs (Liu, 
Pouliot et al. 2004). This is evidenced by its epistatic relationships with 
components of the homologous recombination repair pathway in S. cerevisiae 
(Vance and Wilson 2002). In higher eukaryotes, TDP1 function appears to be 
more intimately linked with SSBR. This is likely to be in part achieved by 
interaction of TDP1, via its N-terminal domain, with Lig3α (El-Khamisy, Saifi et al. 
2005). Incidentally, XRCC1-Lig3α is absent in S. cerevisiae, perhaps indicating 
less strict requirements for coordination of SSBR in lower eukaryotes (Caldecott 
2008).  
 
TDP1 has been shown by multiple groups to be phosphorylated by ATM 
and DNA-PK at S81, within its N-terminal domain (Das, Antony et al. 2009, 
Chiang, Carroll et al. 2010). Both groups reported that this phosphorylation 
stabilizes TDP1 protein, and that its mutation to alanine compromises survival 
following treatment with CPT. Using an anti-pS81 antibody, Das et al could show 
that the phosphorylation of S81 is induced by CPT, and that it is reduced by both 
transcription and replication inhibition (with DRB and Aphidicolin, respectively). 
Furthermore, Das et al report a colocalization of anti-pS81 and γ-H2AX foci, 
suggesting that the modification may be induced at DSBs which result from 
replication collision with Top1ccs (Das, Antony et al. 2009). Lacking a specific 
anti-pS81 antibody, Chiang et al instead utilized a yeast two-hybrid (Y2H) 
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approach to identify that S81 is critical for the interaction of TDP1 with Lig3α 
(Chiang, Carroll et al. 2010). 
 
 The N-terminal domain of TDP1 also contains a SUMOylation site (K111), 
which is conserved amongst vertebrates (Hudson, Chiang et al. 2012). Mutation 
of this site to arginine, or depletion of the obligate SUMO-conjugating enzyme 
UBC9, has been shown to reduce TDP1 accumulation at sites of DNA damage 
(Hudson, Chiang et al. 2012). More recently, a direct interaction between the 
TDP1 N-terminal domain and PARP1 has been reported by Das et al. The 
authors report that this interaction is independent of damage induction or PARP1 
activity, and serves to recruit TDP1 upstream of the XRCC1 repair complex (Das, 
Huang et al. 2014). They also report that PARP1 can poly ADP-ribosylate TDP1 
in vitro, but that this does not impact TDP1 enzyme activity; instead they suggest 
that this may stabilize TDP1 (Das, Huang et al. 2014). It has been further reported 
that the PARP1-TDP1 interaction may promote an intrinsic AP-endonuclease 
activity of TDP1 (Lebedeva, Anarbaev et al. 2015). The existence of this activity 
remains controversial, however, as it is not universally observed in other 
recombinant TDP1 preparations (Pouliot, Robertson et al. 2001). Furthermore, 
the original authors did not observe the activity in TDP1 preparations which had 
been renatured following further purification by SDS-PAGE, suggesting that it 
may be have been caused by a contaminating endonuclease in the original 
preparation (Lebedeva, Rechkunova et al. 2011). Finally, it is important to note 
that abasic sites are prone to thermal degradation (Sugiyama, Fujiwara et al. 
1994, Zheng and Sheppard 2004) and alkaline lysis (Lindahl and Andersson 
1972), which can potentially introduce spurious results when conducting AP 
endonuclease assays in vitro. 
 
1.5.2.3.4. Polβ 
SSBs generated by the class II AP endonuclease activity of APE1 harbour 
canonical 3’-hydroxyl and non-canonical 5’-dRP termini. These 5’-blocked SSBs 
contrast with the 3’-blocked SSBs which predominate following direct oxidation 
of the deoxyribose phosphate backbone, and those generated by the AP lyase 
activity of the bifunctional glycosylases. The removal of 5’-dRP is catalysed by 
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Polβ, a PolX family polymerase which is also responsible for the gap-filling step 
in short patch repair (see section 1.5.2.4).  
 
Polβ was discovered in 1971, following its purification from rabbit bone 
marrow (Chang and Bollum 1971). The authors of this early work noted that the 
39 KDa polymerase was considerably smaller than the first identified mammalian 
polymerase catalytic subunit pol α (~165 KDa). Observations that Polβ could fill 
small gaps in DNA (Wang and Korn 1980), coupled with its constant expression 
throughout the cell cycle (Zmudzka, Fornace et al. 1988), lead to suggestions 
that it was the predominant DNA polymerase involved in BER. This hypothesis 
was subsequently confirmed, following in vitro experiments with mammalian and 
frog cell extracts (Wiebauer and Jiricny 1990, Dianov, Price et al. 1992, 
Matsumoto, Kim et al. 1994, Singhal, Prasad et al. 1995). 
 
In 1995, it was shown that Polβ also possesses a 5’-dRP lyase activity in 
addition to its polymerase activity, and that this was attributable to its 8 KDa N-
terminal domain (absent in the replicative polymerases α, δ and ε) (Matsumoto 
and Kim 1995). Polb-/- mice die in utero, before day 10.5 of gestation (Gu, Marth 
et al. 1994). However, Polb-/- mouse embryonic fibroblasts have been isolated 
and have been shown to be sensitive to alkylating agents and hydrogen peroxide 
(Sobol, Horton et al. 1996, Fortini, Pascucci et al. 2000), and this can be 
complemented by expression of Polb harbouring mutations in the catalytic, but 
not dRP lyase domain (Sobol, Prasad et al. 2000). These experiments highlight 
the importance of Polβ as an end-processing enzyme. 
 
1.5.2.3.5. Aprataxin  
One of the most recently identified DNA end-blocking groups results from the 
catalytic mechanism of DNA ligases, which involves the formation of a transient 
DNA 5’-AMP intermediate (see section 1.5.2.4) (Ahel, Rass et al. 2006, 
Tomkinson, Vijayakumar et al. 2006). In productive ligation, nucleophilic attack 
by the 3’-hydroxyl DNA end then results in formation of the phosphodiester bond, 
with concurrent release of AMP. If the 3’-DNA end is not in proximity, as is the 
case in a single-strand gap; or if it harbours a non-canonical chemical group, then 
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the adenylate moiety will remain on the 5’-DNA terminus. In 2006, Aprataxin was 
identified as the enzyme which removes the adenylate, restoring a 5’-phosphate 
terminus (Ahel, Rass et al. 2006). The gene encoding Aprataxin, APTX, was 
originally described following the identification of its mutation in a subset of 
Freidreich ataxia (FRDA)–like patients (Date, Onodera et al. 2001). The similarity 
in the clinical presentations of these patients to those with ataxia with oculomotor 
apraxia (AOA) was noted, and the disease was subsequently named ataxia with 
oculomotor apraxia type 1 (AOA1). It was shown that AOA1 patient cells were 
sensitive to MMS, H2O2 and CPT (Clements, Breslin et al. 2004, Gueven, 
Becherel et al. 2004, Luo, Chan et al. 2004, Mosesso, Piane et al. 2005). This 
sensitivity to diverse SSB-inducing agents is unsurprising, because all SSBR 
pathways must end in ligation, regardless of the initial type of lesion. Further 
highlighting its importance as an integral component of SSBR, Aprataxin was 
identified as an interaction partner of XRCC1 (see section 1.5.2.2) (Clements, 
Breslin et al. 2004).  
 
1.5.2.4. Gap-filling and ligation 
The restoration of a canonical 3’-OH terminus through the activities of APE1, 
TDP1 and/or PNKP allows gap-filling to be conducted by DNA polymerases. It is 
important to note that the repair of some SSBs does not require this activity, 
because they do not involve DNA gaps (for example some types of Top1-SSBs 
and direct ROS-induced SSBs) (Caldecott 2008). By comparison, SSBs 
generated by the DNA glycosylases in BER harbour a one nucleotide gap. 
Furthermore it has been suggested that proximal tandem SSBs can result in the 
loss of an oligonucleotide and the formation of longer gaps (Sage and Harrison 
2011, Schiml, Fauser et al. 2016), which would also require polymerase activity 
for repair. 
 
Gap-filling can occur via a short-patch (SP-SSBR; AKA SP-BER) or 
long-patch (LP-SSBR; AKA LP-BER) mechanism (Fig. 1.10.). SP-SSBR refers to 
the synthesis of one nucleotide, usually by the PolX family repair polymerase 
Polβ (see section 1.5.2.3.4), whereas LP-SSBR refers to the synthesis of a longer 
DNA tract of 2-12 nucleotides, usually by the replicative polymerases δ and ε in 
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Figure 1.10. Simplified model of the gap-filling and ligation steps of
SSBR. Following end-processing, SSBR can proceed by a short patch (SP-
SSBR) or long patch (LP-SSBR) mechanism. SP-SSBR involves one
nucleotide gap-filling by Polβ (in complex with XRCC1-Lig3). This step is
closely coordinated with the end-processing 5’-dRP lyase activity of Polβ (A).
SP-SSBR is usually completed by Lig3-mediated ligation of the DNA nick (B).
By comparison, LP-SSBR involves polymerisation of a 2-12 nucleotide tract
of DNA, usually by Polδ/ε (in complex with the accessory clamp PCNA),
displacing a 5’-DNA flap which is cleaved by FEN1. This pathway is thought
to be important when processing breaks with 5’-blocking lesions which cannot
be removed by Polβ (C). LP-SSBR is completed by Lig1-mediated ligation of
the DNA nick (D).
SP-SSBR                                               LP-SSBR
Lig1
FEN1
Polδ/ε
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complex with proliferating cell nuclear antigen (PCNA) (Frosina, Fortini et al. 
1996). This displaces a 5’-DNA flap which is cleaved by flap endonuclease 1 
(FEN1) (Klungland and Lindahl 1997, Kim, Biade et al. 1998). The long-patch 
system averts the requirement to directly recognize and remove a 5’-blocking 
lesion, and may serve as an important mechanism when 5’-dRP termini are 
oxidized, reduced, or otherwise modified, preventing their removal by Polβ 
(Klungland and Lindahl 1997). 
 
The final ligation of the nicked DNA is conducted by either ligase III (LIG3), 
in complex with its constitutive partner XRCC1 (exclusive to SP-BER); or by 
ligase I (LIG1), via its interaction with PCNA (predominately in LP-BER) (Barnes, 
Tomkinson et al. 1992, Cappelli, Taylor et al. 1997, Sleeth, Robson et al. 2004). 
As mentioned above (see section 1.5.2.3.5), the mechanism catalysed by these 
ligases (and by LIG4-XRCC4, operating in NHEJ) involves a DNA 5’-AMP 
intermediate (Tomkinson, Vijayakumar et al. 2006). When ligases become 
abortive, this adenylated DNA terminus remains; and it must be removed by 
Aprataxin prior to a successful ligation attempt (Ahel, Rass et al. 2006). 
 
1.6. SSBR and Human Disease 
The previous sections have reviewed the mechanisms of SSBR which defend the 
integrity of the genome. This has implications for our understanding and 
treatment of human diseases. In this section, two areas of clinical significance will 
be reviewed: the rationale for the use of PARP inhibitors in treating HR-deficient 
cancers, and the neurodegenerative genetic diseases associated with defective 
SSBR. 
 
1.6.1.  Synthetic Lethality of PARP1 inhibition and HR deficiency 
In proliferating cells, SSBs are an impediment to replication forks, and can cause 
their collapse to produce one-ended DSBs (see section 1.3.2). The absence of 
another DNA end necessitates that these lesions be repaired by Homologous 
Recombination (HR – see section 1.4.2), which gives rise to the selective 
sensitivity of HR-deficient cells to SSBR-blocking PARP inhibitors (Bryant, 
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Schultz et al. 2005, Farmer, McCabe et al. 2005, Saleh-Gohari, Bryant et al. 
2005). This mechanism is the rationale behind the FDA and EMA-approved use 
of PARP inhibitors for the treatment of BRCA1/BRCA2 -deficient tumours in 
patients with advanced ovarian cancer (EMA 2014, FDA 2014).  
 
Synthetic lethality is a term used to describe a lethal genetic interaction 
between two genes which only exists upon their coincident deficiency, and not 
upon deficiency of either individually. Since the late 1990s, it was suggested that 
this might be used in the selective killing of tumour cells, which often have 
mutations in genes involved in DNA repair or the maintenance of genome stability 
(Hartwell, Szankasi et al. 1997); and in 2005 this effect was definitively 
demonstrated for the first time between PARP1 and BRCA2 (Bryant, Schultz et 
al. 2005). In this original publication, the authors noted that BRCA2-/- cells were 
more sensitive to PARP inhibition than genetic loss of PARP1, which they 
suggested could be due to the formation of a more dangerous lesion upon 
inhibition of the enzyme (Bryant, Schultz et al. 2005). This hypothesis was 
supported by the observation of increased sensitivity of WT cells cotreated with 
PARP inhibitors and SSB-inducing agents, relative to Parp1-/- cells treated with 
MMS alone (Horton, Stefanick et al. 2005). It was subsequently demonstrated 
that PARP inhibitors trap PARP1 and PARP2 bound to DNA breaks (Kedar, 
Stefanick et al. 2012, Murai, Huang et al. 2012, Murai, Huang et al. 2012), and 
these complexes are suspected to be a more robust block to replication (Helleday 
2011) and/or to preclude redundant repair pathways which could act on naked 
SSBs. This effect can be understood from the mechanism described above (see 
section 1.5.2.1.1), whereby PARP automodification normally mediates release 
from DNA strand breaks, but inhibition or genetic loss of this activity prevents 
release (Satoh and Lindahl 1992). 
 
Further supporting the hypothesis that this example of synthetic lethality 
results from a more complex mechanism than a reduction in SSBR kinetics 
mediated by catalytic inhibition of PARP1, it has been shown that other SSBR 
genes do not exhibit the same genetic relationship with BRCA1/BRCA2. For 
example, depletion of XRCC1, which significantly slows SSBR (Thompson, 
Brookman et al. 1982), does not reduce survival of BRCA2-/- cells (Patel, Sarkaria 
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et al. 2011). Furthemore, limiting NHEJ by depletion of Ku80 or inhibition of DNA-
PKcs results in suppression of the PARP inhibitor sensitivity of BRCA2-/- cells 
(Patel, Sarkaria et al. 2011), suggesting that this pathway is involved in the 
mechanism of cell death. 
 
1.6.2.  Defective SSBR and Neurodegeneration 
The proficiency of HR has been suggested to account for the fact that genetic 
defects in SSBR do not result in significant pathology in proliferating tissues 
(Rulten and Caldecott 2013). This is evidenced by the fact that defective SSBR 
results in an increased frequency of sister chromatid exchanges – one hallmark 
of HR (El-Khamisy, Saifi et al. 2005). By contrast, SSBR is thought to be 
particularly important in postmitotic cells, where SSBs cannot be repaired by 
replication coupled-HR processes (Rulten and Caldecott 2013). In recent years, 
a group of recessive human diseases have been identified which are caused by 
mutations in the SSBR genes TDP1, APTX, PNKP and, recently, XRCC1 
(SCAN1, AOA1, AOA4, and AOA-XRCC1, respectively) (Date, Onodera et al. 
2001, Takashima, Boerkoel et al. 2002, El-Khamisy, Saifi et al. 2005, Shen, 
Gilmore et al. 2010, Bras, Alonso et al. 2015, Hoch, Hanzlikova et al. 2017). A 
hallmark of all of these diseases is neurodegeneration: typically, peripheral 
axonal neuropathy (dysfunction of the neurons which control sensory and motor 
functions), and early onset cerebellar ataxia (defective control and coordination 
of muscle movements resulting from degeneration in a region of the brain called 
the cerebellum) (Rulten and Caldecott 2013). Patients with AOA1, AOA2 or AOA-
XRCC1 additionally also exhibit oculomotor apraxia (defective control and 
coordination of eye movements) (Rulten and Caldecott 2013).  
 
There are several hypotheses to explain why neurons are more sensitive 
to defective SSBR than other terminally differentiated cell types. Firstly, oxidative 
stress is thought to be particularly high in the brain (Barzilai, Rotman et al. 2002), 
due to a combination of relatively high metabolic rate (Wang, Ying et al. 2010), 
low levels of antioxidants (Uttara, Singh et al. 2009), and the production of the 
ROS cellular signalling molecule nitric oxide (NO) by neuronal NO synthase 
(nNOS) (Eliasson, Sampei et al. 1997). This combination of factors is thought to 
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elevate the frequency of SSBs (Rulten and Caldecott 2013). Another hypothesis 
implicates the reliance of neurons on very high levels of transcription, which may 
increase the frequency of Top1-SSBs whilst simultaneously rendering the cells 
more dependent on production of essential mRNAs, and more susceptible to 
apoptosis mechanisms which result from transcription blockage (Hetman, 
Vashishta et al. 2010, Rulten and Caldecott 2013). Finally, it appears that 
neurons are particularly sensitive to programmed cell death via Parthanatos (see 
section 1.5.2.1), which is illustrated by the current model of cerebral ischaemia, 
a brain injury caused by a focal loss of blood supply. In cerebral ischaemia, tissue 
damage is thought to result from blood reperfusion of the deprived region, 
triggering an excessive release of the neurotransmitter glutamate which is bound 
by several receptors of the N-methyl-D-aspartate (NMDA) class (Curtis and 
Watkins 1965, Watkins and Olverman 2000). The excitation of these receptors 
triggers an influx of Ca2+ into the neurons, which in turn stimulates the production 
of ROS by enzymes such as nNOS (Bredt, Hwang et al. 1991, Rameau, Chiu et 
al. 2004). It has been shown that genetic loss of Parp1 protects cultured cerebral 
cortical cells from NMDA-induced cell death, and reduces the extent of brain 
injury following induction of cerebral ischaemia in mice (Eliasson, Sampei et al. 
1997), suggesting that Parthanatos may be the mechanism responsible for 
excitotoxicity. More recent evidence has implicated Parthanatos as a mechanism 
of neuronal cell death in mice with brain specific loss of Xrcc1 (Hoch, Hanzlikova 
et al. 2017). Co-workers in the Caldecott laboratory found that genetic loss of 
Parp1 reduced the loss of cerebellar neurons and ataxia in these mice (Hoch, 
Hanzlikova et al. 2017).  
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1.7.  General Aims of the Thesis 
SSBR is a complex and multifaceted pathway which repairs SSBs arising from 
various endogenous and exogenous sources. Despite great advances in our 
knowledge of how this pathway operates, many questions remain. Developing 
our understanding of SSBR from a basic research perspective is crucial for the 
comprehension and treatment of human diseases. The broad and general aim of 
this thesis is to elucidate novel features of how SSBR operates on physiological 
substrates in vivo, in human cells.  
 
Chapter Three will focus on attempting to establish a single gene system for 
studying how CPT-induced Top1-SSBs influence transcription and recruitment of 
the central SSBR scaffold XRCC1. 
 
Chapter Four will focus on establishing novel knockout human diploid cell lines 
using CRISPR-Cas9, for use in subsequent parts of the project, and in future 
work. 
 
Chapter Five will focus on establishing controlled high-content microscopic 
methods for measuring cellular ADP-ribosylation and the recruitment of 
endogenous XRCC1 into the chromatin. 
 
Chapter Six will use cell lines and methods developed in Chapter Four and Five 
to investigate the role of the three DNA-dependent PARPs in cellular responses 
to oxidative DNA damage, including: ADP-ribosylation, recruitment of XRCC1 to 
the chromatin, and rates of SSBR. 
 
Chapter Seven will use cell lines and methods developed in Chapter Four and 
Five to investigate cellular responses to Top1-SSBs induced by CPT; with a focus 
on the genetic relationships between TDP1, XRCC1 and the DNA dependent 
PARPs. 
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2.1. Materials 
2.1.1. Primary antibodies 
 
 
 
 
 
 
 
Primary 
Antibody Supplier 
Reported 
Target Host 
WB 
Cond. 
IF 
Cond. 
ChIP 
Cond. 
A300-231A Bethyl XRCC1 Rabbit 1/5000 10% milk TBST Not used 2 µg / IP 
ABC738 Millipore XRCC1 Rabbit 1/2000 10% milk TBST 
1/200   
10% FCS Not used 
MCA1522G Serotec PARP1 Mouse 1/2000 10% milk TBST Not used Not used 
39743 Active Motif PARP2 Rabbit 1/500 10% milk TBST 
1/200   
10% FCS Not used 
4699 Gift of F. Dantzer PARP3 Rabbit 
1/500 10% 
milk TBST Not used Not used 
MABE1016 Millipore PAR Rabbit 1/2000 10% milk TBST 
1/1000 
10% FCS Not used 
8WG16 Santa Cruz RNAP2 Mouse 1/1000 3% BSA TBST Not used 1 µg / IP 
A301-618A Bethyl TDP1 Rabbit 1/500 10% milk TBST Not used Not used 
SK3195 Own hybridoma PNKP Rabbit 
1/500 10% 
milk TBST 
1/1000      
10% FCS Not used 
TL25 Own hybridoma Lig3α Rabbit 
1/1500 10% 
milk TBST Not used Not used 
66009 Protein Tech β-Actin Mouse 1/2000 10% milk TBST Not used Not used 
Ab6160 Abcam α-Tubulin Rat 1/5000 10% milk TBST Not used Not used 
Ab17677 Abcam Histone 1.2 Rabbit 1/2000 10% milk TBST Not used Not used 
4974-7808 Serotec Histone 1 Mouse Not used 1/500 10% FCS Not used 
Ab3825 Abcam Top1 Rabbit 1/200 10% milk TBST Not used Not used 
Table 2.1. Details of primary antibodies used in this project. The catalogue 
or clone number is indicated, together with the supplier, the reported protein 
target, and the host species in which the antibody was generated. Also 
indicated are the conditions in which the antibody was used for Western Blot 
(WB), Immunofluorescence (IF), or Chromatin Immunoprecipitation (ChIP), 
where relevant.  
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2.1.2. Secondary antibodies 
2.1.3. Mammalian expression plasmids  
 
 
 
 
 
Secondary Antibody Supplier Reported Target Host 
WB 
Cond. 
IF 
Cond. 
ChIP 
Cond. 
P0448 HRP-GαR Dako Rabbit Ig Goat 1/10,000 10% milk Not used Not used 
P0260 HRP-MαR Dako Mouse Ig Rabbit 1/10,000 10% milk Not used Not used 
Ab6734 Abcam Rat Ig Rabbit 1/10,000 10% milk Not used Not used 
Alexa 488 - GαR Life Rabbit Ig Goat Not used 1/1000 10% FCS Not used 
Alexa 647 - DαM Life Mouse Ig Donkey Not used 1/1000    10% FCS Not used 
Name Plasmid Expresses 
Bacterial 
Antibiotic 
Resistance 
Mammalian 
Antibiotic 
Resistance 
Created by 
pEGFP-XRCC1 pEGFP-C1 EGFP-XRCC1 Kan G418 Akira Yasui 
pEGFP pEGFP-C1 EGFP Kan G418 Commercial 
pGR.TDP1.1 Addgene #41824 gRNA TDP1.1 Kan Bleomycin 
William 
Gittens 
pGR.TDP1.2 Addgene #41824 gRNA TDP1.2 Kan Bleomycin 
William 
Gittens 
pGR.PARP2. Addgene #41824 gRNA PARP2.2 Kan Bleomycin 
Zhihong 
Zeng 
pCas9 Addgene #41815 Cas9 Amp G418 
(Mali, Yang 
et al. 2013) 
Table 2.2. Details of secondary antibodies used in this project. The 
catalogue or clone number is indicated, together with the supplier, the reported 
protein target, and the host species in which the antibody was generated. Also 
indicated are the conditions in which the antibody was used for Western Blot 
(WB), Immunofluorescence (IF), or Chromatin Immunoprecipitation (ChIP), 
where relevant.  
Table 2.3. Details of mammalian expression plasmids used in this 
project. The name of the plasmid is indicated, together with the parent vector, 
and the expressed construct. Also indicated are the antibiotic resistances 
conferred for bacterial or mammalian selection, and the original creator of the 
plasmid.  
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2.1.4. siRNAs 
 
2.1.5. qPCR primers 
qPCR 
Primer Name Name on tube 
qRT- 
PCR 
ChIP- 
qPCR Sequence 
H.s  FOS A (fw) FOS.ChIP.F(fw) No Yes AGGTTTCCACGGCCTTTCC 
H.s  FOS A (r) FOS.ChIP.F(r) No Yes TTTCGCAGTTCCTGTCTCAGAG 
H.s  FOS B (fw) FOS.ChIP.A(fw) No Yes ACTCATTCATAAAACGCTTG 
H.s  FOS B (r) FOS.ChIP.A(r) No Yes GTAGGAGCACGGTCACTG 
H.s  FOS C (fw) FOS.ChIP.H(fw) No Yes TTCGTTCTGAGCAACCTCTGG 
H.s  FOS C (r) FOS.ChIP.H(r) No Yes TTAGCGAGTTTGTGCTTGGG 
H.s  FOS D (fw) FOS.ChIP.C(fw) Yes Yes ATTCCATCCCAACTCAGAC 
H.s  FOS D (r) FOS.ChIP.C(r) Yes Yes AGATCCTCAGCAAGAGAAC 
H.s  FOS E (fw) RT-FOSfw(E4) Yes No GCTTCCCTTGATCTGACTGG 
H.s  FOS E (r) RT-FOSr(E4) Yes No GCTGCTGATGCTCTTGACAG 
H.s  FOS F (fw) FOS.ChIP.D(fw) Yes Yes CTTCCCTTGATCTGACTGG 
H.s  FOS F (r) FOS.ChIP.D(r) Yes Yes CTGATGCTCTTGACAGGTTC 
H.s  FOS G (fw) FOS.ChIP.P(fw) No Yes ATTAGCCTGGTGTGGTGGTG 
H.s  FOS G (r) FOS.ChIP.P(r) No Yes TCTCAGTTCGCTGCAACATC 
H.s  Actin (fw) hACTBrv Yes No CTCGTCATACTCCTGCTTGC 
H.s  Actin (r) hACTBfw Yes No GAAGTGTGACGTGGACATCC 
H.s  MLN51 (fw) hMLN51fw Yes No CTAAGGAAGCCAGTCACCTT 
H.s  MLN51 (r) hMLN51rv Yes No AGGAATCTCTTCCACAGAGG 
C.g  FOS E4 (fw) CHO.C-FOS.3414.fw No Yes TTTCCTTGTGCAGGAGACAG 
C.g  FOS E4 (r) CHO.C-FOS.3414.r No Yes GCTGCCAAAATGAACTCCAG 
 
siRNA Target Supplier Type 
D-001810-10-05 Non-targetting Dharmacon ON-TARGETplus SmartPool 
L-010127-02-005 PARP2 Dharmacon ON-TARGETplus SmartPool 
L-009297-00-0005 PARP3 Dharmacon ON-TARGETplus SmartPool 
Table 2.4. Details of siRNAs used in this project. The catalogue number of 
the siRNA is indicated, together with the reported target, the supplier, and the 
type of reagent. 
Table 2.5. Details of qPCR primers used in this project. The name of the 
qPCR primer is given, both as it is referred to within this thesis, and as it 
appears on the tube. Whether the primer was used for qRT-PCR or ChIP-
qPCR is also indicated, along with the sequence of the primer. 
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2.2. Methods 
2.2.1. Molecular cloning methods 
2.2.1.1. Polymerase Chain Reaction (PCR) 
PCR was conducted using Phusion High Fidelity Polymerase (NEB) as per the 
manufacturer’s instructions. Reaction products were purified using a PCR 
purification kit (QIAGEN). 
 
2.2.1.2. Restriction digests 
Restriction of plasmid or PCR product DNA was conducted with Restriction 
enzymes (NEB, Roche) as per the manufacturer’s instructions. Digest products 
were purified using a PCR purification kit (QIAGEN) or Gel extraction kit 
(QIAGEN), depending on the downstream application. 
 
2.2.1.3. Ligation 
Ligations were conducted with T4 DNA Ligase (NEB) as per the manufacturer’s 
instructions. Briefly, a 3:1 molar ratio of insert to vector was combined with T4 
DNA Ligase and 1x T4 Ligase Buffer. The reaction was incubated overnight at 
16°C, prior to bacterial transformation (see section 2.2.1.7), and plating on 
LB-agar with suitable antibiotic selection. 
 
2.2.1.4. Gibson assembly 
Gibson assembly was conducted with Gibson Assembly Master Mix (NEB), as 
per the manufacturer’s instructions. Briefly, 0.02 pmol linearized plasmid and 0.3 
pmol insert (15:1 molar ratio) were combined with master mix (2X) and deionized 
water to a final master mix concentration of 1X. Reactions were incubated at 50°C 
for 1 hr, prior to bacterial transformation (see section 2.2.1.7) and plating on 
LB-agar with suitable antibiotic selection. 
 
2.2.1.5. TOPO TA cloning 
TOPO cloning was conducted with TOPO TA Cloning Kit (ThermoFisher) as per 
the manufacturer’s instructions. Briefly, 2-5 µg of unpurified PCR products were 
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combined with pCR 2.1-TOPO plasmid, Salt Solution and deionized water (final 
NaCl and MgCl2 concentration: 200 mM and 10 mM MgCl2, respectively). 
Reactions were incubated at room temperature (RT) for 1 h, prior to bacterial 
transformation (see section 2.2.1.7) and plating on LB-agar with suitable 
antibiotic selection and X-gal (0.2 mg/ml), for blue-white colony screening. 
 
2.2.1.6. DNA TAE-agarose electrophoresis 
Agarose gels were prepared by dissolving Agarose powder (Sigma) in 1X TAE 
Buffer (40 mM Tris-acetate, 1 mM EDTA) with heating, to a percentage suitable 
for the downstream application. Prior to casting, the mixture was cooled and 
ethidium bromide was added to a final concentration of 0.3 µg/ml. DNA samples 
were prepared in 1X GelPilot DNA Loading Dye (QIAGEN). Electrophoresis was 
conducted at 4 V/cm, with 1X TAE Running Buffer. 1 kb Plus DNA Ladder 
(ThermoFisher) was included as a size marker. DNA was visualised by UV 
illumination (UV Transilluminator Appligene Inc QBiogene). 
 
2.2.1.7. Bacterial transformation, amplification and preparation of plasmid 
DNA 
Unless otherwise stated, 0.1-2 µg plasmid DNA was mixed with 50 µL chemically 
competent DH5α cells and incubated on ice for 10 min. The mixture was 
subjected to heat shock in a 42°C water bath for 30 s, before being returned to 
ice for 2 min. 500 µL of LB was added and cultures were incubated at 37 °C for 1 
h with agitation. Cultures were centrifuged at 6000 g and pellets were suspended 
in a small volume of supernatant and plated on LB-agar with kanamycin or 
ampicillin (both 50 µg/ml).  Plates were incubated at 37°C overnight to allow 
colony formation. Single colonies were selected and transferred to 3 ml or 100 ml 
LB containing kanamycin or ampicillin (both 50 µg/ml), depending on the scale of 
preparation. Cultures were incubated overnight at 37°C, and pellets were 
processed with QIAprep Spin Miniprep Kit (QIAGEN) or QIAfilter Plasmid Midi Kit 
(QIAGEN), according to the manufacturer’s instructions. 
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2.2.2. Mammalian cell culture  
2.2.2.1. General Maintenance of Cell lines 
A431 cells (ATCC) were maintained as monolayers in DMEM (Gibco) 
supplemented with 10% fetal calf serum (FCS), 2 mM L-glutamine (Gibco), 100 
U/ml Penicillin (Gibco) and 100 µg/ml Streptomycin (Gibco). CHO EM9 derivative 
cell lines were maintained in α-MEM (Gibco) supplemented with 10% FCS, 100 
U/ml Penicillin (Gibco) and 100 µg/ml Streptomycin (Gibco). RPE-1 cells (ATCC) 
and derivatives were maintained in DMEM/F12 (Sigma) supplemented with 10% 
FCS, 100 U/ml Penicillin (Gibco) and 100 µg/ml Streptomycin (Gibco). A431 and 
CHO cells were maintained in a humidified atmosphere at 37°C with atmospheric 
O2 and 5% CO2. RPE-1 cells were maintained in a humidified atmosphere at 37°C 
with 3% O2 and 5% CO2. Care was taken to passage all cell lines before 100% 
confluence. Monolayers were washed with PBS prior to RT incubation with 0.25% 
Trypsin (w/v), 2.21 mM EDTA in Hank’s Balanced Salt Solution (HBSS) (Litmus 
Scientific), until detachment was observed. Trypsin activity was quenched with 
complete media and cells were pelleted by centrifugation at 300 g for 5 min. Cells 
were then resuspended in complete media. Cells were counted, as required, with 
a haemocytometer, prior to plating as necessary.  
 
2.2.2.2. Neon nucleofection of plasmid DNA 
The Neon nucleofection system (ThermoFisher) was used to transfect RPE-1 
cells with plasmid DNA, according to the manufacturer’s instructions. Briefly, 
1.2x106 tyrpsinised and PBS-washed cells were resuspended in 30 µL buffer R 
and combined with a total of 3 µg plasmid DNA. The mixture was electroporated 
with the device (2 x 20 ms 1350 V pulses), prior to immediate plating in complete 
DMEM/F12. A plating density of 4x105 cells per 35 mm dish was used. 
 
2.2.2.3. Amaxa transfection of plasmid DNA 
The Amaxa Kit T nucleofection system (Lonza) was used to transfect A431 cells 
with plasmid DNA, according to the manufacturer’s instructions. Briefly, 1x106 
trypsinised and PBS-washed cells were resuspended in 100 µL Nucleofector 
Solution and combined with 2 µg plasmid DNA. The mixture was electroporated 
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with the device, using program X-001 as per the manufacturer’s 
recommendation, prior to immediate plating in complete DMEM. A plating density 
of 1X106 cells per 35 mm dish was used. 
 
2.2.2.4. RNAimax transfection of siRNA 
The Lipofectamine RNAimax Reagent (ThermoFisher) was used to reverse 
transfect RPE-1 cells with siRNA according to the following method. 90 µL 
Optimem (Gibco) was combined with 12.5 µL siRNA solution in water (1 µM) in a 
microcentrifuge tube. Separately, 100 µL Optimem was combined with 2.7 µL 
Lipofectamine RNAimax reagent and mixed with a pipette tip. The mixtures were 
combined and mixed gently with a pipette tip, prior to dropwise distribution of 200 
µL of the mixture over the surface of a 35 mm dish. The dish was then incubated 
for 20 min at RT.  7x105 trypsinised and PBS-washed cells were resuspended in 
1 ml complete DMEM/F12 and added dropwise to the dish, prior to overnight 
incubation at 37°C. 0.8 ml complete DMEM/F12 was then added. Unless 
otherwise stated, all subsequent experiments were conducted 72 h after 
transfection. 
 
2.2.2.5. Generation of A431 cell lines stably expression GFP and 
GFP-XRCC1 
A431 cells were transfected with 2 µg pEGFP or pEGFP-XRCC1 using Amaxa 
Kit T (Lonza) (see section 2.2.2.3). 24 h later, GFP positive cells were observed 
by live fluorescent microscopy to assess transfection efficiency. G418 was then 
added to a final concentration of 0.6 mg/ml and cells were incubated for 7 days, 
prior to passaging to 10 cm dishes for single colony formation. 2-3 weeks later, 
single GFP +ve colonies were individually passaged to 12 well plates using 
cloning cylinders (Agar Scientific). Cells were then expanded prior to screening 
for presence of protein expression by Western Blot (WB) (see section 2.2.6). 
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2.2.3. qRT-PCR 
2.2.3.1. Total RNA extraction 
Cells growing in 35 mm dishes were treated according to specific time courses 
detailed in the results. At the indicated time points, cells were washed with 1 ml 
ice cold PBS and scraped into 500 µL ice cold PBS. The cells were then pelleted 
by 500 g centrifugation (4°C). The supernatant was aspirated and cells were snap 
frozen in liquid nitrogen. Pellets were stored at -80°C until further use. Total RNA 
was extracted using the RNAeasy Mini Kit (QIAGEN), according to 
manufacturer’s instructions with a few modifications. All centrifugation steps were 
conducted at 21,000 g for 1 min. Pellets were lysed in 350 µL Buffer RLT with 
vortexing. The lysate was transferred to a gDNA Eliminator spin column and 
centrifuged. 350 µL 70% EtOH was added to the flow through and the mixture 
was transferred to a RNAeasy spin column and centrifuged. The flow through 
was discarded and the column was washed with 700 µL Buffer RW1, with 
centrifugation. The column was washed with 400 µL Buffer RPE. 10 µL of a 
solution of DNAse I (NEB) in 1X DNAse I Reaction Buffer (4 units), was added to 
the centre of the column, prior to incubation for 5 min at RT. The column was 
washed with 400 µL Buffer RPE, with centrifugation. The column was then 
washed once more with 200 µL Buffer RPE, with centrifugation. The flow through 
was discarded and the column was dried by centrifugation. Finally, RNA was 
eluted in 50 µL milli-q filtered water. RNA samples were maintained on ice and 
used immediately.  
 
2.2.3.2. RNA integrity analysis by TBE-Agarose Electrophoresis 
1.5% Agarose gels were prepared as described (see section 2.2.1.6), with the 
exception that 1X TAE buffer was replaced with 1X TBE buffer (89 Mm 
Tris-Borate, 2 mM EDTA). 2 µL of RNA sample was prepared in 1X RNA Loading 
Dye (NEB) and loaded onto the gel. Electrophoresis was conducted at 60 V for 
45 min. RNA was visualised by UV illumination (UV Transilluminator Appligene 
Inc QBiogene). 
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2.2.3.3. DNA Synthesis 
Total RNA concentration of samples was measured using the Nanodrop 2000c 
Spectrophotometer. 0.5-1 µg RNA was combined with 0.5 µL of 100 µM oligo-dT 
primer solution (Eurogentec) and Milli-Q filtered water, to a final volume of 12.5 
µL. The mixture was incubated at 70°C for 5 min, before being returned to ice for 
2 min. 37.25 µL of the following mixture was added: 10 µL 5X RT-buffer (NEB), 
2 µL 25 mM dNTPs (NEB), 1 µL Murine RNASE Inhibitor (NEB), 0.25 µL Reverse 
Transcriptase (NEB), and 24 µL milli-q water. Reactions were incubated at 42°C 
for 1 h. Reactions were spiked with a further 0.25 µL Reverse Transcriptase and 
incubated at 42°C for 1 h. Finally, 1 µL RNAse A (ThermoFisher) was added and 
the reactions were incubated at 37°C for 30 min. Reactions were purified using 
PCR Purification Kit (QIAGEN) and eluted in 100 µL milli-Q purified water. cDNA 
samples were used immediately or maintained at -20°C until further use.  
 
2.2.3.4. Identification of qRT-PCR primer pairs 
FOS qRT-PCR primer pairs were identified using the Primer3Plus web 
application operating in qPCR mode (Rozen and Skaletsky 1999). The following 
parameters were specified: product length of 90-150 bp, and primer dissociation 
temperature of 55°C.  
 
2.2.3.5. Validation of primers used for FOS qRT-PCR 
To quantify the relative abundance of FOS mRNA accurately by qRT-PCR, primer 
sets (see table 2.5) were carefully validated to ensure specific amplification of the 
target sequence. The human FOS genomic locus is shown in Fig. 2.1.a, together 
with the mRNA and protein maps. The positions of the amplicons of three pairs 
of primers (D, E and F) are shown. Primer pair D targets the region 1499-1617 
bp downstream of the transcription start site (TSS), within intron 2. Primer pairs 
E and F target an almost identical region in exon 4 (2163-2291 and 2164-2287 
bp downstream of the TSS, respectively). Total RNA, from untreated A431 cells, 
was extracted and used as a template for cDNA synthesis with oligo-dT primers, 
to amplify poly(A)-tailed mRNA (see sections 2.2.3.1 and 2.2.3.3). This cDNA 
was then subjected to qPCR with primers pairs D, E, and F targeting FOS (see 
section 2.2.3.6). In addition, primers targeting human Actin or MLN51 were used, 
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Figure 2.1. Validation of primers used for RT-qPCR with human cells. The 
positions of primers pairs used for RT-PCR are shown in a diagram of the 
human FOS gene (numbers are bp). Orange rectangles represent the 
amplicon of each primer pair. The amplicon of primer pair E is almost identical 
to that of primer pair F (see section 2.2.3.5), so both are indicated by a single 
orange rectangle.  (A).  Dissociation curves of the products of qPCR reactions 
using primer pairs D, E, F, Act and MLN51 are shown in (see Table 2.5. for 
sequences) (B). PCR products were separated and visualised by 1.5% 
agarose electrophoresis and ethidium bromide staining. A molecular weight 
marker has been included, showing size in bp (C) and (D).  
E Ac
t 
M
LN
51
 
100 
500 
FOS Gene 
FOS mRNA 
c-Fos Protein 
F   A H D E/F P O 
0                                   2000                                4000 
Homo sapiens 
Figure 2.2. qRT-PCR Reaction Steps. The temperature and duration of each 
step of the qRT-PCR is illustrated. Segment 1,2 and 3 correspond to the hot-
start polymerase activation, the PCR itself, and the dissociation curve, 
respectively. The source of the image is a screen capture from the MxPro 
software. 
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as these genes are expressed at relatively constant rates and serve as internal 
sample controls. Following amplification by PCR, the reactions were subjected to 
a temperature gradient with constant fluorescence detection. A dissociation curve 
was generated, which reveals the melting temperature of the products (Fig. 
2.1.b). For each primer set a single sharp peak was observed in the graph of the 
first derivative of the fluorescence (-Rn’ (T)) vs temperature. This is a good 
indicator that PCR with each of the primer sets produces a single specific product. 
To confirm this, the products of the qPCRs were separated and visualised by 
1.5% agarose EtBr electrophoresis (Fig. 2.1.c and d). In each case, a single band 
corresponding to the expected amplicon size was detected. 
 
2.2.3.6. qPCR and Data Analysis 
Per qPCR well and for each primer pair of interest, the following mixture was 
assembled: 10 µL 2X SYBR G qPCR Master Mix (ThermoFisher), 0.8 µL 10 µM 
each fw/rv primer mix, 7.2 µL milli-Q filtered water. 18 µL of this was added to 
each tube of 8 x optical plastic tube strips (Agilent Technologies), as required. 2 
µL of each cDNA sample was added to each tube, as required. Each sample / 
primer combination was conducted in technical triplicate. qPCR reactions were 
conducted with the Mx3000p (Agilent Technologies). The reaction steps are 
illustrated in Fig. 2.2. mRNA fold changes were calculated by the ΔΔct method, 
using Actin as the internal control gene. The threshold cycle (ct) of Actin was 
subtracted from that of the gene of interest (GOI), for each sample to calculate 
the Δct. Then, the Δct of the untreated sample was subtracted from the Δct of 
each time point sample, to calculate the ΔΔct. Finally, the following equation was 
used to find the fold change: 
𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑓𝑓𝑓𝑓𝑓𝑓𝑓𝑓 𝑐𝑐ℎ𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 =  2−𝛥𝛥𝛥𝛥𝛥𝛥𝛥𝛥 
 
2.2.4. ChIP-qPCR 
2.2.4.1. Identification of ChIP-qPCR primer pairs 
FOS ChIP-qPCR primer pairs were identified using the Primer3Plus web 
application operating in qPCR mode (Rozen and Skaletsky 1999). The following 
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parameters were specified: product length of 90-110 bp, and primer dissociation 
temperature of 55°C.  
 
2.2.4.2. Validation of primers used for ChIP-qPCR in A431 cells  
To investigate the effect of RNAPII and XRCC1 occupancy at FOS following CPT 
treatment, ChIP-qPCR was employed. As described for RT-PCR primer sets, 
ChIP-qPCR primer sets (see table 2.5) were carefully validated to ensure specific 
amplification of the target sequence. The human FOS genomic locus is shown, 
together with the mRNA and protein maps (Fig. 2.3.a). The positions of the 
amplicons of primer pairs (A, B, C, D, F, and G) are shown. Note that primer pairs 
D and F (targeting intron 2 and exon 4, respectively) were used for both qRT-PCR 
and ChIP-qPCR. Primer pair A targets the promoter region (-236 to -139 bp 
relative to the TSS). Primer pair B targets a region immediately downstream of 
the TSS, where RNAPII is known to pause after initiation (1 to 138 bp downstream 
of the TSS). Primer pair C targets a region in intron 1 (565 to 651 bp downstream 
of the TSS). Primer pair G targets a region 690 to 793 bp downstream of the 
transcription termination site (TTS). qPCR was conducted using each of the 
ChIP-qPCR primer pairs and A431 gDNA as the template (see section 2.2.3.6). 
Following this, a dissociation curve was generated as described above (Fig. 
2.3.b). qPCRs conducted with primer pairs A-F had dissociation curves with a 
single clear peak, suggesting single products. qPCR with primer pair G also 
produced a strong peak in the dissociation curve at 83.9°C. However, there was 
elevated region of the curve centred at ~ 78°C. This is likely to be due to an 
intermediate state between single and double strand product, rather than multiple 
products; because when separated and visualised on 1.5% agarose EtBr gels, a 
single band was observed for each qPCR product (Fig. 2.3.c.). 
 
2.2.4.3. Validation of primers used for ChIP-qPCR in EM9 cells. 
A map of the Cricetulus griseus FOS genomic locus is depicted (Fig. 2.4.a), 
together with the mRNA and protein maps. A qPCR primer pair (cgE4) was 
identified in exon 4 (1990 to 2097 bp downstream of TSS), slightly upstream of 
the locus orthologous to F in human FOS (2164 to 287 bp downstream of TSS). 
qPCR was conducted using the cgE4 primer pair and EM9 XH gDNA as the 
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Figure 2.3. Validation of primers used for ChIP-qPCR with human cells. 
The positions of primer pairs used for ChIP-qPCR are shown in a diagram of 
the FOS gene (numbers are bp from the TSS) (A). Orange rectangles 
represent the amplicon of each primer pair.  Dissociation curves of the 
products of qPCR reactions using primer pairs A, B, C, D, F and G are shown 
(see Table 2.5. for sequences) (B). PCR products were separated and 
visualised by 1.5% agarose electrophoresis and ethidium bromide staining. A 
molecular size marker is included, showing sizes in bp. (C). 
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Figure 2.4. Validation of primers used for ChIP-qPCR in CHO cells. The 
positions of primer set cgE4 used for ChIP-qPCR is shown in a diagram of the 
FOS gene (numbers are bp from the TSS). The orange rectangle represents 
the amplicon of the primer pair (A).  Dissociation curves of the product of qPCR 
reaction using primer set cgE4 is shown in (B) (see Table 2.5. for sequences). 
PCR products were separated and visualised by 1.5% agarose 
electrophoresis and ethidium bromide staining (C). 
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template (see section 2.2.3.6).  Dissociation curve analysis of a qPCR reaction 
conducted with cgE4 indicated a single product with a melting point of 86.4°C 
(Fig. 2.4.b), and this was confirmed by 1.5% Agarose EtBr (Fig. 2.4.c). 
 
2.2.4.4. Formaldehyde crosslinking 
Crosslinking of 8x106 A431, A431 GFP, A431 GFP-XRCC1, or CHO cells was 
conducted by direct addition of 0.27 ml 37% w/v Formaldehyde with 10-15% 
methanol stabilizer (Sigma) cells in 10 ml complete media, to a final concentration 
of 1% formaldehyde. Cells were incubated with gentle rocking at RT for 10 min, 
prior to quenching of fixation by addition of 1.25 ml 1M Glycine 1M, to a final 
concentration of 111 mM. Cells were collected by scraping and centrifugation at 
4°C.  The flask was washed with 3 x 15 ml ice cold PBS. The pellet was 
resuspended and washed in these PBS volumes. Finally, cell pellets were snap 
frozen and maintained at -80°C until further use. 
 
2.2.4.5. Lysis and sonication 
Immediately prior to lysis, ChIP Lysis Buffer (1% SDS, 50 mM Tris-HCl pH 8.0, 
10 mM EDTA) was completed with 1X Protease Inhibitor Cocktail (Sigma), 50 
µg/ml PMSF (Sigma) and 1 mM DTT (ThermoFisher). 8x106 fixed cells were lysed 
by resuspension of the pellet in 610 µL Complete ChIP Lysis Buffer (4°C), with 
agitation by pipetting. The lysate was divided into 2x300 µL fractions in 1.5 ml 
Bioruptor Pico Microtubes (Diagenode), and each was subjected to 3 cycles (30 
s ON/ 30 s OFF) sonication using a Bioruptor Pico (Diagenode) water bath 
sonicator (4°C), as per the protocol identified by optimization detailed in Chapter 
Three (See Fig. 3.6., Fig. 3.10. and Fig. 3.12.). The fractions were then 
recombined and clarified by centrifugation at 10,000 g for 10 min (4°C). The 
supernatant of each was removed to a separate tube on ice. Chromatin 
immunoprecipitation was conducted immediately. 
 
2.2.4.6. Chromatin Immunoprecipitation with A300-231A and 8WG16 
Immediately prior to dilution, ChIP Dilution Buffer (1.1% Triton X-100, 167 mM 
NaCl, 16.7 mM Tris-HCl pH 8.0, 1.2 mM EDTA) was completed with 1X Protease 
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Inhibitor Cocktail (Sigma) and 50 µg/ml PMSF (Sigma). 10 µL of sonicated and 
clarified cell lysate was preserved on ice as an input sample. 150 µL (~2x106 
cells) was diluted 10-fold with 1.35 ml Complete ChIP Dilution Buffer. 10 µL 
Saturated Protein G Dynabeads (ThermoFisher) were added and the mixture was 
incubated for 1 h on a rotary mixer (4°C). The Dynabeads were pelleted using the 
DynaMag (ThermoFisher) magnet. The supernatant was removed a new 
microcentrifuge tube on ice. This preclearing step was conducted to remove any 
material which binds non-specifically to the Protein G Dynabeads, and might 
therefore increase background qPCR signal. Antibody (2 µg A300-231A 
anti-XRCC1, 1 µg 8WG16 anti-RNAPII, 1 µg Rabbit -ve IgG) was added directly 
to the precleared material and immunoprecipitation was carried out for 16 h on a 
rotary mixer (4°C). 20 µL Saturated Protein G Dynabeads were added and the 
mixture was incubated for 3 h on a rotary mixer (4°C). The beads were then 
pelleted on the DynaMag magnet, the supernatant was discarded. The beads 
were washed serially with 2x500 µL ice cold NaCl Wash Buffer (0.1% SDS, 1% 
Triton-X100, 20 mM Tris-HCl pH 8.0, 500 mM NaCl, 2 mM EDTA), , 2x500 µL ice 
cold LiCl Wash Buffer (1% Deoxycholate, 1% NP-40, 10 mM Tris-HCl, 250 mM 
LiCl, 1 mM EDTA) and 2x500 µL ice cold 1X TE (10 mM Tris-HCL pH 8.0, 1 mM 
EDTA). The immunoprecipitation was eluted by addition of 110 µL ChIP Elution 
Buffer (2% SDS, 10 mM Tris-HCl pH 8.0, 1 mM EDTA) to the beads, vortexing 
and 10 min incubation (65°C), followed by removal of 100 µL supernatant to a 
separate tube. This process was repeated with a further 100 µL ChIP Elution 
Buffer, and the fractions were combined. 190 µL Elution Buffer was added to the 
input samples. The Input and IP samples were incubated overnight at 65°C to 
reverse formaldehyde crosslinks. Samples were then incubated with 100 µg 
Proteinase K (Sigma) for 1.5 h at 50°C. Finally, the samples were purified with 
the PCR Purification Kit (QIAGEN), and eluted in 100 µL milli-Q filtered water. 
The samples were maintained at -20°C until further use. 
 
2.2.4.7. Chromatin Immunoprecipitation with ab290 
Immediately prior to dilution, ChIP Dilution Buffer (1.1% Triton X-100, 167 mM 
NaCl, 16.7 mM Tris-HCl pH 8.0, 1.2 mM EDTA) was completed with 1X Protease 
Inhibitor Cocktail (Sigma) and 50 µg/ml PMSF (Sigma). 10 µL of sonicated and 
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clarified cell lysate was preserved on ice as an input sample. 300 µL (~4x106 
cells) was diluted 5-fold with 1.2 ml Complete ChIP Dilution Buffer. 10 µL 
Saturated Protein A Dynabeads (ThermoFisher) were added and the mixture was 
incubated for 1 h on a rotary mixer (4°C). The Dynabeads were pelleted using the 
DynaMag (ThermoFisher) magnet. The supernatant was removed a new 
microcentrifuge tube on ice. This preclearing step was conducted to remove any 
material which binds non-specifically to the Protein A Dynabeads, and might 
therefore increase background qPCR signal. Antibody (10 µg ab290 anti-GFP) 
was added directly to the precleared material and immunoprecipitation was 
carried out for 16 h on a rotary mixer (4°C). 30 µL Saturated Protein G Dynabeads 
were added and the mixture was incubated for 3 h on a rotary mixer (4°C). The 
beads were then pelleted on the DynaMag magnet, the supernatant was 
discarded. The beads were washed serially with 2x500 µL ice cold NaCl Wash 
Buffer (0.1% SDS, 1% Triton-X100, 20 mM Tris-HCl pH 8.0, 500 mM NaCl, 2 mM 
EDTA), 2x500 µL ice cold LiCl Wash Buffer (1% Deoxycholate, 1% NP-40, 10 
mM Tris-HCl, 250 mM LiCl, 1 mM EDTA) and 2x500 µL ice cold 1X TE (10 mM 
Tris-HCL pH 8.0, 1 mM EDTA). The immunoprecipitation was eluted by addition 
of 110 µL ChIP Elution Buffer (2% SDS, 10 mM Tris-HCl pH 8.0, 1 mM EDTA) to 
the beads, vortexing and 10 min incubation (65°C), followed by removal of 100 
µL supernatant to a separate tube. This process was repeated with a further 100 
µL ChIP Elution Buffer, and the fractions were combined. 190 µL Elution Buffer 
was added to the input samples. The Input and IP samples were incubated 
overnight at 65°C to reverse formaldehyde crosslinks. Samples were then 
incubated with 100 µg Proteinase K (Sigma) for 1.5 h at 50°C. Finally, the samples 
were purified with the PCR Purification Kit (QIAGEN), and eluted in 100 µL milli-Q 
filtered water. The samples were maintained at -20°C until further use. 
 
2.2.4.8. qPCR and Data Analysis 
Per qPCR well and for each primer pair of interest, the following mixture was 
assembled: 10 µL 2X SYBR G qPCR Master Mix, 0.8 µL fw/rv primer mix (10 µM 
each), 6.8 µL milli-Q filtered water. 17.6 µL of this was added to each tube of 8 x 
optical plastic tube strips, as required. 2.4 µL of each ChIP sample was added to 
each tube, as required. Each sample / primer combination was conducted in 
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technical triplicate. qPCR reactions were conducted with the Mx3000p. A 
standard curve was prepared by 10-fold serial dilution of one untreated input 
sample. This standard curve was measured for each primer pair, along with the 
input and IP samples. Each input sample was diluted 10-fold. All input and IP 
samples were quantified using the standard curve. Enrichments were then 
calculated as % of input.  
 
2.2.5. CRISPR-Cas9 
2.2.5.1. Identification of gRNA target sequences in TDP1 
gRNA sequences targeting TDP1 were identified using the web application 
Benchling (https://benchling.com). The following parameters were specified: 
target sequence length of 17 bp (Tru-gRNA); target sequence begins with a G; 
PAM is of the form NGG. Potential off-target sites were assessed by BLAST 
(https://blast.ncbi.nlm.nih.gov). 
 
2.2.5.2. Cloning of gRNAs targeting TDP1 into gRNA expression plasmid 
Oligodeoxynucleotides composed of the sense and antisense Tru-gRNA 
sequences fused to left and right homology arms were annealed and extended 
using Phusion polymerase. Separately, the gRNA expression plasmid was 
linearized with AflII. The two fragments were combined by Gibson Assembly (see 
section 2.2.1.4). This process was conducted for two gRNA sequences targeting 
TDP1 (shown below), to produce the plasmids pGR.TDP1.1 and pGR.TDP1.2. 
 
gRNA Primer Sequence 
TDP1.1 fw TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGAGGTAGATGGCTTGTC 
TDP1.1 r GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACGACAAGCCATCTACCTC 
TDP1.2 fw TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACCGACGAGTATGAGACATC 
TDP1.2 r GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAACGATGTCTCATACTCGTC 
 
 
2.2.5.3. Generation of TDP1-/- (#4A2, #5B3, #5B4 and #5B5) RPE-1 cells 
RPE-1 cells were co-transfected with 1.5 µg hCas9 expression plasmid and 1.5 
µg pGR.TDP1.1 or pGR.TDP1.2 by Neon nucleofection (see section 2.2.2.2). 
Following overnight incubation, the cells were passaged to 10 cm dishes and 
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incubated for 5 days with complete DMEM/F12 containing 1 mg/ml G418. After 
selection, cells were trypsinised and plated at density of 50 cells per 10 cm dish. 
Following 2-week incubation in G418-free media, colonies were selected and 
passaged individually to duplicate wells of a 24-well plates using cloning cylinders 
(Agar Scientific). After a subsequent week of incubation, confluent wells were 
lysed in LB and subjected to SDS-PAGE and WB with anti-TDP1 (A301-618A) 
and anti-actin (66009) antibodies. Clones with apparently absent TDP1 protein 
(#4A2, #4A4, #5B3, #5B4 and #5B5) were selected and expanded further into 
T75 flasks. A second WB was conducted at this stage to confirm the absence of 
TDP1 protein. Clone #4A4 had a small remaining TDP1 band. All clones with 
absent TDP1 protein (#4A2, #5B3, #5B4 and #5B5) were passaged to T175. After 
this expansion step, cells were trypsinised; resuspended in complete DMEM/F12 
with 10% DMSO; and multiple aliquots were frozen in cryovials at -80°C, using a 
Mr Frosty Freezing Containing (ThermoFisher). Vials were maintained by cell 
cryopreservation in the vapor phase of liquid nitrogen. 
 
2.2.5.4. Generation of XRCC1-/-/TDP1-/- (#3A2) RPE-1 cells  
XRCC1-/- RPE-1 (#3) cells were co-transfected with 1.5 µg hCas9 expression 
plasmid and 1.5 µg pGR.TDP1.1 or pGR.TDP1.2 by Neon nucleofection (see 
section 2.2.2.2). Following overnight incubation, the cells were trypsinised and 
plated at density of 50 cells per 10 cm dish. Following 2-week incubation, colonies 
were selected and passaged individually to duplicate wells of multiple 24-well 
plates using cloning cylinders (Agar Scientific). After a subsequent week of 
incubation, confluent wells were lysed in LB and subjected to SDS-PAGE and 
WB with anti-TDP1 (A301-618A) and anti-actin (66009) antibodies. 2 clones had 
apparently absent TDP1 protein (#1D2 and #3A2). These were selected and 
expanded further into T75 flasks. A second WB was conducted at this stage to 
confirm the absence of TDP1 and XRCC1 proteins. Clone #1D6 had a small 
remaining TDP1 band. Clone #3A2 had absent TDP1 and XRCC1 protein, and 
was passaged to T175. After this expansion step, cells were trypsinised; 
resuspended in complete DMEM/F12 with 10% DMSO; and multiple aliquots 
were frozen in cryovials at -80°C, using a Mr Frosty Freezing Containing 
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(ThermoFisher). Vials were maintained by cell cryopreservation in the vapor 
phase of liquid nitrogen. 
 
2.2.5.5. Generation of PARP1-/-/PARP2-/- (#E6) RPE-1 cells 
PARP1-/- RPE-1 (#G7) cells were co-transfected with 1.5 µg hCas9 expression 
plasmid and 1.5 µg pGR.PARP2.2 by Neon nucleofection (see section 2.2.2.2). 
Following overnight incubation, the cells were trypsinised and plated at density of 
50 cells per 10 cm dish. Following 2-week incubation, colonies were selected and 
passaged individually to wells of 1x96 and 2x24-well plates, using cloning 
cylinders (Agar Scientific). After 2 days, cells in the 96-well plate were fixed with 
formaldehyde and subjected to anti-PARP2 (39743) IF (see section 2.2.7). Cells 
were observed manually on an Olympus IX83 fluorescence; 13 clones with 
absent or low anti-PARP2 IF signal were noted. These clones were selected from 
one of the 24-well plates, lysed in LB, and subjected to SDS-PAGE and WB with 
anti-PARP2 (39743) and anti-actin (66009) antibodies (see section 2.2.6). 1 clone 
exhibited PARP2 absence by WB (#E6). Clone #E6 was expanded further into a 
T75 flask. A second WB was conducted at this stage to confirm the absence of 
PARP1 and PARP2 proteins. Clone #E6 was passaged to T175. After this 
expansion step, cells were trypsinised; resuspended in complete DMEM/F12 with 
10% DMSO; and multiple 1 ml aliquots were frozen in cryovials at -80°C, using a 
Mr Frosty Freezing Containing (ThermoFisher). Vials were maintained by cell 
cryopreservation in the vapor phase of liquid nitrogen. 
 
2.2.5.6. Sequencing of TDP1 gRNA 2 locus in WT, TDP1-/- (#5B5) and 
XRCC1-/-/TDP1-/- (#3A2) RPE-1 cells 
Genomic DNA was extracted from 1x106 WT, TDP1-/- (#5B5) and 
XRCC1-/-/TDP1-/- (#3A2) RPE-1 cells using Extract-N-Amp Tissue PCR kit 
(Sigma). A pair of primers were designed which spanned 277 bp around the 
TDP1 gRNA 2 target locus (TDP1.2.seq.fw and TDP1.2.seq.rv; see below for 
sequences), using Primer3Plus. PCR was conducted using the gDNA and this 
primer pair (see section 2.2.1.1). PCR products were separated and visualised 
by TAE-agarose electrophoresis (see section 2.2.1.6). PCR products were 
Topo-cloned into pCR 2.1-TOPO plasmid and single colonies were mini-prepped 
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(see section 2.2.1.5). Plasmid DNA from individual colonies was subjected to a 
diagnostic restriction digest with EcoRI-HF (see section 2.2.1.2), and those 
containing an insert were sent for sanger sequencing (Genewiz) with M13 fw 
primers. Sequences were aligned to the TDP1 gDNA sequence (NCBI) and 
mutations were noted. 
 
Primer Sequence 
TDP1.2.seq.fw GAAGCAGGCTGAGAAAGTGG 
TDP1.2.seq.r CTTGACACCCAGCATCCTCT 
 
 
2.2.6. Western Blot (WB) 
2.2.6.1. Total protein extraction with Laemmli Buffer or Sample Buffer 
Cell pellets or adherent cells were washed twice with PBS, prior to direct addition 
of 95°C 1X Laemmli Buffer (2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 
0.001% bromophenol blue, 62.5 µM Tris-HCl pH 6.8) or 1X Sample Buffer (2% 
SDS, 10% glycerol, 62.5 µM Tris-HCl pH 6.8). Samples were boiled for 10 min 
(95°C) in a Thermomixer R (Eppendorf) hot block shaker, at 2000rpm. One cycle 
of sonication (30 s ON/ 30 s OFF) in the Bioruptor Pico was used where 
necessary to reduce viscosity. Samples were cooled on ice and used 
immediately, or maintained at -20°C until further use. 
 
2.2.6.2. Chromatin fractionation 
Immediately prior to the experiment, all buffers were completed with 1X Protease 
Inhibitor Cocktail (Sigma) and 1X Phosphatase Inhibitor Cocktail (Sigma). 2x106 
RPE-1 cells were scraped into ice cold PBS and pelleted by centrifugation at 400 
g. The pellet was resuspended in 200 µL complete LB1 (0.1% Triton-X100, 1X 
PIC, 1X PhIC, 50 mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA). 20 µL of this 
was snap frozen as input. The remaining 180 µL was incubated on ice for 3 min, 
prior to centrifugation at 21,000 g for 3 min. The supernatant was snap frozen as 
fraction S1. The pellet was washed once with 200 µL LB2 (1X PIC, 1X PhIC, 50 
mM HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA), with centrifugation at 21,000 g 
for 3 min. The supernatant was discarded and the pellet was resuspended in 100 
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µL LB3 (0.2 mg/ml RNAse A,  1X PIC, 1X PhIC, 50 mM HEPES pH 7.5, 150 mM 
NaCl, 1 mM EDTA). The suspension was incubated on a rotary mixer for 30 min 
at RT, prior to centrifugation at 21,000 g for 3 min. The supernatant was snap 
frozen as fraction S2. The pellet was snap frozen as fraction P2, containing the 
chromatin. All samples were maintained at -80°C until further use.  
 
2.2.6.3. Total protein quantification by BCA assay 
2 µL of total protein extract in 1X SB (see section 2.2.6.1) was combined with 8 
µL deionized water and 200 µL BCA Working Reagent (Pierce) (3.9 µL BCA 
reagent B, 196.1 µL BCA reagent A) in triplicate wells of an optical 96-well plate. 
10 µL of protein standards A-I was combined with 200 µL BCA working reagent 
in separate wells. The 96-well plate was covered with Parafilm (Sigma) and 
incubated for 30 min at 36°C. Absorbance was measured at 562 nm using a 
POLARstar Omega Microplate Spectrophotometer (BMG Lab Tech). Protein 
concentration of each sample was calculated from the average absorbance of 
triplicate wells, using the standard curve. DTT and Bromophenol Blue were added 
to final concentrations of 100 mM DTT and 0.001%, respectively. 
 
2.2.6.4. SDS-PAGE 
Resolving polyacrylamide gels of various acrylamide percentages were cast as 
described previously (Sambrook and Russell, 2001); by combining different 
volumes of deionized water, 30% acrylamide mix (Flowgen), 1.5M Tris-HCl pH 
8.8, 10% (w/v) SDS, 10% (w/v) APS and TEMED (ThermoFisher). After 
polymerisation of the resolving gel, stacking gels were cast by combining different 
volumes of deionized water, 30% acrylamide mix (Flowgen), 1M Tris-HCl pH 6.8, 
10% (w/v) SDS, 10% (w/v) APS and TEMED (ThermoFisher). Samples were 
loaded along with protein marker (Biorad), and electrophoresis was conducted at 
150V in a Mini-PROTEAN Tetra Cell electrophoresis tank (Biorad), using 1X 
Running Buffer (25 mM Tris-Hcl, 250 mM glycine, 0.01% SDS). 
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2.2.6.5. Gel-Membrane Transfer 
After SDS-PAGE, proteins were electrophoretically transferred from 
polyacrylamide gels to nitrocellulose membrane (ThermoFisher) at 90 V for 90 
min, in the Mini-PROTEAN Tetra Cell tank, using 1X Towbin buffer (25 mM 
Tris-HCl, 192 mM glycine, 20% methanol). Membranes were stained with 0.1% 
(w/v) Ponceau S in 5% acetic acid (Sigma) to visualise total protein levels. 
Ponceau S staining was imaged using an Epson Perfection 2400 PHOTO 
desktop scanner. Ponceau S staining was removed by serial washing with 1x 
TBST (20 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20). The membrane was 
blocked with 10% milk in 1X TBST for 1 h with rocking at RT. 
 
2.2.6.6. Immunodetection 
The blocked membrane was probed with various primary antibodies diluted in 
10% milk-TBST (see Table 2.1), either for 1 h at RT, or overnight at 4°C. Following 
primary antibody incubation, the membrane was washed for with 4x20 ml TBST 
for 5 min each, with rocking at RT. The membrane was then probed with a 
secondary antibody-HRP, according to the host of the primary antibody (see 
Table 2.2), for 1 h with rocking at RT. The membrane was then washed for 4x5 
min with 20 ml TBST. Finally, the membrane was incubated for 1 min in enhanced 
chemiluminescence (ECL) detection reagent (GE Healthcare), prior to exposure 
to blue autoradiography film (GRI) and developing. 
 
2.2.7. Immunofluorescence (IF) 
2.2.7.1. Fixation 
Cells growing on glass coverslips were fixed for 10 min with 0.3 ml 4% 
formaldehyde in PBS, at RT. Cells were then washed for 3x2 min with 0.5 ml 
PBS; prior to being used immediately, or maintained in 0.5 ml PBS at 4°C until 
further use. 
 
2.2.7.2. Detergent Pre-extraction of soluble proteins 
Cells growing on glass coverslips in 24-well plates were washed with 0.3 ml ice 
cold Pre-extraction Buffer (0.2% Triton-X100 in PBS) for 2 min on ice with gentle 
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rocking (5 rpm), prior to immediate fixation with 0.3 ml 4% formaldehyde in PBS, 
at RT. Cells were then washed for 3x2 min with 0.5 ml PBS; prior to being used 
immediately, or maintained in 0.5 ml PBS at 4°C until further use. 
2.2.7.3. Immunodetection 
Fixed cells were permeabilized with 0.3 ml methanol/acetone (1:1) for 5 min 
at -20°C, prior to washing for 3x2 min with 0.5 ml PBS. Cells were blocked with 
0.3 ml IF Buffer (10% Fetal Calf Serum in PBS) for 1 h at RT. Primary antibody 
dilutions were made in IF buffer (see Table 2.1). Coverslips were carefully placed 
inverted on 30 µL droplets of primary antibody dilution, on a sheet of parafilm. 
Incubations were conducted in a humidified chamber for 1.5 h at RT. Coverslips 
were then turned face-up and washed for 3x5 min with 0.3 ml PBS. Fluorescently 
labelled-secondary antibody dilutions were made in IF buffer (see Table 2.2). 80 
µL secondary antibody dilution was carefully added to the surface of the coverslip. 
Incubations were conducted in a humidified chamber for 1 h at RT. Coverslips 
were washed for 3x5 min with 0.3 ml PBS and 1x2 min with 0.3 ml deionised 
water. Coverslips were then allowed to dry for 10 min on Whatman Filter Paper 
(ThermoFisher), prior to mounting on glass slides with 4 µL Vectashield Antifade 
Mounting Medium with DAPI (Vector Laboratories). Slides were imaged 
immediately or maintained at 4°C until further use. 
 
2.2.8. ScanR Microscopy 
Automated widefield microscopy was performed on an Olympus ScanR system 
(motorized IX83 microscope) with ScanR Image Acquisition and Analysis 
Software, 20x/0.45 (LUCPLFLN 20x PH) and 40x/0.6 (LUCPLFLN 40x PH) dry 
objectives and a Hamamatsu ORCA-R2 digital CCD camera C10600. Definition 
of the main object was based on an intensity threshold of DAPI signal. Definition 
of the sub-object was based on an intensity threshold of B23-Alexa 647 signal, 
as illustrated in Chapter Five (See Fig. 5.5.). In this way, it was possible to derive 
the mean ex-nucleolar signal with the following formula: 
 
𝑀𝑀𝑎𝑎𝑎𝑎𝑎𝑎 𝐸𝐸𝐸𝐸𝑎𝑎𝐸𝐸𝑐𝑐𝑓𝑓𝑎𝑎𝑓𝑓𝑓𝑓𝑎𝑎𝐸𝐸 𝑆𝑆𝑆𝑆𝑎𝑎𝑎𝑎𝑎𝑎𝑓𝑓 = ∑𝑇𝑇𝑓𝑓𝑇𝑇𝑎𝑎𝑓𝑓 𝑎𝑎𝐸𝐸𝑐𝑐𝑓𝑓𝑎𝑎𝑎𝑎𝐸𝐸 𝑠𝑠𝑆𝑆𝑎𝑎𝑎𝑎𝑎𝑎𝑓𝑓 −  ∑𝑇𝑇𝑓𝑓𝑇𝑇𝑎𝑎𝑓𝑓 𝑎𝑎𝐸𝐸𝑐𝑐𝑓𝑓𝑎𝑎𝑓𝑓𝑓𝑓𝑎𝑎𝐸𝐸 𝑠𝑠𝑆𝑆𝑎𝑎𝑎𝑎𝑎𝑎𝑓𝑓
𝑚𝑚𝐸𝐸𝑚𝑚𝑁𝑁𝑎𝑎𝐸𝐸 𝑓𝑓𝑓𝑓 𝑎𝑎𝐸𝐸𝑐𝑐𝑓𝑓𝑎𝑎𝑆𝑆  
 
 A                                               B                                     
C                                               D 
E                                             F  
G                                            H 
Figure 2.5. Population gating removes unwanted anomalies. RPE-1 cells 
were formaldehyde fixed, stained with DAPI and imaged using the ScanR 
system. ScanR Analysis software was used to assess nuclear area and 
circularity factor from DAPI signal. Scatterplots of area vs circularity factor (A-
D) showing the defined gate region and position of a representative average 
nucleus (E), large nucleus (F), imaging aberration (G) and double nucleus (H), 
respectively. 
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To further improve the accuracy of the method, gating was applied to exclude 
factors which might skew the data (Fig. 2.5.). The first such gate was defined 
following visual examination of the scatter plot of nuclear size vs circularity factor. 
This plot revealed that while most correctly identified single nuclei were 
distributed in a single population of low size and low circularity factor (Fig. 2.5.a 
and e), there were also some of significantly larger size (Fig. 2.5.b and f). In 
contrast, those objects with a high circularity factor were predominantly caused 
by failure of watershedding, resulting in multiple adjacent nuclei being detected 
as a single object (Fig. 2.5.d and h). Furthermore, some of these anomalies were 
caused by imaging aberrations such as poor autofocusing, or fluorescence of 
debris (Fig. 2.5.c and g). A 2d region was defined on the scatterplot to exclude 
as many of these anomalies whilst still retaining a complete size range of nuclei. 
The second gate employed was used to exclude those nuclei with undetectable 
nucleoli, as these were generally due to poor B23-Alexa 647 signal detection.  
 
2.2.9. Single Cell Alkaline Electrophoresis (Comet assay) 
2.2.9.1. H2O2 Treatment 
A total of 3x106 RPE-1 cells were trypsinised, washed and resuspended in ice 
cold PBS. A total of 5x105 cells were removed and stored on ice (‘undamaged’ 
sample). The remaining cells were then treated with H2O2 (50 µM) in PBS for 10 
min on ice, before mixing with complete DMEM/F12 medium, and recovery of the 
cells by centrifugation and resuspension in ice cold complete DMEM/F12. A total 
of 5x105 cells were removed and stored on ice (‘no repair’ sample) and the 
remaining cells resuspended in complete DMEM/F12 (37◦C) and incubated at 
37◦C for the indicated repair period. At 7.5, 15 and 30 min, 5x105 cells were 
removed and stored on ice. 
 
2.2.9.2. CPT Treatment 
Per condition, 5x105 RPE-1 cells were trypsinised, washed and resuspended in 
0.5 ml complete DMEM/F12 (37°C), containing 10 or 100 µM CPT or an 
equivalent concentration of DMSO vehicle. Cells were incubated for 1 h (37°C) in 
a water bath, prior to being returned to ice. 
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2.2.9.3. Single Cell Alkaline Electrophoresis 
Finally, all samples were resuspended in 200 µL ice cold PBS, rapidly mixed with 
200 µL 1.2% low melting point agarose (Sigma) in PBS and plated on frosted 
glass slides coated with 0.6% ultrapure agarose (ThermoFisher), on ice. The 
agarose was allowed to solidify prior to incubation in Comet Lysis Buffer (2.5 M 
NaCl, 100 mM EDTA, 10 mM Tris-HCl pH 10) for 1 h at 4◦C. Slides were washed 
3 times with 4◦C H2O and incubated for 45 min in Comet Electrophoresis Buffer 
(1 mM EDTA, 50 mM NaOH). Electrophoresis was carried out at 12V for 25 min, 
prior to overnight neutralization with 1 M Tris-HCl. Finally, slides were stained 
with 1 M Tris-HCl containing SYBR-G (1:10000) and Antifade (40 µg/ml), and 
imaged (Nikon Eclipse 50i). Average tail moments from 100 cells per sample 
were obtained using Comet Assay IV software (Perceptive Instruments). 
 
2.2.10. Clonogenic Survival Assay 
2.2.10.1. Plating Cells 
Each condition was performed on triplicate dishes per replicate. RPE-1 cells were 
trypsinised, washed and resuspended at a density of 33.3 ml-1 in complete 
DMEM/F12 (37°C). 9 ml of this suspension was added to each 10 cm dish (300 
cells per dish). Dishes were rocked gently to evenly distribute single cells, prior 
to being incubated for 4 h (37°C) to allow adherence.  
 
2.2.10.2. H2O2Treatment 
Plating media was removed by aspiration. 6 ml PBS (RT) containing 10, 20, 35, 
50 µM H2O2, was added to each dish. The dishes were incubated for 20 min (RT), 
prior to aspiration of the treatment buffer, washing with 6 ml PBS, and addition of 
10 ml complete DMEM/F12. The dishes were incubated for 12 days (37°C) to 
allow colony formation.  
 
2.2.10.3. CPT treatment 
1 ml of DMEM/F12 containing 5, 10, 15, 20 nM CPT, or an equivalent 
concentration of DMSO vehicle was added to each dish (final concentrations of 
74 
 
CPT: 0.5, 1, 1.5 and 2 nM CPT, respectively). The dishes were incubated for 12 
days (37°C) to allow colony formation.  
 
2.2.10.4. Staining and Scoring of Colonies 
Dishes were washed once with 6 ml PBS (RT), fixed with 6 ml industrial 
methylated spirit for 5 min (RT), and stained with 10 ml 2% (w/v) methylene blue 
in 70% (v/v) ethanol for 30 min (RT). The staining solution was removed and 
recycled, and the dishes were washed collectively in a large volume of tap water 
(0°C). The dishes were finally allowed to dry, prior to scoring of colonies of >50 
cells using a digital colony counter (Stuart SC6Plus). 
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Chapter Three  
 
Investigating SSBR at a 
Highly-Transcribed Gene Locus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.  
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3.1. Introduction and Aims 
Defective SSBR resulting from mutation of TDP1, APTX, PNKP and XRCC1 is 
associated with the neurodegenerative genetic diseases SCAN1, AOA1, AOA4 
and AOA-XRCC1, respectively (Date, Onodera et al. 2001, Takashima, Boerkoel 
et al. 2002, El-Khamisy, Saifi et al. 2005, Shen, Gilmore et al. 2010, Bras, Alonso 
et al. 2015, Hoch, Hanzlikova et al. 2017). These diseases share the common 
clinical presentation of cerebellar atrophy resulting in progressive ataxia. Several 
hypotheses have been suggested to explain the sensitivity of post-mitotic 
neuronal subtypes to defective SSBR. High levels of oxygen consumption and 
low levels of antioxidant enzymes may result in high oxidative stress in the brain 
(Barzilai, Rotman et al. 2002, Caldecott 2003). This in turn is likely to elevate 
levels of various lesions repaired by BER and SSBR (Barzilai, Rotman et al. 2002, 
Caldecott 2003, El-Khamisy and Caldecott 2006, Caldecott 2008). Additionally, 
in the absence of redundant replication-coupled repair mechanisms, 
single-strand lesions may accumulate in post-mitotic cells (Rulten and Caldecott 
2013). However, other tissues of the body containing post-mitotic cells seem 
largely unaffected by disruption of SSBR, for example the skeletal muscle. A 
further hypothesis to explain neurodegeneration implicates the reliance of 
neurons upon a high rate of transcription, often of particularly long genes (Zylka, 
Simon et al. 2015). Single-strand lesions block transcription of essential mRNAs 
and non-coding RNAs (Zhou and Doetsch 1993, Zhou and Doetsch 1994, 
Lehmann 2003, Kathe, Shen et al. 2004), and may trigger apoptosis via the 
detection of persistent single stranded DNA by RPA/ATR and the subsequent 
phosphorylation of p53 (Ljungman and Zhang 1996, Ljungman, Zhang et al. 
1999, Derheimer, O'Hagan et al. 2007, Vrouwe, Pines et al. 2011). One aim of 
this chapter is to investigate the effect of defective SSBR on transcription directly.  
Nucleotide excision repair (NER), which repairs a subset of single strand 
lesions (cyclobutene primidine dimers, 6-4 photoproducts and bulky adducts), 
operates in a specialised mode for repair of transcribed DNA (transcription 
coupled- nucleotide excision repair; TC-NER). Genetic defects in this specialised 
pathway lead to neurological symptoms which are less frequently seen when only 
global genome-NER (GG-NER) is disrupted (Lehmann 2003). By comparison to 
NER, our understanding of SSBR processes at the gene level remains limited. 
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Consequently, another aim of this chapter is to investigate any specialised SSBR 
mechanisms which may operate at transcribed loci. 
FOS is an immediate early-response gene which is induced to a very high 
level of transcription in response to external stimuli, including in the brain where 
it is a marker of neuronal activity (Morgan and Curran 1986, Morgan, Cohen et 
al. 1987, Day, Masini et al. 2004). Given its ease of manipulation and relevance 
as a highly-transcribed locus in neurons, it is a good model system for 
investigating SSBR processes at the gene level. Furthermore, the body of the 
gene has been previously demonstrated to contain multiple Top1 cleavage sites 
(Francis Stewart, Herrera et al. 1990, Listerman, Sapra et al. 2006), allowing 
SSBs to be induced with camptothecin (CPT). This chapter will utilize ChIP-qPCR 
and RT-PCR to investigate the interplay between SSBR and transcription 
occurring at the FOS locus.  
 
3.2. Results  
3.2.1. FOS induction with A23187 calcium ionophore 
FOS is rapidly induced by diverse external stimuli; including application of 
A23187, a calcium ionophore that increases intracellular calcium levels (Francis 
Stewart, Herrera et al. 1990). To test this, confluent A431 cells were treated with 
5 µM A23187 or an equal concentration of DMSO vehicle; prior to snap freezing 
of samples at 30, 60 or 90 minutes and subsequent quantitation of FOS mRNA 
by qRT-PCR (Fig. 3.1.). Serum is another known FOS transcription stimulus. For 
this reason, incubation in the absence of serum is necessary to pre-sensitise the 
cells before addition of A23187. qRT-PCR was conducted with primer set E, 
targeting exon 4 of FOS, and primer sets targeting Actin and MLN51. A rapid and 
transient induction of FOS was observed, which peaked 60 min after A23187 
addition. Little difference was seen in the FOS expression profile when MLN51 
was used as an internal control (Fig. 3.1.b), instead of Actin (Fig. 3.1.a). Notably, 
the addition of DMSO alone caused some induction of FOS mRNA at 30 min 
(14.5-fold over untreated), highlighting the diversity of FOS stimuli. This was 
transient, as it was significantly reduced by 60 min. By comparison, induction with 
A23187 caused significantly greater (ANOVA p-value = 2.71x10-4) increase in 
  
Figure 3.1. FOS can be rapidly induced with A23187 calcium ionophore. 
Subconfluent A431 cells were incubated in serum-free media for 2.5 hr prior 
to treatment with serum-free media containing 5 µM A23187, or an equivalent 
concentration of DMSO vehicle. At the indicated timepoints cells were 
collected by scraping and snap freezing in liquid nitrogen. Subsequently, total 
RNA was extracted and cDNA was synthesized with oligo-dT primers, using 1 
µg total RNA as the template. RNA was degraded with RNAse A and samples 
were purified. Finally, samples were subjected to qPCR using primer set E, 
targeting FOS Exon 4. Data were calculated by the ΔΔct method and are 
presented as fold over untreated, relative to Actin (A) or MLN51 (B). Data are 
mean ±SEM of 3 biological replicates. Statistical significance was calculated 
by two-factor ANOVA. 
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FOS mRNA abundance by 60 min (108.6-fold over untreated), which decreased 
by 90 min (65.7-fold over untreated). This experiment highlights the transient 
nature of FOS transcription induction and FOS mRNA stability, which has been 
noted previously (Francis Stewart, Herrera et al. 1990). 
  
3.2.2. FOS induction is inhibited by treatment with CPT 
CPT has been reported previously to block transcription of FOS and lead to the 
formation of Top1-SSBs within the gene (Francis Stewart, Herrera et al. 1990). 
To test this, A431 cells were pre-incubated in serum-free media prior to induction 
with A23187. 10 µM CPT or DMSO vehicle was added 20 min after A23187 
induction and samples were collected at the time points indicated (Fig. 3.2.a). 
Upon A23187 induction alone, qRT-PCR with primer set F revealed an 
accumulation of exon 4-containing mRNA which peaked at 60 min (113.1-fold 
over untreated) (Fig. 3.2.b). Treatment with CPT significantly reduced (ANOVA 
p-value = 1.83x10-4) the accumulation of exon 4-containing mRNA at 30, 60 and 
90 min (28.7, 45.0 and 30.4-fold over untreated, respectively), suggesting 
transcriptional inhibition. qPCR was also conducted with primer set D, targeting 
intron 2 (Fig. 3.2.c). By comparison with exon 4-containing mRNA, the fold 
change of intron 2-containing mRNA was notably lower after addition of A23187 
alone (51.5, 40.1 and 29.1-fold at 30, 60 and 90 min, respectively). Furthermore, 
the fold change of intron 2-containing mRNA peaked earlier than exon 
4-containing mRNA. This is unsurprising, as splicing of FOS mRNA occurs rapidly 
and co-transcriptionally (Listerman, Sapra et al. 2006). Co-treatment with CPT 
lead to a gradual accumulation of intron 2-containing transcripts (13.9, 29.1 and 
42.5-fold at 30, 60 and 90 min, respectively), which was significantly different 
from that observed in the absence of CPT (ANOVA p-value = 7.02x10-3).  
 
3.2.3. FOS transcription in the presence of CPT and/or PARP inhibitor 
The sustained accumulation of FOS mRNA in the presence of CPT, albeit at 
lower levels than in the absence of CPT, could be dependent on SSBR at 
transcription-blocking lesions. To test this, A431 cells were pre-incubated in 
serum-free media for 4 h prior to treatment with A23187 (5 µM) in the presence 
  
Figure 3.2. CPT treatment inhibits A23187-induced transcription of FOS. 
Subconfluent A431 cells were incubated in serum-free media for 2.5 hr prior 
to treatment with serum-free media containing 5 µM A23187. After 20 min, 10 
µM CPT or DMSO vehicle was added. At the indicated timepoints cells were 
collected by scraping and snap freezing in liquid nitrogen (A). Subsequently, 
total RNA was extracted and cDNA was synthesized with oligo-dT primers, 
using 1 µg total RNA as the template. RNA was degraded with RNAse A and 
samples were purified. Finally, samples were subjected to qPCR using primer 
sets F and D, targeting Exon 4 (B) and Intron 2 (C), respectively. Data were 
calculated by the ΔΔct method and are presented as fold over untreated, 
relative to the level of Actin mRNA. Data are mean ±SEM of 3 biological 
replicates. Statistical significance was calculated by two-factor ANOVA. 
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Figure 3.3. PARP inhibition does not prevent A23187-induced FOS 
transcription in the presence of CPT. Subconfluent A431 cells were treated 
according to the depicted (A). At the indicated time points cells were collected 
by scraping and snap freezing in liquid nitrogen. Subsequently total RNA was 
extracted and cDNA was synthesized with oligo-dT primers. RNA was 
degraded with RNAse A and samples were purified. Finally, samples were 
subjected to qPCR using primer set F, targeting FOS Exon 4. Data were 
calculated by the ΔΔct method and are presented as fold over untreated, 
relative to the level of Actin mRNA (B). For clarity, data are replotted after 
omitting samples treated with A23187 only (C). All data are mean ±SEM of 4 
biological replicates. 
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or absence of CPT (10 µM) and/or KU0058948 PARP inhibitor (500 nM) (Fig. 
3.3.a). Where KU0058948 was used, cells were incubated with the drug for 1 h 
prior to induction with A23187, and throughout the time course. A longer 
pre-incubation in serum-free medium was conducted to increase FOS mRNA fold 
induction. This was evidently the case, as treatment with A23187 alone lead to a 
notably higher fold change in FOS exon 4-containing mRNA (primer set F) at 1 h 
(600.7-fold over untreated) (Fig. 3.3.b). Upon co-treatment with CPT, 
accumulation of FOS mRNA was significantly delayed. Notably, whilst the 
induction of FOS in the absence of CPT lead to a transient induction (Fig. 3.2.b 
and Fig. 3.3.b) the continued presence of CPT throughout lead to a continued 
gradual accumulation of exon 4-containing transcripts. Co-incubation with PARP 
inhibitor KU0058948 failed to prevent FOS mRNA accumulation in the presence 
of CPT (Fig. 3.3.b and c). This suggests that FOS induction in the presence of 
CPT is independent of PARP activity. Whilst this result might indicate that SSBR 
is not required for the residual induction of FOS observed in the presence of CPT, 
alternatively it might indicate that SSBR following CPT treatment is PARP1 
independent.  
 
3.2.4. FOS transcription in the presence of CPT and/or proteasome 
inhibitor 
Proteasomal degradation of Top1-SSBs has been shown to occur prior to 
downstream steps of SSBR (Zhang, Tomida et al. 2004, Lin, Ban et al. 2008). To 
further investigate the Top1-SSB repair-dependence of FOS transcription in the 
presence of CPT, cells were co-incubated with MG132 proteasome inhibitor (50 
µM) (Fig. 3.4.a). In this case, MG132 was found to significantly reduce (ANOVA 
p-value = 3.95x10-3) accumulation of FOS exon 4-containing mRNA (primer set 
F) in the presence of CPT (Fig. 3.4.b and c). Whilst this could suggest that 
transcription in the presence of CPT is dependent on repair of Top1-SSBs, it 
could also be due to a general effect of proteasome inhibition on FOS 
transcription. To test this, serum starved A431 cells were pre-treated with MG132 
(50 µM) for 1 h prior to treatment with A23187 in the continued presence or 
absence of MG132 (Fig. 3.5.a). It was found that MG132 did indeed limit FOS 
mRNA accumulation in the absence of CPT (Fig. 3.5.b).  
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Figure 3.4. Proteasome inhibition limits A23187-induced FOS 
transcription in the presence of CPT. Subconfluent A431 cells were treated 
according to the time course depicted (A). At the indicated time points cells 
were collected by scraping and snap freezing in liquid nitrogen. Subsequently 
total RNA was extracted and cDNA was synthesized with oligo-dT primers. 
RNA was degraded with RNAse A and samples were purified. Finally, samples 
were subjected to qPCR using primer set F, targeting FOS Exon 4. Data were 
calculated by the ΔΔct method and are presented as fold over untreated, 
relative to the level of Actin mRNA (B). For clarity, data are replotted after 
omitting samples treated with A23187 only (C). All data are mean ±SEM of 4 
biological replicates. Statistical significance was calculated using two-factor 
ANOVA. 
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Figure 3.5. Proteasome inhibition limits A23187-induced FOS 
transcription in the absence of CPT. Subconfluent A431 cells were treated 
according to the time course depicted (A). At the indicated time points cells 
were collected by scraping and snap freezing in liquid nitrogen. Subsequently 
total RNA was extracted and cDNA was synthesized with oligo-dT primers. 
RNA was degraded with RNAse A and samples were purified. Finally, samples 
were subjected to qPCR using primer set F, targeting FOS Exon 4. Data were 
calculated by the ΔΔct method and are presented as fold over untreated, 
relative to the level of Actin mRNA. Data are presented for one experiment. 
(B). 
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3.2.5. Optimization of A431 ChIP sonication conditions  
Successful ChIP is reliant upon many different variables which must be carefully 
optimized for every cell line and antibody combination. One particularly important 
factor is the quality of chromatin sonication. Sonication should be sufficient to 
produce chromatin fragments with an average size of 300-500 bp, whilst 
minimising degradation of the epitope of interest. Optimization was conducted by 
subjecting 4% formaldehyde -fixed A431 cells to lysis in 1% SDS buffer, followed 
by water bath sonication for increasing numbers of cycles (30 s ON / 30 s OFF). 
Samples were then divided into two to allow separate analysis of chromatin 
fragments by 1% agarose EtBr (Fig. 3.6.a and b) and XRCC1 protein by WB 
(Fig. 3.6.c). Three cycles were sufficient to produce chromatin fragments with an 
average size of 300-500 bp. Three cycles also resulted in minimal XRCC1 protein 
loss, which was very apparent with increasing sonication cycles. 
 
3.2.6. RNAPII binding at FOS measured by ChIP.  
The genomic distribution of RNAPII has been measured previously using 
ChIP-seq/qPCR with several different antibodies. The most commonly used are 
H5, H14 and 8WG16 monoclonal antibodies. These all target the C-terminal 
domain of RNAPII, which is differentially phosphorylated at specific residues in 
its YSPTSPS repeat motif, depending on the stage of transcription in which the 
polymerase is engaged. The CTD of RNAPII is hypophosphorylated in the 
pre-initiation complex. Phosphorylation of CTD Ser5 is found in early elongating 
complexes, and Ser2 is additionally phosphorylated in productively elongating 
complexes. H14 and H5 antibodies recognise CTD epitopes with Ser5 or Ser2 
Ser5 phosphorylation. By comparison 8WG16 recognizes unphosphorylated 
CTD and CTD phosphorylated on Ser5 but not Ser2 (Morris, Michelotti et al. 
2005). However, given that even productively elongating RNAPII complexes will 
contain some unphosphorylated CTD sequences, 8WG16 has traditionally been 
used as a measure of total RNAPII. For this reason, 8WG16 was selected for use 
in this study. 
A431 cells were treated with A23187 (5 µM) and/or CPT (10 µM) prior to 
fixation, according to the time course in (Fig. 3.7.a). ChIP was conducted with 
  
Figure 3.6. Optimization of sonication conditions for ChIP with A431 
cells. A431 cells were formaldehyde fixed and collected by scraping and 
centrifugation. Pellets were lysed in 1% SDS ChIP lysis buffer and sonicated 
for the indicate number of cycles (1 cycle = 30 s ON, 30 s OFF). One aliquot 
of each sample was incubated at 65oC overnight to reverse formaldehyde 
crosslinks, prior to separation and visualisation of chromatin fragments by 
agarose electrophoresis with ethidium bromide staining. A molecular weight 
marker is included, showing sizes in bp. (A). A longer exposure is shown in 
(B). The other fraction of each sample was boiled immediately in LB and 
subjected to SDS-PAGE and WB with anti-XRCC1 antibody A231-300A. A 
molecular weight marker is included, showing sizes in KDa. (C). 
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8WG16 antibody or anti-IgG antibody as detailed in the methods, using the 
sonication conditions established above. qPCR was subsequently conducted 
using primer sets A, B, C, D, F and G (Fig. 3.7.b). The profile of RNAPII 
distribution in untreated cells is characteristic of many immediate early response 
(IED) genes, with a significant fraction being located immediately downstream of 
the TSS in a state of promoter proximal pausing. Upon induction with A23187, 
RNAPII association increased at all gene loci, but did not significantly increase at 
the downstream locus G. This indicates that sonication is optimal to produce 
small enough fragments for high resolution ChIP-qPCR. Whilst an increase in 
RNAPII association was detected at all gene loci, the fold increase was 
particularly pronounced at the downstream loci detected by primer sets C, D, and 
F (t-test p-values: 3.06x10-3, 1.17x10-3, and 1.34x10-3, respectively). This 
enrichment of RNAPII at downstream loci indicates release from a paused state 
to productive elongation upon induction with A23187. Upon treatment with 
A23187 and CPT, a significant reduction in RNAPII association at all loci was 
detected, relative to A23187 treatment alone (ANOVA p-value = 1.05x10-2). It is 
important to note that treatment with CPT in the absence of FOS induction did 
not result in any significant alteration of the RNAPII distribution within FOS 
(ANOVA p-value = 6.86x10-1).  
 
3.2.7. Optimization of XRCC1 ChIP immunoprecipitation with A431 cells 
Next, protocols were established for the direct measurement of XRCC1 
recruitment to FOS, by ChIP. First, the immunoprecipitation (IP) of XRCC1 was 
optimized by ChIP-WB. Fixed and lysed A431 cells were sonicated for 3 cycles 
prior to dilution and overnight IP with 1, 2, or 5 µg A300-231A antibody. This 
polyclonal antibody is affinity purified using an immobilized peptide 
encompassing the phosphorylated S485 and T488 residues. It has been used 
extensively in the literature for WB, IF, IP, and IHC, but not for ChIP. Following 
IP, Protein G -conjugated dynabeads were added to precipitate antibody-antigen 
complexes, prior to washing and elution. Fractions of input, unbound, washes 
and elution were subjected to 10% SDS-PAGE and WB with A300-231 
anti-XRCC1 antibody (Fig. 3.8.). XRCC1 was successfully recovered in all IPs to 
a varying extent. IP with 2 µg of antibody resulted in the best recovery of XRCC1, 
  
 
Figure 3.7. ChIP reveals distribution of RNAPII within FOS in cells treated 
with A23187 and/or CPT. A431 cells were treated or not with A23187 (5 µM) 
and/or CPT (10 µM) as in (A). RNAPII ChIP-qPCR was conducted with 8WG16 
antibody, as described in section 2.2.4.6. The enrichment values of the primer 
pairs A, B, C, D, F, and G are expressed as % of input. The positions of these 
primer pairs relative to the FOS gene are indicated (B). All data are mean 
±SEM of at least 2 biological replicates. 
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Figure 3.8. Optimization of immunoprecipitation conditions for XRCC1 
ChIP with A431 cells. A431 cells were formaldehyde fixed and subjected to 
anti-XRCC1 ChIP-WB as described in the methods. For the 
immunoprecipitation, a titration of 1, 2 or 5 uL of A300-231A antibody was 
used. Samples of input, unbound, washes and elution were retained and 
subjected to WB with anti-XRCC1 antibody (A300-231A). The loaded cell 
equivalents are expressed relative to input. The position of XRCC1 and the 
heavy and light antibody chains is indicated. 
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whereas IP with 5 µg resulted in the worst recovery. This is likely to be due to 
saturation of the binding capacity of the Protein G beads. Protein G dynabeads 
have an estimated capacity of 0.24 µg of IgG per 1 µL beads, which would be an 
estimated 4.8 µg A300-231A for the 20 uL beads used here. However, this 
estimate is for human rather than rabbit IgG, and was estimated by the 
manufacturer using different IP conditions. In the unbound fraction of the 5 µg IP 
there is a strong band at ~50 KDa corresponding to the heavy chain of the 
A300-231A antibody, indicating that the capacity of the protein G beads has 
indeed been exceeded. This may result in lower recovery of XRCC1 in the IP, as 
some of the recoverable fraction remains associated with the unbound 
A300-231A antibody. It may be possible to increase the volume of beads used in 
the IP to recover more XRCC1 with 5 µg A300-231A. However, the recovery was 
deemed sufficient for the purposes of the ChIP-qPCR with 2 µg A300-231A. 
 
3.2.8. XRCC1 localization at FOS measured by ChIP  
Untreated cells, and cells treated with A23198 and/or CPT were fixed according 
to the time course depicted in (Fig. 3.9.a). Cells were then subjected to 
anti-XRCC1 ChIP with A300-231A antibody, using the sonication and IP 
conditions established above (see section 2.2.4.6 for detailed protocol). As for 
RNAPII ChIP, primer sets A, B, C, D, F, and G were used to measure XRCC1 
localization at the FOS locus (Fig. 3.9.b). A300-231A signal was low at all tested 
loci in untreated cells. Upon treatment with A23187, A300-231A ChIP signal 
significantly increased in the gene body at loci C, D and F (t-test p-values: 
1.61x10-2, 1.12x10-2 and 2.10x10-3, respectively). By comparison, the small 
increases in ChIP signal at the promoter locus (A), the transcription pausing locus 
(B) and the downstream locus (G) were not significant (t-test p-values: 1.09x10-1, 
6.49x10-2, 9.51x10-2, respectively). The signal increase was correlated with 
distance from the TSS, with the downstream loci D and F having the largest fold 
changes (3.6 and 3.5-fold respectively). By comparison, the signal at the 
promoter (A) and RNAPII pause site (B) remained relatively low. Upon treatment 
with A23187 and CPT, A300-231A signal at all FOS loci was not significantly 
different to treatment with A23187 alone (t-test p-values: 9.76x10-1, 7.67x10-1, 
8.09x10-1, 5.29x10-1 and 2.54x10-1 for A, B, C, D and F, respectively). This result 
  
 
Figure 3.9. ChIP reveals apparent distribution of XRCC1 within FOS in 
cells treated with A23187 and/or CPT. A431 cells were treated or not with 
A23187 (5 µM) and/or CPT (10 µM) in the manner depicted in (A). XRCC1 
ChIP-qPCR was conducted with A231-300A antibody, as described in section 
2.2.4.6. The enrichment values of the primer pairs A, B, C, D, F and G are 
expressed as % of input. The positions of these primer pairs relative to the 
FOS gene are indicated (B). All data are mean ±SEM of at least 2 biological 
replicates. 
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was surprising as it implied that XRCC1 recruitment might occur 
co-transcriptionally, in the absence of DNA damage. To validate that the results 
of the A300-231A ChIP specifically reflected XRCC1 localization, further 
experiments were conducted.  
 
3.2.9. Optimization of conditions for XRCC1 ChIP with EM9 cells. 
At the time that these experiments were being conducted, a human XRCC1 KO 
cell line was not available for use as an antigen negative control. Instead, the 
Chinese Hamster Ovary (CHO) XRCC1 KO cell line EM9 was the most suitable 
choice to test the specificity of the A300-231A antibody. ChIP sonication and IP 
conditions were established in EM9 cells stably complemented with WT XRCC1 
(EM9-XH) (Fig. 3.10.). Three cycles of sonication produced suitable chromatin 
fragments of 300-500 bp (Fig. 3.10.a). The IP resulted in a good recovery of 
XRCC1, with little remaining in the unbound fraction (Fig. 3.10.b). 
 
3.2.10. XRCC1 ChIP with A300-231A antibody in EM9 cells reveals 
non-specific signal.   
EM9 cells complemented with wild type human XRCC1-His or vector, denoted 
XRCC1-XH (XH) or EM9-V (V), respectively were treated or not with A23187 
and/or CPT, prior to fixation according to the time course as for A431 cells 
(Fig. 3.9.a). Cells were then subjected to ChIP with A300-231A anti-XRCC1 
antibody, or a negative control antibody targeting rabbit IgG, as per the sonication 
and IP conditions identified above (see section 2.2.4.6 for detailed protocol). 
qPCR was conducted with pimer set cgE4, targeting a comparable region of FUS 
exon 4 to primer set F in A431 cells (see section 2.2.4.3). Unfortunately, a strong 
A300-231A ChIP signal was observed in both EM9 XH and EM9 V cells upon 
treatment with A23187 and/or CPT (Fig. 3.11.a). Moreover, the signal was even 
higher in EM9 V than EM9 XH cells, indicating that the signal observed with this 
antibody is not specific to XRCC1. The signal was two orders of magnitude higher 
than the background signal observed in the mock anti-IgG ChIP. A WB with 
A300-231A antibody was conducted in parallel with the ChIP, demonstrating the 
absence of XRCC1 protein in EM9 V cells (Fig. 3.11.b). The WB did not detect 
  
 
Figure 3.10. Optimization of conditions for XRCC1 ChIP with EM9 cells. 
EM9 cells were formaldehyde fixed, lysed in 1% SDS lysis buffer and 
subjected to sonication for the indicated number of cycles (1 cycle = 30 s ON/ 
30 s OFF); prior to 65oC incubation overnight to reverse crosslinks. Chromatin 
fragments were separated and visualised by 1% agarose electrophoresis with 
EtBr staining (A). EM9 cells stably expressing XRCC1 were subjected to anti-
XRCC1 ChIP-WB with A231A-300A antibody as described in the methods. 
Samples of input, unbound, washes and elution were retained and subjected 
to WB with anti-XRCC1 antibody (A300-231A). The loaded cell equivalents 
are expressed relative to input. The position of XRCC1 and the heavy antibody 
chain are indicated (B). 
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Figure 3.11. XRCC1 ChIP with A300-231A antibody in EM9 cells reveals 
non-specific signal. EM9 cells stably complemented with wild type XRCC1 
(XH) or vector (V) were treated with A23187 (5 µM) and/or CPT (10 µM) 
according to the time course depicted in (A), before being subjected to ChIP 
with anti-XRCC1 A300-231A antibody and anti-IgG antibody, as described in 
section 2.2.4.6. qPCR was conducted with the Exon 4 primer pair (B). 
Enrichments are expressed as % of input. A representative experiment is 
shown. A fraction of the indicated sample inputs was boiled in LB and 
subjected to SDS-PAGE and WB with anti-XRCC1 antibody A300-231A (C).  
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any obvious non-specific bands in the EM9 V cells. However, this may be 
because A300-231A recognizes non-specific epitopes in the ChIP that are 
destroyed by the denaturing conditions of the WB.  
Many proteins localize to actively transcribing genes, any of which may be 
non-specific targets of A300-231A. In addition, the relaxed conformation of active 
genes is thought to lead to their overrepresentation in ChIP data, possibly due to 
an increased susceptibility to formaldehyde fixation (Park, Lee et al. 2013, 
Teytelman, Thurtle et al. 2013) (see section 3.3 for further discussion). These 
details are likely to explain the A23187-inducible nature of the non-specific signal. 
 
3.2.11. A431 GFP-XRCC1 ChIP optimization 
Due to the inherent bias of ChIP data towards transcriptionally active DNA (Park, 
Lee et al. 2013, Teytelman, Thurtle et al. 2013), the enrichment of any nuclear 
protein could be falsely detected at FOS. To try to control for this, and to 
circumvent a lack of other suitable anti-XRCC1 antibodies available at the time 
of these experiments, a new strategy was devised. A431 cells were transfected 
with GFP-XRCC1 or GFP expression plasmids. Transfected cells were subjected 
to antibiotic selection with G418, prior to isolation of single clones by observation 
of GFP fluorescence. To confirm the expression of the transgenes, a WB with 
anti-GFP antibody (ab290) was performed on cell lysates from these two cell lines 
(Fig. 3.12.a). Next, using A431 GFP-XRCC1 cells ChIP sonication conditions 
were again optimized: for minimal degradation of GFP-XRCC1 (Fig. 3.12.b), and 
to produce chromatin fragments of 300-500 bp (Fig. 3.12.c). In each case, three 
cycles produced optimum results. Finally, the IP of GFP-XRCC1 with anti-GFP 
antibody (AB290) was tested (Fig. 3.12.d). Approximately 10-15% of input 
GFP-XRCC1 was recovered in the IP (compare GFP-XRCC1 band in input vs 
10-fold elution). 
 
3.2.12. Anti-GFP ChIP cannot detect GFP-XRCC1 enrichment in C-FOS 
following transcription induction or CPT exposure 
A431, A431 GFP, or A431 GFP-XRCC1 cells were treated or not with A23187 
and/or CPT, prior to fixation according to the time course depicted in (Fig. 3.13.a). 
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Figure 3.12. GFP-XRCC1 ChIP optimization. A431 cells stably expressing 
GFP or GFP-XRCC1 were generated by transfection and selection in G418 
(see section 2.2.2.5), prior to western blotting of whole cell extracts with anti-
GFP (α-GFP) and anti-Actin antibodies (A). GFP-XRCC1 cells were fixed with 
4% formaldehyde and collected by scraping and centrifugation. Cells were 
lysed in 1% SDS lysis buffer and sonicated for the indicated number of cycles 
(30 s ON/ 30 s OFF), prior to being subjected to SDS-PAGE and western 
blotting with anti-XRCC1 antibody (A300-231A) (B), or agarose 
electrophoresis and ethidium bromide staining (C). GFP-XRCC1 cells were 
subjected to anti-GFP ChIP-WB as described in the section 2.2.4.7 (3 cycles 
of sonication). Samples of input, unbound, washes and elution were retained 
and subjected to western blotting with anti-XRCC1 antibody (A300-231A) (D). 
The loaded cell equivalents are expressed relative to input. A molecular weight 
marker was included in all electrophoresis experiments and sizes are indicated 
in bp (C) or KDa (A, B and D). 
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Figure 3.13. Anti-GFP ChIP cannot detect GFP-XRCC1 enrichment in FOS 
following transcription induction or CPT. A431, A431 GFP or A431 GFP-
XRCC1 cells were treated or not with A23187 (5 µM) in the presence or 
absence of CPT (10 µM), according to the time course illustrated in (A). Fixed 
cells were then subjected to anti-GFP ChIP-qPCR (primer set F) as described 
in section 2.2.4.7. A representative experiment is shown (B). 
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Cells were then subjected to ChIP with anti-GFP antibody (ab290), as per the 
sonication and IP conditions identified above (see section 2.2.4.7 for detailed 
protocol). qPCR was conducted with primer set F, and the results of a 
representative experiment are shown in (Fig. 3.13.b). Unfortunately, despite 
repeated attempts (not shown), ChIP-qPCR failed to detect any enrichment of 
GFP-XRCC1 in FOS following A23187 and/or CPT. 
 
3.3. Conclusions and Discussion 
This chapter attempted to establish a model system for studying the interplay 
between SSBR and transcription at the level of a single endogenous gene. 
Induction of FOS transcription with the calcium ionophore A23187 was 
successfully demonstrated by RT-PCR and RNAPII ChIP-qPCR. The 
accumulation of FOS mRNA was shown to be very transient, which has been 
noted previously (Francis Stewart, Herrera et al. 1990). This is due to rapid 
degradation of the FOS transcript (Shyu, Greenberg et al. 1989), coupled with an 
autoinhibitory effect of FOS protein at its own promoter (Schönthal, Herrlich et al. 
1988). Upon additional treatment with 10 µM CPT, FOS mRNA accumulation was 
limited but not prevented. Furthermore, in contrast to the kinetics in the absence 
of CPT, FOS mRNA continued to accumulate during the time course of the 
experiments in the presence of CPT, which may be because FOS protein levels 
are too low in the presence of CPT to trigger the negative feedback mechanism. 
To test whether ongoing transcription in the presence of CPT was dependent on 
repair of Top1-SSBs, two known steps in this process were perturbed. Co-
treatment with MG132, which blocks proteasomal degradation of Top1-SSBs, 
was found to limit accumulation of FOS mRNA in the presence of CPT. However, 
subsequent experiments revealed that this was also limited in the absence of 
CPT, suggesting a more general effect on the regulation of FOS transcription. 
FOS protein, which represses its own transcription (Schönthal, Herrlich et al. 
1988), is known to be degraded rapidly by the proteasome (Ito, Inoue et al. 2005). 
Upon treatment with MG132, increased FOS protein levels may therefore repress 
FOS transcription.  
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Inhibition of PARP activity by co-treatment with KU0058948 failed to limit 
FOS mRNA accumulation in the presence of CPT, suggesting independence of 
this phenomenon from SSBR involving ADP-ribosylation. There are several 
possible explanations for this. One possibility is that alternative repair pathways 
can compensate, such as NER. Supporting this, the endonuclease XPF-ERCC1, 
which acts in global and transcription coupled-NER, has been reported to function 
in an alternative pathway for the repair of CPT-induced damage (Zhang, Regairaz 
et al. 2011). In the future, the accumulation of FOS mRNA in the presence of CPT 
could be measured in a context of XPF or ERCC1 depletion.  
The reduced accumulation of FOS mRNA upon CPT treatment coincided 
with a reduction in RNAPII ChIP-qPCR signal at the promoter and in the gene 
body. Prolonged DNA damage-dependent (Desai, Zhang et al. 2003) and 
independent (Ratner, Balasubramanian et al. 1998, Karakasili, Burkert-Kautzsch 
et al. 2014) stalling of transcription leads to proteasomal degradation of Rpb1, 
the largest subunit of RNAPII, which contains the CTD. A more immediate effect 
of exposure of cells to CPT is the CDK7-mediated hyperphosphorylation of Rpb1 
at Ser5 residues of the CTD repeat motif (Sordet, Larochelle et al. 2008), which 
may result in reduced affinity of 8WG16 binding and thus also contribute to the 
loss of RNAPII ChIP-qPCR signal (Cho, Kobor et al. 2001, Jones, Phatnani et al. 
2004).  
 Following successful application of the ChIP protocol to RNAPII, attempts 
were made then made to apply the same techniques to XRCC1, in order to 
measure recruitment of this central SSBR scaffold to FOS in response to 
transcription induction with or without DNA damage. Initial experiments, using 
A300-231A antibody, indicated transcription-dependent XRCC1 recruitment 
concentrated in downstream transcribed regions of FOS. However, concerns 
about the specificity of this signal prompted further experiments in XRCC1 KO 
EM9 cells. Unfortunately, it was found that A23187-induced A300-231A 
ChIP-qPCR signal was present at FOS in EM9 V cells, revealing its 
non-specificity. This finding highlights the importance of including epitope 
depletion controls when conducting ChIP, especially when using an antibody 
which has not been verified with the technique. Unfortunately, the majority of 
published ChIP data includes only a mock IP control (Landt, Marinov et al. 2012). 
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In this case, the non-specific A300-231A signal is two orders of magnitude greater 
than the anti-IgG signal, which demonstrates the unsuitability of mock IPs as 
ChIP negative controls (Landt, Marinov et al. 2012). 
Heavily transcribed loci, such as FOS, have recently been shown to be 
overrepresented in ChIP-qPCR/seq data (Auerbach, Euskirchen et al. 2009, 
Park, Lee et al. 2013, Teytelman, Thurtle et al. 2013, Jain, Baldi et al. 2015), 
possibly due to increased crosslinking or sonication of active chromatin. This 
widespread, systematic artifact may be particularly troublesome when attempting 
to ChIP proteins which interact transiently with chromatin, such as chromatin 
remodellers and repair proteins (Jain, Baldi et al. 2015).  Considering this, a 
different strategy was devised to conduct anti-GFP ChIP-qPCR in cells stably 
transfected with GFP or GFP-XRCC1. This approach, which has been suggested 
previously (Teytelman, Thurtle et al. 2013), should control for the ChIP bias 
towards transcriptionally active regions. The advantage over other 
traditionally-used controls, such as mock IPs, is that the negative control involves 
precipitation of a real epitope (GFP) with the same antibody (anti-GFP), and 
should therefore be subject to the same inherent ChIP bias as precipitation of the 
tagged protein of interest (GFP-XRCC1). Unfortunately, despite many attempts 
to optimise and improve the protocol, anti-GFP ChIP-qPCR was not able to detect 
GFP-XRCC1 recruitment to FOS following treatment with A23187 and/or CPT. 
There are several reasons why this may not have been successful. Firstly, it is 
possible that the overexpression of GFP-XRCC1 results in a very large fraction 
which is not associated with chromatin. As only 10-15% of the input GFP-XRCC1 
was recovered by IP, this may reduce the signal to noise ratio appreciably. 
Secondly, the epitope bound by ab290 may be sterically hindered by the 
orientation of GFP-XRCC1 chromatin binding. Thirdly, it is important to note that 
strong ChIP signal is generally only seen for proteins which interact strongly with 
chromatin for extended periods of time (transcription factors, polymerases etc) 
(Landt, Marinov et al. 2012). A combination of these issues may result in a signal 
to background ratio which is below the limit of detection of the assay. Finally, it is 
possible that GFP-XRCC1 is truly not recruited to FOS under the treatment 
conditions employed here. This final point highlights a significant obstacle which 
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was faced throughout this research: the lack of a validated genomic locus with 
enriched XRCC1 association, for use as a positive control. 
Establishing the A300-231A ChIP-qPCR protocol in EM9 cells, whilst 
necessary to check the specificity of the signal, was time consuming. 
Furthermore, it raised the possibility of detecting non-specific signal unique to 
CHO cells. If this project were to be reattempted in the future, either with XRCC1 
or another SSBR protein, it would be useful to have a panel of KO human cell 
lines for use as epitope negative controls. With these, it would be possible to 
screen a panel of antibodies for high specificity and affinity. The advent of 
CRISPR-Cas9 technology, allowing relatively straightforward modification of 
genomic DNA in vivo, makes the generation of such cells possible. This will be 
the subject of the following chapter. 
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Chapter Four 
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Diploid Human Cells with 
CRISPR-Cas9 -mediated deletion of 
SSBR genes  
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4.1. Introduction and Aims 
The previous chapter attempted to establish protocols for XRCC1 ChIP with 
limited success. One limitation that proved a barrier was the absence of a suitable 
human XRCC1-deleted cell line for use as an antigen negative control. Eventually 
this lead to establishing the ChIP protocol in Chinese hamster ovary (CHO) cells, 
where an XRCC1 KO cell line was available (EM9). This highlights a clear dearth 
of published human cell lines with SSBR gene KOs, with most studies instead 
utilizing siRNA-mediated depletion or mouse embryonic fibroblasts (MEFs) 
derived from transgenic animals. Whilst these tools have greatly advanced our 
understanding of SSBR gene function, they are not without limitations. Depletion 
by siRNA can often be incomplete and a seemingly negligible remaining fraction 
of protein, for example a highly active enzyme such as PARP1, can mask 
phenotypes and lead to erroneous conclusions. One example of this is the 
observation that complemented XRCC1-/- mice possessing approximately 10% 
WT levels of XRCC1 protein exhibit normal embryogenesis and post-natal 
development, and that MEFs generated from these animals display comparable 
methyl methanesulfonate (MMS) sensitivity to WT cells (Tebbs, Thompson et al. 
2003). 
 By comparison with siRNA depletion, KO MEFs offer complete deletion of 
gene function and are thought to be a good model of most features of human 
DNA repair. However, there are known instances where DNA repair pathway 
choice may differ in human and mouse. For example the relative abundance of 
Ku80 and DNA-PKcs is dramatically higher in human than mouse cells (Lorenzini, 
Johnson et al. 2009). Furthermore, there are multiple examples where KO mouse 
models do not fully recapitulate the phenotypes of human patients (van der Horst, 
van Steeg et al. 1997, Lombard, Beard et al. 2000, Yeo, Becherel et al. 2014).  
For these reasons, it would be useful to have a panel of immortalized 
human KO cell lines for studying SSBR. With the advent of CRISPR-Cas9 
mediated gene editing technology, this is now feasible. This chapter will describe 
the generation of three novel KO cell lines derived from human diploid retinal 
pigmented epithelium (RPE-1) cells. These cells were chosen for several 
reasons. Firstly, they are not tumour-derived and instead were initially generated 
91 
 
by human telomerase reverse transcriptase (hTERT) – mediated immortalization 
of the non-cancerous RPE-340 cell line, in a landmark study which was first to 
employ this technique (Bodnar, Ouellette et al. 1998). Consequently, the cells 
have a relatively normal karyotype (modal chromosome number of 46, present in 
>90% of cells) when compared to other commonly used human cell lines, which 
are often remarkably polyploid. This is important because the hyperploidy of 
tumour-derived cell lines, such as U2OS (hypertriploid), is likely to result in altered 
gene dosage and may have phenotypic consequences (Birchler and Veitia 2012). 
Also, from a practical perspective, lower ploidy is likely to improve efficiency of 
KO generation (H. Hanzlikova and N. Hegarat, personal communication; and 
(Horii and Hatada 2015).  
CRISPR-Cas9 is a technology which utilizes components of the 
prokaryotic adaptive immune system (Mojica, Diez-Villasenor et al. 2005, 
Pourcel, Salvignol et al. 2005) to introduce precise and specific site-directed 
alterations to genomic DNA (Cong, Ran et al. 2013, Mali, Yang et al. 2013). This 
is typically accomplished by transient coexpression of two components: the 
RNA-directed deoxyriboendonuclease Cas9, and a guide RNA (gRNA) 
comprised of a structural region and a region which is complementary to the 
target genomic locus. NLS-tagged Cas9 binds to the structural region of the 
gRNA, which is derived from the trans-activating crRNA; and is directed to the 
target gDNA locus by the complementary region of the gRNA (Cong, Ran et al. 
2013, Mali, Yang et al. 2013). This target sequence must precede a Protospacer 
Adjacent Motif (PAM), which varies for nucleases of different prokaryotic species 
(Mojica, Díez-Villaseñor et al. 2009). In the case of the most commonly used 
nuclease from Streptococcus pyogenes, spCas9, the PAM sequence is NGG 
(Mojica, Díez-Villaseñor et al. 2009). Cas9 subsequently makes a blunt 
double-strand DNA break three base pairs (bp) upstream of the PAM. This 
double-strand break is subject to homologous recombination (HR) and non-
homologous end joining (NHEJ) repair pathways.  Error-free events, such as 
those which predominate in HR, will restore the target sequence and allow 
successive rounds of Cas9 activity. Eventually an erroneous repair event is likely 
to occur, introducing an indel (an insertion or deletion) which disrupts the target 
sequence and prevents further nuclease activity. If this indel is within an exon 
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and is not a multiple of three nucleotides in length; a frame shift will occur, which 
will often lead to the introduction of a premature stop codon downstream. These 
nonsense transcripts are then detected and degraded by a co-translational 
surveillance pathway termed Nonsense Mediated Decay (NMD), preventing the 
expression of the target gene at the protein level (Losson and Lacroute 1979). 
 
4.2. Results 
4.2.1. Design of gRNAs for deletion of TDP1 by CRISPR-CAS9 
The Benchling web application (https://benchling.com) was used to design two 
gRNAs for use in deletion of human TDP1. The algorithm was constrained to 
search for gRNA target loci that were of the form: 
5’-GNNNNNNNNNNNNNNNNNGG-3’ 
gRNAs were selected that were 17 bp in length (without PAM), as these truncated 
gRNAs (tru-gRNAs) have been demonstrated to minimize off-target activity of 
Cas9 nuclease, without compromising the on-target efficiency (Fu, Sander et al. 
2014). Secondly, gRNAs were selected with 5’-guaninosine, because this aids 
efficient transcription from the U6 promoter present on the gRNA expression 
plasmid. Thirdly, only gRNA loci with a PAM sequence of the form NGG were 
selected, which is the consensus PAM sequence for the S. pyogenes Cas9 used 
in this protocol (Mojica, Díez-Villaseñor et al. 2009). Finally, the search was 
confined to the first exon of TDP1, to maximise the chance of a frame-shift 
nonsense mutation at the beginning of the coding sequence. The Benchling 
algorithm identified a number of potential gRNA sequences which were ranked 
by an Off-target Score, which is defined based on a previous study (Hsu, Scott et 
al. 2013). High scoring candidate sequences were aligned to the human genome 
(BLAST) to look for potential off-target loci (https://blast.ncbi.nlm.nih.gov). Two 
gRNA sequences were identified (5’-GAGGUAGAUGGCUUGUCUGG and 
5’-GACGAGUAUGAGACAUCAGG), and are hereafter referred to as gRNA 
TDP1.1 and TDP1.2, respectively. The positions of these target loci are indicated 
in Fig. 4.1. 
 
 Figure 4.1. The genomic loci targeted by gRNAs TDP1.1 and TDP1.2. Full 
length TDP1 gene (dark green), mRNA (dark blue) and protein coding (red) 
sequences are depicted (A). The region of exon 1 containing the loci targeted 
by gRNA TDP1.1 and TDP1.2 is enlarged in (B). The target loci of gRNAs 
TDP1.1 and TDP1.2 are further enlarged in (C) and (D), respectively.  
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Figure 4.2. An overview of the CRISPR-Cas9 method. gRNA constructs 
were assembled and cloned into the gRNA vector to generate the gRNA 
expression plasmid (A). This was cotransfected with the Cas9 expression 
vector into RPE-1 cells by Neon nucleofection (B). Cells were selected for five 
days with G418 antibiotic (C), prior to plating at low density (D). After two 
weeks incubation in antibiotic-free media (E), single colonies were passaged 
to duplicate wells of 24-well plates (F). After one week, confluent wells were 
lysed and screened by western blot for absence of the target protein (G). 
Positive KO clones were expanded and further characterized by PCR and 
Sanger sequencing (H).  
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4.2.2. Generation of TDP1-/- and XRCC1-/-/TDP1-/- RPE-1 cells 
The CRISPR-Cas9 genome editing protocol employed herein is depicted in 
Fig. 4.2. Firstly, oligodeoxynucleotides encoding gRNAs TDP1.1 and TDP1.2 
were cloned into a previously reported expression plasmid (Mali, Yang et al. 
2013), to generate plasmids pGR.TDP1.1 and pGR.TDP1.2, respectively. These 
plasmids were co-transfected with the Cas9 expression plasmid (Mali, Yang et 
al. 2013) into RPE-1 cells using the Neon nucleofection system. After twenty-four 
hours, complete media containing 0.5 mg/ml G418 was added and cells were 
incubated for five days. This strategy of antibiotic selection for five days only was 
chosen to eradicate non-transfected cells, based on the G418 resistance 
cassette present on the Cas9 expression construct, whilst minimising the 
likelihood of selecting for stable Cas9 integrants. After selection, cells were 
trypsinised and plated at low density. Following two weeks incubation in 
antibiotic-free media, colonies were selected and seeded individually into 
duplicate wells of a 24-well dish. After a subsequent week of incubation, confluent 
wells were lysed directly in Laemmli Buffer (LB) and subjected to SDS-PAGE and 
Western Blot (WB) with anti-TDP1 and anti-actin antibodies (Fig. 4.3.a). 
 TDP1 protein was present in all sixteen clones selected following 
transfection with pGR.TDP1.1, suggesting inefficient Cas9 nuclease activity with 
this gRNA sequence. One clone (#5C6) appeared to have a small insertion, 
leading to a shift in the TDP1 band. Additionally, one clone (#1B2) may have had 
reduced TDP1 protein levels, but this was inconclusive due to poor loading in this 
lane. By contrast, five out of ten clones transfected with pGR.TDP1.2 appeared 
to have absent or minimal TDP1 expression. Five of the apparent KO clones 
(#4A2, #4A4, #4B3, #4B4 and #4B5) were expanded and the WB repeated (Fig. 
4.3.b). WT RPE-1 cell lysate was used as a positive control for TDP1 protein. 
Lysate from RPE-1 cells transiently transfected with Cas9 expression plasmid 
alone was used as a positive control for expression of Cas9. Four clones (#4A2, 
#4B3, #4B4 and #4B5) again exhibited an absence of TDP1 protein, under the 
conditions employed. These clones also lacked Cas9 expression, suggesting that 
the Cas9 expression cassette was not stably integrated. A band that migrated 
slightly faster than WT TDP1 was detected in clone #4A4, suggesting an in-frame 
 Figure 4.3. Screening for TDP1-/- RPE-1 clones by Western blot. Isolated 
RPE-1 clones processed as in Fig. 4.2. were subjected to Western blotting with 
anti-TDP1 and anti-actin antibodies (A). Highlighted clones (red) were 
expanded and subjected to repeated WB (B). Note the apparent absence of 
TDP1 protein in #4A2, #4A4, #4B3, #4B4 and #4B5. WT cells transiently 
expressing Cas9 alone were used as a control to demonstrate the absence of 
stable Cas9 expression in the TDP1-/- RPE-1 clones. A molecular weight 
marker was included, indicating the approximate molecular weight in KDa. 
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 Figure 4.4. Screening for XRCC1-/-/ TDP1-/- RPE-1 clones by Western blot. 
Isolated RPE-1 clones were subjected to SDS-PAGE and Western blotting with 
Ponceau S staining and anti-TDP1 antibody (A). Highlighted clones (red) #1D2 
and #3A2 were expanded and WB repeated. WT, TDP1-/-, XRCC1-/- RPE-1 cell 
lysates were included as controls (B). Note the apparent absence of TDP1 and 
XRCC1 proteins in #3A2. A molecular weight marker was included, indicating 
the approximate molecular weight in KDa. 
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deletion. Clone #4B5 was selected for more extensive characterization by 
sequencing.  
 Next, pGR.TDP1.2 was co-transfected with Cas9 expression plasmid to 
delete TDP1 in XRCC1-/- RPE-1 cells (#3). This XRCC1-/- RPE-1 cell line was 
previously generated by co-workers in the Caldecott laboratory. Fifty-one clones 
were screened by WB for TDP1 (Fig. 4.4.). Of these clones, two appeared to have 
low or absent TDP1 protein (#1D2 and #3A2), and repeated WB confirmed the 
absence of both XRCC1 and TDP1 in #3A2. In contrast, a low level of TDP1 was 
observed in #1D2, suggesting deletion of TDP1 was incomplete. 
 
4.2.3. Sanger sequencing of the gDNA 2 locus in TDP1-/- (#4B5) and 
XRCC1-/-/TDP1-/- (#3A2) RPE-1 cells 
To determine the mutations introduced in TDP1-/- RPE-1 #4B5 and 
XRCC1-/-/TDP1-/- RPE-1 #3A2, genomic DNA was extracted and PCR was 
conducted using primers flanking the gRNA TDP1.2 target locus (277 bp 
amplicon). As a control, gDNA from WT RPE-1 cells was subjected to the same 
PCR. Separation of the PCR products by 1% agarose electrophoresis revealed 
a band in WT and #4B5 at the expected size of 277 bp, indicating that any indels 
in #4B5 must be smaller than the size resolution of the gel (Fig. 4.5.a). In contrast, 
the PCR product with #3A2 gDNA was ~200 bp larger, indicating a larger 
insertion. PCR products were purified and cloned, and expanded in DH5α. DNA 
prepared from multiple bacterial colonies was then Sanger sequenced (eight 
bacterial colonies each). Alignment of the resulting sequencing reads to the 
reference genome revealed mutations in #4B5 and #3A2 cells (Fig. 4.5.b). Of the 
eight mutated PCR clones in #4B5, five had a deletion of “AT” and three had an 
insertion of “C” at the target locus. Given that RPE-1 are diploid, the presence of 
two mutations in a single clone suggests that both alleles have been successfully 
targeted, resulting in a compound heterozygous mutant. Both the insertion and 
deletion mutations result in a +1 frame shift and the introduction of premature 
stop codons at the 161st and 160th amino acids, respectively (Fig. 4.5.c). No 
evidence was found for a truncated TDP1 protein by WB, using a polyclonal 
antibody raised against the first fifty amino acids of TDP1. This suggests that the 
mutant TDP1 mRNA is subject to nonsense-mediated decay (NMD).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.5. PCR and Sanger sequencing of the gRNA TDP1.2 target locus in 
RPE-1 WT, TDP1-/- #4B5 and XRCC1-/-/TDP1-/- #3A2. The products of PCR with 
primers spanning the target locus in WT RPE-1, TDP1-/- #4B5 and XRCC1-/-/TDP1-/- 
#3A2 were subjected to 1% agarose electrophoresis (A). PCR products were purified, 
Topo-cloned, and Sanger sequenced. Alignment to TDP1 gDNA from the reference 
genome reveals 7/7 WT PCR clones from RPE-1 WT, 8/8 mutated PCR clones from 
#4B5 and 8/8 mutated PCR clones from #3A2 (B). The PAM and CRISPR cut site are 
indicated by a yellow box and red dashed line, respectively. Of the eight mutated PCR 
clones in #4B5, five had an insertion of “C”, and three had a deletion of “AT”. Both of 
the mutations in #4B5 result in a +1 frame shift, leading to premature stop codons 
being introduced at the 161st and 160th amino acid, respectively. The 194 bp insertion 
in #3A2 results in a +2 frame shift and leads to a premature stop codon at the 277th 
amino acid (C). 
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Sanger sequencing of the #3A2 PCR products confirmed an insertion of 
194 bp at the gRNA TDP1.2 target locus in all eight bacterial clones (Fig. 4.5.b), 
resulting in a +2 frame shift and the introduction of a premature stop codon at the 
277th amino acid (Fig. 4.5.c). Comparison of the sequence to those in the NCBI 
databases using BLAST revealed 100% homology to several plasmid sequences 
(https://blast.ncbi.nlm.nih.gov). Direct comparison with the known sequence of 
the gRNA expression plasmid revealed that the insertion comprised an 
out-of-frame fragment of the bleomycin resistance cassette. As for TDP1-/- RPE-1 
#4B5, the absence of any TDP1 protein detected by WB suggested that the #3A2 
mutant mRNA is subject to NMD. 
 
4.2.4. Generation of PARP1-/-/PARP2-/- RPE-1 cells 
To generate PARP1-/-/PARP2-/- cells, PARP1-/- RPE-1 (#G7) cells were 
co-transfected with pGR.PARP2 and Cas9 expression plasmids. Both 
PARP1-/- RPE-1 (#G7) cells and the pGR.PARP2 plasmid were generated 
previously by co-workers in the Caldecott laboratory. Since an anti-PARP2 
antibody suitable for IF was available, 96 colonies were screened in 
glass-bottomed 96-well plates by immunofluorescence (IF). Thirteen clones were 
selected and subject to WB with anti-PARP2 antibody (Fig. 4.6.a). Of these 
clones, only one (#E6) appeared to lack PARP2 protein, and this was confirmed 
by additional WB, including extracts from WT, PARP1-/- (#G7) and PARP2-/- (#A1) 
cells as controls (Fig. 4.6.b and 4.6.c). PARP2-/- RPE-1 (#A1) cells were also 
generated previously by co-workers in the Caldecott laboratory. 
 
4.2.5. Levels of SSBR proteins in a panel of RPE-1 KO cell lines. 
The TDP1-/-, XRCC1-/-/TDP1-/- and PARP1-/-/PARP2-/- RPE-1 cells generated in 
this chapter join a panel of RPE-1 KO cell lines generated by other members of 
the laboratory. It is known that many proteins involved in SSBR heterodimerise. 
Loss of one protein in the heterodimer can destabilise the interacting partner. One 
example which has been repeatedly demonstrated in the literature is the 
XRCC1-Lig3α interaction (Caldecott, Tucker et al. 1995). To check for other such 
interactions, cell lysates from the panel of RPE-1 cell lines were subjected to 
 Figure 4.6. Screening for PARP1-/-/PARP2-/- RPE-1 clones by Western blot. 
Thirteen isolated RPE-1 clones with low or absent PARP2 
immunofluorescence were subjected to Western blot with anti-PARP2 antibody 
(A). Clone #E6 was expanded and subjected to Western blotting with 
anti-PARP2 (B), anti-actin (B) and anti-PARP1 antibodies (C). Included are cell 
lysates from WT, PARP1-/- and PARP2-/- RPE-1 cells. Note the apparent 
absence of PARP1 and PARP2 proteins in clone #E6. A molecular weight 
marker was included, indicating the approximate molecular weight in KDa. 
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Figure 4.7. The levels of SSBR proteins in a panel of RPE-1 KO cell lines. 
Cell lysates containing 30 µg of total protein, from the indicated genotypes, 
were subjected to SDS-PAGE and Western blotting with antibodies targeting 
PARP1, PARP2, PARP3, XRCC1, TDP1, Lig3, PNKP and β-Tub (A, B and C). 
Total protein loading revealed by Ponceau S staining of A, B and C is shown 
overleaf (C, D and E, respectively).  
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SDS-PAGE, and WB with antibodies targeting PARP1, PARP2, PARP3, XRCC1, 
Lig3α, TDP1, PNKP and β-Tub (Fig. 4.7.). As reported previously (Caldecott, 
Tucker et al. 1995), loss of XRCC1 was seen to significantly destabilize Lig3α. 
PNKP is another protein which interacts directly with XRCC1 (Whitehouse, Taylor 
et al. 2001). However, loss of XRCC1 did not appear to destabilize PNKP, nor 
any of the other proteins examined here. Furthermore, in each of the other 
knockout cell lines, only the targeted protein was absent, with no apparent 
depletion of the other examined SSBR factors.  
 
4.3. Conclusions and Discussion 
The mutations characterized in TDP1-/- and XRCC1-/-/TDP1-/- RPE-1 cells can be 
compared to those identified in other CRISPR-generated RPE-1 KO cell lines, 
including the PARP1-/-/PARP2-/- cells generated herein (Fig. 4.8.). In every case, 
the indels occur precisely at the position of the Cas9-induced double strand 
break. Seven out of eight of the sequenced mutations were small indels of one 
or two bp. This is expected based on the prevalent model of 
CRISPR-Cas9-induced mutagenesis, which posits that the small insertions and 
deletions introduced at most target loci result from the activity of nucleases (Ma, 
Pannicke et al. 2002) and the PolX family of DNA polymerases functioning within 
the NHEJ repair pathway (Yang, Guell et al. 2013, Bétermier, Bertrand et al. 
2014). The PolX family can catalyse DNA polymerisation across discontinuous 
templates. The members of this family are variously able to add entirely 
untemplated nucleotides or nucleotides templated from downstream positions, 
resulting in insertions or deletions, respectively (Ramadan, Maga et al. 2003, 
Ramadan, Shevelev et al. 2004, Bertocci, De Smet et al. 2006).  
Only one out of eight of the mutations (detected in XRCC1-/-/TDP1-/- RPE-1 
#3A2) was a longer insertion (194 bp). No significant microhomology was found 
at either end of the insertion, and there was no loss of genomic or gain of 
untemplated nucleotides, suggesting that this event may have occurred by direct 
ligation of the blunt-ended fragments within c-NHEJ. It is important to note that 
mutations detected may be the result of rare events of infidelity. However, given 
that error-free repair by HR or c-NHEJ would result in restoration of the gRNA 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 4.8. Sanger sequenced mutations at gRNA loci in a panel of RPE-1 
KO cell lines. The gRNA target loci in the indicated RPE-1 clones were 
sequenced as described herein for RPE-1 #4B5 and #3A2 (Z. Zeng). The 
sequenced PCR products were aligned to the target loci sequences from the 
reference genome. The positions of the gRNA target sequence and PAM are 
indicated in cyan and green, respectively. The position of the Cas9-induced 
double-strand break is indicated by a red arrow. Frame-shift insertions and 
deletions in the sequenced PCR products are indicated in magenta and yellow, 
respectively. The resulting amino acid changes are indicated in red. Positions 
of premature stop codons (*) are given in number of amino acids. 
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target sequence, successive rounds of Cas9 cleavage would likely result in 
mutation eventually. Notably, in all but one RPE-1 cell line (TDP1-/- #4B5) only a 
single mutation was detected. The surprising frequency of homozygous indels 
has been reported previously in the literature (Li, Wang et al. 2014). Given that 
the PCR amplicon was 200-300 bp in each case, it is not possible to rule out that 
larger indels allow some alleles to escape amplification and lead to their 
underrepresentation. Alternatively, these may be real homozygous mutations. 
This could feasibly result from a gene conversion event which transfers the 
nascent mutation of one allele to the other. The frequency of G1 interallelic HR 
events is thought to be very low in mammals (Liang, Han et al. 1998, Johnson 
and Jasin 2000), which is compensated for by the efficiency of NHEJ in G1. 
However, given the high efficiency of the Cas9 nuclease, an intact sister 
chromatid may not be available in S/G2; which may bias HR towards utilizing the 
only available intact and homologous template: that of the other mutated allele.  
The RPE-1 knockout cell lines generated herein, along with those 
generated by co-workers in the Caldecott laboratory, were characterized by WB 
using antibodies targeting SSBR factors. Lig3α exists as an obligate heterodimer 
with XRCC1, such that loss of XRCC1 leads to pronounced destabilization of 
Lig3α (Caldecott, Tucker et al. 1995), as observed here. Given that abortive 
ligation at non-canonical termini results in 5’-AMP generation (Ahel, Rass et al. 
2006), this may be an evolutionary adaption to prevent unscheduled Lig3α activity 
in the absence of chaperoning by XRCC1. By comparison, no destabilization of 
PNKP was observed upon loss of XRCC1. This may be explained from an 
evolutionary perspective by a requirement for a pool of free PNKP. The 
PNKP-XRCC1 interface overlaps with that of XRCC1-APLF and XRCC1-APTX 
and these interactions are thought to be mutually exclusive (Luo, Chan et al. 
2004, Ahel, Rass et al. 2006, Rass, Ahel et al. 2007). The presence of the CK2 
phosphorylation motif in the shared interface suggests that the affinities of these 
interactions may be fine-tuned by phosphorylation and/or other post-translation 
modifications (Luo, Chan et al. 2004). CK2 is a ubiquitously-expressed and well 
conserved eukaryotic kinase, and its regulation has been the subject of 
controversy and contradiction (Litchfield 2003). It does appear to be the case that 
levels of CK2 are higher in highly proliferative cells (Munstermann, Fritz et al. 
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1990). In this way, it is possible that levels of XRCC1-PNKP, XRCC1-APLF and 
XRCC1-APTX may be regulated according to cell type or proliferative state. More 
elaborately, the regulation may occur on an ad-hoc basis at specific lesions or 
repair intermediates, although this has yet to be demonstrated. Given the 
non-constitutive nature of these interactions (as opposed to the XRCC1-Lig3α 
interaction), XRCC1-free stability of PNKP, APLF and APTX would be required.  
PARP1 and PARP2 have been reported to heterodimerise (Schreiber, 
Amé et al. 2002). Here it was found that loss of either did not result in 
destabilization of the other, nor indeed of PARP3, confirming that whilst these 
proteins may heterodimerise, these interactions do not provide reciprocal 
stabilization. Furthermore, whilst PARP1 has been reported to interact directly 
with TDP1 (Das, Huang et al. 2014), reciprocal stabilization was not observed 
here.  
In conclusion, this chapter has described the generation and 
characterization of three novel diploid human cell lines with knockout mutations 
in TDP1 (RPE-1 #4B5), XRCC1 and TDP1 (RPE-1 #3A2) or PARP1 and PARP2 
(RPE-1 #E6). These join a panel of RPE-1 cell lines with KO mutations in other 
SSBR genes. In Chapters Six and Seven these cell lines will be used to 
investigate fundamental features of human SSBR. 
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Establishing High Content Imaging 
Methods for the Sensitive 
Quantification of ADP-ribose and 
Chromatin-associated XRCC1 
 
 
 
 
 
 
 
 
 
 
 
100 
 
5.1. Introduction and aims 
Rapid and extensive nuclear ADP-ribosylation is a well-documented response to 
many DNA damaging agents, including H2O2 (Schraufstatter, Hinshaw et al. 
1986, Cantoni, Cattabeni et al. 1989). One aim of this chapter is to introduce a 
methodology for the sensitive quantification of this ADP-ribose. In the past, this 
has typically been achieved by Immunofluorescence (IF) or Western Blot (WB) 
using an antibody raised against a heterogenous poly(ADP-ribose) (PAR) 
antigen. One such antibody which has been used extensively in the literature is 
the 10H monoclonal antibody (Kawamitsu, Hoshino et al. 1984). This has proved 
popular due to its reported ability to recognise ADP-ribose from a variety of 
sources, including PARP1, PARP2 and PARP3. However others have reported 
that 10H fails to recognize mono-ADP-ribose (MAR) and oligo-ADP-ribose (OAR) 
(Kraus 2015, Vivelo and Leung 2015), such as that produced by PARP3. Indeed, 
the initial study reporting generation of this antibody found that the PAR-10H 
interaction was only weakly inhibited by competition with the smallest structural 
unit of PAR, iso-ADP-ribose, and not at all by ADP-ribose (Kawamitsu, Hoshino 
et al. 1984). Furthermore, a subsequent study revealed that one 63mer PAR 
molecule is bound by twenty-one 10H molecules, suggesting a binding 
stoichiometry of one 10H antibody to every 3-4 ADP-ribose units (Fahrer, 
Kranaster et al. 2007).  In this chapter, the sensitivity of the 10H antibody will be 
compared with other available reagents, including the pan-ADP-ribose binding 
reagent. This commercial reagent is a recombinant protein composed of a rabbit 
immunoglobulin fragment crystallisable (Fc) domain fused to a macrodomain 
(Kraus 2015). The specific identity of this macrodomain is proprietary but it has 
been demonstrated to recognize MAR, OAR and PAR with high affinity (Kraus 
2015, Gibson, Zhang et al. 2016). 
XRCC1 has been demonstrated previously to relocate to into subnuclear 
foci in response to oxidative DNA damage (El-Khamisy, Masutani et al. 2003), 
supporting the role of this protein in promoting BER/SSBR. Chromatin binding by 
a protein of interest has traditionally been observed by several different 
approaches. Biochemical fractionation of cell extracts can yield 
chromatin-enriched samples which can then be subjected to SDS-PAGE and WB 
with appropriate antibodies (Andegeko, Moyal et al. 2001, Cheng, Barboule et al. 
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2011). Due to the requirement for lengthy serial incubations with various 
extraction buffers, this method has poor temporal resolution. Other methods have 
used microscopy to observe relocalization of exogenously overexpressed 
flurescent protein (FP) -tagged XRCC1 into discrete nuclear foci (El-Khamisy, 
Masutani et al. 2003). These foci are typically very large and far fewer than the 
number of H2O2-induced single strand breaks reported by more quantitative 
methods (own observations, and (Breslin, Hornyak et al. 2015)).  
Whilst attractive for their ability to be observed in real time in live cells, FP-
tagged protein fusions are often exogenously overexpressed at such an elevated 
level that their behaviour may not accurately reflect that of the endogenous 
protein (Moriya 2015). Additionally, several high-profile studies have 
demonstrated that FP-tags have a propensity to dimerise or oligomerise under 
certain conditions (Zacharias, Violin et al. 2002, Snapp, Hegde et al. 2003, 
Costantini, Fossati et al. 2012). In particular, a high local concentration of 
FP-tagged proteins can cause assembly into artefactual macromolecular 
complexes. Previous studies have investigated this effect for FP-tagged, 
membrane-associated proteins, where the local concentration is elevated by 
virtue of 2D confinement (Zacharias, Violin et al. 2002, Snapp, Hegde et al. 2003). 
It is likely that other mechanisms which dramatically elevate local concentrations 
of FP-tagged proteins could nucleate similar oligomerisation. One conceivable 
mechanism is formation of a PAR molecule with multiple binding sites for FP-
tagged XRCC1. Initial PAR-binding via the BRCT domain of XRCC1 might be 
followed by dimerisation via the FP-tag. Conceivably this could lead to clustering 
of SSBR complexes from independent but proximal lesions. This could explain 
observation of the large, persisting EGFP-XRCC1 foci which form in response to 
H2O2 exposure (Breslin, Hornyak et al. 2015). It is currently unclear whether 
endogenous XRCC1 also forms these large macromolecular foci. This chapter 
aims to establish a method for quantifying endogenous XRCC1 chromatin 
recruitment which avoids some of the pitfalls of traditional methods.  
IF protocols typically involve formaldehyde-fixation of cells prior to a 
detergent or organic solvent-based membrane permeabilization step which 
allows access of the antibodies to intracellular epitopes. One notable recent study 
employed a pre-fixation incubation with cytoskeleton (CSK) buffer containing 
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Triton X100 and RNAse A to remove soluble nucleoplasmic Ku70, allowing 
observation of single foci by super resolution microscopy (Britton, Coates et al. 
2013). A variation of this method has been widely used in the cytoskeleton field 
since first being reported (Cramer and Mitchison 1995). The method is attractive 
for the purposes of this study as it does not require lengthy incubation times prior 
to fixation, which greatly improves the temporal resolution. During preliminary 
work on this project it was found that the technique could be adapted further for 
use with XRCC1 IF (Hana Hanzlikova, unpublished observations). This involved 
replacing the CSK buffer with PBS, lowering the detergent concentration to 0.2% 
Triton X100 and shortening the incubation to two min. Additionally, to limit rapid 
cellular processes during the pre-extraction, the incubation was carried out on 
ice.  
Developments in the automation of microscopy and image processing 
have led to the emergence of High Content Analysis (HCA). This term is used to 
describe the algorithmic analysis of multiple parameters of many cells in a 
population, allowing accurate quantification of cellular phenotypes which would 
be difficult and time consuming when conducted manually (Zock 2009). 
Examples of parameters which might be analysed include nuclear size and 
shape, the distribution of fluorescently labelled proteins and their associated 
intensity. From these variables, inferences can be made about cell status, such 
as cell cycle phase (Barabasz, Foley et al. 2006) or apoptosis (Inglefield, Larson 
et al. 2006). The technique is a particularly powerful drug discovery tool (A. 
Giuliano, L. DeBiasio et al. 1997), especially when coupled to high throughput 
screening approaches, such as those employing siRNA (Bjorklund, Taipale et al. 
2006) or compound libraries (Vogt, Cooley et al. 2003). In addition to its utility in 
translational research, HCA is also an effective tool in basic research, owing to 
the ease with which it can quantify all manner of cellular phenotypes. This chapter 
will apply HCA to streamline protocols which would be manually unfeasible when 
conducted with multiple cell lines and treatment conditions. 
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5.2. Results 
5.2.1. Comparison of anti ADP-ribose antibodies and binding reagents 
In the interest of establishing protocols with the highest possible sensitivity for 
ADP-ribose, three detection reagents were tested by WB and IF (Fig. 5.1.). These 
were the 10H monoclonal antibody, 4336-BPC-100 polyclonal antibody, and the 
MABE1016 Pan-ADP-ribose binding reagent. For the WB (Fig. 5.1.a, contributing 
WB from K. Krejcikova), WT RPE-1 cells were pre-incubated or not with 1 or 10 
µM KU0058948 PARP inhibitor for one hour prior to treatment with 150 µM H2O2 
on ice for 10 min in the continued presence of KU0058948. Cells were then lysed 
and subjected to SDS-PAGE and WB with the three detection reagents. In the 
absence of H2O2 treatment, all three reagents failed to detect any significant 
immunological signal, suggesting that the level of ADP-ribosylation in 
unperturbed cells is very low.  Upon treatment with H2O2, all three reagents 
successfully detected the presence of ADP-ribosylated proteins. Both the 
pan-ADP-ribose binding reagent and 4336-BPC-100 polyclonal were able to 
detect ADP-ribosylation of low molecular weight proteins (<25 KDa), whilst the 
10H monoclonal was not. Furthermore, the signal detected with 10H was 
concentrated at a high molecular weight, possibly reflecting a propensity for 
binding auto-PARylated PARP1. In all cases, the ADP-ribosylation signal was 
prevented by co-treatment with 1 and 10 µM KU0058948.  
For the IF experiments (Fig. 5.1.b), WT RPE-1 cells growing on glass 
coverslips were treated as described above, prior to formaldehyde fixation and 
fluorescent labelling with the three described reagents. In the case of 
pan-ADP-ribose binding reagent and 4336-BPC-100 polyclonal antibody, a 
strong pan-nuclear signal was observed upon treatment with H2O2. Furthermore, 
both reagents were able to detect residual H2O2-induced ADP-ribosylation signal 
in the presence of 1 µM but not 10 µM KU0058948. In contrast, the signal 
detected by 10H monoclonal antibody was dramatically weaker in the H2O2 
treated cells, and entirely absent upon co-incubation with both 1 and 10 µM 
KU0058948. 
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Figure 5.1. Impact of PARP inhibitor on ADP-ribosylation detected using 
different anti-(ADP-ribose) detection reagents. WT RPE-1 cells were pre-
incubated or not with 1 or 10 µM PARP inhibitor KU0058948 (Pi) for 1 h and 
subsequently treated for 10 min with 150 µM H2O2 on ice in the continued 
presence or absence of PARP inhibitor as indicated. ADP-ribosylated proteins 
were detected by WB (A) or IF (B). Corner numbers are the mean nuclear 
ADP-ribose signal in >1500 cells relative (%) to the signal detected by anti-
pan-ADP-ribose binding reagent in H2O2-treated cells (set at 100%). Data 
were quantified by Olympus ScanR acquisition and analysis software. A 
molecular weight marker was included in the WB, and approximate sizes are 
indicated in KDa. Contributing WB from K. Krejcikova 
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5.2.2. Limitations of Conventional Chromatin Fractionation Methods  
Different techniques were considered for measuring XRCC1 recruitment into 
chromatin. Firstly, RPE-1 cells were subjected to biochemical fractionation of 
chromatin by a previously published method (Drouet, Delteil et al. 2005). WT 
RPE-1 cells were pre-incubated or not with 10 µM KU0058948 PARP inhibitor for 
1 hr, and then treated in suspension with 10 mM H2O2 for 7 or 15 min in the 
continued presence or absence of KU0058948. H2O2 was quenched with 
complete media and the cells then lysed and fractionated using buffer containing 
detergent into soluble and insoluble fractions (see Materials and Methods). 
Samples were subjected to SDS-PAGE and WB with antibodies targeting 
XRCC1, Histone 1.2, and with pan-ADP-ribose binding reagent (Fig. 5.2.). 
Whereas ADP-ribose was not detected in untreated cells in these experiments, a 
strong ADP-ribose signal was detected in samples from H2O2-treated cells which 
increased with duration of H2O2 treatment. This signal was prevented by 
treatment with the PARP inhibitor KU0058948, consistent with it reflecting protein 
ADP-ribosylation.  
In untreated cells, there was a low level of XRCC1 in the chromatin 
fraction. Following 7 and 15 min H2O2-treatment, XRCC1 progressively increased 
in the chromatin fraction, and this was inhibited by KU0058948. Despite apparent 
success in detecting XRCC1 recruitment or retention in chromatin in these 
experiments, the method was found to be time-consuming and difficult to perform 
with multiple samples, which resulted in poor reproducibility (data not shown). 
This makes the technique unsuitable for use with multiple cell lines in parallel. 
Additionally, whilst quantification is possible, qualitative information, such as the 
sub-nuclear distribution of signal, is lost. By comparison quantitative IF and high 
content analysis offer higher throughput and the ability to determine the 
sub-nuclear distribution of signal. For these reasons, attention turned to a method 
of chromatin enrichment which could be coupled with IF.  
  
 
 Fig 5.2. H2O2 induced DNA damage triggers ADP-ribosylation and 
recruitment of XRCC1 to the chromatin. RPE-1 cells were trypsinised and 
washed with PBS prior to being treated for the indicated times with 10 mM 
H2O2 in the presence or absence of 10 µM KU0058948 PARP inhibitor (Pi). 
H2O2 was quenched with complete media and the cells were subjected to 
biochemical subcellular fractionation. Whole cell extract (WCE), soluble 
protein and pellet were lysed in Laemmli buffer and subject to 8% SDS-PAGE 
and WB with antibodies targeting XRCC1, Histone 1.2, or with pan-ADP-ribose 
binding reagent. A molecular weight marker was included and approximate 
sizes are indicated in KDa. 
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5.2.3. Removal of soluble XRCC1 by detergent pre-extraction  
Pre-extraction of adherent cells with low concentrations of detergent has been 
demonstrated previously to remove soluble nuclear proteins, leaving behind 
chromatin bound proteins and components of the cytoskeleton (Cramer and 
Mitchison 1995, Britton, Coates et al. 2013). To demonstrate that the 
pre-extraction is stringent enough to remove soluble nuclear XRCC1, but not 
chromatin proteins such as histones, untreated WT RPE-1 cells were subjected 
to IF with anti-XRCC1 and anti-H1 antibodies, with or without pre-extraction 
(Fig. 5.3.). Without pre-extraction, XRCC1 was observed throughout the nucleus 
in untreated WT RPE-1 cells. Pre-extraction was found to effectively remove 
~90% of the nuclear XRCC1 signal. The residual signal remaining after 
pre-extraction (10.85%) was specific for XRCC1, as it was further significantly 
reduced to 4.00% of the non-pre-extracted WT signal in pre-extracted 
XRCC1-/- cells (t-test p-value = 1.02x10-2). Similarly to XRCC1, H1 was observed 
throughout the nucleus in non-pre-extracted cells, consistent with it being an 
integral and ubiquitous component of chromatin. However, in comparison to 
XRCC1, H1 signal was not reduced by pre-extraction (t-test p-value = 2.79x10-1), 
confirming that the stringency of the technique is suitable for removing only 
soluble nuclear proteins and not those in the chromatin. 
 
5.2.4. Detergent insoluble XRCC1 co-localizes with the nucleolus in 
untreated cells 
The residual XRCC1 in pre-extracted WT cells appeared to be localized at 
specific focal sites in the nucleus. To determine if the focal sites reflected nucleoli, 
pre-extracted WT and XRCC1-/- RPE-1 cells were subjected to co-IF with 
anti-XRCC1 antibody and an antibody targeting the nucleolar phosphoprotein 
B23 (Fig. 5.4.). The colocalization of B23 and XRCC1 was evident in 
pre-extracted untreated WT cells. This reflected specific XRCC1 signal because 
it was absent from XRCC1-/- cells immunostained in parallel.  In order to delineate 
the nucleolar and ex-nucleolar XRCC1 fractions, the B23 signal was used to 
define a sub-object within the DAPI-defined main object (Fig. 5.5.). The main and 
sub-object, were then used to define nuclear, nucleolar and exnucleolar regions, 
as detailed in the methods (see section 2.2.8). Unless otherwise stated, all 
   
Figure 5.3. Pre-extraction removes soluble nuclear XRRC1 but not 
chromatin-associated H1. Untreated WT and XRCC1-/- RPE-1 cells growing 
on glass coverslips were formaldehyde fixed with or without pre-extraction 
(PX). Co-immunolabelling was carried out with antibodies against XRCC1 and 
H1. Slides were imaged using the Olympus ScanR system and ScanR 
Analysis software was used to generate galleries of 16 randomly selected cells 
for each condition (A). XRCC1 fluorescence from >1000 cells was quantified 
in the nuclear region and is expressed as percentage of WT -PX (B, overleaf). 
H1 fluorescence from >1000 cells was quantified in the nuclear region and is 
expressed as percentage of WT -PX (C, overleaf). Data are mean +/- S.E.M 
from 3 experiments. Statistical significance was calculated by paired student’s 
t-test. 
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 Figure 5.4. XRCC1 is localized to the nucleolus in untreated, 
pre-extracted cells. Untreated WT and XRCC1-/- RPE-1 cells were 
pre-extracted with 0.2% Triton-X100 for 2 min prior to formaldehyde fixation 
and immunofluorescence with antibodies targeting XRCC1 (green) and B23 
(red), and staining of DNA with DAPI (blue). Slides were imaged using the 
Olympus ScanR system and ScanR Analysis software was used to generate 
a gallery of 16 randomly selected cells. The brightness of the residual XRCC1 
signal has been increased to demonstrate colocalization with the nucleolar 
marker, phosphoprotein B23. 
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 Figure 5.5. The delineation of nuclear, nucleolar and exnucleolar regions. 
DAPI (A) and B23 (B) fluorescence signal are thresholded to define the 
nuclear (C) and nucleolar (D) regions, respectively. By subtracting the sum 
total fluorescence intensity of the nucleolar region from that of the nuclear 
region, the fluorescence intensity in the exnucleolar region (E) can be derived. 
Images A-E are adapted screenshots from ScanR Analysis software. 
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subsequent XRCC1 fluorescence quantifications are of this exnucleolar region. 
This was to avoid artefactual replicate-to-replicate variability originating from 
incomplete washing of the nucleoli (see section 5.3 for further discussion).   
 
5.2.5. H2O2-induced recruitment and/or retention of XRCC1 into chromatin  
To demonstrate that the pre-extraction method can detect and quantify 
H2O2-induced XRCC1 localization into chromatin, a dose response was 
conducted (Fig. 5.6.). Cells were treated or not with 50, 100, 400 µM or 10 mM 
H2O2 for 10 min at RT, prior to pre-extraction, fixation and IF with anti-XRCC1 
and anti-B23 antibodies. In untreated cells, a very low background anti-XRCC1 
signal was observed, and as before this was largely restricted to the nucleolar 
region. Upon treatment with each dose of H2O2, anti-XRCC1 signal increased 
throughout the nucleus. The increased retention of XRCC1 in detergent-insoluble 
material suggests that the pre-extraction technique is able to enrich the XRCC1 
fraction which is responding to oxidative damage. A 2.19-fold increase in 
exnuclear anti-XRCC1 signal was detected at the lowest dose of 50 µM and this 
increased to approximately 3.46-fold at the highest dose of 10 mM. 10 mM H2O2 
did not result in a dramatically higher response than 400 µM, which may reflect a 
saturation of the response before this dose. It was observed that the high dose 
of 10 mM induced some morphological changes the cells, and resulted in some 
detachment from the coverslip. Therefore, for the purposes of this study 400 µM 
H2O2 will be used, unless otherwise indicated.  
To investigate the nature of the detergent-insoluble material further, 
pre-extracted and fixed cells were subjected to overnight DNAse I digestion, prior 
to subsequent IF with anti-XRCC1 and anti-H1 antibodies (Fig 5.7.). 
DNAse I -treated cells exhibited a very low DAPI signal (2.7 and 2.3% that of cells 
not treated with DNAse I, for undamaged and H2O2-treated cells, respectively), 
demonstrating that the digestion worked as intended. The remaining DAPI signal 
was enough, however, to allow detection of the main object (nuclear region) by 
the ScanR analysis software. In addition to reducing of DAPI signal, DNAse I 
treatment also reduced or ablated the anti-H1 signal of untreated and 
H2O2-treated cells (both 0.2% of H2O2-treated, undigested cells), suggesting that 
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Figure 5.6. H2O2 dose response of XRCC1 chromatin-loading in RPE-1 
cells. WT and XRCC1-/- RPE-1 cells growing on glass coverslips were treated 
or not with 0, 50, 100, 400 µM or 10 mM H2O2 for 10 min, prior to pre-extraction, 
formaldehyde fixation and immunofluorescence with antibodies against 
XRCC1 (green) and B23 (red), and DNA-staining with DAPI (blue). Slides were 
imaged using the Olympus ScanR system and ScanR Analysis software was 
used to generate galleries of 16 randomly selected WT cells for each condition 
(A). XRCC1 fluorescence from >1000 cells was quantified in the exnucleolar 
region and is expressed as fold over untreated WT (B, overleaf). Data are 
mean +/- S.E.M from 3 experiments. 
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Figure 5.7. Detergent-insoluble XRCC1 signal is associated with 
chromatin.  WT RPE-1 cells growing on glass coverslips were treated or not 
with 400 µM H2O2 for 7 min at RT. Cells were pre-extracted, formaldehyde 
fixed and subjected to overnight incubation with DNAse I buffer ±DNAse I, prior 
to immunofluorescence with antibodies targeting XRCC1 (green) and H1 (red), 
and DNA-staining with DAPI (blue). Slides were imaged using the Olympus 
ScanR system and ScanR Analysis software was used to generate galleries 
of 16 randomly selected cells for each condition (a). Total XRCC1 (b), H1 (c) 
and DAPI (d) fluorescence from >1000 cells were quantified in the nuclear 
region and are expressed as percentage of signal in H2O2-treated, undigested 
cells. Data is presented from one experiment. 
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DNA digestion also releases the associated chromatin proteins. DNAse I 
treatment also decreased the detergent-insoluble XRCC1 signal in untreated and 
H2O2-treated cells (5.3 and 11.1% of H2O2-treated, undigested cells, 
respectively), suggesting that it is indeed reflective of chromatin-associated 
XRCC1. 
5.3. Conclusions and Discussion 
Previous attempts to characterize rapid cellular responses to H2O2 have had 
several disadvantages. Traditional methods for the biochemical fractionation of 
chromatin are often time-consuming to perform with multiple samples, making 
them unsuitable when many cell lines are assayed in parallel. Alternatively, the 
use of FP-tags allows the observation of protein localization in real time. 
However, the overexpression of such constructs may produce responses which 
are not representative of the endogenous repair proteins (Moriya 2015). 
Additionally, FP-tags have a propensity to oligomerise (Zacharias, Violin et al. 
2002, Snapp, Hegde et al. 2003, Costantini, Fossati et al. 2012), which may 
explain the large macromolecular FP-XRCC1 foci which form in response to H2O2 
(Breslin, Hornyak et al. 2015). Here, I employed a detergent pre-extraction-IF 
approach to demonstrate that endogenous XRCC1 does not form these large foci 
but rather distributes uniformly throughout the chromatin in H2O2-treated cells.   
Interest in ADP-ribosylation and the PARP enzymes has increased 
dramatically over the decades. This is evident from the exponential growth in the 
yearly number of papers published on the topic (NCBI Resource NCBI 2016). In 
recent years this has been partly driven by the observation of sensitivity of 
HR-deficient cells to PARP inhibitors (Bryant, Schultz et al. 2005, Farmer, 
McCabe et al. 2005) and the resulting U.S. Food and Drug Administration (FDA) 
and European Medicines Agency (EMA) approval of their use in treating BRCA1 
and BRCA2 mutated patients with advanced ovarian cancer (EMA 2014, FDA 
2014). Accurate and sensitive quantification of ADP-ribosylation in vivo is 
important for future work in the field. Despite this, the anti-PAR 10H monoclonal 
antibody (Kawamitsu, Hoshino et al. 1984) remains the most popular detection 
reagent (NCBI 2016). This chapter conclusively demonstrates its inferior 
sensitivity when compared to other reagents in parallel. This was particularly true 
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for the IF application, where the signal detected with 10H was dramatically lower 
than that detected by pan-ADP-Ribose binding reagent or 4336-BPC-100 
polyclonal antibody. By comparison, the signal detected by 10H on a WB was 
more comparable to that of the other reagents. This difference in sensitivity 
depending on application might be due to 10H requiring or preferring an epitope 
which is more accessible under the conditions of a WB. For example, it is possible 
that interaction of the PAR chain with the nitrocellulose membrane exposes a 
confirmation preferred by 10H. Alternatively, the formaldehyde-fixation step of IF 
may alter the PAR epitope normally recognized by 10H. Using the other reagents, 
it was clear that IF allowed more sensitive detection of PAR than by WB, revealing 
that very high doses of PARP inhibitor are required to completely block 
H2O2-induced ADP-ribosylation in vivo. This has not been widely reported before, 
and is of particular significance for the validation of future PARP inhibitor 
therapeutics.  
In untreated cells, the detergent-insoluble XRCC1 is largely confined to 
the nucleolar region. It is tempting to speculate that this may reflect a 
physiologically relevant role of XRCC1 in concentrating SSBR machinery at 
regions of high transcriptional activity. Although XRCC1 does not have a clear 
nucleolar localization signal, PARP1 and PARP2, the major sources of PAR, are 
both reported to (Meder, Boeglin et al. 2005). However, as demonstrated in 
Chapter Six, deletion of PARP1 and PARP2 does not significantly or specifically 
reduce XRCC1 nucleolar localization in untreated pre-extracted cells (see section 
6.2.6). Whilst it is certainly possible that XRCC1 is enriched in the nucleolus by 
another mechanism independent of PARP1/PARP2 activity, it is also possible 
that the residual signal results as an artefact of incomplete extraction from this 
structure. Nucleoli can be thought of as non-membranous subnuclear organelles 
(Lam and Trinkle-Mulcahy 2015), with a structure that is maintained by elaborate 
RNA-protein interactions. These interactions cause the nucleolus to have a 
significantly higher density than the surrounding nucleoplasm (estimated values 
of 0.215 g/cm3 and 0.106 g/cm3, respectively (Handwerger, Cordero et al. 2005)), 
which incidentally allows their convenient observation by phase contrast or 
differential interference contrast microscopy (Zernike 1942), and the relative ease 
of their isolation by centrifugation (Busch, Adams et al. 1963). It is conceivable 
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that their higher density also renders them intrinsically less permeable to 
detergent-containing buffers. In 1992, Melan et al conducted a study of the effects 
of different IF fixation protocols on the apparent distribution of a panel of 
FITC-labelled proteins (Melan and Sluder 1992), introduced exogenously using 
a bead-loading technique. The authors tested several pre-fixation detergent 
extraction steps, including the use of 0.2% Triton-X100 buffer. Interestingly, they 
observed a strong enrichment in the nucleus and nucleolus for several of the 
tested proteins, including lactate dehydrogenase (LDH), β-lactoglobulin, and 
globin. This is particularly pertinent, as β-lactoglobulin and globin have no 
intracellular role, suggesting that their nucleolar enrichment following 
pre-extraction is entirely artificial (Melan and Sluder 1992). Notably, a similar 
localization of residual anti-Ku80 signal has been observed following 
pre-extraction of cells with CSK buffer (Britton, Coates et al. 2013). In their study, 
Britton et al attribute the residual anti-Ku80 signal that they observe in 
CSK-extracted cells to Ku80 RNA-binding, citing a previously published 
interaction with the RNA component of human telomerase hTR (Ting, Yu et al. 
2005). This explanation is supported by their observation that inclusion of RNAse 
A in the CSK pre-extraction buffer dramatically reduces residual Ku80 signal 
throughout the nucleus. Furthermore, a subsequent publication has reported 
another specific interaction of Ku80 with RNA; in this case the long non-coding 
RNA LINP1 (Zhang, He et al. 2016). Britton et al do not comment directly on the 
nucleolar fraction of the residual signal, but there is no reason to suspect that 
hTR or LINP1 preferentially localize to the nucleolus. It is possible that other 
Ku80-binding RNAs exist which are generated in or localized to the nucleolus. 
However, it is notable that the inclusion of RNAse A by Britton et al also ablated 
nucleolin signal, revealing total nucleolar disruption. This is expected, as 
nucleolar integrity is dependent on its constituent RNA (Caudron‐Herger, Pankert 
et al. 2015).  
No evidence was found herein to suggest that the residual XRCC1 signal 
observed in the nucleolus reflected a functional role, and its inclusion in 
fluorescence quantification lowered the signal to noise ratio and reproducibility of 
experiments. For this these reasons, fluorescence quantification was restricted 
to the ex-nucleolar nuclear region for the remainder of the project.  
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 In summary, this chapter has introduced a method for enrichment of the 
XRCC1 fraction responding to DNA damage, and provided evidence that this 
detergent-insoluble fraction represents chromatin-associated protein. In the 
following chapter, this technique will be combined with the panel of KO RPE-1 
cell lines introduced in Chapter Four to investigate the role of PARP1, PARP2 
and PARP3 in the recruitment of endogenous XRCC1 into oxidised human 
chromatin. 
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6.1. Introduction and Aims 
Single-strand breaks (SSBs) are one of the commonest lesions in DNA, arising 
at a frequency of tens-of-thousands per cell per day (Lindahl 1993, Caldecott 
2008). One major source of SSBs are ROS that generate DNA breaks directly by 
attack of deoxyribose and indirectly by triggering the excision repair of oxidized 
DNA bases and abasic sites. An early step in the repair of SSBs is the activation 
of poly (ADP-ribose) polymerases (PARPs); enzymes that covalently modify 
themselves and other proteins at the site of the break with mono and/or poly 
(ADP-ribose) and thereby serve as molecular SSB sensors (de Murcia and 
Menissier de Murcia 1994, Ame, Spenlehauer et al. 2004, Caldecott 2014). 
Poly(ADP-ribose) (PAR) is then bound by X-ray repair cross-complementing 
protein 1 (XRCC1), a molecular scaffold protein that interacts with, stabilizes and 
stimulates multiple enzymatic components of SSB repair (SSBR), and 
accelerates the overall process (Caldecott 2003, Li, Lu et al. 2013, Caldecott 
2014, Breslin, Hornyak et al. 2015). The first PARP to be identified was PARP1 
(AKA ARTD1), a 113 KDa enzyme that is responsible for ∼85–95% of the total 
cellular PARP activity triggered in response to DNA breaks (Amé, Rolli et al. 
1999). Subsequently, following the observation of residual PAR synthesis in 
Parp1-/- mouse embryonic fibroblasts (MEFs) treated with high doses of 
damaging agents, Parp2 (AKA ARTD2) was identified (Amé, Rolli et al. 1999, 
Johansson 1999). More recently multiple research groups have identified PARP3 
(AKA ARTD3) as a third Diphtheria toxin-like ADP-ribosyl transferase (ARTD) that 
is stimulated by DNA breaks (Boehler, Gauthier et al. 2011, Rulten, Fisher et al. 
2011, Langelier, Riccio et al. 2014). PARP1, PARP2 and PARP3 share ∼60% 
homology within their catalytic and tryptophan-glycine-arginine (WGR) domains, 
but diverge at their N-termini. The N-terminal region of PARP1 is comprised of 
∼500 amino acids and includes three zinc finger domains, two of which promote 
binding to DNA breaks and a third that is believed to trigger stimulation of catalytic 
activity by up to ∼500-fold. PARP2 and PARP3 lack these zinc finger domains 
and instead possess shorter N-terminal regions of 78 and 40 amino acids, 
respectively, the functions of which are poorly understood. In contrast to PARP1, 
PARP2 and PARP3 are reliant on their WGR domains for DNA binding, perhaps 
explaining their lower catalytic activity. 
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 Despite a great deal of interest in the precise roles of PARP enzymes in 
DNA repair, their relative contribution to specific DNA repair processes remains 
unclear. Previous studies employing overexpressed GFP-tagged or RFP-tagged 
XRCC1 have demonstrated that the re-localization of these fusion proteins to 
focal sites of laser microirradiation or chromatin oxidized by H2O2 is largely or 
entirely dependent upon PARP1 (El-Khamisy, Masutani et al. 2003, Okano, Lan 
et al. 2003, Fisher, Hochegger et al. 2007, Mortusewicz, Amé et al. 2007). 
However, the overexpression of tagged XRCC1 might not accurately reflect the 
behaviour of endogenous XRCC1 (see Chapter Five). Moreover, the role of 
PARP1 in promoting XRCC1 recruitment to sites of DNA damage has recently 
been challenged (Parsons, Dianova et al. 2005, Hanssen-Bauer, Solvang-Garten 
et al. 2011, Abdou, Poirier et al. 2015). Consequently, the PARP1-/-, PARP2-/-, 
PARP1-/-/PARP2-/- and PARP3-/- diploid human hTERT RPE-1 cell lines 
generated herein (See Chapter Four) and by co-workers in the Caldecott 
laboratory using CRISPR-Cas9 technology will be used to assess the impact of 
the three DNA strand break-stimulated PARPs on the recruitment of endogenous 
XRCC1 into oxidized human chromatin. [Adapted from (Hanzlikova, Gittens et 
al. 2016) – own writing]. 
To further investigate the overlapping roles of PARP1 and PARP2 in 
SSBR, observations will be extended to another protein involved in this repair 
pathway. PNKP is an enzyme involved in catalysing the phosphorylation and 
dephosphorylation of 5’-OH and 3’-phosphate termini, respectively. As such, it is 
often an essential enzymatic activity prior to DNA synthesis and ligation. PNKP 
interacts with the XRCC1 CK2 phosphorylation motif via its forkhead associated 
(FHA) domain. Perturbing this interaction by mutation of XRCC1, or loss of 
XRCC1 entirely in EM9 cells, has been demonstrated to decrease PNKP 
recruitment/retention at damage sites (Loizou, El-Khamisy et al. 2004, Della-
Maria, Hegde et al. 2012). The prevailing model has been that XRCC1 
PAR-binding co-recruits PNKP to damage sites. However, this model has been 
challenged by others who report direct PAR-binding by PNKP (Li, Lu et al. 2013) 
and has led to the suggestion that XRCC1-Lig3α recruitment to damage sites 
might follow binding of end-processing factors, including PNKP. 
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 The previous chapter introduced methodologies for the sensitive 
quantification of nuclear ADP-ribose and chromatin-localized XRCC1. In this 
chapter, these methods will be combined with the panel of diploid human cell 
lines generated by CRISPR, to answer a fundamental question which has been 
debated in the literature, namely the relative contributions of PARP1, PARP2 and 
PARP3 to the chromatin loading of XRCC1 and PNKP in response to 
H2O2-induced DNA damage. Finally, the consequences of deletion of XRCC1, 
PARP1 and/or PARP2 for rates of SSBR will be compared. 
 
6.2. Results 
6.2.1. PARP Inhibition blocks H2O2-induced XRCC1 chromatin recruitment. 
To check the requirement for ADP-ribosylation for the chromatin recruitment of 
XRCC1 in response to H2O2, WT RPE-1 cells growing on glass coverslips were 
preincubated or not with 10 µM KU0058948 PARP inhibitor for 1 h, prior to 
treatment with 400 µM H2O2 for 7 min at room temperature (RT) in the continued 
absence or presence of 10 µM KU0058948. Cells were then pre-extracted, 
formaldehyde fixed and subjected to immunofluorescence (IF) with anti-XRCC1 
antibody. As previously observed (see Chapter Five), treatment with 400 µM 
H2O2 induced a significant 3.86-fold enrichment of XRCC1 in the chromatin 
outside of the nucleolus (t-test p-value = 8.58x10-4) (Fig. 6.1.). This enrichment 
was significantly reduced (t-test p-value = 1.94x10-3) by preincubation with 10 µM 
KU0058948, to a level that was not significantly different from untreated cells 
(t-test p-value = 1.29x10-1), confirming that recruitment of endogenous XRCC1 
into chromatin requires PARP activity (Masson, Niedergang et al. 1998, El-
Khamisy, Masutani et al. 2003). The concentration of KU0058948 used here is 
likely to potently inhibit PARP1, PARP2 and PARP3 (IC50 values of 3.4, 1.5 and 
40 nM, respectively) (Farmer, McCabe et al. 2005). 
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Figure 6.1. H2O2-induced XRCC1 chromatin loading is blocked by PARP 
inhibition. WT and XRCC1-/- RPE-1 cells growing on glass coverslips were 
preincubated or not with 10 µM KUU0058948 PARP inhibitor for 1 h prior to 
treatment or not with 400 µM H2O2 for 7 min at RT. Cells were pre-extracted, 
formaldehyde fixed and subjected to immunofluorescence with anti-XRCC1 
and anti-B23 antibodies. Slides were imaged using the Olympus ScanR 
system and ScanR Analysis software was used to generate galleries of 16 
randomly selected cells for each condition. For clarity, only WT cells are shown 
(A). XRCC1 fluorescence from >1000 cells was quantified in the nuclear region 
excluding phosphoprotein B23 signal and is expressed as fold over signal in 
untreated. All data are mean ± S.E.M of 3 replicates. Statistical significance 
was calculated by student’s t-test. “n.d” (not done) indicates a condition which 
was not assessed.  (B).  
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6.2.2. Levels of H2O2-induced ADP-ribosylation in PARP-deleted RPE-1 
cells. 
Next, H2O2 induced ADP-ribosylation was measured in WT, PARP1-/-, PARP2-/- 
PARP3-/- and XRCC1-/- RPE-1 cells by Western Blot (WB) and IF. For the WB, 
asynchronous RPE-1 cells of different genotypes were treated with 400 µM H2O2 
for 7 min in PBS at RT, prior to lysis, 10% SDS-PAGE and detection with 
pan-ADP-ribose binding reagent (Fig. 6.2.a). In WT RPE-1 cells, H2O2 induces a 
strong signal corresponding to ADP-ribosylation of targets across the mass range 
(<20 to >250 kDa). Within this smear, faint bands are visible, corresponding to 
heavily ADP-ribosylated protein targets. The signal was indistinguishable, both in 
terms of intensity and pattern, from that observed in PARP2-/- and PARP3-/- and 
XRCC1-/- cells. In the PARP1-/- cells however, the signal was dramatically and 
uniformly reduced. Despite the clear reduction in intensity, ADP-ribosylation 
signal was still detected over a wide mass range, albeit more faintly than in the 
WT cells.  
To verify that the ADP-ribosylation pattern observed above in PARP1-/- 
and PARP2-/- cells was indeed dependent upon the deletion of these genes, 
rather than any other clonally inherited characteristic, multiple clones were tested 
by the same method (Fig. 6.2.b). All three PARP1-/- RPE-1 cell clones (#D4, #F5 
and #G7) exhibited the same reduced ADP-ribosylation phenotype. Similarly, 
both PARP2-/- cell clones (#A1 and #B1) exhibited levels of ADP-ribosylation that 
were indistinguishable from that in WT cells. [Contributing WB from Hana 
Hanzlikova]. 
To more sensitively quantitate the H2O2-induced ADP-ribosylation, cells 
were subjected to IF and ScanR analysis following 400 µM H2O2 treatment, as 
described previously (Fig. 6.3.). Treatment with H2O2 increased ADP-ribosylation 
25.7-fold in WT cells. This was not significantly reduced in either PARP2-/- or 
PARP3-/- cells (t-test p-values: 8.81x10-1 and 3.56x10-1, respectively). In contrast, 
in PARP1-/- cells ADP-ribosylation was significantly reduced to 5.5-fold relative to 
WT untreated (t-test p-value = 1.08x10-2). This 78.4% reduction in the 
H2O2-induced signal is consistent with previous observations demonstrating that 
PARP1 accounts for 80–90% of total ADP-ribosylation following DNA damage 
(Amé, Rolli et al. 1999).  
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Figure 6.2. Western blots of H2O2-induced ADP-ribosylation in WT, 
PARP1-/-, PARP2-/- and PARP3-/- RPE-1 cells. WT, PARP1-/- (#G7), PARP2-/- 
(#A1), PARP3-/- (#20) and XRCC1-/- (#3) RPE-1 cells were treated or not with 
400 µM H2O2 for 7 min at room temperature, prior to whole cell lysis and 
immunoblotting with pan-ADP-ribose binding reagent (A). Multiple PARP1-/- 
and PARP2-/- RPE-1 clones were treated or not with 10 mM H2O2 for 10 min 
at RT, prior to whole cell lysis and immunoblotting with pan-ADP-ribose 
binding reagent (B). [Contributing WB from Hana Hanzlikova] 
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Figure 6.3. Immunofluorescence of H2O2-induced ADP-ribosylation in 
WT, PARP1-/-, PARP2-/- and PARP3-/- RPE-1 cells. WT, PARP1-/-, 
PARP2-/- and PARP3-/- RPE-1 cells were treated with 400 µM H2O2 for 7 min 
prior to formaldehyde fixation and labelling with Pan-ADP-ribose binding 
reagent (green) and DNA-staining with DAPI (blue). Slides were imaged using 
the Olympus ScanR system and ScanR Analysis software was used to 
generate galleries of 16 randomly selected cells for each condition (A). 
ADP-ribose fluorescence from >1000 cells was quantified and is expressed as 
fold over signal in untreated NT-transfected cells. Data are means ±SEM of 3 
experiments. Statistical significance was calculated by students t-test (B, 
overleaf). 
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6.2.3. Levels of H2O2-induced XRCC1 chromatin recruitment in 
PARP-deleted cells remain comparable to WT cells. 
Next, H2O2-induced XRCC1 recruitment was tested in WT, PARP1-/-, 
PARP2-/- and PARP3-/- cell lines, using the pre-extraction method established in 
the previous chapter. Surprisingly, this was not significantly reduced in any single 
PARP-deleted cell line, including in PARP1-/- cells (Fig. 6.4.). Since there is 
significant remaining ADP-ribosylation in PARP1-/- cells (Fig. 6.3.), I hypothesised 
that the residual ADP-ribosylation in PARP1-/- cells is sufficient for near WT levels 
of XRCC1 chromatin loading. Supporting this, it was found that inhibition of the 
remaining ADP-ribosylation in PARP1-/- cells with 10 µM KU0058948 significantly 
reduced XRCC1 chromatin recruitment (t-test p-value = 6.21x10-3) (Fig. 6.5.). 
 
6.2.4. Simultaneous depletion of PARP1/PARP2 ablates H2O2-induced 
ADP-ribosylation. 
To test which of the other PARPs was responsible for the remaining 
H2O2-induced ADP-ribosylation in the absence of PARP1, siRNA was used to 
deplete PARP2 and/or PARP3 in PARP1-/- RPE-1 cells. Cells were lysed and 
subjected to anti-PARP2 and anti-PARP3 WB 72 h after transfection with siRNA 
targeting PARP2, PARP3, PARP2 and PARP3 in combination, or a non-targeting 
siRNA (Fig. 6.6.c). Depletion of each protein from the whole cell extract was 
effective. In parallel to the WB, transfected cells were plated onto glass coverslips 
and subjected to IF protocols at the same 72 h time point (Fig. 6.6.a and b). 
H2O2-induced ADP-ribosylation was significantly reduced in PARP2-depleted 
and PARP2+PARP3-depleted (t-test p-value = 1.83x10-3 and 1.98x10-3, 
respectively) but not PARP3 depleted PARP1-/- cells (t-test p-value = 2.54x10-1). 
While ADP-ribosylation is entirely absent from most PARP2-depleted 
PARP1-/- cells, it was retained in a small population. This could be due to 
heterogenous transfection efficiency of the siRNA, with some cells being 
unsuccessfully depleted of PARP2. This further highlights the superiority of this 
IF over WB quantification, as the population of ADP-ribose positive cells is likely 
small enough that it would be below the detection limit by WB. Additionally, there 
was no significant further reduction in ADP-ribosylation when PARP2 depletion 
was combined with PARP3 depletion (t-test p-value = 3.65x10-1). These 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4. H2O2-induced XRCC1 chromatin-loading in WT, PARP1-/-, 
PARP2-/- and PARP3-/- RPE-1 cells WT, PARP1-/-, PARP2-/-, PARP3-/- and 
XRCC1-/- RPE-1 cells were treated with 400 µM H2O2 for 7 min prior to pre-
extraction, formaldehyde fixation and labelling with antibodies targeting 
XRCC1 (green) and B23 (red), and DNA staining with DAPI (blue). Slides were 
imaged using the Olympus ScanR system and ScanR Analysis software was 
used to generate galleries of 16 randomly selected cells for each condition. 
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Figure 6.5. XRCC1 chromatin-loading in PARP1-/- cells is blocked by PARP 
inhibition. PARP1-/- and XRCC1-/- RPE-1 cells growing on glass coverslips were 
treated or not with 10 µM KU0058948 for 1 hr prior to being treated or not with 400 
µM H2O2 for 7 min prior to pre-extraction, formaldehyde fixation and 
immunolabelling with antibodies against XRCC1 (green) and phosphoprotein B23 
(red), and DNA-staining with DAPI (blue). Slides were imaged using the Olympus 
ScanR system and ScanR Analysis software was used to generate galleries of 16 
randomly selected PARP1-/- cells for each condition (A) XRCC1 fluorescence from 
>1000 cells was quantified in the nuclear region excluding phosphoprotein B23 
signal and is expressed as fold over signal in untreated PARP1-/- cells. Data are 
mean ±SEM of 3 biological replicates. Statistical significance was calculated by 
students t-test (B). 
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Figure 6.6. Depletion of PARP2 but not PARP3 significantly reduces 
H2O2-induced ADP-ribosylation in PARP1-/- RPE-1 cells. PARP1-/- RPE-1 
cells were reverse transfected with siRNA targeting PARP2, PARP3, 
PARP2+PARP3 or a non-targeting siRNA. 48 h later, cells were seeded onto 
glass coverslips. 24 h later cells were treated or not with 400 µM H2O2 for 7 
min prior to formaldehyde fixation and labelling with Pan ADP-ribose binding 
reagent (green), and DNA labelling with DAPI (blue). Slides were imaged using 
the Olympus ScanR system and ScanR Analysis software was used to 
generate galleries of 16 randomly selected cells for each condition (A). ADP-
ribose fluorescence from >1000 cells was quantified and is expressed as fold 
over signal in untreated NT-transfected cells. Data are means ±SEM of 3 
experiments. Statistical significance was calculated by students t-test (B). 
PARP2 and/or PARP3 depletion is demonstrated by a representative 
immunoblot (C). 
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observations therefore do not statistically support the hypothesis that the residual 
signal is due to PARP3 activity. However, this result does not exclude a role for 
PARP3 in the response to ROS. 
 
6.2.5. Simultaneous depletion of PARP1/PARP2 significantly reduces 
H2O2-induced XRCC1 chromatin-loading. 
In parallel to ADP-ribosylation quantification, XRCC1 chromatin recruitment was 
measured in PARP2 and PARP3-depleted PARP1-/- RPE-1 cells (Fig. 6.7.). In 
agreement with the reduction in ADP-ribosylation, only PARP2 depletion caused 
a significant reduction in XRCC1 chromatin-loading in PARP1-/- RPE-1 cells 
(t-test p-values: 2.07x10-3 and 2.04x10-3, respectively). Whilst the residual level 
of H2O2-induced XRCC1-loading in PARP2-depleted cells (2.1-fold relative to 
untreated WT) was significantly greater than in untreated cells (t-test p-value = 
1.95x10-3), this could be explained by incomplete or heterogenous transfection 
efficiency, as described above. PARP3 depletion did not result in a significant 
reduction in H2O2-induced XRCC1-chromatin loading in PARP1-/- cells (t-test p-
value = 1.51x10-1). Furthermore, PARP2 and PARP3 depletion in combination 
did not result in a significant reduction in XRCC1-chromatin loading vs PARP2 
depletion alone (t-test p-value = 4.84x10-1). These assays therefore find no 
significant evidence to support a role for PARP3 in the loading of XRCC1 into 
oxidized chromatin. 
 
6.2.6. PARP1-/-/PARP2-/- RPE-1 cells lack significant H2O2-induced 
ADP-ribosylation and XRCC1 chromatin-loading. 
To avoid the problems of incomplete or heterogenous target depletion by siRNA 
described above, and to determine conclusively if XRCC1 chromatin loading is 
entirely dependent on PARP1 and PARP2, CRISPR technology was used to 
generate a cell line in which both PARP1 and PARP2 were deleted (see Chapter 
Four).  H2O2-induced ADP-ribosylation (Fig. 6.8.) and XRCC1 chromatin-loading 
(Fig. 6.9.) was measured in these cells as described above. Notably, I failed to 
detect ADP-ribosylation in H2O2-treated PARP1-/-/PARP2-/- cells (t-test p-value = 
1.62x10-1), confirming that PARP2 accounted for the residual ADP-ribosylation in 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7. Depletion of PARP2 but not PARP3 significantly reduces 
H2O2-induced XRCC1 chromatin loading in PARP1-/- RPE-1 cells. 
PARP1-/- RPE-1 cells were reverse transfected with siRNA targeting PARP2, 
PARP3, PARP2+PARP3 or a non-targeting siRNA. 48 hr later, cells were 
seeded onto glass coverslips. 24 hr later cells were treated or not with 400 µM 
H2O2 for 7 min prior to pre-extraction, formaldehyde fixation and labelling with 
anti-XRCC1 (green) and anti-B23 antibodies (red), and DNA-staining with 
DAPI (blue). Slides were imaged using the Olympus ScanR system and 
ScanR Analysis software was used to generate galleries of 16 randomly 
selected cells for each condition (A). XRCC1 from >1000 cells was quantified 
in the nuclear region excluding the nucleolus and is expressed as fold over 
signal in untreated NT-transfected cells. Data are means ±SEM of 3 
experiments. Statistical significance was calculated by students t-test (B, 
overleaf). 
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Figure 6.8. Deletion of PARP1 and PARP2 significantly reduces 
H2O2-induced ADP-ribosylation. WT, PARP1-/-, PARP2-/- and 
PARP1-/-/PARP2-/- RPE-1 cells growing on glass coverslips were treated or 
not with 400 µM H2O2 for 7 min prior to formaldehyde fixation and labelling with 
pan-ADP-ribose binding reagent (green), and DNA-labelling with DAPI (blue). 
Slides were imaged using the Olympus ScanR system and ScanR Analysis 
software was used to generate galleries of 16 randomly selected cells for each 
condition (A). ADP-ribose from >1000 cells was quantified in the nucleus and 
is expressed as fold over signal in untreated WT cells. Data are mean ±S.E.M 
of 3 replicates. Statistical significance was calculated by students t-test (B). 
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PARP1-/- cells. In addition, H2O2-induced XRCC1 chromatin-loading (1.34-fold) 
was significantly reduced in PARP1-/-/PARP2-/- cells, compared to PARP1-/- cells 
(3.56-fold), to a level that was not significantly different from the background level 
in untreated cells (t-test p-value = 2.10x10-1).  
In untreated PARP1-/-/PARP2-/- cells, the nucleolar signal of XRCC1 was 
74% that of untreated WT cells, but this was not significant at the 5% level (t-test 
p-value: 8.38x10-2). Furthermore, this reduction was also evident in the 
exnucleolar region (75% XRCC1 signal in untreated PARP1-/-/PARP2-/- cells 
relative to untreated WT cells), implying that it is not specific to the nucleolus.   As 
discussed in Chapter Five, there is therefore no significant evidence to suggest 
that the nucleolar XRCC1 signal in untreated cells is due to elevated association 
with ADP-ribosylated proteins in these regions. An alternative hypothesis is that 
the observed effect may be a consequence of poorer detergent extraction from 
the dense nucleolar region than from the surrounding nucleoplasm (see section 
5.3). 
 
6.2.7. H2O2- induced PNKP chromatin-loading is significantly reduced in 
PARP1-/-/PARP2-/- cells. 
Next, the chromatin loading of PNKP was investigated by IF following H2O2 
treatment (Fig. 6.10.). Prior to H2O2 treatment, background PNKP signal was 
observed throughout the nucleus in WT cells, rather than predominately in the 
nucleolus, in contrast with XRCC1 (Fig. 5.4.). In WT cells, H2O2 treatment 
increased PNKP chromatin-loading 1.85-fold. This was not significantly 
diminished in PARP1-/-, PARP2-/- or PARP3-/- cells (t-test p-values: 9.10x10-1, 
2.15x10-1 and 4.15x10-1, respectively). However, in both XRCC1-/- and 
PARP1-/-/PARP2-/- cells, the PNKP signal in chromatin was reduced to 0.69 and 
0.95-fold that of WT untreated cells, respectively (t-test p-values: 4.34x10-3 and 
1.16x10-2, respectively). This result confirms that PNKP localization at damage 
sites is largely dependent on XRCC1 and PARP1/2 activity. Chromatin-localized 
PNKP signal was notably more punctate than H2O2-induced XRCC1 signal. Co-
IF experiments were not possible, due to both the anti-PNKP and anti-XRCC1 
antibodies being raised in the same host species. However, the punctate nature 
   
Figure 6.9. Deletion of PARP1 and PARP2 significantly reduces 
H2O2-induced XRCC1 chromatin loading. WT, PARP1-/-, PARP2-/-, 
XRCC1-/- and PARP1-/-/PARP2-/- RPE-1 cells growing on glass coverslips were 
treated or not with 400 µM H2O2 for 7 min prior to pre-extraction, formaldehyde 
fixation and immunolabelling with antibodies against XRCC1 (green) and B23 
(red), and DNA-staining with DAPI (blue). Slides were imaged using the 
Olympus ScanR system and ScanR Analysis software was used to generate 
galleries of 16 randomly selected cells for each condition (A). XRCC1 
fluorescence from >1000 cells was quantified in the nuclear region excluding 
phosphoprotein B23 signal and is expressed as fold over signal in untreated 
WT cells. Data are mean ± SEM of 3 biological replicates. Statistical 
significance was calculated by students t-test (B, overleaf). 
 
XRCC1           XRCC1/B23               DAPI         XRCC1/B23/DAPI         
PA
R
P1
-/-
/P
AR
P2
-/-
   
   
PA
R
P2
-/-
   
   
   
   
  P
AR
P1
-/-
   
   
   
   
   
   
W
T 
   
   
   
   
   
   
   
 W
T 
+H
2O
2  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
 U
nt
re
at
ed
   
   
   
   
   
   
   
  
A 
 0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
5
Untreated h2o2
R
el
at
iv
e 
Fl
uo
re
sc
en
ce
 In
te
ns
ity
WT
PARP1
PARP2
PARP1/PARP2
XRCC1
Untr t d                                     +H2O2 
T 
ARP1-/- 
ARP2-/- 
ARP1-/-/ ARP2-/- 
R C1-/- 
ns 
ns ** 
ns 
B 
  
Figure X Deletion of PARP1 and PARP2 significantly reduces H2O2-
+ 
H
2O
2  
   
   
   
 U
nt
re
at
ed
  
                                                                                       PARP1-/- 
WT          XRCC1-/-   PARP1-/-    PARP2-/-    PARP3-/-    /PARP2-/-                                                                                                                                 A  
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
Untreated                                     +H2O2 
0
0.5
1
1.5
2
2.5
treated   H2O2
R
el
at
iv
e 
Fl
uo
re
sc
en
ce
 In
te
ns
ity
WT
XRCC1-/-
PARP1-/-
PARP2-/-
PARP3-/-
P1-/-/P2-/-
** 
ns 
ns 
ns * 
T 
R C1-/- 
ARP1-/- 
ARP2-/- 
ARP3-/- 
AR 1-/-/PARP2-/- 
Figure 6.10. Deletion of XRCC1 or PARP1 and PARP2 significantly 
reduces H2O2-induced PNKP chromatin loading. WT, XRCC1-/-, PARP1-/-, 
PARP2-/-, PARP3-/- and PARP1-/-/PARP2-/- RPE-1 cells growing on glass 
coverslips were treated or not with 400 µM H2O2 for 7 min prior to 
pre-extraction, formaldehyde fixation and immunolabelling with anti-PNKP 
antibody (green) and DNA-staining with DAPI (not shown). Slides were imaged 
using the Olympus ScanR system and ScanR Analysis software was used to 
generate galleries of 8 randomly selected cells for each condition (A). PNKP 
fluorescence from >1000 cells was quantified in the nucleus and is expressed 
as fold over signal in untreated WT cells. Data are mean ±SEM of 3 biological 
replicates. Statistical significance was calculated by students t-test (B). 
 
119 
 
of the PNKP signal may reflect its association with a subset of XRCC1 complexes 
(see section 6.3 for further discussion).  
6.2.8. Rates of SSBR in WT, PARP1-/-, PARP2-/-, PARP1-/-/PARP2-/- and 
XRCC1-/- cells. 
Thus far, this chapter has dealt specifically with the ADP-ribosylation 
requirements for H2O2-induced chromatin-loading of the repair factors XRCC1 
and PNKP. It has been suggested however that ADP-ribosylation at damaged 
DNA loci might serve additional functions beyond the rapid localization of the 
XRCC1 repair complex. Some such functions include modulation of chromatin 
superstructure (de Murcia, Huletsky et al. 1986, Kim, Mauro et al. 2004, Wacker, 
Ruhl et al. 2007), chromatin remodelling (Messner and Hottiger 2011) and rapid 
nuclear ATP generation (Wright, Lioutas et al. 2016). It is feasible that whilst 
either PARP1 or PARP2 is capable of supporting XRCC1 chromatin-recruitment, 
they are not equivalent for these other potential roles. To approach this problem, 
the alkaline single cell electrophoresis (Comet) assay was employed to measure 
levels of DNA breaks and therefore SSBR rates directly (Fig. 6.11.). Previous use 
of γ-Ray calibration curves in combination with this protocol allows approximate 
conversion of Comet tail moment to number of breaks per cell (Fisher, Hochegger 
et al. 2007). Based on this calibration, 1 unit of Comet tail moment is 
approximately equal to 1000 DNA breaks per cell. Whilst the alkaline Comet 
assay cannot distinguish single and double strand breaks, it has been previously 
demonstrated that H2O2 induces an approximate DSB:SSB ratio of 1:2000 
(Bradley and Kohn 1979), suggesting that the Comet tails observed here are 
largely a measurement of SSBs. 
 WT, PARP1-/-, PARP2-/-, PARP1-/-/PARP2-/- and XRCC1-/- RPE-1 cells 
were treated in suspension with 50 µM H2O2 for 10 min on ice. Samples were 
taken immediately after this treatment, or following increasing 37°C incubation 
repair times. Regardless of genotype, untreated cells had a very low average tail 
moment (0.12 for WT), indicating that the level of endogenous damage in these 
cells is below the detection limit of the assay. Immediately following H2O2 
treatment the Comet tail moment in WT cells increased to ~20.41; indicative of 
~20,000 DNA breaks per cell (Fig. 6.11a). There was some variation in the 
damage induction between genotypes. However, this also varied between 
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Figure 6.11. Rates of SSBR in H2O2-induced WT, PARP1-/-, PARP2-/-, 
PARP1-/-/PARP2-/- and XRCC1-/- RPE-1 cells. Subconfluent RPE-1 cells of 
the indicated genotypes were trypsinised, washed with PBS and resuspended 
in ice cold 50 µM H2O2 PBS on ice for 10 min, prior to quenching, washing and 
resuspension with ice cold complete media. Samples were taken immediately 
prior to addition of H2O2 (untreated), immediately after treatment and 
resuspension in ice cold media (no repair), and following 7.5, 15 and 30 min 
subsequent incubation at 37oC. Samples were subjected to alkaline single cell 
electrophoresis and comet tail moments were measured with Comet IV 
software. Data are presented as absolute (A) or relative (B) values. All data 
are expressed as mean ±SEM of 4 independent experiments. Statistical 
significance was calculated by two factor ANOVA. 
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replicates, indicating that it is likely to be due to experimental variation, rather 
than cellular genotype. In WT cells, the Comet tail moment decreased to 0.19 
within 30 min following drug removal, which was not significantly different from 
that of untreated cells (t-test p-value = 1.66x10-1), and so indicated complete 
repair. By comparison, the repair of damage was significantly delayed in 
PARP1-/-, XRCC1-/- and PARP1-/-/PARP2-/- cells (ANOVA p-values: 2.59x10-3, 
5.49x10-5 and 1.47x10-4, respectively).  
As mentioned above, the induction of damage was variable between 
replicates, which decreased the reproducibility of the absolute tail moments. For 
this reason, the data were also expressed as a percentage of the no repair value 
(Fig. 6.11.b). This method increased the precision of the data, which is evident 
from a general decrease in the relative SEM values. When expressed as relative 
Comet tail moments, a significant difference was found between repair in 
PARP1-/- and PARP1-/-/PARP2-/- cells by analysis of variance (ANOVA p-value: 
2.97x10-2).  
The number of DNA breaks over time follow exponential decay kinetics 
(Fig. 6.11). To quantify the rates of SSBR in the different genotypes, exponential 
regression was used to fit an exponential curve to the relative tail moment data, 
with an equation of the form:  
𝑚𝑚𝛥𝛥 = 𝑚𝑚0𝑎𝑎−𝜆𝜆𝛥𝛥 
This equation relates the proportion of strand breaks remaining (Nt) at a given 
time (t) to the number of strand breaks without repair (N0) and the exponential 
decay constant (λ). The exponential decay constant (λ) was used to calculate the 
half-life of strand breaks in each genotype (Table 6.1). These calculations reveal 
a half-life of H2O2-induced damage of 3.03 min in WT RPE-1 cells, which is 
comparable to that estimated from a previous study employing A549 cells (Fisher, 
Hochegger et al. 2007). Relative to this value, the half-lives in 
PARP1-/- (6.43 min), XRCC1-/- (7.44 min) and PARP1-/-/PARP2-/- cells (8.11 min) 
were all significantly increased (extra sum-of-squares F test p-values <1x10-4) In 
comparison, the half-life of strand breaks in PARP2-/- (3.45 min) was not 
significantly different from that in WT cells (extra sum-of-squares F test p-value = 
5.07x10-2). Furthermore, the half-life of H2O2-induced strand breaks in PARP1-/-
 WT 
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Figure 6.12. Deletion of XRCC1 does not sensitise RPE-1 cells to H2O2.. 
WT and XRCC1-/- cells RPE-1 cells were plated at low density (300 per 10 cm 
dish) and incubated at 37oC for 4 h to allow adherence. Dishes were then 
treated with the indicated dose of H2O2 for 20 min in PBS at RT, prior to 
washing with PBS and incubation at 37oC in complete DMEM/F12 media for 
12 days. Dishes were then stained with 2% methylene blue and colonies of 
>50 cells were counted. Each dose was conducted on triplicate 10 cm dishes 
per experiment. The data are expressed as mean ±SEM of 4 independent 
biological replicates. 
  
Cell Line Exponential Decay Constant / λ Half-life / min R2 
WT 0.229, CI 95% [0.204, 0.253] 3.03, CI 95% [2.74, 3.40] 0.997 
PARP1-/- 0.108, CI 95% [0.084, 0.131] 6.43, CI 95% [5.28, 8.24] 0.981 
PARP2-/- 0.201, CI 95% [0.172, 0.230] 3.45, CI 95% [3.02, 4.02] 0.994 
XRCC1-/- 0.093, CI 95% [0.076, 0.110] 7.44, CI 95% [6.30, 9.08] 0.988 
PARP1-/-/ PARP2-/- 0.085, CI 95% [0.054, 0.117] 8.11, CI 95% [5.95, 12.75] 0.949 
Table 6.1. Exponential decay equations for the proportion of SSBs 
remaining (Nt) against time (t) for WT, PARP1-/-, PARP2-/-, XRCC1-/- and 
PARP1-/-/PARP2-/- RPE-1 cells. Exponential regression was used to fit 
equations to the repair kinetics. Exponential decay constants, and half-lives 
(min), including upper and lower 95% confidence intervals, are provided for 
each cell line. R2 values are also provided for each regression, demonstrating 
high goodness of fit.  
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/PARP2-/- cells was significantly different from that in PARP1-/- cells (extra sum-
of-squares F test p-value = 3.32x10-2), but not significantly different than that in 
XRCC1-/- cells (extra sum-of-squares F test p-value = 3.29x10-1). 
 
6.2.9. Sensitivity of RPE-1 cells to H2O2 
Cellular sensitivity of RPE-1 cells to H2O2 was investigated by clonogenic survival 
assay (Fig. 6.12.). Subconfluent WT and XRCC1-/- RPE-1 cells were plated at a 
low density (300 per 10 cm dish) and incubated for 4 h to allow cell adhesion. 
Cells were then treated with 0, 10, 20, 35 or 50 µM H2O2 in PBS for 20 min at RT, 
prior to PBS washing and incubation for 12 days at 37°C in complete media. 
Dishes were then stained with 2% methylene blue to allow counting of colonies 
of more than 50 cells. Unfortunately, despite clear killing of WT RPE-1 cells over 
the tested dose range, XRCC1-/- cells were not more sensitive. The lack of 
sensitivity of XRCC1-/- vs WT implies that SSBR rate is not the limiting factor for 
H2O2 cytotoxicity in RPE-1 cells. ROS are known to be important signalling 
molecules in mediating caspase-dependent apoptosis (Pierce, Parchment et al. 
1991). It is possible that RPE-1 cells may be particularly sensitive to the pro-
apoptotic effects of ROS which are independent of persistent SSBs. In support of 
this, the EC50 for WT RPE-1s (~18 µM) was notably at least an order of magnitude 
lower than the EC50 values of some other commonly used cell lines (Table 6.2.), 
all of which have been demonstrated to be sensitised to H2O2 by XRCC1 loss.  
 
6.3. Conclusions and Discussion 
The results of this chapter reveal that whilst PARP1-/- cells had significantly 
reduced H2O2-induced ADP-ribosylation, the chromatin-loading of XRCC1 and 
PNKP was not significantly reduced. Furthermore, individual deletion of PARP2 
or PARP3 failed to significantly reduce H2O2-induced ADP-ribosylation or 
chromatin-loading of XRCC1 or PNKP. Despite this, the chromatin-loading of 
XRCC1 in PARP1-/- cells was found to be ADP-ribosylation dependent, as it was 
blocked by PARP inhibition. Considering this, it was found that simultaneous loss 
of PARP1 and PARP2 could ablate H2O2-induced ADP-ribosylation and 
Cell 
line 
Treatment 
Time / min 
Treatment 
Buffer 
Treatment 
Temperature 
/ oC 
Estimated 
EC5o / µM  
Ref. 
CHO 15 PBS 37 300 (Breslin, 2004) 
MCF-7 30 PBS 20 300 (Nyaga, 2006) 
U2OS 30 Serum-free 
Media 
37 185 (Paquet, 2015) 
RPE-1 20 PBS 20 18 Fig. 7.13 
 
 
 
Table 6.2. Estimated H2O2 EC50 values of commonly used cell lines. The 
EC50 values for the indicated H2O2 treatments, estimated from the referenced 
publications.  
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significantly reduce or ablate XRCC1 chromatin-loading. This was demonstrated 
by siRNA mediated depletion of PARP2 mRNA, and by successful generation of 
the first reported PARP1-/-/PARP2-/- cell line (Hanzlikova, Gittens et al. 2016). 
Depletion of PARP3 mRNA did not significantly impact on XRCC1 chromatin-
loading in PARP1-/- cells, nor did it significantly further reduce XRCC1 chromatin 
loading in PARP2-depleted PARP1-/- cells, suggesting that PARP3 does not 
function in XRCC1 chromatin-loading in response to H2O2. 
The complete absence of ADP-ribosylation in H2O2-treated 
PARP1-/-/PARP2-/- cells was notable and requires discussion. PARP3 has been 
reported previously to interact with components of BER/SSBR (Rouleau, 
McDonald et al. 2007) and to be stimulated by nicked oligonucleotide substrates 
(Rulten, Fisher et al. 2011, Langelier, Riccio et al. 2014), leading to speculation 
about an undescribed role in SSBR in addition to its role in promoting DSBR by 
NHEJ (Boehler, Gauthier et al. 2011, Rulten, Fisher et al. 2011, Beck, Boehler et 
al. 2014). Recent work in the Caldecott laboratory has identified H2BGlu2 as a site 
of PARP3 mono-ADP-ribosylation in nucleosomes containing nicks and 
3’-overhang DSBs. Considering this, the absence of Pan-ADP-ribose signal in 
H2O2-treated PARP1-/-/PARP2-/- cells is perhaps surprising. Pan-ADP-ribose 
binding reagent is reported to recognize mono-ADP-ribose on recombinant 
PARP3 (Kraus 2015). Despite this, it is likely that the multiple terminal ADP-ribose 
moieties in branched PAR provide many more binding sites than MAR for 
Pan-ADP-ribose binding reagent, resulting in an amplification of the signal. This 
may result in PARP3 ADP-ribosylation signal being below the detection limit of 
this assay. An alternative but not mutually exclusive explanation is that PARP3 
acts upon a repair intermediate which is downstream of PARP1/PARP2 activity 
and thus reduced in PARP1-/-/PARP2-/- cells. Given that, in contrast to PARP1, 
PARP3 activity is specifically stimulated by 5’-phosphorylated nicks (Langelier, 
Riccio et al. 2014), these data do not exclude the possibility that the role of these 
respective enzymes may be to sense SSBs that arise before and after restoration 
of canonical termini. 
In addition to quantification of XRCC1 chromatin-loading and ADP-
ribosylation, repair rates were measured directly using the alkaline Comet assay. 
These data were expressed in terms of absolute values, and also relative to the 
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no-repair level in each experiment. Additionally, non-linear regression was used 
to fit exponential decay kinetics to the relative Comet tail moments, allowing 
quantification of the rates of repair in the different genotypes. By all analyses, the 
repair in PARP1-/-, PARP1-/-/PARP2-/- and XRCC1-/- cells was significantly slower 
than in WT cells, whereas repair in PARP2-/- cells was not. Whilst the rate of repair 
in XRCC1-/- cells was slower than in PARP1-/- cells (indicated by SSB half-lives 
of 7.44 and 6.43 min, respectively), this was not significant at the 5% level. Given 
that XRCC1 chromatin-loading is not significantly decreased in PARP1-/- cells, 
this supports PARP1 fulfilling other roles in SSBR independent of XRCC1 
chromatin-loading, such as the relaxation of chromatin (Poirier, de Murcia et al. 
1982, Aubin, Fréchette et al. 1983, de Murcia, Huletsky et al. 1986, Kim, Mauro 
et al. 2004, Strickfaden, McDonald et al. 2016). Only when expressed in terms of 
relative Comet tail moments, was a significant difference was found between 
H2O2-induced Comet tail moments in PARP1-/- and PARP1-/-/PARP2-/- cells by 
analysis of variance (ANOVA). This is likely to be due to the two cell lines having 
significantly different relative Comet tail moments at 30 min repair (t-test p-value 
= 2.25x10-2), as the values were not significantly different at 7.5 or 15 min of repair 
(t-test p-values: 4.62x10-1 and 1.9x10-1, respectively). In support of this, an extra 
sum-of-squares F-test confirmed that the rate of repair in PARP1-/-/PARP2-/- cells 
(SSB half-life of 8.11 min) was significantly slower than in PARP1-/- cells, 
suggesting a role for PARP2 in SSBR in the absence of PARP1. It is important to 
note that the Comet tail moment at 30 min of repair was also significantly elevated 
in PARP1-/-/PARP2-/- relative to XRCC1-/- cells, suggesting that this phenotype is 
not caused by a failure to load XRCC1 into chromatin. Future work could focus 
on other mechanisms mediated by ADP-ribosylation which may accelerate SSBR 
in addition to XRCC1 chromatin localization. In particular, the relative contribution 
of PARP1, PARP2 and PARP3 to these mechanisms must be assessed. 
Observation of ablated PNKP chromatin-loading in XRCC1-/- cells 
supports previous observations in EM9 (XRCC1-/-) cells (Loizou, El-Khamisy et 
al. 2004), and confirms that PNKP localization to damage sites is largely 
dependent on its interaction with XRCC1, which has been previously questioned 
(Parsons, Dianova et al. 2005). In agreement with this, PARP1-/-/PARP2-/- cells, 
which fail to efficiently load XRCC1, consequently also exhibit reduced PNKP 
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chromatin-loading. The H2O2-induced PNKP signal was notably more punctate 
than XRCC1 signal. The reason for this is unclear and will require further study. 
PNKP retention at damage sites has been shown previously to be more transient 
than XRCC1 retention (Della-Maria, Hegde et al. 2012). Thus, we may not expect 
PNKP to exactly colocalize with XRCC1 in damaged chromatin. Instead, at a 
given time point, PNKP might occupy a subset of damage sites, making its focal 
distribution more apparent. 
In summary, this chapter has employed WB, IF, high-content microscopy 
and the alkaline Comet assay to reveal the contributions of PARP1 and PARP2 
to H2O2-induced ADP-ribosylation, XRCC1 and PNKP chromatin loading; and to 
rates of SSBR. In the concluding results chapter, SSBR will be investigated at 
another type of physiologically relevant SSBs: those which result from abortive 
Topoisomerase 1 activity. 
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Chapter Seven 
 
The Role of PARP1, TDP1 and 
XRCC1 in the Repair of CPT-induced 
DNA Damage 
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7.1. Introduction and Aims 
The previous chapter utilized a panel of isogenic human cell lines to investigate 
the roles of PARP1, PARP2 and PARP3 in H2O2-induced ADP-ribosylation, 
XRCC1 chromatin-loading and rates of SSBR.  In addition to oxidation of DNA, 
another physiologically relevant source of SSBs is the abortive action of 
Topoisomerase 1 (Top1), which will be the focus of this chapter.  
Top1 acts to relax torsional stress associated with replication and 
transcription, via a Top1-DNA covalent intermediate termed the Top1-cleavage 
complex (Top1cc). Top1ccs can be stabilized under certain physiological 
conditions, such as by the presence of proximal DNA lesions (Pourquier, Ueng 
et al. 1997, Lesher, Pommier et al. 2002), which disrupt re-ligation efficiency. 
Additionally, Top1ccs can be stabilized by exogenous agents such as 
camptothecin (CPT). Collision of RNA or DNA polymerases (Wu and Liu 1997, 
Strumberg, Pilon et al. 2000) can convert reversible Top1ccs on the template 
strand into irreversible Top1-linked SSBs (Top1-SSBs). Repair can proceed by 
proteolysis of the Top1 polypeptide, followed by the action of Tyrosyl-DNA 
phosphodiesterase 1 (TDP1) to cleave the tyrosyl-3’-DNA phosphodiester. This 
reaction reveals a 3’-phosphate DNA terminus which, along with the 5’-hydroxyl 
terminus generated by the Top1 initially, must be processed by PNKP to restore 
ligatable 3’-hydroxyl and 5’-phosphate termini. Finally, the nick can be ligated by 
XRCC1-Lig3 (Fig. 7.1.). 
PARP1 activity has been implicated in the repair of Top1-SSBs (Pommier, 
Barcelo et al. 2006, Zhang, Regairaz et al. 2011, Das, Huang et al. 2014). This 
has been demonstrated genetically by the sensitivity of PARP1-/- Chicken DT40 
cells (Das, Huang et al. 2014) to CPT and other Top1 poisons. In contrast, 
another study employing PARP1-/- MEFs found that deletion of PARP1 did not 
sensitise cells to CPT (Patel, Flatten et al. 2012). Since DT40 cells do not encode 
a PARP2 ortholog (Hochegger, Dejsuphong et al. 2006), we wondered if the 
conflicting conclusions of these studies might be explained by the availability of 
PARP2 in mammalian cells. Therefore, one aim of section is to examine the 
functional redundancy between PARP1, PARP2 and PARP3 proteins for cellular 
responses to CPT in human cells. 
 Figure 7.1.  A model of Top1-SSB formation and repair.  Top1 cleaves a 
single strand of DNA, forming a DNA 3’-tyrosyl phosphodiester-linked 
cleavage complex (Top1cc) and a non-canonical 5’-hydroxyl terminus (A). 
Whilst Top1ccs are usually rapidly reversible, they can be stabilized by the 
exogenous agent camptothecin (CPT). Top1ccs can also be converted into 
irreversible Top1-SSBs by the presence of other proximal lesions or by the 
collision of RNA and DNA polymerases (red arrow). Top1-SSBs are degraded 
by the proteasome, leaving a short peptide (B), which can be cleaved from the 
DNA by tyrosyl-DNA phosphodiesterase 1 (TDP1) (C). Cleavage of the 
tyrosyl-DNA phosphodiester bond reveals a non-canonical 3’-phosphate 
terminus. Polynucleotide kinase 3’-phosphatase (PNKP), in complex with the 
scaffold protein X-ray cross-complementing 1 (XRCC1), restores canonical 
5’-phosphate and 3’-hydroxyl termini (D), which can then be ligated by Lig3, 
also in complex with XRCC1 (E). This completes repair of the lesion (F). 
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Recent work by co-workers in the Caldecott laboratory has identified a 
novel human ataxia caused by hypomorphic mutation of XRCC1 (Hoch, 
Hanzlikova et al. 2017): AOA-XRCC1. This joins a group of recessive ataxias 
caused by mutation of other SSBR genes, including TDP1, APTX and PNKP 
(Date, Onodera et al. 2001, Takashima, Boerkoel et al. 2002, El-Khamisy, Saifi 
et al. 2005, Shen, Gilmore et al. 2010, Bras, Alonso et al. 2015, Hoch, Hanzlikova 
et al. 2017)). One hypothesis to explain the neurotoxicity caused by defective 
SSBR involves programmed cell-death via Parthanatos, in a mechanism 
involving hyper-ADP-ribosylation triggered by PARP activity at persistent SSBs 
(Yu, Andrabi et al. 2006) (Hoch, Hanzlikova et al. 2017). For this reason, this 
chapter will also directly investigate CPT-induced SSB formation and ADP-
ribosylation in several models of perturbed SSBR, including: XRCC1-/- cells 
generated by co-workers in the Caldecott laboratory, and TDP1-/- and 
XRCC1-/-/TDP1-/- cells generated in Chapter Four. 
 
7.2. Results  
7.2.1. Impact of PARP enzymes on the sensitivity of RPE-1 cells to CPT 
To investigate the roles of PARP enzymes in repair of CPT-induced damage, 
clonogenic survival assays of PARP1-/-, PARP2-/-, PARP3-/-, 
PARP1-/-/PARP2-/- and TDP1-/- RPE-1 cells were conducted (Fig. 7.2.). It is well 
described that acute treatments with micromolar concentrations of CPT kill 
predominately S-phase cells, resulting in biphasic survival curves (Bhuyan, 
Fraser et al. 1973). If the genotypes have different cell cycle profiles this can 
make comparison of the data difficult. For this reason, continuous rather than 
acute treatment was chosen.  
The clonogenic survival assay revealed that PARP1-/- and TDP1-/- cells 
were significantly more sensitive than WT cells (ANOVA p-values : 1.3x10-5 and 
7.94x10-6, respectively); however, PARP2-/- and PARP3-/- cells were not (ANOVA 
p-values: 7.69x10-1 and 7.38x10-1, respectively). The sensitivity of PARP1-/- cells 
was notably similar to that of TDP1-/- cells, indicating that this is the primary PARP 
enzyme promoting cellular resistance to CPT-induced lesions. Interestingly, 
PARP1-/-/PARP2-/- cells were significantly more sensitive than PARP1-/- cells 
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Figure 7.2. Sensitivity of RPE-1 PARP KO cell lines to CPT.  WT, TDP1-/-, 
PARP1-/-, PARP2-/-, PARP3-/- and PARP1-/-/PARP2-/- RPE-1 cells were plated 
at a density of 300 cells per 10 cm dish, 4 h prior to addition of complete 
DMEM/F12 containing 0, 0.5 ,1, 1.5 or 2 nM CPT. Cells were incubated for 12 
days prior to staining with 2% methylene blue and scoring of colonies with 
more than 50 cells.  For each biological replicate, the surviving fraction was as 
calculated from the average number of colonies on duplicate treated plates, 
expressed as a fraction of average number of colonies on triplicate untreated 
plates. Data are mean ±SEM of 3 biological replicates. Statistical significance 
was calculated by two factor ANOVA.  
 
128 
 
(ANOVA p-value = 3.90x10-4), suggesting that PARP2 promotes cell survival in 
response to CPT in the absence of PARP1.  
7.2.2. PARP1 and XRCC1 are epistatic for cellular resistance to CPT 
After identifying PARP1 as the predominant PARP enzyme promoting 
CPT-resistance in WT cells, its genetic relationship with XRCC1 was 
investigated. The clonogenic survival assay was employed to determine the 
sensitivity of WT, XRCC1-/-, PARP1-/- and XRCC1-/-/PARP1-/- cells to continuous 
CPT treatment (Fig. 7.3.).  It was found that XRCC1-/-, PARP1-/- and 
XRCC1-/-/PARP1-/- cells were significantly more sensitive to CPT than WT cells 
(ANOVA p-values: 1.75x10-7, 4.19x10-10, 8.14x10-7, respectively). However, 
XRCC1-/-/PARP1-/- cells were significantly more sensitive than XRCC1-/- or 
PARP1-/- cells, suggesting that that XRCC1 and PARP1 exhibit an epistatic 
relationship for cellular resistance to CPT. This epistasis is indicative of PARP1 
and XRCC1 operating in the same pathway for the repair of CPT-induced lesions.  
 
7.2.3. XRCC1 and TDP1 are epistatic for cellular resistance to CPT 
To investigate the genetic relationship between XRCC1 and TDP1 following 
CPT-induced damage, clonogenic survival assays were used to determine the 
sensitivity of WT, TDP1-/- and XRCC1-/-/TDP1-/- cells to continuous CPT treatment 
(Fig. 7.4.). These experiments were conducted together with the PARP KO cell 
lines in Fig. 7.1, but for clarity the data are plotted separately. It was found that 
TDP1-/- and XRCC1-/-/TDP1-/- cells were significantly more sensitive to the 
anti-proliferative effects of CPT than WT RPE-1 cells (ANOVA p-values: 
7.94x10-6 and 6.30x10-6, respectively), demonstrating a role of these genes in 
SSBR at CPT-induced lesions. Importantly, the hypersensitivity of TDP1-/- cells 
to CPT was not further increased by additional loss of XRCC1 (ANOVA p-value 
= 9.06x10-1), arguing that TDP1 and XRCC1 operate in the same pathway for 
repair of CPT-induced lesions. Together with Fig. 7.3., this result suggests that 
PARP1, XRCC1 and TDP1 are in the same epistasis group for cellular resistance 
to CPT. 
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Figure 7.3.  XRCC1 and PARP1 are epistatic for promoting cell 
proliferation in the presence of CPT. WT, PARP1-/-, XRCC1-/- and 
XRCC1-/-/PARP1-/- RPE-1 cells were plated at a density of 300 cells per 10 cm 
dish 4 h prior to addition of complete DMEM/F12 containing 0, 0.5 ,1, 1.5 or 2 
nM CPT. Cells were incubated for 12 days prior to staining with 3% crystal 
violet and scoring of colonies with more than 50 cells.  For each biological 
replicate, the surviving fraction was as calculated from the average number of 
colonies on duplicate treated plates, expressed as a fraction of average 
number of colonies on triplicate untreated plates. Data are mean ±SEM of 3 
biological replicates. Statistical significance was calculated by two factor 
ANOVA. 
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Figure 7.4.  XRCC1 and TDP1 are epistatic for promoting cell proliferation 
in the presence of CPT. WT, TDP1-/- and XRCC1-/-/TDP1-/- RPE-1 cells were 
plated at a density of 300 cells per 10 cm dish 4 h prior to addition of complete 
DMEM/F12 containing 0, 0.5 ,1, 1.5 or 2 nM CPT. Cells were incubated for 12 
days prior to staining with 2% methylene blue and scoring of colonies with 
more than 50 cells.  For each biological replicate, the surviving fraction was 
calculated from the average number of colonies on duplicate treated plates, 
expressed as a fraction of average number of colonies on triplicate untreated 
plates. Data are mean ±SEM of 3 biological replicates. Statistical significance 
was calculated by two factor ANOVA. Data for TDP1-/- cells are replotted from 
Fig. 7.2. for comparison, as these experiments were conducted together. 
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7.2.4. Levels of CPT-induced DNA strand breaks are elevated in XRCC1-/-, 
TDP1-/- and XRCC1-/-/TDP1-/- RPE-1 cells 
To determine if the loss of cellular resistance to CPT in XRCC1-/- and TDP1-/- cells 
reflected reduced repair of CPT-induced strand breaks, the alkaline Comet assay 
was used to directly compare the steady-state levels of CPT-induced strand 
breakage in WT, XRCC1-/-, TDP1-/- and XRCC1-/-/TDP1-/- RPE-1 cells (Fig. 7.5.). 
Without treatment, all genotypes had very low Comet tail moments (0.19, 0.15, 
0.16 and 0.18 for WT, XRCC1-/-, TDP1-/- and XRCC1-/-/TDP1-/-, respectively), 
indicating that the level of endogenous lesions is not significantly elevated by loss 
of TDP1 and/or XRCC1, or that this is below the detection limit of the assay. Upon 
treatment with 10 or 100 µM CPT, the Comet tail moment in WT cells increased 
to 0.63 and 1.43, respectively. Whilst dramatically lower than the Comet tail 
moments resulting from H2O2 treatment, these values were nonetheless 
significantly higher than those of untreated cells (t-test p-values: 5.45x10-4 and 
2.55x10-2, respectively). In comparison, Comet tail moments in CPT treated 
TDP1-/-, XRCC1-/- and XRCC1-/-/TDP1-/- cells were significantly greater (ANOVA 
p-values: 5.95x10-5, 3.13x10-4 and 4.22x10-7, respectively), indicating perturbed 
SSBR and elevated steady-state numbers of strand breaks in all three cell lines. 
No significant difference was found between TDP1-/- and XRCC1-/- cells (ANOVA 
p-value = 5.38x10-1), indicating that deletion of TDP1 or XRCC1 results in 
comparable blockage of SSBR. Moreover, combined deletion of both genes 
imposed only a very minor additional effect on the level of strand breakage 
induced by CPT, consistent with these proteins operating in the same SSBR 
pathway and supporting the results of the clonogenic survival assay (Fig. 7.4.). 
 
7.2.5. CPT-induced Comet tail moments are not elevated in PARP1-/-, 
PARP2-/-, PARP3-/-, or PARP1-/-/PARP2-/- RPE-1 cells 
Given that PARP1-/- cells exhibit a similar CPT-sensitivity to XRCC1-/- and 
TDP1-/- cells, it was hypothesised that the level of CPT-induced strand breaks 
would be similarly elevated. To investigate this, the alkaline Comet assay was 
conducted with WT, PARP1-/-, PARP2-/-, PARP3-/- and PARP1-/-/PARP2-/- RPE-1 
cells (Fig. 7.6.). These experiments were conducted together with TDP1-/-, 
XRCC1-/- and XRCC1-/-/TDP1-/- (Fig. 7.5.), but for clarity are plotted separately. 
  
 
 
 
 
 
 
Figure 7.5. Steady-state levels of CPT-induced strand breaks in WT, 
TDP1-/-, XRCC1-/- and XRCC1-/-/TDP1-/- RPE-1 cells. Subconfluent RPE-1 
cells of the indicated genotypes were trypsinised, washed with DMEM/F12 and 
resuspended in DMEM/F12 containing 0, 10 or 100 µM CPT. Cells were 
incubated for 1 h at 37oC prior to being subjected to alkaline single cell 
electrophoresis.  Comet tail moments from 100 cells per condition were 
measured with Comet IV software. Data are expressed as mean ±SEM of 3 
independent experiments. Statistical significance was calculated by two factor 
ANOVA. 
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Figure 7.6. Steady-state levels of CPT-induced strand breaks in WT, 
PARP1-/-, PARP2-/-, PARP3-/-, PARP1-/-/PARP2-/- and TDP1-/- RPE-1 cells. 
Sub-confluent RPE-1 cells of the indicated genotypes were trypsinised, 
washed with DMEM/F12 and resuspended in DMEM/F12 containing 0, 10 or 
100 µM CPT. Cells were incubated for 1 h at 37oC prior to being subjected to 
alkaline single cell electrophoresis.  Comet tail moments from 100 cells per 
condition were measured with Comet IV software. Data are expressed as 
mean ±SEM of 3 independent experiments. Statistical significance was 
calculated by two factor ANOVA. Data for TDP1-/- cells are replotted from Fig. 
7.5. for comparison, as these experiments were conducted together. 
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For comparison, the data for TDP1-/- is replotted. Surprisingly, it was found that 
the average tail moment was not significantly elevated in any of the PARP KO 
cell lines.  
 
7.2.6. Deletion of PARP1 supresses the elevated CPT-induced Comet tail 
moment in XRCC1-/- cells 
It was observed that PARP1-/- cells generally appeared to have slightly lower 
CPT-induced Comet tails than WT cells. Whilst this was not significant at the 5% 
level, it was evident in all 4 replicates following treatment with 100 µM CPT. This 
led to the hypothesis that PARP1 loss might supress elevated Comet tail 
moments seen in other cell lines. To investigate this, the alkaline Comet assay 
was conducted with WT, PARP1-/-, XRCC1-/- and XRCC1-/-/PARP1-/- cells (Fig. 
7.7.). Strikingly, it was found that the Comet tail moment of CPT-treated 
XRCC1-/-/PARP1-/- cells (1.44) was indeed supressed to 0.41-fold that of 
CPT-treated XRCC1-/- cells (3.52; t-test p-value = 2.75x10-4). The suppression 
was not complete, in that the Comet tail moment of CPT-treated 
XRCC1-/-/PARP1-/- cells was still 2.84-fold that of CPT-treated WT cells (0.51; 
t-test p-value = 5.88x10-4). 
 
7.2.7. CPT induces very low steady-state levels of ADP-ribose in WT cells. 
In summary of the chapter so far, the clonogenic survival assays in Fig. 7.3. and 
7.4. demonstrate that PARP1, XRCC1 and TDP1 are epistatic for cellular 
resistance to CPT. However, the alkaline Comet assays in Fig. 7.5, 7.6. and 7.7. 
demonstrate that whereas TDP1 and XRCC1 appear to be in the same epistasis 
group for levels of CPT-induced DNA strand breakage, PARP1 behaves 
differently. To investigate this in more detail, CPT-induced ADP-ribosylation was 
measured directly by quantitative immunofluorescence (IF). WT RPE-1 cells 
growing on glass coverslips were treated with 30 µM CPT in complete DMEM/F12 
for 1 h at 37°C, prior to formaldehyde fixation and IF with pan-ADP-ribose binding 
reagent. ScanR image analysis was used to quantify nuclear pan-ADP-ribose 
signal as described for H2O2-treated cells (Fig. 7.8.). The ADP-ribose signal 
induced by CPT in WT cells (1.09-fold), whilst significantly greater than the 
background in untreated cells (t-test p-value = 8.08x10-3), was dramatically lower 
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Figure 7.7. Steady-state levels of CPT-induced strand breaks in WT, 
PARP1-/-, XRCC1-/- and XRCC1-/-/PARP1-/- RPE-1 cells. Sub-confluent 
RPE-1 cells of the indicated genotypes were trypsinised, washed with 
DMEM/F12 and resuspended in DMEM/F12 containing 0 or 10 µM CPT. Cells 
were incubated for 1 h at 37oC prior to being subjected to alkaline single cell 
electrophoresis.  Comet tail moments from 100 cells per condition were 
measured with Comet IV software. Data are expressed as mean ±SEM of at 3 
independent experiments (A). T-test p values between pairwise CPT-treated 
data are tabulated. Cell colour coding indicates the significance level, 
according to the key (bottom) (B). 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
Untreated 10uM
Av
er
ag
e 
co
m
et
 ta
il 
m
om
en
t WT
PARP1-/-
XRCC1-/-
XRCC1-/-'/ PARP1
T 
ARP1-/- 
XRCC1-/- 
XRCC1-/-/PARP1-/- 
t                                       +CPT 
A 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
Key: 
  
 
Figure 7.8.  CPT induces a very low steady state level of ADP-ribosylation 
in WT RPE-1 cells. WT RPE-1 cells growing on glass coverslips were treated 
or not with 30 µM CPT for 1 h prior to formaldehyde fixation and 
immunolabelling with Pan-ADP-ribose binding reagent. Slides were imaged 
using the Olympus ScanR system and ScanR Analysis software. 
Pan-ADP-ribose fluorescence from >1000 cells was quantified in the nucleus 
and is expressed as fold over signal in untreated WT. Data are mean ±SEM 
of 6 independent replicates. 
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than that induced by 400 µM H2O2 (>25-fold; see Fig. 6.8.). It was hypothesised 
that this was due to the kinetics of the damage induction, which are likely to be 
slower than for H2O2 as they are dependent on other factors such as active 
transcription and replication. In the presence of competent and rapid downstream 
SSBR, this would result in a low steady state level of Top1-SSB lesions and a 
low steady state ADP-ribose signal. Alternatively, the level of PARP activation 
per SSB could be less for CPT-induced lesions than H2O2-induced lesions. A 
prediction of the first hypothesis is that disruption of the downstream repair of 
Top1-SSBs might lead to an increase in the observed CPT-induced 
ADP-ribosylation; this was investigated next. 
 
7.2.8. Loss of XRCC1 or TDP1 causes a dramatic elevation of CPT-induced 
ADP-ribosylation 
The level of CPT-induced ADP-ribosylation was compared in WT, TDP1-/- and 
XRCC1-/- cells (Fig. 7.9.). As predicted, the level of CPT-induced 
ADP-ribosylation in XRCC1-/- RPE-1 cells (8.95-fold) was dramatically higher 
than in WT cells (t-test p-value = 3.39x10-3). The level of ADP-ribosylation 
observed in four independent TDP1-/- cell lines (#4A2, #5B3, #5B4 and #5B5), 
was also dramatically elevated relative to WT cells (3.11, 2.96, 3.35 and 3.78-fold 
relative to WT untreated, respectively). However, this was ~30% of that observed 
in XRCC1-/- cells.  Importantly, the phenotype of TDP1-/- RPE-1 cells was unlikely 
to be attributable to any other clonal characteristic, as it was comparable in all 
four clonally isolated TDP1-/- RPE-1 cell lines. 
 
7.2.9. PARP1 is responsible for the CPT-induced ADP-ribosylation 
observed in XRCC1-/- cells 
To test which PARP was responsible for the elevated CPT-induced 
ADP-ribosylation observed in the absence of XRCC1, XRCC1-/-/PARP1-/- cells 
were compared with WT and XRCC1-/- cells. Simultaneous loss of XRCC1 and 
PARP1 resulted in a significant (t-test p-value = 5.03x10-3) ablation in 
CPT-induced ADP-ribosylation (1.00 ± 0.02 fold relative to WT untreated), to a 
level that was not significantly different from that in untreated WT or 
  
 
  
Figure 7.9. CPT-induced ADP-ribosylation is elevated in XRCC1-/- and 
four clonally-isolated TDP1-/- RPE-1 cell lines. WT, XRCC1-/- and four 
independent TDP1-/- RPE-1 clones (#4A2, #5B3, #5B4, #5B5) growing on 
glass coverslips were treated or not with 30 µM CPT for 1 h prior to 
formaldehyde fixation and immunolabelling with pan-ADP-ribose binding 
reagent (green), and DNA staining with DAPI (blue). Slides were imaged using 
the Olympus ScanR system. Pan-ADP-ribose fluorescence from >1000 cells 
was quantified in the nucleus and is expressed as fold over signal in untreated 
WT (A). ScanR Analysis software was used to generate galleries of 16 
randomly selected cells for each condition (B, overleaf). Data are mean ±SEM 
of 2 independent replicates. 
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Figure 7.10. PARP1 is responsible for the elevated CPT-induced 
ADP-ribosylation in XRCC1-/- RPE-1 cells. WT, XRCC1-/- and 
XRCC1-/-/PARP1-/- RPE-1 cells growing on glass coverslips were treated or 
not with 30 µM CPT for 1 hr prior to formaldehyde fixation and immunolabelling 
with pan-ADP-ribose binding reagent (green), and DNA labelling with DAPI 
(blue). Slides were imaged using the Olympus ScanR system and ScanR 
Analysis software was used to generate galleries of 16 randomly selected cells 
for each condition. See Fig. 7.14. for quantification. 
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XRCC1-/-/PARP1-/- cells (t-test p-values: 3.86x10-1 and 9.68x10-1, respectively) 
(Fig. 7.10. and 7.14.). This result suggests that PARP1 contributes significantly 
to the elevated ADP-ribosylation observed in CPT-treated XRCC1-/- cells. 
 
7.2.10. PARP1 is responsible for CPT-induced loading of XRCC1 into the 
chromatin 
In order to test which PARP was responsible for loading XRCC1 into the 
chromatin in response to CPT, the IF assay developed in Chapter Five was 
employed. WT, PARP1-/-, PARP2-/-, PARP3-/-, PARP1-/-/PARP2-/- and XRCC1-/- 
RPE-1 cells growing on glass coverslips were treated for 1 h with 30 µM CPT, 
prior to detergent pre-extraction, fixation and IF with antibodies targeting XRCC1 
and B23. XRCC1 fluorescence was quantified in the region excluding the 
nucleolus, as described above. In WT cells, CPT-induced a low but reproducible 
increase in XRCC1 fluorescence in the chromatin (1.4-fold relative to untreated) 
(Fig. 7.11.a).  In all other genotypes, the level of XRCC1 fluorescence in CPT-
treated cells was lower than this. However, it is notable that in all other genotypes 
the level of chromatin-localized XRCC1 fluorescence was also lower in untreated 
cells, perhaps due to a loss of PARP activity in unchallenged cells. To account 
for this, the CPT-induced change in XRCC1 fluorescence is also plotted, in 
arbitrary units (Fig. 7.11.b). It was found that the CPT-induced change in XRCC1 
fluorescence in the chromatin was not significantly different between WT and 
PARP2-/- or PARP3-/- cells (t-test p-values: 9.90x10-1 and 3.96x10-1, respectively). 
By comparison, in PARP1-/- and PARP1-/-/PARP2-/- cells this increase was 
completely abolished, which was significantly different from the increase 
observed in WT cells (t-test p-values: 9.46x10-3 and 1.35x10-2, respectively). 
 
7.2.11. XRCC1 and TDP1 are epistatic for the level of CPT-induced 
ADP-ribosylation 
TDP1 has recently been reported to be recruited to CPT-induced damage sites 
upstream of XRCC1 recruitment, via a direct interaction with PARP1 (Das, Huang 
et al. 2014). Given that cleavage of the DNA 3’-tyrosyl phosphodiester bond must 
occur prior to subsequent catalytic activities of the XRCC1 interaction partners 
  
Figure 7.11. Deletion of PARP1 prevents a CPT-induced increase in 
XRCC1 chromatin-localization. WT, PARP1-/-, PARP2-/-, PARP3-/-, 
PARP1-/-/PARP2-/- and XRCC1-/- RPE-1 cells growing on glass coverslips were 
treated or not with 30 µM CPT for 1 h prior to pre-extraction, formaldehyde 
fixation and immunolabelling with antibodies against XRCC1 and B23, and 
DNA-staining with DAPI. Slides were imaged using the Olympus ScanR 
system. XRCC1 fluorescence from >1000 cells was quantified in the nuclear 
region excluding phosphoprotein B23 signal and is expressed as fold over 
signal in untreated WT cells (A). Data are also expressed as CPT-induced 
change in XRCC1 fluorescence, calculated by subtracted the level of XRCC1 
fluorescence in untreated cells from that of CPT-treated cells, for each 
genotype (B). Data are mean ± SEM of 4 biological replicates. Statistical 
significance was calculated by students t-test. 
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PNKP and Lig3α, it was expected that TDP1 or XRCC1 deletion would result in 
a comparable block to repair of CPT-induced SSBs. This was demonstrated by 
the accumulation of similar levels of DNA strand breaks in CPT-treated 
TDP1-/- and XRCC1-/- by alkaline Comet assay (Fig. 7.5.). The fact that 
TDP1-/- cells exhibited a lower level of CPT-induced ADP-ribosylation than 
XRCC1-/- cells therefore suggests that the level of PARP1 activation is not directly 
proportional to the level of DNA strand breaks. One possibility is that repair 
intermediates that accumulate in TDP1-/- cells do not activate PARP1 to the same 
extent as those which accumulate in XRCC1-/- cells. To investigate this 
relationship in more detail, XRCC1-/-/TDP1-/- cells were compared to WT, 
XRCC1-/- and TDP1-/- cells (Fig. 7.12 and 7.14.). As before, XRCC1-/- and 
TDP1-/- (#5B5) cells exhibited an elevated level of CPT-induced ADP-ribosylation 
(11.46 and 5.03-fold relative to WT untreated, respectively). The effects of 
XRCC1 and TDP1 loss were not additive, as CPT-induced ADP-ribosylation in 
XRCC1-/-/TDP1-/- cells (11.80-fold relative to WT untreated) was not significantly 
different from in XRCC1-/- cells (t-test p-value = 8.39x10-1). This epistatic 
relationship suggests that the two proteins operate in the same pathway for repair 
of CPT-induced DNA strand breaks. However, this result does not support a 
model in which the difference in the level of PARP1 hyperactivation between 
TDP1-/- and XRCC1-/- cells is only due to the accumulation of different repair 
intermediates in each cell line. This is because based on the order of events in 
SSBR, we would expect XRCC1-/-/TDP1-/- cells to accumulate the same repair 
intermediates as TDP1-/- cells: SSBs with 3’-phosphotyrosyl-linked Top1 peptides 
(see section 7.3 for further discussion). 
 
7.2.12. Loss of TDP2 further elevates CPT-induced ADP-ribosylation in 
TDP1-/- cells. 
The combined loss of XRCC1 and TDP1 resulted in a small but significant 
additive increase in CPT-induced DNA strand breaks by alkaline Comet assay 
(Fig. 7.5.). This might suggest that loss of either protein is not a complete block 
to SSBR of CPT-induced DNA strand breaks, such that their combined loss 
causes a more severe block to SSBR than loss of either protein alone. If this is 
the case, the presence of alternative redundant activities which circumvent the 
  
 
Figure 7.12.  XRCC1 and TDP1 are epistatic for the level of CPT-induced 
ADP-ribosylation. WT, XRCC1-/-, TDP1-/- and XRCC1-/-/TDP1-/- RPE-1 cells 
growing on glass coverslips were treated or not with 30 µM CPT for 1 h prior 
to formaldehyde fixation and immunolabelling with pan-ADP-ribose binding 
reagent (green), and DNA labelling with DAPI (blue). Slides were imaged using 
the Olympus ScanR system and ScanR Analysis software was used to 
generate galleries of 16 randomly selected cells for each condition. See Fig. 
7.14. for quantification. 
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requirement for TDP1 might be a contributing factor to the lower level of 
CPT-induced ADP-ribosylation observed in TDP1-/- cells. This could also explain 
why the XRCC1-/-/TDP1-/- cells exhibit similar levels of CPT-induced 
ADP-ribosylation to XRCC1-/- cells, rather than TDP1-/- cells. In addition to TDP1, 
cells possess another tyrosyl-DNA phosphodiesterase: TDP2. Whilst this 
enzyme’s primary activity is hydrolysis of DNA 5’-phosphotyrosyl bonds which 
result from abortive Top2 action, it has been shown to also have a weaker activity 
upon DNA 3’-phosphotyrosyl bonds in vitro (Cortes Ledesma, El Khamisy et al. 
2009, Zeng, Sharma et al. 2012). It was hypothesised that TDP2 could act on 
SSBs with 3’-phosphotyrosyl termini in the absence of TDP1. To test this, the 
level of CPT-induced ADP-ribose was measured in TDP2-/- and 
TDP1-/-/TDP2-/- RPE-1 cells (Fig. 7.13. and 7.14.), which were generated by a 
coworker in the Caldecott laboratory: G. Zagnoli. It was found that the level of 
CPT-induced ADP-ribose observed in TDP1-/-/TDP2-/- cells (8.03 +1.23-fold 
relative to WT untreated) was significantly higher than in TDP1-/- cells (t-test p-
value = 9.23x10-3), suggesting that TDP2 does act on CPT-induced lesions in the 
absence of TDP1. Notably, however, the loss of TDP2 alone did not result in 
elevated levels of CPT-induced ADP-ribose relative to WT cells (t-test p-value = 
1.17x10-1), indicating that TDP2 does not act appreciably in the presence of 
TDP1. Interestingly, the level of CPT-induced ADP-ribosylation in 
TDP1-/-/TDP2-/- cells was lower than in XRCC1-/- cells (11.46-fold). Whilst not 
significant at the 5% level, this result may indicate that TDP2 activity does not 
account entirely for the difference in CPT-induced ADP-ribosylation between 
XRCC1-/- and TDP1-/- cells.  It is possible that there are other pathways which 
circumvent the requirement for TDP1 activity, or that the types of breaks which 
accumulate in TDP1-/-/TDP2-/-- cells do not stimulate ADP-ribosylation to the 
same extent as those which accumulate in XRCC1-/- cells, as suggested above. 
Alternatively, it is possible that XRCC1 deletion causes hyperactivation of PARP1 
by another mechanism, independent from the repair of DNA strand breaks (see 
section 7.3 for further discussion). 
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Figure 7.13. Deletion of TDP2 further elevates CPT-induced ADP-
ribosylation in TDP1-/- cells. WT, TDP1-/-, TDP1-/-/TDP2-/ and TDP2-/- RPE-1 
cells growing on glass coverslips were treated or not with 30 µM CPT for 1 h 
prior to formaldehyde fixation and immunolabelling with pan-ADP-ribose 
binding reagent (green), and DNA labelling with DAPI (blue). Slides were 
imaged using the Olympus ScanR system and ScanR Analysis software was 
used to generate galleries of 16 randomly selected cells for each condition. 
See Fig. 7.14. for quantification.  
 
  
 
V.S 
+CPT 
WT TDP1-/- TDP2-/- TDP1
-/-
/TDP2-/- XRCC1
-/- XRCC1
-/-
/PARP1-/- 
XRCC1-/-
/TDP1-/- 
+C
PT
 
WT   1.90E-07 1.20E-01 1.70E-04 3.80E-05 6.10E-02 1.40E-06 
TDP1-/- 1.90E-07   8.30E-05 9.20E-03 7.10E-04 7.60E-05 2.90E-05 
TDP2-/- 1.20E-01 8.30E-05   3.00E-02 5.20E-03 1.20E-01 1.50E-03 
TDP1-/-
/TDP2-/- 1.70E-04 9.20E-03 3.00E-02   1.70E-01 2.90E-02 6.50E-02 
XRCC1-/- 3.80E-05 7.10E-04 5.20E-03 1.70E-01   5.10E-03 8.40E-01 
XRCC1-/-
/PARP1-/- 6.10E-02 7.60E-05 1.20E-01 2.90E-02 5.10E-03   1.50E-03 
XRCC1-/-
/TDP1-/- 1.40E-06 2.90E-05 1.50E-03 6.50E-02 8.40E-01 1.50E-03   
ns 
(0.05<p) 
*  
(0.01<p<0.05) 
** 
(0.001<p<0.01) 
*** 
(0.0001<p<0.001) 
**** 
(p<0.0001) 
0.00
2.00
4.00
6.00
8.00
10.00
12.00
14.00
Untreated + CPT
R
el
at
iv
e 
Fl
uo
re
sc
en
ce
 In
te
ns
ity
WT
TDP1-/-
TDP2-/-
TDP1-/-/TDP2-/-
XRCC1-/-
XRCC1-/-/PARP1-/-
XRCC1-/-TDP1-/-
T 
TDP1-/- 
TDP2-/- 
TDP1-/-/TDP2-/- 
R C1-/- 
R C1-/-/PARP1-/- 
R C1-/-/TDP1-/- 
 
A 
 
 
 
 
 
 
 
 
 
 
 
B 
Figure 7.14. CPT-induced ADP-ribosylation levels in RPE-1 knockout cell 
lines. Quantification of Pan-ADP-ribose fluorescence in untreated and 
CPT-treated RPE-1 cells of the indicated genotypes. Representative images 
are presented in Fig. 7.10, 7.12. and 7.13.  Pan-ADP-ribose fluorescence from 
>1000 cells was quantified in the nucleus and is expressed as fold over signal 
in untreated WT. Data are mean ±SEM of at least 2 independent replicates 
(A). T-test p-values between pairwise CPT-treated data are tabulated. Cell 
colour coding indicates the significance level, according to the key (bottom) 
(B). 
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Figure 7.15. CPT-induced degradation of Top1 is not blocked by loss of 
PARP1. Sub-confluent RPE-1 cells of different genotypes were treated or not 
with complete DMEM/F12 containing 30 µM CPT for 1 or 3 h, prior to PBS 
washing and recovery in complete DMEM/F12 for 30 min. Cells were then 
washed, lysed, and subjected to 10% SDS-PAGE with anti-Top1 antibody. 
Equal loading is demonstrated by equivalence of Ponceau S staining, and 
equivalence of a non-specific (N.S) band detected by the anti-Top1 antibody. 
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7.2.13. Loss of PARP1 does/does not block CPT-induced degradation of 
Top1 
Having demonstrated that PARP1 is activated by CPT-induced DNA strand 
breaks which accumulate in XRCC1-/- cells (Fig. 7.10. and 7.14.), the mechanism 
by which PARP1 deletion suppresses the elevated Comet tail moment of 
CPT-treated XRCC1-/- cells was investigated. One explanation for how this might 
occur is by affecting the proteasomal degradation of Top1-SSBs. It has been 
reported previously that pre-treating cells with MG132 proteasome inhibitor 
reduces CPT-induced Comet tails (Alagoz, Chiang et al. 2013). To test whether 
PARP1 is involved in the proteasomal degradation of Top1-SSBs, WT, PARP1-/-, 
XRCC1-/- and XRCC1-/-/PARP1-/- RPE-1 cells were treated or not with 30 µM CPT 
for 1 or 3 h (WT only), prior to washing and recovery in complete media. Whole 
cell lysates were subjected to SDS-PAGE and anti-Top1 Western Blot (WB) (Fig. 
7.15.).  CPT-induced degradation of Top1 was evident in WT cells by 1 h, with 
limited further degradation by 3 h. Strikingly, all other genotypes exhibited 
comparable degradation of Top1 by 1 h; suggesting that neither PARP1 nor 
XRCC1 are involved in this step of Top1-SSB repair, and arguing against this 
hypothesis to explain the results of the Comet assay (see section 7.3 for further 
discussion). 
 
7.3. Conclusions and Discussion 
In this chapter, the genetic relationship between PARP1, XRCC1 and TDP1 in 
the cellular response to CPT was investigated by three main methodologies: 
clonogenic survival, Comet assay and PAR IF. Deletion of PARP1, XRCC1 or 
TDP1 was found to result in comparable sensitivity to CPT by clonogenic survival 
assay. Unfortunately, the generation of PARP1-/-/TDP1-/- cells was unsuccessful 
here. However, by using XRCC1-/-/PARP1-/- and XRCC1-/-/TDP1-/- cells to 
demonstrate epistatic relationships between PARP1 and XRCC1, and between 
XRCC1 and TDP1, we can infer that all three genes are in the same epistasis 
group for cellular resistance to CPT. The very similar sensitivity of PARP1-/- and 
TDP1-/- cells is in agreement with a previous study which reported epistasis of 
these two genes for resistance of chicken DT40 cells to continuous CPT 
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treatment (Das, Huang et al. 2014). Notably, this result contradicts a previous 
study which found no sensitivity of PARP1-/- MEFs or PARP1-depleted A2780 
human cells to CPT (Patel, Flatten et al. 2012). The explanation for this 
discrepancy is unclear. In the cited publication, cells were exposed to CPT for 24 
h prior to washing and incubation in drug-free media, which contrasts with the 
continuous treatment used here. It is possible that these different treatment 
protocols could be a factor in the different responses observed.  
Here it was found that loss of PARP2 sensitised PARP1-/- but not WT cells 
to CPT. This suggests that in the presence of PARP1, PARP2 does not play any 
appreciable role in the repair of CPT-induced damage, but that it may be 
providing a backup role in the absence of PARP1. As PARP1 deletion fully 
blocked CPT-induced ADP-ribosylation in XRCC1-/- cells, this backup role of 
PARP2 is unclear. Either the function is independent of the catalytic activity of 
PARP2, or the catalytic activity is so low that it is below the detection limit of the 
IF assay. Alternatively, it may be a catalytic role which is downstream of the 
rate-limiting SSBR step in XRCC1-/- cells. For example PARP2 is likely to respond 
to 5’-phosphate termini which result after PNKP activity (Langelier, Riccio et al. 
2014). If this activity is the rate-limiting step in XRCC1-/- cells, we might be unlikely 
to detect PARP2-mediated ADP-ribosylation in these cells. Alternatively, if Lig3 
activity is rate-limiting in XRCC1-/- cells we might expect an accumulation of 
5’-phosphate termini which would be expected to activate PARP2. In the future, 
this model could be tested by quantification of CPT-induced ADP-ribosylation in 
PARP1-/- and PARP1-/-/PARP2-/- cells depleted of PNKP or Lig3α. 
PARP1 was shown in this chapter to be entirely responsible for the CPT-
induced increase in chromatin-localized XRCC1. This is contrast to the findings 
of Chapter Six, which revealed overlapping functions of PARP1 and PARP2 in 
H2O2-induced XRCC1 chromatin-localization. One model to explain this 
difference involves differences in the types of termini generated following 
exposure to the two damaging agents. It is notable that SSBs generated both by 
direct oxidation of the dRP moiety, or by excision of oxidized bases by the 
bifunctional glycosylases, often harbour a 5’-phosphate terminus. CPT, on the 
other hand, induces SSBs which do not harbour a 5’-phosphate terminus until 
after processing by TDP1 and PNKP (see Fig. 7.1.). As mentioned above, 5’-
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phosphate termini have been demonstrated previously to stimulate PARP2 to a 
greater degree than other types of termini (Langelier, Riccio et al. 2014); by 
comparison, PARP1 exhibits no such selectivity. This may explain the apparent 
involvement of PARP2 in XRCC1 chromatin-localization following H2O2, but not 
CPT treatment. 
Alkaline single cell electrophoresis revealed that PARP1-/- cells do not 
exhibit the elevated CPT-induced Comet tail moments of TDP1-/- or 
XRCC1-/- cells; nor indeed do any of the other PARP KO cell lines, including 
PARP1-/-/PARP2-/- cells. Furthermore, deletion of PARP1 supressed the elevated 
CPT-induced Comet tail moment observed in XRCC1-/- cells. These surprising 
results are notably distinct from the published effect of PARP inhibitors, which 
reportedly do cause elevated CPT-induced Comet tail moments (Lin, Ban et al. 
2008, Znojek, Willmore et al. 2014). In order to investigate the role of PARP1 at 
Top1-SSBs in more detail, quantitative IF was used to measure CPT-induced 
ADP-ribosylation directly. As discussed above, it was found that deletion of 
PARP1 in XRCC1-/- cells completely abolished CPT-induced ADP-ribosylation, 
suggesting that at least in the absence of XRCC1, the CPT-induced lesions which 
accumulate trigger activation of PARP1 alone. It has been reported previously 
that inhibition of the proteasome blocks CPT-induced Comet tail moments 
(Alagoz, Chiang et al. 2013). Inclusion of a proteinase K digestion step in the 
Comet protocol removes this block, suggesting that it is probably due to retarded 
electrophoretic mobility of unproteolyzed Top1-SSBs (Alagoz, Chiang et al. 
2013). It was therefore hypothesised that PARP1 may be playing a previously 
unreported role in this process. However, WB failed to detect a difference in 
CPT-induced degradation of Top1 between WT, PARP1-/- or 
XRCC1-/-/PARP1-/- cells. This approach has been used previously to establish a 
link between ATM loss and suppressed Top1 degradation (Katyal, Lee et al. 
2014). It is important to note that the reported difference in CPT-induced Top1 
degradation between WT and ATM-/- cells was small (59% and 37%, 
respectively), and not immediately apparent by eye. This suggests that the assay 
may not be sufficiently sensitive for detecting proteolysis of Top1-SSBs. Future 
work will focus more directly on the ubiquitylation and sumoylation which is known 
to be involved in this process (Mao, Sun et al. 2000, Lin, Ban et al. 2008, Lin, Ban 
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et al. 2009). Unfortunately, the suppression of elevated CPT-induced Comet tail 
moments in PARP1-deficient cell lines was observed at a late stage of this 
project, and time constraints have prevented further investigation here. These 
observations will therefore serve as preliminary work for future experiments 
concerning this intriguing phenotype.  
Previous work has identified the human neurodegenerative disease 
SCAN1, caused by mutations in TDP1 (Takashima, Boerkoel et al. 2002, El-
Khamisy, Saifi et al. 2005). Recent work in this laboratory has identified a novel 
human disease (AOA-XRCC1) with similar clinical features, caused by mutation 
of XRCC1 (Hoch, Hanzlikova et al. 2017). In this chapter, a common feature of 
XRCC1-/- and TDP1-/- RPE-1 cells was identified: hyper-ADP-ribosylation in 
response to CPT. This result is pertinent for several reasons. Firstly, one 
mechanism of cell death which is thought to act in SSBR-defective neurons is the 
programmed response Parthanatos, which is initiated by excessive PAR 
generation and concurrent depletion of NAD. The relevance of this mechanism is 
demonstrated by the fact that heterozygous and homozygous deletion of Parp1 
suppresses disease-associated phenotypes of an Xrcc1 brain-specific knockout 
mouse (Hoch, Hanzlikova et al. 2017), and that cells derived from the 
AOA-XRCC4 patient also exhibit CPT-induced hyper-ADP-ribosylation (Hoch, 
Hanzlikova et al. 2017). Here it is reported for the first time that TDP1-/- RPE-1 
cells also exhibit a PARP hyperactivation phenotype. It remains to be seen 
whether this phenotype is present upon mutation of other SSBR genes 
associated with autosomal recessive cerebellar ataxias, such as APTX and 
PNKP. More generally, it is conceivable that PARP hyperactivation might be a 
contributing factor in the onset or progression of other more common 
neurodegenerative diseases, such as Parkinson’s (Cosi, Chopin et al. 1996, 
Mandir, Przedborski et al. 1999, Martire, Mosca et al. 2015) and Alzheimer’s 
diseases (Love, Barber et al. 1999, Kauppinen, Suh et al. 2011, Martire, Fuso et 
al. 2013, Martire, Mosca et al. 2015). If this is indeed the case, the development 
of small molecules which inhibit PARP activity, without trapping the enzyme at 
the site of damage, could provide a therapeutic opportunity. Furthermore, the 
strikingly elevated levels of ADP-ribosylation in CPT-treated XRCC1-/- and 
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TDP1-/- cells suggests a paradigm which could be used to identify other genes 
with novel functions in SSBR.  
Whilst elevated relative to WT, the CPT-induced ADP-ribosylation in 
TDP1-/- cells was found to be significantly lower than in XRCC1-/-- cells.  When 
combined, deletion of XRCC1 and TDP1 did not result in an additive effect in 
CPT-induced ADP-ribosylation, or on cell proliferation in the presence of CPT, 
and had only a very small additive effect on levels of CPT-induced strand 
breakage. Together these data indicate that these proteins operate in the same 
repair pathway for CPT-induced DNA damage. A number of factors could explain 
the lower levels of CPT-induced ADP ribosylation observed in TDP1-/- cells 
relative to XRCC1-/- cells. Firstly, it is possible that there are alternative enzymatic 
activities in the cell which bypass the requirement for TDP1 and allow 
downstream XRCC1-dependent repair. In this case, the loss of TDP1 might not 
be a robust block to SSBR, leading to a lower steady state number of 
CPT-induced Top1-SSBs and lower ADP-ribosylation. Some evidence was found 
for this hypothesis, as the combined deletion of TDP1 and TDP2 (which 
possesses a weak 3’-tyrosyl-phosphodiesterase activity) (Cortes Ledesma, El 
Khamisy et al. 2009, Zeng, Sharma et al. 2012) led to significantly higher levels 
of CPT-induced ADP-ribosylation than loss of TDP1 alone. This finding is in 
agreement with a previous study which observed elevated levels of CPT-induced 
strand breaks in TDP1-/-/TDP2-/- vs TDP1-/- MEFs by alkaline Comet assay (Zeng, 
Sharma et al. 2012). Here, however, steady state levels of strand breaks were 
found by alkaline Comet assay to be approximately equivalent in XRCC1-/- and 
TDP1-/- cells. This result suggests that the steady-state level of ADP-ribosylation 
is not directly proportional to the number of CPT-induced DNA strand-breaks and 
that circumvention of TDP1 activity is unlikely to be the sole explanation for the 
lower hyper-ADP-ribosylation in TDP1-/- vs XRCC1-/- cells. CPT-treated 
TDP1-/- cells are likely to accumulate DNA 3’-tyrosyl-linked SSBs, whereas the 
identity of the lesions which accumulate in CPT-treated XRCC1-/- cells is less 
clear. XRCC1 promotes the stability, recruitment and activity of several SSBR 
enzymes involved in the repair of Top1-SSBs downstream of TDP1 activity, 
including PNKP and Lig3α. Additionally XRCC1 interacts with TDP1 itself via its 
constitutive partner Lig3α and may promote the recruitment and activity of TDP1 
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(Plo, Liao et al. 2003).  It remains to be seen which enzymatic step is rate-limiting 
in XRCC1-/- cells, but if it is PNKP or Lig3α activity we would expect the 
accumulation of 5’-hydroxyl and 3’-phosphate, or DNA nicks, respectively.  It is 
possible that repair intermediates that accumulate in CPT-treated XRCC1-/- cells 
may activate PARP1 to a greater extent than those which accumulate in 
CPT-treated TDP1-/- cells. Interestingly, recent work in this laboratory found that 
the levels of CPT-induced ADP-ribosylation were 2-fold greater in PNKP patient 
fibroblasts than XRCC1 patient fibroblasts (Hoch, Hanzlikova et al. 2017). This 
might suggest that the PARP1 hyperactivation phenotype in XRCC1-/- RPE-1 
cells and XRCC1 patient fibroblasts results indirectly from a failure to efficiently 
recruit PNKP, although further work would be required to confirm this. For 
example, generation of PNKP-/- and XRCC1-/-/PNKP-/- isogenic RPE-1 cells would 
allow the genetic relationship to be examined in more detail.  Additionally, 
complementation of XRCC1-/- cells with XRCC1A482T, which has disrupted PNKP 
binding, would allow separation of XRCC1 PAR-binding from PNKP recruitment. 
A final hypothesis for the elevated level of hyper-ADP-ribosylation 
observed in XRCC1-/- cells is direct inhibition of PARP1 activity by XRCC1. In this 
case, XRCC1 recruitment could inhibit the level of ADP-ribosylation regardless of 
blocked repair in TDP1-/- cells. This has been suggested previously in the 
literature based on the observation that titration with recombinant XRCC1 
reduces the activity of PARP1 in vitro (Masson, Niedergang et al. 1998, Keil, 
Gröbe et al. 2006). However, another study found that in contrast to 
overexpression of full length XRCC1, overexpression of the PAR-binding BRCT 
I domain alone actually stimulated ADP-ribosylation in untreated and 
H2O2-treated cells (Lévy, Oehlmann et al. 2009). This could be due to the BRCT 
I domain competing with the endogenous XRCC1 complex and thus inhibiting 
repair, but further work will be required to fully clarify this.  
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8.1. Introduction 
In this thesis, new data have been provided which clarify mechanisms of SSBR 
as they occur in vivo in human cells. The scope of the project was relatively broad, 
encompassing two subpathways of SSBR: the repair of oxidative SSBs and the 
repair of Top1-SSBs. In this concluding section, the notable findings of each 
chapter will be briefly summarised and discussed in relation to one another, and 
in relation to the recent literature. In particularly, suggestions will be made for 
future work in this area. 
 
8.2. Chapter Summaries 
8.2.1. Chapter Three – Investigating SSBR at a Highly-transcribed Gene 
Locus 
Chapter Three constituted some of the early work undertaken on this project, 
which began with the aim of investigating the interplay between transcription and 
SSBR at the inducible early-response gene FOS: a marker of neuronal activity 
(Morgan and Curran 1986, Morgan, Cohen et al. 1987, Day, Masini et al. 2004) 
with known Top1 cleavage sites within its transcribed region (Francis Stewart, 
Herrera et al. 1990). A23187-induced FOS transcription and its inhibition by CPT 
was successfully demonstrated by qRT-PCR and RNAPII ChIP-qPCR.  
Attention was focussed on the minimal level of transcription which 
persisted in the presence of CPT, as we hypothesised that this might be 
dependent upon functional SSBR. This hypothesis was first tested with the use 
of the PARP inhibitor KU0058948, which was found not to reduce transcription in 
the presence of CPT. At the time of these experiments, the consensus amongst 
myself and co-workers was that incubation of cells with 500 nM KU0058948 
would essentially abolish cellular ADP-ribosylation by PARP1, PARP2 and 
PARP3. In latter stages of the project (see section 5.2.1), it was found that even 
a 2-fold higher concentration of KU0058948 (1 µM) failed to completely abolish 
H2O2-induced ADP-ribose IF signal. In the future, the level of FOS transcription 
in the presence of CPT could be tested with a higher concentration of 
KU0058948, or in the various PARP-deleted cell lines now available in the 
laboratory.  
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Inhibition of the proteasome with MG132 was used to block proteolysis of 
Top1-SSBs, in another attempt to determine if ongoing transcription in the 
presence of CPT was dependent on repair. This was problematic, as it was found 
that MG132 treatment lowered FOS transcription even in the absence of CPT. In 
the future, the TDP1-/- RPE-1 cells generated in subsequent stages of this project 
(see section 4.2.2) could be used to more specifically perturb repair of Top1-
SSBs. 
The primary aim of this chapter was to establish ChIP methods to detect 
enrichment of XRCC1 at FOS following gene induction and/or CPT treatment. 
Early attempts were apparently successful, suggesting an increased localization 
of XRCC1 to FOS upon gene induction. To test the specificity of this signal, the 
protocol was then established in CHO cells, where an XRCC1 KO (EM9) was 
available. It became evident that the ChIP-qPCR signal detected with the 
A300-231A antibody was not specific to XRCC1, which prompted further 
experiments employing a GFP-tagging strategy (Teytelman, Thurtle et al. 2013). 
At the time of these experiments, there were not adequate tools to easily test the 
specificity of anti-XRCC1 signal in human cells. Following the generation of the 
XRCC1-/- RPE-1 cells by co-workers, these experiments would be far more 
tractable. For example, it was possible to select the anti-XRCC1 antibody used 
for many of the subsequent stages of the project (ABC738) based on its lack of 
immunoreactivity with XRCC1-/- cells by Western Blot (WB) and 
Immunofluorescence (IF). In the future, this antibody may also find use for the 
XRCC1 ChIP experiments.   
 
8.2.2. Chapter Four - Generation and Characterization of Diploid Human 
Cells with CRISPR/Cas9 Mediated Deletion of SSBR Genes. 
In attempting to develop a specific XRCC1 ChIP-qPCR protocol at an early stage 
of this project, it became apparent that there was a lack of human cell lines with 
KO mutations in SSBR genes, which would have been very useful as antigen 
depletion controls. In the year that this work was initiated, two pioneering 
publications detailed the RNA-guided genetic modification of human cells using 
CRISPR/Cas9 technology (Cong, Ran et al. 2013, Mali, Yang et al. 2013). Myself 
and other co-workers began employing this technology to generate a panel of 
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isogenic diploid human cells with deletions of SSBR genes. I successfully 
generated TDP1-/-, XRCC1-/-/TDP1-/- and PARP1-/-/PARP2-/- RPE-1 cells, and 
characterized them by WB and sequencing of the mutations introduced.  
 The previous literature does not include any mention of cell lines which are 
doubly deleted of XRCC1 and TDP1, or of PARP1 and PARP2: implying that 
these may be the first such cell lines to be generated. In particular, the successful 
generation of PARP1-/-/PARP2-/- cells was very exciting, because this 
combination of mutations leads to early embryonic lethality in mice (Ménissier de 
Murcia, Ricoul et al. 2003), and had an unknown phenotype at the cellular level.  
Since the observation of a synthetically lethal interaction between PARP 
inhibition and HR-deficiency (Bryant, Schultz et al. 2005), and the subsequent 
FDA and EMA approval of PARP inhibitors for the treatment of BRCA1/BRCA2 
deficient ovarian cancers (EMA 2014, FDA 2014), clinical research into 
poly(ADP-ribosyl)ation has increased dramatically (NCBI 2016). The PARP1-/-
/PARP2-/- cells generated here may useful for future work in this area, for example 
in testing the specificity, potency, and DNA-PARP trapping propensity of novel 
PARP inhibitors. In support of this, since publication of the cell line (Hanzlikova, 
Gittens et al. 2016), it has been requested by and distributed to several external 
research groups.  
 In the future, it would be useful to generate a complete panel of cell lines 
with combined deletion of the three known DNA-dependent PARPs. This would 
involve generation of PARP1-/-/PARP3-/-, PARP2-/-/PARP3-/- and PARP1-/-
/PARP2-/-/PARP3-/- cells. This complete panel might prove useful, for example in 
identifying the ADP-ribosylation targets of the three enzymes in vivo. 
 
8.2.3. Chapter Five – Establishing High-Content Imaging Methods for the 
Sensitive Quantification of ADP-ribose and Chromatin-associated XRCC1. 
The aim of Chapter Five was to develop and characterize a method for the 
quantification of endogenous ADP-ribosylation and XRCC1 chromatin-
association which avoided some negative aspects of previously-employed 
methods, such as: poor signal from the use of insensitive detection reagents, 
artefacts caused by overexpression of fluorescent protein (FP) –tagged 
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constructs, and poor reproducibility and temporal resolution of chromatin 
fractionation methods. In the case of ADP-ribosylation, this involved comparing 
the sensitivity of multiple available antibodies/ recombinant reagents. In the case 
of detecting the chromatin localization of XRCC1, a pre-extraction technique 
based on previous work (Cramer and Mitchison 1995, Britton, Coates et al. 2013) 
was employed. Both IF methods were coupled to a high-content imaging platform 
which allowed the sensitive quantification of ADP-ribosylation and chromatin-
associated endogenous XRCC1 in thousands of single cells. 
 It was found that the ADP-ribose binding reagent MABE1016 (Kraus 2015) 
was significantly more sensitive than the 10H monoclonal in widespread use, and 
furthermore it appeared to detect a broader molecular weight range of ADP-
ribosylated protein targets. High content imaging of IF conducted with this reagent 
revealed that treatment with 1 µM KU0058948 fails to abolish H2O2-induced ADP-
ribosylation. 
 XRCC1 appeared to be localized predominately to the nucleolar chromatin 
in unchallenged cells, which may be explained by a resistance of these structures 
to detergent-extraction (Melan and Sluder 1992, Britton, Coates et al. 2013), or 
alternatively may reflect a functional role of XRCC1 in the nucleolus. PARP1 and 
PARP2 both possess nucleolar localization sequences, which might suggest a 
model of XRCC1 nucleolar localization involving elevated ADP-ribosylation at 
these regions. However, no enrichment of ADP-ribosylation was detected in the 
nucleolus in unchallenged cells, and in Chapter Six, it was demonstrated that 
there was no specific reduction in nucleolar XRCC1 signal in PARP1-/-/PARP2-/- 
cells. Both of these observations suggest that if the nucleolar XRCC1 signal 
reflects a functional enrichment, then this enrichment is independent of 
PARP1/PARP2 mediated ADP-ribosylation. 
 
8.2.4. Chapter Six – Overlapping Roles of PARP1 and PARP2 for the 
Loading of Endogenous XRCC1 and PNKP into Oxidised Human 
Chromatin 
Chapter Six aimed to utilize the techniques developed in Chapter Five to assess 
the contributions of PARP1, PARP2 and PARP3 to H2O2-induced ADP-
ribosylation, XRCC1 and PNKP chromatin-loading, and to rates of SSBR. The 
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pattern of H2O2-induced ADP-ribosylated targets in WT, PARP1-/-, PARP2-/- and 
PARP3-/- cell extracts were visually similar by WB, as was the distribution of 
nuclear signal detected by high-content IF. The levels of total H2O2-induced ADP-
ribosylation were comparable in WT, PARP2-/- and PARP3-/- cells, but were 
significantly lower in PARP1-/- cells, in agreement with previous research (Ame, 
Rolli et al. 1999). Surprisingly, the remaining level of ADP-ribosylation, which was 
shown to be PARP2-dependent, was found to be sufficient for proficient XRCC1 
chromatin-localization (Hanzlikova, Gittens et al. 2016). These experiments were 
first conducted using siRNA-mediated depletion of PARP2 and/or PARP3 in a 
PARP1-/- background, and subsequently repeated following the generation of the 
PARP1-/-/PARP2-/- RPE-1 cell line. 
 The role of PARP2-mediated ADP-ribosylation in recruiting XRCC1 to 
sites of DNA damage had been previously questioned, in part due to observations 
that the relocalization of overexpressed GFP-XRCC1 into H2O2-induced foci or to 
sites of UVA laser-mediated damage was entirely reliant on PARP1 activity (El-
Khamisy, Masutani et al. 2003, Okano, Lan et al. 2003, Fisher, Hochegger et al. 
2007, Mortusewicz, Amé et al. 2007). As detailed in Chapter Seven, the role of 
PARP2 in promoting XRCC1 recruitment to sites of oxidative damage does not 
appear to extend to the other type of lesion considered in this project: Top1-SSBs 
(see section 7.2.10). This can be rationalised by considering that 5’-phosphate 
termini, which most stimulate PARP2 activity, are commonly generated following 
direct oxidative scission of the dRP DNA moiety, or excision of oxidized bases by 
the bifunctional glycosylases; but are not generated at Top1-SSBs until after end-
processing by TDP1 and PNKP. By comparison, PARP1 is potently stimulated by 
SSBs with diverse chemical termini, owing to the mechanism by which it 
coordinates them (Dawicki-McKenna, Langelier et al. 2015, Eustermann, Wu et 
al. 2015). This is likely to explain its involvement in CPT-induced XRCC1 
chromatin localization. 
 The role of PARP3 was also investigated, as it has been previously 
reported to be a sensor of nicked nucleosomes and to be implicated in SSBR in 
chicken DT40 cells (Grundy, Polo et al. 2016). In this human cell system, PARP3 
appeared to play no role in either H2O2-induced ADP-ribosylation, XRCC1 
chromatin-localization, or rates of SSBR in H2O2 -treated cells. It is possible that 
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H2O2-induced damage does stimulate PARP3 activity, but that this technique is 
not sensitive enough to detect mono(ADP-ribosyl)ated targets. However, it does 
seem clear that any PARP3-mediated ADP-ribosylation does not have a role in 
XRCC1 recruitment into oxidised chromatin, and if present must instead promote 
other aspects of SSBR.  
The mechanism of PNKP recruitment at sites of DNA damage has been 
the subject of controversy in the literature, with some suggesting that this is 
mediated by its interaction with XRCC1 (Loizou, El-Khamisy et al. 2004, Della-
Maria, Hegde et al. 2012), and others suggesting that PNKP interacts with PAR 
directly (Li, Lu et al. 2013). Here it was shown that XRCC1-/- cells had significantly 
reduced or ablated PNKP chromatin-loading in response to H2O2 treatment, 
which is consistent with the former model. In comparison to XRCC1, the PNKP 
signal was notably punctate, which might indicate recruitment of PNKP to only a 
subset of H2O2-induced lesions. This will require further study, for example by 
using an anti-PNKP antibody raised in a different host to the anti-XRCC1 
antibody, which would allow an analysis of signal colocalization.  
PARP1-/- and XRCC1-/- cells exhibited similarly delayed SSBR kinetics 
following H2O2 treatment. Given that XRCC1 chromatin-loading is proficient in the 
PARP1-/- cells, this implies that this is not the source of their SSBR defect. In the 
future, other known roles of PARylation must be assessed in this system, for 
example relaxation of chromatin superstructure (Aubin, Fréchette et al. 1983, de 
Murcia, Huletsky et al. 1986, Kim, Mauro et al. 2004, Strickfaden, McDonald et 
al. 2016). The extent to which PARP2 can support these other functions will be 
particularly interesting. At the time of these experiments, a PARP1-/-/XRCC1-/- cell 
line was not available, but this has been subsequently generated by co-workers. 
Using these cells, we have reported that loss of PARP1 and XRCC1 does not 
have an additive effect in delaying SSBR (Hoch, Hanzlikova et al. 2017), which 
would support the consensus model whereby the additional roles of PARP1 in 
modulating chromatin structure, for example, are in the same pathway and thus 
epistatic with XRCC1. 
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8.2.5. Chapter Seven - The Role of PARP1, TDP1 and XRCC1 in the Repair 
of CPT-induced DNA Damage 
Chapter Seven aimed to use the cell lines generated in Chapter Four, and the 
methods developed in Chapter Five, to investigate the SSBR of CPT-induced 
Top1-SSBs. It was found by clonogenic survival assay that PARP1-/- cells, but 
not PARP2-/- or PARP3-/- cells, were sensitive to CPT. PARP1-/-/PARP2-/- cells 
were more sensitive than PARP1-/- cells, implying that in the absence of PARP1, 
PARP2 may be able to support some of its roles in promoting cellular resistance 
to CPT. Despite this, the absence of sensitivity of PARP2-/- cells to CPT suggests 
that in WT cells, PARP1 is mainly responsible for promoting cellular resistance to 
CPT. This was supported by the finding that loss of PARP1, but not PARP2 or 
PARP3, ablated the CPT-induced increase in XRCC1 chromatin-localization. 
 Unfortunately, the generation of PARP1-/-/TDP1-/- cells was unsuccessful 
here. However, the similarity of the CPT survival curves of PARP1-/-, TDP1-/- and 
XRCC1-/- cells, coupled with the demonstration of epistasis between PARP1 and 
XRCC1 and between TDP1 and XRCC1, strongly suggests that these three 
genes all operate in the same epistasis group for CPT tolerance. In support of 
this, it was found that TDP1-/- and XRCC1-/- cells exhibited comparably elevated 
levels of CPT-induced SSBs, relative to WT. However, unexpectedly, PARP1-/- 
cells did not exhibit the same elevated Comet tail moment, and it was 
subsequently shown that loss of PARP1 was able to supress the Comet tail 
moment of XRCC1-/- cells. This intriguing phenotype has not been reported 
previously in the literature, and is the subject of ongoing research in the Caldecott 
laboratory. Since completion of this project, the phenotype has been confirmed 
with siRNA-mediated depletion of PARP1 in XRCC1-/- cells (J. Wang, personal 
communication), arguing that it is not due to any other clonal characteristic of 
XRCC1-/-/PARP1-/- cells. At the point of writing, the focus is on two potential 
models. Firstly, PARP1 may have a previously undescribed role in promoting the 
proteolysis of Top1-SSBs, such that its loss leads to an accumulation of 
unproteolysed Top1-SSBs, which are undetectable by alkaline Comet assay 
((Alagoz, Chiang et al. 2013) and J. Wang, personal communication). Another 
hypothesis is that PARP1 is actively involved in converting Top1ccs to Top1-
SSBs. Whilst the induction of Top1ccs by CPT appears to be comparable in WT 
149 
 
and PARP1-/- cells (J. Wang, personal communication), the level of Top1-SSBs 
which remain after CPT removal has yet to be assessed. If PARP1-mediated 
ADP-ribosylation prevents the reversal of CPT-stabilized Top1ccs which 
otherwise might occur under the conditions of the alkaline Comet assay, this 
could explain the phenotype. To test this, the levels of Top1-SSBs should be 
determined following removal of CPT in WT vs PARP1-/- cells, using an assay 
which directly quantifies covalently linked DNA-Top1 molecules. 
 In Chapter Seven, a striking phenotype of XRCC1-/- and TDP1-/- cells was 
reported: hyper-ADP-ribosylation in response to CPT. This was rationalised by a 
model in which perturbation of SSBR causes an accumulation of CPT-induced 
SSBs which would otherwise be rapidly repaired, and these SSBs activate ADP-
ribosylation. In the case of XRCC1-/- RPE-1 cells, the CPT-induced ADP-
ribosylation was shown to be entirely dependent on PARP1, because in 
XRCC1-/-/PARP1-/- cells it was completely ablated. In the future, it will be 
important to demonstrate whether PARP1 is similarly entirely responsible for the 
hyper-ADP-ribosylation observed in CPT-treated TDP1-/- cells. It will also be 
important to identify the types of SSB which accumulate in TDP1-/- and XRCC1-/- 
cells, as these appear to activate ADP-ribosylation to differing degrees.  
 The hyper-ADP-ribosylation phenotype described above was 
subsequently observed in fibroblasts derived from patients with mutations in 
XRCC1 and PNKP (Hoch, Hanzlikova et al. 2017), by co-workers in the Caldecott 
lab. It was further demonstrated that deletion of Parp1 was able to reduce 
cerebellar neurodegeneration and ataxic phenotypes of Xrcc1 brain-specific KO 
mice, indicating that PARthanatos is involved in the pathogenesis (Hoch, 
Hanzlikova et al. 2017), and that non-trapping PARP inhibition might provide a 
therapeutic opportunity for human diseases in which this cell death programme 
is implicated. This publication additionally demonstrated that the 
hyper-ADP-ribosylation phenotype was also observed 1 h after H2O2 treatment, 
demonstrating that other types of persistent SSB also trigger 
hyper-ADP-ribosylation (Hoch, Hanzlikova et al. 2017). Given the work presented 
in this thesis, it will be interesting to determine whether H2O2-induced hyper-ADP-
ribosylation in XRCC1-/- cells is entirely dependent on PARP1, or whether PARP2 
also contributes in this case. More generally, by treating various SSBR-deficient 
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cells with different types of SSB-inducing agent, it should be possible to elucidate 
the roles of the DNA-dependent PARPs in each subpathway of SSBR. Finally, by 
coupling high-content analysis of hyper-ADP-ribosylation with a high-throughput 
screening approach, it should be possible to identify genes with novel functions 
in promoting SSBR. 
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ABSTRACT
A critical step of DNA single-strand break repair is
the rapid recruitment of the scaffold protein XRCC1
that interacts with, stabilizes and stimulates multiple
enzymatic components of the repair process. XRCC1
recruitment is promoted by PARP1, an enzyme that
is activated following DNA damage and synthesizes
ADP-ribose polymers that XRCC1 binds directly.
However, cells possess two other DNA strand break-
induced PARP enzymes, PARP2 and PARP3, for
which the roles are unclear. To address their involve-
ment in the recruitment of endogenous XRCC1 into
oxidized chromatin we have established ‘isogenic’
human diploid cells in which PARP1 and/or PARP2,
or PARP3 are deleted. Surprisingly, we show that ei-
ther PARP1 or PARP2 are sufficient for near-normal
XRCC1 recruitment at oxidative single-strand breaks
(SSBs) as indicated by the requirement for loss of
both proteins to greatly reduce or ablate XRCC1 chro-
matin binding following H2O2 treatment. Similar re-
sults were observed for PNKP; an XRCC1 protein
partner important for repair of oxidative SSBs. No-
tably, concentrations of PARP inhibitor >1000-fold
higher than the IC50 were required to ablate both
ADP-ribosylation and XRCC1 chromatin binding fol-
lowing H2O2 treatment. These results demonstrate
that very low levels of ADP-ribosylation, synthesized
by either PARP1 or PARP2, are sufficient for XRCC1
recruitment following oxidative stress.
INTRODUCTION
Single-strand breaks (SSBs) are one of the commonest le-
sions in DNA, arising at a frequency of tens-of-thousands
per cell per day (1,2). One major source of SSBs are reac-
tive oxygen species that generate DNA breaks directly by
attack of deoxyribose and indirectly by triggering the ex-
cision repair of oxidized DNA bases and abasic sites. An
early step in the repair of SSBs is the activation of poly
(ADP-ribose) polymerases (PARPs); enzymes that cova-
lentlymodify themselves and other proteins at the site of the
break with mono and/or poly (ADP-ribose) and thereby
serve as molecular SSB sensors (3–5). Poly (ADP-ribose)
(PAR) is then bound by X-ray repair cross-complementing
protein 1 (XRCC1), a molecular scaffold protein that in-
teracts with, stabilizes and stimulates multiple enzymatic
components of SSB repair and accelerates the overall pro-
cess (6–9). One of the most important XRCC1 protein part-
ners is DNA polynucleotide kinase phosphatase (PNKP)
(10,11). PNKP is a dual function 5′-DNA kinase and 3′-
DNA phosphatase that can convert oxidative DNA termini
into canonical 5′-phosphate and 3′-hydroxyl termini that
can supportDNAgap filling andDNA ligation (12,13). The
importance of this activity is illustrated by existence of neu-
rological diseases in which PNKP is mutated (14–17).
The first PARP to be identified was PARP1 (ADPRT1),
a 113 KDa enzyme that is responsible for ∼85–95% of
the total cellular PARP activity triggered in response to
DNA breaks (18). Subsequently, following the observa-
tion of residual PAR synthesis in Parp1-/- mouse embry-
onic fibroblasts (MEFs) treated with high doses of damag-
ing agents, PARP2 (ADPRT2) was identified (18,19). More
recently we, and others, identified PARP3 (ADPRT3) as a
third ADP-ribosyl transferase (ADPRT) that is stimulated
byDNAbreaks (20–23). PARP1, PARP2 and PARP3 share
∼60% homology within their catalytic and tryptophan-
glycine-arginine (WGR) domains, but diverge at their N-
termini. The N-terminal region of PARP1 is comprised of
∼500 amino acids and includes three zinc finger domains,
two of which promote binding to DNA breaks and a third
that is believed to trigger stimulation of catalytic activity by
up to ∼500-fold. PARP2 and PARP3 lack these zinc finger
domains and instead possess shorter N-terminal regions of
∼78 and 40 amino acids, respectively, the functions of which
are poorly understood. In contrast to PARP1, PARP2 and
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PARP3 are reliant on their WGR domains for DNA bind-
ing, perhaps explaining their lower catalytic activity.
Despite a great deal of interest in the precise roles of
PARP enzymes in DNA repair their relative contribution
to specific DNA repair processes remains unclear. Previ-
ous studies employing overexpressed GFP-tagged or RFP-
tagged XRCC1 have demonstrated that the re-localization
of these fusion proteins to focal sites of laser micro-
irradiation or chromatin oxidized by hydrogen peroxide
(H2O2) is largely or entirely dependent upon PARP1 (24–
27). However, the overexpression of tagged XRCC1 might
not accurately reflect the behaviour of endogenous XRCC1.
Moreover, the role of PARP1 in promoting XRCC1 recruit-
ment to sites of DNA damage has recently been challenged
(28–31). Consequently, we have now generated PARP1-/-,
PARP2-/-, PARP1-/-/PARP2-/- and PARP3-/- diploid hu-
man hTERT RPE-1 cell lines using CRISPR-Cas9 tech-
nology and developed high-content imaging approaches to
measure the relative activity and impact of PARP1, PARP2
and PARP3 on the recruitment of endogenous XRCC1
into oxidized human chromatin. Surprisingly, we find that
deletion of PARP1 alone does not dramatically impact on
XRCC1 recruitment, despite the deletion of this protein re-
ducing total ADP-ribosylation by ∼4- to 5-fold. Indeed,
loss of both PARP1 and PARP2 was required to greatly re-
duce or ablate chromatin binding by endogenous XRCC1.
Moreover, similar results were observed for endogenous
PNKP, the recruitment of whichwas dependent onXRCC1.
Consistent with these data, we show that relatively small
amounts of ADP-ribosylation are required for recruitment
of endogenous XRCC1 into chromatin following DNA ox-
idation, explaining the ability of PARP2 to substitute for
PARP1.
MATERIALS AND METHODS
Antibodies and chemicals
The antibodies used in this study were the rabbit polyclon-
als anti-XRCC1 (Millipore; ABC738), anti-PARP2 (Ac-
tive Motif; 39743), anti-PARP3 (4699; a kind gift from
F. Dantzer), anti-PNKP (SK3195) (32), anti-poly (ADP-
ribose) (Trevigen; 4336), rabbit Fc-fused anti-pan-ADP-
ribose binding reagent (Millipore; MABE1016) and the
mouse monoclonals anti-PARP1 (Serotec; MCA1522G),
anti-poly (ADP-ribose) 10H (Enzo; ALX-804-2), anti-
nucleophosmin (B23) (Invitrogen; 325200) and anti-actin
(Sigma; A4700). The secondary antibodies employed for
Western blotting were HRP-conjugated goat anti-rabbit
(Bio-Rad; 170-6515) and goat anti-mouse (Bio-Rad; 170-
6516) and for indirect immunofluorescence were goat anti-
mouse or anti-rabbit Alexa 488 (Invitrogen; A11001 and
A31628), goat anti-mouse Alexa 555 (Invitrogen; A21422)
and donkey anti-mouse Alexa 647 (Invitrogen; A39571).
8.8 MH2O2 was obtained from Fischer Scientific. Olaparib
(S1060) was purchased from Selleckchem and KU0058948
hydrochloride from Axon. Both PARP inhibitors were dis-
solved in dimethyl sulfoxide (Sigma) to a working concen-
tration of 10 mM.
Cell culture, treatment and siRNA transfection
Human hTERT RPE-1 cells obtained from ATCC
were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM/F12; Sigma) supplemented with 10% fetal calf
serum (FCS) and 0.01 mg/ml hygromycin B at 37◦C and
5% CO2. Human U2OS cells and MEFs from wild type
or Parp1-/- mice (33) were cultured in DMEM (Gibco)
containing 10% FCS, 2 mM glutamine and the antibiotics
penicillin (100 units/ml) and streptomycin (100 g/ml) at
37◦C and 5% CO2. Wild-type primary human fibroblasts
(1BR) and primary human fibroblasts from a PNKP-
mutated patient (15) were cultured in Minimum Essential
Media (Gibco) containing 15% FCS, 2 mM glutamine and
the antibiotics penicillin (100 units/ml) and streptomycin
(100 g/ml) at 37◦C and 5% CO2. Where indicated, cells
were treated with H2O2 diluted in phosphate buffered
saline (PBS) or serum free medium at the indicated con-
centrations immediately prior to use for 7 min at room
temperature (RT) or 10 min on ice. PARP inhibitors
(Olaparib or KU0058948) were employed where indicated
at a final concentration of 1 M or 10 M and were
added to the cells 1 h prior to and during H2O2 treatment.
Non-targeting siRNA (ON-TARGETplus, Dharmacon),
siPARP2 or siPARP3 SMARTpool (Dharmacon) were
reverse-transfected into the cells using Lipofectamine®
RNAiMAX (Invitrogen) according to the manufac-
turer’s instructions. All experiments were carried out 72 h
post-transfection, at the observed peak of target protein
depletion.
Generation of PARP1-/-, PARP2-/-, PARP1-/-/PARP2-/-,
PARP3-/- and XRCC1-/- cells
Human hTERT RPE-1 gene edited cell lines were prepared
using Cas9 and guides identified using either E-CRISP
(http://www.e-crisp.org/E-CRISP/) or CRISPRdirect (http:
//crispr.dbcls.jp). For XRCC1, the 21-mer Tru-guide (34)
sequences were 5′-GACACGACAUGGCGGAGGCGG-
3′ and 5′-CCGCCUCCGCCAUGUCGUGUC-3′ (PAM
underlined) and spanned nucleotides 12–32 of the human
XRCC1 ORF. The 58-mer synthetic oligonucleotides
XCr2F: 5′-TTTCTTGGCTTTATATATCTTGTGGAAA
GGACGAAACACCGACACGACATGGCGGAGG-3′
andXCr2R: 5′-GACTAGCCTTATTTTAACTTGCTATT
TCTAGCTCTAAAACCCTCCGCCATGTCGTGTC-3′
(Eurofins) encoding the 18 bp Tru-guide sequence (un-
derlined) minus the PAM were annealed and extended
into a 98-mer double-stranded fragment using Phusion
polymerase (NEB) which was then subcloned into the guide
RNA vector (Addgene; #41824) using Gibson Assembly
(NEB).
For PARP1 deletion in RPE-1 cells we used the 22-mer
Tru-guide sequences 5′-GAAGGUGGGCCACUCCAU
CCGG-3′ and 5′-CCGGAUGGAGUGGCCCACCUUC-
3′ (PAM underlined) spanning nucleotides 174–
195 of the human PARP1 ORF. For these ex-
periments, the synthetic 59-mers PARP1-4F:5′-
TTTCTTGGCTTTATATATCTTGTGGAAAGGAC
GAAACACCGAAGGTGGGCCACTCCATC-3′ and
PARP1-4R: 5′-GACTAGCCTTATTTTAACTTGCTATT
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TCTAGCTCTAAAACGATGGAGTGGCCCACCTTC-
3′ encoding the 19 bp Tru-guide (underlined) minus
the PAM were subcloned as above. For PARP1 dele-
tion in U2OS cells, we used the 20-mer Tru-guide se-
quences 5′-GCACCCUGACGUUGAGGUGG-3′ and 5′-
CCACCUCAACGUCAGGGUGC-3′ (PAM underlined)
spanning nucleotides 195–214 of the human PARP1 ORF.
For these experiments, the synthetic 57-mers PARP1-2F: 5′-
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGA
AACACCGCACCCTGACGTTGAGG-3′ and PARP1-
2R: 5′-GACTAGCCTTATTTTAACTTGCTATTTCTA
GCTCTAAAACCCTCAACGTCAGGGTGC-3′ encod-
ing the 17 bp Tru-guide (underlined) minus the PAM were
subcloned as above. For PARP2, the 20-mer ‘Tru-guide′
sequences were 5′-GCAUCUACGAGUUUUCUUGG-
3′ and 5′-CCAAGAAAACUCGUAGAUGC-3′ (PAM
underlined) and spanned nucleotides 107–126 of the
human PARP2 ORF. The synthetic 57-mers PARP2-F:
5′-TTTCTTGGCTTTATATATCTTGTGGAAAGG
ACGAAACACCGCATCTACGAGTTTTCT-3′ and
PARP2-R: 5′-GACTAGCCTTATTTTAACTTGCTATT
TCTAGCTCTAAAACAGAAAACTCGTAGATGC-
3′ encoding the 17 bp Tru-guide sequence (under-
lined) minus the PAM were subcloned as above.
For PARP3, the 20-mer ‘Tru-guide’ sequences were
5′-GAUUAUGCGCUUCUCUGCGG-3′ and 5′-
CCGCAGAGAAGCGCAUAAUC-3′ (PAM under-
lined) and spanned nucleotides 119–138 of the human
PARP3 ORF. The synthetic 57-mers PARP3-1F: 5′-
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGA
AACACCGATTATGCGCTTCTCTG-3′ and PARP3-
1R: 5′-GACTAGCCTTATTTTAACTTGCTATTTCTA
GCTCTAAAACCAGAGAAGCGCATAATC-3′ encod-
ing the 17 bp Tru-guide sequence (underlined) minus the
PAM were subcloned as above.
Generation of PARP1-/-/PARP2-/- RPE-1 cells was
carried out by targeting PARP2 in PARP1-/- RPE-1 cells.
The 20-mer ‘Tru-guide’ sequences targeting PARP2 in this
case were 5′-GAGGAUUGUAUUCGGGCUGG-3′ and
5′-CCAGCCCGAAUACAAUCCUC-3′ (PAM under-
lined) and spanned nucleotides 11821–11841 of the human
PARP2 ORF. The synthetic 57-mers PARP2-B-F: 5′-
TTTCTTGGCTTTATATATCTTGTGGAAAGGACGA
AACACCGAGGATTGTATTCGGGC-3′ and PARP2-
B-R: 5′-GACTAGCCTTATTTTAACTTGCTATTTCTA
GCTCTAAAACGCCCGAATACAATCCTC-3′ encod-
ing the 17 bp Tru-guide (underlined) minus the PAM were
subcloned as above.
For gene editing, hTERT RPE-1 or U2OS cells were co-
transfected with the appropriate guide RNA construct in-
dicated above and a Cas9 expression construct (Addgene;
#41815) using a NEON Transfection System (Invitrogen).
Twenty four hours later, the transfected cells were selected
in medium containing 0.5 mg/ml G418 for 5 days and then
subcloned into 96-wells plates. Once at sufficient cell den-
sity the subclones were analysed for presence of the target
protein by indirect immunofluorescence (PARP1, PARP2,
XRCC1) or by Western blotting (PARP3). The absence of
the targeted protein in cell clones selected as above was con-
firmed by Western blotting and one clone of each genotype
was chosen for further analysis (clone #G7 for PARP1-/-,
#A1 for PARP2-/-, #E6 for PARP1-/-/PARP2-/-, #20 for
PARP3-/- and #3 for XRCC1-/- cells).
Confirmation of gene editing by sanger sequencing
GenomicDNAwas purified fromWT,PARP1-/-,PARP2-/-,
PARP3-/-, PARP1-/-/PARP2-/- and XRCC1-/- RPE-1 cells
using Extract-N-Amp Tissue PCR kit (Sigma) as per the
manufacturer’s instructions. PCR was used to amplify
regions of interest surrounding the specific gRNA tar-
get loci (primer sequences can be found in Supplemen-
tary Table S1). Amplicons were cloned and expanded in
pCR®2.1-TOPO® (Invitrogen) prior to Sanger sequenc-
ing. WT RPE-1 cells were sequenced by whole exome se-
quencing (Source BioScience). Consensus sequences for
each pCR®2.1-TOPO® clone were aligned with the con-
sensus sequences for the corresponding loci fromWTRPE-
1 exome sequencing, allowing identification of indels close
to the gRNA target loci.
SDS-PAGE and Western blotting
Collected cells were lysed in standard 1x Laemmli load-
ing buffer, denaturated for 10 min at 95◦C and sonicated
for 30 s using Bioruptor® Pico (Diagenode). Protein con-
centrations were determined using the BCA assay (Pierce).
Samples were subjected to SDS-PAGE (8% or gradient
gel), proteins transferred onto nitrocellulose membrane
and detected by relevant specific antibodies combined with
horseradish peroxidase-conjugated secondary antibodies.
Peroxidase activity was detected by ECL reagent (GE
Healthcare) and Amersham Hyperfilm ECL (GE Health-
care) or ImageQuant LAS-4000 system connected with
high-sensitivity Super CCD camera (GE Healthcare).
Immunofluorescence and microscopy
Cells grown on coverslips were washed with PBS and fixed
with 4% paraformaldehyde in PBS 10 min at RT. After fix-
ation, cells were washed twice with PBS, treated with ice-
cold methanol/acetone solution (1:1) for 5 min, washed
twice with PBS and blocked at least 30 min in 10% FCS in
PBS. Incubation with the primary antibody (60 min, RT)
was followed by wash (3 × 5 min in PBS) and incuba-
tion with appropriate fluorescently-labelled secondary an-
tibody (60 min, RT). Coverslips were washed (3 × 5 min
in PBS), stained with DAPI (1 g/ml in water, 2 min) and
mounted using VECTASHIELD (Vector Laboratories). To
measure chromatin retention of proteins, cells were pre-
extracted in cold 0.2% Triton X-100 for 2 min on ice prior
to fixation as above. High-resolution microscopy of fixed
samples was carried out on a Zeiss AxioObserver.Z1 mi-
croscope, equipped with oil immersion objectives (Plan-
Apochromat 63x/1.4), Hamamatsu ORCA-Flash4.0 LT
camera andZEN2 core imaging software. Automatedwide-
field microscopy was performed on an Olympus ScanR sys-
tem (motorized IX83 microscope) with ScanR Image Ac-
quisition and Analysis Software, 20x/0.45 (LUCPLFLN
20x PH) and 40x/0.6 (LUCPLFLN 40x PH) dry objectives
and Hamamatsu ORCA-R2 digital CCD camera C10600.
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Total nuclear ADP-ribose fluorescence signal was quanti-
fied in the region colocalizing with DAPI. Non-nucleolar
anti-XRCC1 fluorescence signal was quantified in the re-
gion colocalizing with DAPI but excluding the nucleolar re-
gion defined by B23 colabelling. Fluorescence was plotted
relative to that in untreatedWT cells.Where indicated, non-
specific anti-XRCC1 background fluorescence was mea-
sured usingXRCC1-/-cells and is indicated by a black dotted
line in the relevant graphs.
Alkaline comet assays
A total of 3 × 106 cells were trypsinized, washed and re-
suspended in ice cold PBS. A total of 5 × 105 cells were
removed and stored on ice (‘undamaged’ sample). The re-
maining cells were then treated with H2O2 (50 M) in PBS
for 10 min on ice before mixing with complete DMEM/F12
medium prior to recovery of the cells by centrifugation and
resuspension in ice cold complete DMEM/F12. A total of
5 × 105 cells were removed and stored on ice (‘no repair’
sample) and the remaining cells resuspended in complete
DMEM/F12 (37◦C) and incubated at 37◦C for the indi-
cated repair period. At 7.5, 15 and 30min, 5× 105 cells were
removed and stored on ice. Finally, all samples were resus-
pended in 200 l ice cold PBS, rapidly mixed with 200 l
1.2% low melting point agarose in PBS and plated on 0.6%
agarose-coated, frosted glass slides on ice. The agarose was
allowed to solidify prior to incubation in lysis buffer (2.5 M
NaCl, 100 mM EDTA, 10 mM Tris-HCl pH 10) for 1 h at
4◦C. Slides were washed 3 times with 4◦C H2O and incu-
bated for 45 min in electrophoresis buffer (1 mMEDTA, 50
mMNaOH). Electrophoresis was carried out at 12 V for 25
min, prior to overnight neutralization with Tris-HCl (1 M).
Finally, slides were stained with Tris-HCl (1 M) containing
SYBR-G (1:10000) and Antifade (40 g/ml), and imaged
(Nikon Eclipse 50i). Average tail moments from 100 cells
per sample were obtained using Comet Assay IV software
(Perceptive Instruments).
RESULTS
To examine the respective roles of PARP1, PARP2 and
PARP3 on the recruitment of endogenous XRCC1 at sites
of DNA damage we generated a set of diploid human
hTERT RPE-1 cell lines (denoted RPE-1 for simplicity) in
which these four proteins were deleted individually using
CRISPR/Cas9-mediated genome editing. Individual clones
in which the relevant protein was absent were identified us-
ing Western blotting and immunofluorescence and a single
clone of each genotype was chosen for further experiments
(Figure 1A and B). That the relevant CRISPR/Cas9 tar-
get site was mutated was confirmed by PCR and Sanger se-
quencing (Supplementary Figure S1A).
The generation of XRCC1-/- RPE-1 cells and the identi-
fication of a specific anti-XRCC1 antibody for immunoflu-
orescence enabled us to develop a high-content imag-
ing approach for measuring the recruitment of endoge-
nousXRCC1 into oxidized human chromatin. Interestingly,
when soluble proteins were extracted with detergent prior
to fixation and immunostaining XRCC1 was localized pri-
marily in the nucleoli in undamaged wild-type RPE-1 cells
(Figure 1C, left). This was not the case in XRCC1-/- RPE-1
cells, confirming that the anti-XRCC1 nucleolar signal was
specific. More importantly, XRCC1 was rapidly recruited
into chromatin globally across the nucleus following treat-
ment with H2O2. H2O2 is a physiologically relevant source
of oxidative stress and SSBs but induces DSBs only very
poorly, with a SSB/DSB ratio of>2000/1 (35). To quantify
XRCC1 recruitment into global nuclear chromatin follow-
ing H2O2 treatment we employed an Olympus ScanR au-
tomated wide-field microscope with image acquisition and
analysis software, and excluded signal co-localising with
the nucleolar marker, nucleophosmin (B23). These data re-
vealed that the amount of chromatin bound XRCC1 in-
creased 5-fold in wild-type RPE-1 cells following treatment
with H2O2, but did not increase above background signal
in XRCC1-/- RPE-1 cells (Figure 1C, right).
Next, we examined levels of ADP-ribosylation and
XRCC1 chromatin loading in RPE-1 cells deleted of the in-
dividual PARP proteins. Importantly, only the level of the
targeted PARP was affected in each of the gene-edited cell
lines (Figure 2A, left). Only in PARP1-/- cells were the lev-
els of ADP-ribosylation visibly reduced, as measured by
Western blotting and indirect immunofluorescence (Figure
2A, right and B). This is consistent with previous obser-
vations demonstrating that PARP1 accounts for 80–90%
of total ADP-ribosylation following DNA damage (18). In
our hands, PARP1 deletion resulted in ∼75–80% reduc-
tion in total ADP-ribosylation under the conditions em-
ployed (Figures 2B and 4B). Surprisingly, however, the level
of XRCC1 recruitment into oxidized chromatin was not
significantly reduced by PARP1 deletion (Figures 2B and
4B). This was not an artefact of clonal selection because
XRCC1 recruitment into chromatin was not measurably re-
duced in two other independent PARP1-/- clones (Supple-
mentary Figure S1B and C).
The high level of XRCC1 recruitment into oxidized chro-
matin observed in PARP1-/- RPE-1 cells suggests that
the residual ADP-ribosylation observed in these cells is
sufficient for XRCC1 recruitment. Consistent with this,
treatment of wild type or PARP1-/- RPE-1 cells with
the PARP inhibitor KU0058948 at 10 M ablated ADP-
ribosylation and reduced H2O2-induced XRCC1 recruit-
ment bymore than 85% (Figure 3). At lower concentrations
ofKU0058948 (1M)we observed a small amount of resid-
ual ADP-ribosylation by immunofluorescence analysis, and
this correlated with increased residual XRCC1 loading in
chromatin (Supplementary Figure S2). It is noteworthy
that the residual ADP-ribosylation remaining in cells pre-
incubated with lower concentrations of KU0058948 was
detected only with highly sensitive ADP-ribose detection
reagents and only by immunofluorescence analysis, high-
lighting the importance of careful analysis when correlating
the impact of PARP inhibitors on ADP-ribosylation with
biological end points (Supplementary Figure S3).
Collectively, the results described above suggest that the
recruitment of endogenous XRCC1 into oxidized chro-
matin in human diploid RPE-1 cells is largely depen-
dent on ADP-ribosylation but does not require the pres-
ence of PARP1. To examine if this was also true in other
cell types we employed wild type and PARP1-/- U2OS
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Figure 1. Development of PARP1-/-, PARP2-/-, PARP3-/- and XRCC1-/- RPE-1 cells and XRCC1 high-content imaging. Wild type (WT), PARP1-/-,
PARP2-/-, PARP3-/- and XRCC1-/- RPE-1 clonal cell lines were analysed for loss of the targeted protein by (A) Western blotting and (B) immunofluores-
cence. Note that the PARP3 antibody available to us was not suitable for immunofluorescence. (C) Left, representative ScanR images ofWT andXRCC1-/-
RPE-1 cells non-treated or treated with 1 mM hydrogen peroxide (H2O2) for 10 min and pre-extracted with detergent prior to fixation and immunostaining
for XRCC1 (green), the nucleolar marker B23 (red) and counterstaining with DAPI (blue). Right, quantification of detergent-insoluble anti-XRCC1 signal
(excluding nucleolar XRCC1 signal) from>1000 cells per sample using Olympus ScanR analysis software. Data are themean (±SEM) of three independent
experiments. The black dotted line denotes non-specific anti-XRCC1 background signal, defined as the residual signal in XRCC1-/- RPE-1 cells.
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Figure 2. Levels of H2O2-induced ADP-ribosylation and XRCC1 recruitment into chromatin in PARP-deleted RPE-1 cells. (A) Levels of the indicated
proteins (left) and ADP-ribosylated proteins (right) were compared in cell lysates from the indicated WT or mutant RPE-1 cells harvested before and after
treatment with 400 MH2O2 for 7 min by Western blotting using appropriate antibodies and anti-pan-ADP-ribose binding reagent. (B) Levels of ADP-
ribosylation and chromatin-bound XRCC1 were analysed by indirect immunofluorescence in cells treated or not with H2O2 (as above) by fixation and
staining with anti-pan-ADP-ribose binding reagent (top panels) or by detergent pre-extraction prior to fixation and staining with anti-XRCC1 antibody
(bottom panels). Representative ScanR images are shown.
cells and MEFs. Indeed, XRCC1 recruitment into oxidized
chromatin was not noticeably affected by PARP1 dele-
tion in U2OS and MEFs, respectively (Supplementary Fig-
ure S4). Once again, the ability to support XRCC1 chro-
matin loading reflected residual levels of ADP-ribosylation
in PARP1-/- cells, because both these residual levels and
XRCC1 loading were ablated by incubation with PARP in-
hibitor (Supplementary Figure S4).
Given the dependence on ADP-ribosylation for recruit-
ment of endogenous XRCC1 into oxidized chromatin, and
the individual dispensability of PARP1, PARP2 andPARP3
for this process, we considered the possibility that two or
more of these enzymes exhibit redundant or overlapping
roles. The possible redundancy betweenPARP1 andPARP2
was of particular interest, because PARP2 has been re-
ported to account for the residual poly ADP-ribosylation
detected in Parp1-/- MEFs (18). Indeed, deletion of PARP2
in PARP1-/- RPE-1 cells (denoted PARP1-/-/PARP2-/-
cells) reduced the residual ADP-ribosylation below the
level of detection under the conditions employed and re-
duced XRCC1 recruitment into oxidized chromatin to lev-
els that were not significantly above background (Figure
4A and B). XRCC1 recruitment into chromatin was simi-
larly selectively reduced in PARP1-/- RPE-1 cells by PARP2
siRNA (Supplementary Figure S5), thereby demonstrating
functional overlap between PARP1 and PARP2 using two
independent approaches. In contrast, loss of PARP3 alone
or togetherwith PARP1 failed to impact onXRCC1 recruit-
ment in RPE-1 cells (Figure 2B and Supplementary Figure
S5). Interestingly, PARP2 was not able to functionally re-
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place PARP1with respect the rate of SSBR, because the rate
at which DNA breaks declined following H2O2 treatment
was equally slow in PARP1-/- and PARP1-/-/PARP2-/- cells
(Figure 4C). This is consistent with our previous findings
(27), and suggests that PARP1 fulfils a second role during
SSBR that is functionally distinct from PARP2.
Finally, we examined whether the functional overlap
between PARP1 and PARP2 in XRCC1 recruitment ex-
tended to another component of the XRCC1-dependent
SSBR pathway. For this we chose PNKP, an important
DNA strand break repair enzyme reported previously to
be recruited to SSBs by interaction with XRCC1 (11). In-
deed, consistent with this, the level of chromatin-bound
nuclear anti-PNKP staining increased 2-fold in wild type
RPE-1 cells following H2O2 treatment, but failed to do
so in XRCC1-/- RPE-1 cells (Figure 5A and B). That the
PNKP immunostaining in these experiments was specific
was confirmed using primary fibroblasts from a patient (15)
in which PNKP is mutated and greatly reduced (Supple-
mentary Figure S6A). More importantly, whereas deletion
of neither PARP1 nor PARP2 alone significantly reduced
PNKP recruitment into oxidised chromatin, co-deletion of
both of these genes did so (Figure 5A and B). This did not
reflect a difference in total PNKP levels because this was
similar in wild type and PARP1-/-/PARP2-/- RPE-1 cells
(Figure 5C and Supplementary Figure S6B).
In summary, we show here that the SSB sensor proteins
PARP1 and PARP2 fulfil overlapping roles in promoting
the recruitment of endogenous XRCC1 and PNKP into ox-
idized human chromatin during chromosomal SSBR, such
that either enzyme can support this function.
DISCUSSION
XRCC1 is a scaffold protein that interacts with multiple en-
zymatic components of SSB repair and thereby accelerates
the overall process (2,8). Here, we have applied CRISPR-
Cas9 technology and quantitative high-content imaging to
investigate, for the first time, the role of PARP1, PARP2
and PARP3 in the recruitment of endogenous XRCC1 to
sites of chromosome damage. Detergent pre-extraction sug-
gested that, prior to exogenous DNA damage, chromatin-
bound XRCC1 is located predominantly in nucleoli. This
is consistent with several previous observations (24,36–38)
and suggests that nucleoli are a storage site for this protein
and/or that XRCC1 has an as yet undefined role in main-
taining ribosomal DNA metabolism.
Importantly, we detected a 5-fold increase in the amount
of detergent-insoluble XRCC1 present outside of the nu-
cleolus following H2O2 treatment, suggesting that XRCC1
becomes distributed throughout the nuclear chromatin in
response to oxidative stress. This is consistent with the ob-
servation that, under the conditions employed here, H2O2
induces 10 000–20 000 SSBs per cell (unpublished ob-
servations). Our experiments employing PARP inhibitors
demonstrate unequivocally that the global recruitment of
endogenous XRCC1 into oxidized chromatin required poly
(ADP-ribose) polymerase activity, a notion that has been
questioned recently (28–31). A surprising finding of this
work, however, is that relatively little ADP-ribosylation is
required for XRCC1 recruitment, compared to the total
cellular level of ADP-ribosylation following H2O2 treat-
ment. For example, to completely block ADP-ribosylation
and ablate XRCC1 recruitment required a concentration of
the PARP inhibitor KU0058948 (10 M) that was 3000-
fold higher than the IC50 (3.4 nM) (39). Indeed, resid-
ual levels of XRCC1 recruitment were observed at levels
of ADP-ribosylation that were too low to be detected by
Western blotting. Only by employing highly sensitive ADP-
ribose antibodies and detection reagents in immunofluores-
cence experiments were we able to detect this level of ADP-
ribosylation.
XRCC1 binds directly to poly (ADP-ribose) via its cen-
tral BRCT1 domain, thereby enabling this scaffold protein
to accumulate at sites of PARP activity (6,7). The recruit-
ment of XRCC1 at sites of chromosomal SSBs has been re-
ported by us and others to be dependent on PARP1, which
is the most abundant and active poly (ADP-ribose) poly-
merase and is the primary source of poly (ADP-ribose) fol-
lowing oxidative stress (24–27,40). However, we have now
found that deletion of PARP1 alone is unable to prevent
the recruitment of endogenous XRCC1 into oxidized chro-
matin globally across the nucleus, suggesting that the level
of ADP-ribosylation remaining in PARP1-/- cells is suffi-
cient for XRCC1 loading into oxidised chromatin. Indeed,
loss of both PARP1 and PARP2 was required to ablate
H2O2-induced ADP-ribosylation and prevent loading of
endogenous XRCC1 into oxidized chromatin. We suggest
that this discrepancy reflects the use in previous studies of
overexpressed XRCC1 and/or the measurement of XRCC1
accumulation at a limited number of focal or highly dam-
aged sites. Whereas only PARP1 has sufficient activity to
load high levels of overexpressed XRCC1 at focal sites of
damage, either PARP1 or PARP2 is able to achieve this
for endogenous XRCC1 at more physiological levels of ox-
idized chromatin induced stochastically across the genome.
This functional overlap between PARP1 and PARP2 in
protein recruitment into oxidized chromatin was not re-
stricted to XRCC1. Indeed, we observed similar results
for recruitment of PNKP, an important partner protein
of XRCC1 that is critical for rapid repair of oxidative
DNA breaks (10,11). PNKP is a dual function 5′-DNA
kinase and 3′-DNA phosphatase which if mutated results
in human neurological disease characterized by progres-
sive cerebellar ataxia and early onset seizures with devel-
opmental delay (14–16). It has been reported previously
that XRCC1 recruits recombinant PNKP at sites of ox-
idative damage, but our data are the first demonstration
that this is true for the endogenous protein. This is impor-
tant because several recent publications have instead con-
cluded that PNKP is recruited to DNA damage sites by al-
ternative mechanism/s including direct binding of PNKP
to DNA and/or poly (ADP-ribose) (6,29,30). However, our
experiments show that most if not all chromatin binding by
endogenous PNKP is XRCC1-dependent following H2O2
treatment.
Our finding that either PARP1 or PARP2 can support
loading of endogenous XRCC1 and PNKP into oxidized
chromatin is consistent with a functional overlap between
these PARP enzymes (41). It has been shown previously
that whereas bothParp1-/-andParp2-/- mice are viable, mice
lacking both enzymes die early during embryogenesis, fur-
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Figure 3. Residual recruitment of endogenous XRCC1 into oxidized chromatin in PARP1-/- RPE-1 cells is greatly reduced by PARP inhibitor. (A) WT
and PARP1-/- RPE-1 cells were pre-incubated or not with 10 MKU0058948 inhibitor for 1 h prior to a 7 min incubation with or without 400 MH2O2.
Cells were pre-extracted with detergent to remove non-chromatin bound proteins prior to fixation and immunostaining with the indicated antibodies or
anti-pan-ADP-ribose binding reagent. Representative ScanR images are shown. (B) Quantification of total nuclear pan-ADP-ribose and chromatin-bound
nuclear XRCC1 (excluding nucleolar XRCC1 signal) in cells treated as in panel A. Nucleoli were located using anti-B23 antibodies. All data are the mean
(±SEM) of three independent experiments with >1000 cells scored per sample in each experiment. Statistical significance was assessed by two-tailed t-
tests. Asterisks ** and *** indicate P-values of<0.01 and<0.001, respectively; ns – not significant. The black dotted line denotes non-specific anti-XRCC1
background signal, defined as the residual signal in XRCC1-/- cells stained in parallel.
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Figure 4. Overlapping roles for PARP1 and PARP2 in recruiting endogenous XRCC1 into oxidized chromatin. (A) Levels of ADP-ribosylation and
chromatin-boundXRCC1were measured by indirect immunofluorescence inWT andPARP1-/-/PARP2-/-cells treated or not with 400MH2O2 for 7 min
by fixation and staining with anti-pan-ADP-ribose binding reagent and DAPI (top panels) or by detergent pre-extraction prior to fixation and staining with
anti-XRCC1 and anti-B23 antibodies (bottom panels). Representative ScanR images are shown. (B) Quantification of total nuclear pan-ADP-ribose and
chromatin bound XRCC1 (excluding nucleolar signal). The black dotted line denotes non-specific anti-XRCC1 background signal, measured by XRCC1
immunostaining in XRCC1-/- cells in parallel. All data are the mean (±SEM) of three independent experiments with >1000 cells scored per sample in
each experiment. Statistical significance was assessed by two tailed t-tests. Asterisks * and ** indicate P-values of <0.05 and <0.01, respectively; ns – not
significant. (C) DNA strand breakage was quantified by alkaline comet assays in indicated RPE-1 cells before, immediately after treatment with 50 M
H2O2 on ice and after the depicted repair periods in drug-free medium. Data are the average comet tail moment (an arbitrary unit-measure of DNA strand
breaks) of 100 cells per sample and are the mean (±SEM) of three independent experiments. Statistically significant differences (two-way ANOVA) are
indicated (**P < 0.01; ***P < 0.001; ****P < 0.0001; ns – not significant).
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Figure 5. Overlapping roles for PARP1 and PARP2 in recruiting endogenous PNKP into oxidised chromatin. (A) Levels of chromatin-bound PNKP were
analysed by indirect immunofluorescence in indicated RPE-1 cell lines untreated or treated with 400 M H2O2 for 7 min by detergent pre-extraction
prior to fixation and staining with anti-PNKP antibody. Representative ScanR images are shown. (B) Quantification of chromatin-bound PNKP in cells
measured as above. All data are the mean (±SEM) of three independent experiments with >2000 cells scored per sample in each experiment. Statistical
significance was assessed by two-tailed t-tests. Asterisks * and ** indicate P-values of <0.05 and <0.01, respectively; ns – not significant. (C) Levels of
PNKP and the relevant proteins in cell extracts from RPE-1 cells of the indicated genotype.
ther demonstrating a functional interplay between these en-
zymes (42). One prediction arising from our data is that
the loss of both PARP1 and PARP2 should be necessary
to reduce the rate of chromosomal SSBR. However, in our
previous work we found that only PARP1 depletion re-
duced this rate, and that PARP2 depletion did not mea-
surably slow SSBR even in cells in which PARP1 was de-
pleted (27). Indeed, we observed the same result in the
current work, in which we compared SSBR rates in RPE-
1 cells deleted of PARP1 or PARP2 separately and to-
gether. This epistatic relationship suggests that whilst loss
of both PARP1 and PARP2 is necessary to impact greatly
on XRCC1 recruitment, PARP1 fulfils an additional role
that is part of the same SSBR pathway but which is down-
stream of XRCC1/PNKP recruitment into chromatin and
cannot be fulfilled by PARP2. That this role is within the
XRCC1-dependent SSBR pathway is supported by the ob-
servation that PARP1 deletion does not further slow SSBR
in XRCC1-/- RPE-1 cells (unpublished observations). In
contrast to PARP1 and PARP2, we did not observe any im-
pact of PARP3 on XRCC1 recruitment into oxidised chro-
matin. This may reflect that PARP3 primarily mono ADP-
ribosylates proteins in response to SSBs, because the central
BRCT1 domain of XRCC1 selectively binds poly (ADP-
ribose) (7,43). The role fulfilled by of PARP3 activation at
SSBs is currently unknown, butmay involve the recruitment
of one or more proteins that can bind mono-ADP ribosy-
lated histone H2B (43).
In summary, we demonstrate here that surprisingly lit-
tle ADP-ribosylation activity is required for the global re-
cruitment of endogenous XRCC1 into oxidized chromatin,
and we show that either PARP1 or PARP2 activity is suffi-
cient for this process. It will now be of interest to determine
whether these enzymes fulfil similar overlapping roles dur-
ing the repair of other types of SSBs.
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XRCC1 mutation is associated with PARP1 
hyperactivation and cerebellar ataxia
nicolas C. Hoch1,2*, Hana Hanzlikova1*, Stuart L. rulten1, Martine Tétreault3, Emilia Komulainen1, Limei ju1, Peter Hornyak1, 
Zhihong Zeng1, William Gittens1, Stephanie a. rey4, Kevin Staras4, Grazia M. S. Mancini5, Peter j. McKinnon6, Zhao-Qi Wang7, 
justin D. Wagner8, Care4rare Canada Consortium†, Grace yoon9 & Keith W. Caldecott1
XRCC1 is a molecular scaffold protein that assembles multi-
protein complexes involved in DNA single-strand break repair1,2. 
Here we show that biallelic mutations in the human XRCC1 gene 
are associated with ocular motor apraxia, axonal neuropathy, and 
progressive cerebellar ataxia. Cells from a patient with mutations 
in XRCC1 exhibited not only reduced rates of single-strand break 
repair but also elevated levels of protein ADP-ribosylation. This 
latter phenotype is recapitulated in a related syndrome caused by 
mutations in the XRCC1 partner protein PNKP3–5 and implicates 
hyperactivation of poly(ADP-ribose) polymerase/s as a cause of 
cerebellar ataxia. Indeed, remarkably, genetic deletion of Parp1 
rescued normal cerebellar ADP-ribose levels and reduced the loss 
of cerebellar neurons and ataxia in Xrcc1-defective mice, identifying 
a molecular mechanism by which endogenous single-strand breaks 
trigger neuropathology. Collectively, these data establish the 
importance of XRCC1 protein complexes for normal neurological 
function and identify PARP1 as a therapeutic target in DNA strand 
break repair-defective disease.
A 47-year-old woman of East Indian descent and non-consanguineous 
parents was diagnosed at age 41 with cerebellar atrophy, gait and limb 
ataxia, ocular motor apraxia, and peripheral neuropathy (Fig. 1a, b). 
Prenatal and early development was completely normal; difficulties 
with balance and gait were first noticed at 28 years, but this was not fully 
investigated until age 40. Magnetic resonance imaging and cerebellar 
examination revealed progressive cerebellar atrophy (Fig. 1c) and mul-
tiple ataxic abnormalities including dysmetria, dysdiadochokinesis, and 
dysarthria; nerve conduction studies revealed chronic length- dependent 
sensory–motor (predominantly axonal) peripheral neuropathy (Fig. 1b 
and Supplementary Information). After ruling out more than ten 
known spinocerebellar ataxias by genetic and metabolic screening 
(Supplementary Information), exome sequencing of the proband iden-
tified compound heterozygous mutations in XRCC1 (NM_006297). 
The mutations were confirmed by Sanger sequencing as c.1293G> C 
(p.K431N) and c.1393C> T (p.Q465* ) and were present in trans, with 
the unaffected sibling of the proband heterozygous for c.1293G> C 
(Fig. 1d). Mutation c.1393C> T has not previously been described 
in the population, whereas c.1293G> C was previously detected in 
heterozygous state in four individuals of South Asian descent (ExAC 
Consortium). After ruling out other rare gene variants on the basis of 
their presence in the unaffected sibling, presence in the homozygous 
state in unaffected in-house controls and/or ExAC, and lack of func-
tional and/or disease relevance, no other candidate causative mutations 
remained.
The c.1393C> T mutation is located within exon 12 and creates 
a premature stop codon at amino acid 465, most likely triggering 
nonsense-mediated messenger RNA (mRNA) decay. The c.1293G> C 
mutation is located at the end of exon 11 and is also part of the donor 
splice site for intron 11, most likely affecting splicing and inducing 
premature stop codons/nonsense-mediated decay and/or encoding 
XRCC1 with the missense mutation K431N. Consistent with this, 
1Genome Damage and Stability Centre, School of Life Sciences, University of Sussex, Falmer, Brighton BN1 9RH, UK. 2CAPES Foundation, Ministry of Education of Brazil, Brasilia/DF 70040-020, 
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Sussex, Falmer, Brighton BN1 9QG, UK. 5Department of Clinical Genetics, Erasmus MC, PO Box 2040, 3000 CA, Rotterdam, the Netherlands. 6St. Jude Children’s Research Hospital, Memphis, 
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Figure 1 | XRCC1 mutations are associated with cerebellar ataxia, 
ocular motor apraxia, and axonal neuropathy. a, Pedigree of the proband 
(III.1; filled circle) and unaffected sibling (III.2; circle/filled dot). b, 
Proband clinical features (see Supplementary Information for  
full description). c, Proband magnetic resonance imaging at 40 and  
47 years. Sagittal T1-weighted images (middle) demonstrating vermian 
atrophy and axial fluid attenuated inversion recovery (FLAIR) images 
(right) demonstrating atrophy of the cortex of the vermis and cerebellar 
hemispheres. The cerebellum is circled and insets (left) are magnifications 
highlighting the cerebellar atrophy. d, Sanger sequencing confirming the 
mutations c.1293G> C (p.K431N) and c.1393C> T (p.Q465* )  
in the proband (III.1) and c.1293G> C (p.K431N) in the unaffected  
sibling (III.2).
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reduced total levels of XRCC1 mRNA were observed in patient-derived 
cells, as well as aberrant splicing of XRCC1 transcripts if nonsense- 
mediated decay was inhibited with cycloheximide (Extended Data Fig. 1).
To establish the pathogenic impact of the biallelic XRCC1 mutations, 
we examined patient-derived fibroblasts and lymphoblastoid cells 
(LCLs) for levels of XRCC1 protein by indirect immunofluorescence 
and western blotting. XRCC1 in patient primary fibroblasts was greatly 
reduced compared with wild-type (WT) primary human fibroblasts 
(1BR) by indirect immunofluorescence and was not measurably higher 
than in human RPE-1 cells in which XRCC1 was deleted by clustered, 
regularly interspaced short palindromic repeats (CRISPR)-Cas9 
(Fig. 2a). However, western blotting suggested that patient fibroblasts 
Figure 3 | Mutations in patient-derived XRCC1 
reduce SSBR. a, DNA strand breaks quantified 
in the indicated fibroblasts (left) or RPE-1 cells 
(right) by alkaline comet assays before and at the 
indicated times after H2O2 treatment. Data are 
the mean (± s.e.m.) comet tail moments  
(an arbitrary-unit measure of DNA strand 
breaks) of three independent experiments. 
Statistical analyses (two-way analysis of variance) 
are indicated (* P < 0.05; * * P < 0.01). b, Double-
strand breaks quantified as γ -H2AX foci in the 
indicated cell lines before and at the indicated 
times after ionizing radiation (2 Gy). Data are 
the mean γ -H2AX foci per cell (± 1 s.d.) from 
three independent experiments (~ 1,000 cells 
per sample per experiment). Statistical analysis 
as above. Representative images are in Extended 
Data Fig. 4. c, Frequencies of sister chromatid 
exchange per chromosome (mean ± 1 s.e.m.) 
quantified in control and XRCC1-patient LCLs 
(36 metaphases per genotype). Representative 
metaphases (arrows, sister chromatid exchanges) 
are shown, left. Statistical analysis, two-tailed  
t-test (* * P < 0.01; NS, not significant). Scale 
bars, 10 μ m.
Figure 2 | Mutations in patient-derived 
XRCC1 reduce XRCC1 levels and recruitment 
into chromatin. a, XRCC1 levels measured by 
immunofluorescence in WT 1BR fibroblasts, 
WT RPE-1 cells, XRCC1-patient fibroblasts, 
and XRCC1−/− RPE-1 cells. b, Top: XRCC1 
and Lig3α levels measured in the above cells 
by western blotting and additionally in WT, 
XRCC1-patient, and sibling LCLs. The source 
data are included in Supplementary Fig. 1.  
Bottom: WT or patient fibroblasts were 
transfected with non-targeting or XRCC1  
siRNA and immunoblotted as above.  
c, XRCC1 chromatin binding measured by 
immunofluorescence in the indicated cells 
before and 10 min after treatment with 1 mM 
H2O2. d, Quantification of XRCC1 in chromatin 
(excluding nucleoli) from more than 1,000 
cells per sample using ScanR software. Data 
are the mean (± 1 s.d.) of three independent 
experiments. Statistical analysis (two-tailed  
t-test) is indicated (* * P < 0.01; NS, not 
significant). Representative ScanR images are  
in Extended Data Fig. 3a. Scale bars, 10 μ m.
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and LCLs both retained a small amount (~ 5%) of residual XRCC1 
(Fig. 2b and Extended Data Fig. 2a). Indeed, this was confirmed 
using XRCC1 short interfering RNA (siRNA), which reduced the 
anti-XRCC1 signal on western blots of patient fibroblasts even 
further (Fig. 2b, bottom). Levels of DNA ligase IIIα (Lig3α ) were 
also greatly reduced (by > 80%) in patient cells, consistent with the 
established impact of XRCC1 on the cellular stability of this partner 
protein6,7 (Fig. 2b, top, and Extended Data Fig. 2b). Since germ-line 
deletion of Xrcc1 in mouse is embryonic lethal8, we suggest that the 
small amount of XRCC1 remaining in the patient was important for 
embryonic viability. Consistent with this idea, embryonic viability in 
mice is supported by as little as approximately 10% of normal Xrcc1 
levels9.
To determine whether the residual XRCC1 in patient cells can 
engage in single-strand break repair (SSBR), we quantified the 
extent to which it bound oxidized chromatin. XRCC1 was primar-
ily detected in  nucleoli in undamaged WT RPE-1 cells and normal 
primary 1BR fibroblasts, after the extraction of soluble proteins with 
detergent, but was rapidly recruited into global nuclear chromatin after 
 treatment with H2O2 (Fig. 2c, d), a physiological source of oxidative 
single-strand breaks (SSBs)10. By contrast, little or no XRCC1 recruit-
ment into  chromatin was detected in XRCC1-patient fibroblasts by 
high- resolution or high-content imaging (Fig. 2c, d and Extended Data 
Fig. 3a). Similar results were observed after treatment with campto-
thecin (CPT), a topoisomerase poison that induces SSBs triggered by 
abortive topoisomerase I activity (Extended Data Fig. 3b).
Figure 4 | XRCC1 mutation elevates ADP-
ribosylation in cells and cerebellum. a, ADP-
ribosylation in WT 1BR fibroblasts, WT RPE-1 
cells, XRCC1-patient fibroblasts, and XRCC1−/− 
RPE-1 cells after H2O2 or CPT treatment. b, Left: 
ADP-ribosylation levels in 1BR or PNKP-patient 
fibroblasts after CPT treatment. Middle: PNKP, 
XRCC1, and PARP1 levels in 1BR and PNKP-
patient fibroblasts. The source data are included 
in Supplementary Fig. 1. Right: ADP-ribose levels 
quantified by ScanR imaging in 1BR, XRCC1-
patient, and PNKP-patient fibroblasts before  
and after CPT treatment. Data are mean  
(± 1 s.d.) ADP-ribose levels (relative to untreated 
1BR cells) from three independent experiments  
(> 1,000 cells per sample). Statistically significant 
differences (two-tailed t-test) are indicated 
(*P < 0.05). c, ADP-ribosylation levels in the 
indicated RPE-1 cells after CPT treatment. 
d, ADP-ribosylation levels quantified by ScanR 
imaging before and after CPT treatment in 
1BR and XRCC1-patient fibroblasts with or 
without transfection with 1 or 2 μ g of bovine 
serum albumin (BSA) or recombinant human 
XRCC1 protein. Statistical analyses as above. 
Representative ScanR images are in Extended 
Data Fig. 8. e, ADP-ribosylation levels measured 
by immunohistochemistry in cerebellar sections 
from WT mice or mice deleted (knockout, 
‘KO’) of Xrcc1 and/or Parp1. Scale bars in 
immunofluorescence images are 10 μ m and in 
histology images are 1 mm.
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Importantly, the defect in XRCC1 recruitment in patient fibroblasts 
was accompanied by a delay in the kinetics of DNA SSBR after H2O2 
treatment (Fig. 3a). This phenotype was recapitulated in XRCC1−/− 
RPE-1 cells and is consistent with the established molecular role of 
XRCC1 (ref. 2). By contrast, we failed to detect a major difference in 
double-strand break repair in XRCC1-patient fibroblasts, as meas-
ured by γ -H2AX immunostaining after ionizing radiation (Fig. 3b 
and Extended Data Fig. 4). In agreement with the defect in SSBR, 
XRCC1-patient LCLs exhibited a fourfold increase in sister chromatid 
exchange, a hyper-recombination phenotype resulting from elevated 
homologous recombination triggered by unrepaired SSBs in the S/G2 
phase of the cell cycle11 (Fig. 3c).
XRCC1 is a scaffold protein that assembles SSBR multi-protein 
 complexes. Importantly, components of these complexes are mutated in 
the cerebellar ataxias spinocerebellar ataxia with axonal neuropathy-1 
(SCAN1; mutated in TDP1)12,13, ataxia oculomotor apraxia-1 (AOA1; 
mutated in aprataxin)14, and ataxia oculomotor apraxia-4 (AOA4; 
mutated in PNKP)3,4. Indeed, it is striking that patients with the XRCC1 
mutation combine features of each of these diseases, consistent with 
the role played by XRCC1 in coordinating their activity. The discovery 
that XRCC1 is itself mutated in cerebellar ataxia is thus notable because 
it demonstrates the importance of these complexes in preventing 
neurodegeneration in humans.
To investigate the mechanism(s) by which unrepaired SSBs  trigger 
neuropathology, we considered the possibility that persistent unre-
paired SSBs might result in prolonged activity of the SSB sensor 
 protein PARP1. This hypothesis was prompted by the observation that 
 excessive synthesis of poly(ADP-ribose) and/or excessive  depletion 
of NAD+ by PARP1 is neurotoxic and associated with ischaemia 
 reperfusion injury15,16. Consistent with this idea, while ADP-ribose 
was rapidly detected in both WT and patient fibroblasts after H2O2 
 treatment, it persisted at a higher level in the latter cells during sub-
sequent incubation in drug-free medium (Fig. 4a, left). This was also 
evident in XRCC1−/− human RPE-1 cells, confirming that this pheno-
type was induced by loss of XRCC1. Elevated ADP-ribose levels were 
also detected in XRCC1-patient fibroblasts and XRCC1−/− RPE-1 cells 
after treatment with CPT (Fig. 4a, right). Indeed, the difference in ADP-
ribose levels between WT and XRCC1-mutant cells was even greater 
after CPT than after H2O2 treatment. The type of SSB induced by 
CPT has been linked previously with SSBR-defective neurodegen-
erative disease and is a possible source of pathogenic SSBs in SSBR- 
defective individuals13,17. Consistent with this idea, CPT-induced 
ADP-ribose levels were also elevated in fibroblasts from a patient with 
ataxia oculomotor apraxia-4 (AOA4); the cerebellar ataxia resulting 
from mutation of the XRCC1 protein partner, PNKP (Fig. 4b and 
Extended Data Fig. 5). Importantly, the elevated ADP-ribose observed 
in CPT-treated XRCC1−/− RPE-1 cells, XRCC1-patient cells, and 
PNKP-patient cells was entirely dependent on PARP1 activity (Fig. 4c 
and Extended Data Figs 6 and 7). Moreover, this phenotype was rescued 
by introducing WT recombinant XRCC1 into XRCC1-patient fibro-
blasts by electroporation (Fig. 4d and Extended Data Fig. 8).
Next, to examine directly whether hyperactive PARP1 triggers 
cerebellar ataxia in the absence of efficient SSBR, we used a mouse 
model in which Xrcc1 was conditionally deleted in brain (Xrcc1Nes-Cre)7. 
Xrcc1Nes-Cre mice exhibit pronounced cerebellar histopathology 
 including increased apoptosis of cerebellar granule neurons, greatly 
reduced numbers of cerebellar interneurons, and decreased electro-
physiological spike activity in Purkinje cells (ref. 4 and Extended Data 
Fig. 9). Moreover, consistent with the pathology of the patient with 
the XRCC1 mutation and other SSBR-defective patients, Xrcc1Nes-Cre 
mice exhibit cerebellar ataxia7. Strikingly, we detected elevated levels 
of ADP-ribose in the cerebellum of Xrcc1Nes-Cre mice, suggesting that 
the loss of Xrcc1 can trigger Parp1 hyperactivation in the brain even 
at endogenous levels of SSBs (Fig. 4e). Indeed, the deletion of Parp1 
ablated both the elevated level of ADP-ribose and the characteristic 
loss of cerebellar interneurons in Xrcc1Nes-Cre mice, thereby increasing 
neuronal density in the molecular layer approximately fourfold to WT 
levels (Fig. 5a, b). This did not reflect an impact of Parp1 deletion on 
the rate of SSBR because the latter was similarly slow in XRCC1−/− 
and XRCC1−/−/PARP1−/− RPE-1 cells (Extended Data Fig. 10). Rather, 
these data demonstrate that in the absence of Xrcc1-dependent SSBR 
Parp1 is hyperactivated, resulting in the loss and/or  dysfunction 
of cerebellar neurons. Finally, to examine whether Parp1 deletion 
also rescued the cerebellar ataxia observed in Xrcc1Nes-Cre mice, we 
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Figure 5 | Parp1 deletion restores normal interneuron density and 
reduces cerebellar ataxia in Xrcc1Nes-Cre mice. a, Representative cerebellar 
sections from WT mice or mice deleted (‘KO’) of Xrcc1 and/or Parp1 
stained with Nissl to detect neurons. Scale bars, 200 μ m. Abbreviations:  
gl, granule layer; ml, molecular layer; pc, Purkinje cells. Black arrows 
indicate interneurons. b, Interneuron density in the molecular layer of 
cerebella of the indicated genotype. Data are the mean (± s.e.m.) Nissl-
positive cells per square micrometre of 5–10 mice per genotype. Indicated 
are t-test comparisons (* * P < 0.01; * * * P < 0.001). c, Motor coordination 
in mice of the indicated genotype measured on a rotarod (mouse numbers 
analysed indicated in/above the bars). Statistical tests as above. d, Model 
for PARP1 hyperactivation and neural death triggered by unrepaired SSBs. 
PARP1 activation at SSBs triggers auto- and trans-protein ADP-ribosylation 
(red wavy lines). XRCC1 binds poly(ADP-ribose) and assembles SSBR 
protein complexes. Mutated XRCC1 or partner proteins cause delayed  
SSBR and PARP1 hyperactivation, resulting in cytotoxic levels of poly 
(ADP-ribose) and/or NAD+ depletion. SSBR proteins and their associated 
cerebellar ataxias are highlighted/boxed in red. SCAN1, spinocerebellar 
ataxia with axonal neuropathy-1 (TDP1-mutated); AOA1, ataxia oculomotor 
apraxia-1 (APTX-mutated); AOA4, ataxia oculomotor apraxia-4 (PNKP-
mutated); AOA-XRCC1, ataxia oculomotor apraxia-XRCC1 mutated18.
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compared Xrcc1Nes-Cre and Xrcc1Nes-Cre/Parp1−/− mice for their 
performance on an accelerating rotarod. Indeed, remarkably, whereas 
Xrcc1Nes-Cre mice were profoundly ataxic and unable to remain on the 
rotarod for more than a few seconds, the additional deletion of Parp1 
improved the rotarod performance of Xrcc1Nes-Cre mice more than 30-fold, 
increasing their mean retention time to approximately 30 s (Fig. 5c).
Collectively, these data identify elevated ADP-ribose levels as a 
biomarker of PARP1 hyperactivity and as a cause of cerebellar ataxia 
induced by unrepaired SSBs (Fig. 5d). This scenario might also extend 
to other more common neurodegenerative diseases because elevated 
levels of oxidative stress and DNA strand breakage are also  implicated 
in disorders such as Alzheimer disease, Huntington  disease, and 
Parkinson disease17–19. Intriguingly, patients with mutations in the 
XRCC1 partner protein PNKP exhibit not only ataxia but also micro-
cephaly and seizures, and we have more recently identified a patient 
with rare, possibly pathogenic mutations (< 0.01% allele  frequency and 
not present in ExAC in homozygous state) in XRCC1 who exhibits this 
same combination of phenotypes3–5. Notably, Xrcc1Nes-Cre mice also 
present with seizures, raising the prospect that PARP1 hyperactivation 
may induce not only ataxia, but also more severe pathologies.
Finally, these data identify PARP1 as a possible drug target for 
 treating cerebellar ataxias associated with unrepaired SSBs. Inhibition 
of PARP1 with currently available chemical inhibitors may not be 
 useful in this context, however, because these inhibitors ‘trap’ PARP1 
on DNA20 and do not mimic PARP1 genetic deletion (Extended Data 
Fig. 10). However, the development of selective inhibitors of PARP1 
that prevent DNA binding by this enzyme may have substantial 
therapeutic potential.
Online Content Methods, along with any additional Extended Data display items and 
Source Data, are available in the online version of the paper; references unique to 
these sections appear only in the online paper.
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Whole-exome sequencing. Whole-exome library preparation, exon capture, 
and sequencing were performed at the Genome Québec Innovation Center 
(Montréal, QC, Canada) as previously described19. Genomic DNA was captured 
using the SureSelect Human 50Mb All Exon kit v5 (Agilent Technologies, Santa 
Clara, California, USA). Sequencing was performed on an Illumina HiSeq2000 
(Illumina, San Diego, California, USA) with paired-end 100-base-pair (bp) reads. 
A mean coverage of 137× was obtained and 97% of the bases were covered at 
more than 10× . Read alignment, variant calling, and annotations were done 
with a pipeline on the basis of BWA, SAMtools, Annovar, and custom  annotation 
scripts. All sequences were aligned to Human genome Hg19. We excluded 
 variants with minor allele frequency greater than 5% in either the 1000 Genomes 
Project (http://browser.1000genomes.org/index.html) or the 6500 NHLBI EVS 
(http://evs.gs.washington.edu/EVS), and seen in more than 30 samples from our 
in-house database (containing approximately 2,000 samples). The whole-exome 
sequencing data were further filtered to keep protein-damaging variants (nonsense, 
missense, frameshift, indel, and splice variants).
Antibodies and chemicals. The antibodies used in this study were anti-XRCC1 
rabbit polyclonal (Millipore; ABC738), anti-Lig3α (TL25) rabbit polyclonal20, 
anti-PNKP (SK3195) rabbit polyclonal21, rabbit Fc-fused Anti-pan-ADP-ribose 
binding reagent (Millipore; MABE1016), anti-poly(ADP-ribose) rabbit polyclonal 
(Trevigen; 4336), anti-α -tubulin rat polyclonal (Abcam; ab6160), anti-BrdU rat 
monoclonal, crossreacting with CldU, (BioRad; OBT0030G), anti-nucleophosmin 
(B23) mouse monoclonal (Invitrogen; 325200), anti-PARP1 mouse monoclonal 
(Serotec; MCA1522G), and anti-γ -H2AX mouse monoclonal (Millipore; 05-636). 
The secondary antibodies used for western blotting were HRP-conjugated goat 
anti-rabbit (Bio-Rad; 170-6515), goat anti-mouse (Bio-Rad; 170-6516), and 
rabbit anti-rat (Abcam; ab6734); and for indirect immunofluorescence they were 
goat anti-mouse or anti-rabbit Alexa 488 (Invitrogen; A11001 and A31628), 
goat anti-rabbit Alexa 568 (Invitrogen; A11036), donkey anti-mouse Alexa 647 
(Invitrogen; A39571), and goat anti-rat Alexa 568 (Invitrogen; A11077). CPT was 
purchased from Sigma and H2O2 was obtained from Fischer Scientific. Veliparib 
(ABT-888) was purchased from Selleckchem and KU0058948 hydrochloride from 
Axon.
Cell lines. All cell lines were tested for the absence of mycoplasma. WT human 
hTERT RPE-1 cells (ATCC; CRL4000) (denoted ‘RPE-1’ for simplicity) and 
their XRCC1−/− derivative (XRCC1−/− RPE-1 cells) were cultured in Dulbecco’s 
 modified Eagle’s medium (DMEM/F12; Sigma) supplemented with 10% fetal calf 
serum and 0.01 mg/ml hygromycin B in a humidified atmosphere of 5% CO2 
at 37 °C. WT control cells were 1BR3 (denoted 1BR in the text for simplicity) 
primary human fibroblasts and the lymphoblastoid cell line (LCL) 11-27 isolated 
from a normal, unaffected control. XRCC1-patient primary fibroblasts  (identifier 
number 5596502b) were generated from a patient’s skin biopsy and the LCL cell lines 
HEP15-00082 and HEP15-00083 were obtained from fresh blood from, respectively, 
the unaffected sibling and affected patient by Epstein-Barr virus transformation. 
Appropriate patient consent was provided for preparation of primary  fibroblasts. 
Primary human fibroblasts from a PNKP-mutated patient with cerebellar 
ataxia have been described previously5. Primary human fibroblasts were grown 
in Minimum Essential Media (MEM; Gibco) containing 15% fetal calf serum, 
2 mM glutamine, and the antibiotics penicillin (100 units/ml) and streptomycin 
(100 μ g/ml) at low oxygen (5%) at 37 °C. LCLs were cultured in RPMI medium 
(Gibco) containing 10% FBS, 2 mM glutamine and penicillin/streptomycin, in a 
humidified atmosphere of 5% CO2 at 37 °C.
Generation of gene-edited RPE-1 cells. Guide sequences were identified using 
either E-CRISP (http://www.e-crisp.org/E-CRISP/) or CRISPRdirect (http://
crispr.dbcls.jp). For XRCC1 gene editing we chose the 23-base CRISPR comple-
mentary guide RNA sequences 5′ -CCGCCUCCGCCAUGUCGUGUCCU-3′ 
and 5′ -AGGGACACGACAUGGCGGAGGCGG-3′ (PAM underlined) 
spanning XRCC1 ORF nucleotides 12–34, and used the 58-base synthetic 
 oligonucleotides (XCr2F; 5 ′ - T TT CT TG GC TT TA TA TA TC TT GT GG AA AG GA 
CG AA AC AC CGACACGACATGGCGGAGG a nd XCr2R; 5′ - GA CT AG CC TT 
AT TT TA AC TT GC TA TT TC TA GC TC TA AA AC CCTCCGCCATGTCGTGTC)  
(Eurofins) encoding 18 bp Tru-guide22 versions of the guide (underlined) minus 
the PAM. For PARP1 gene editing we chose the 22-base ‘Tru-guide’ sequences 
5′ -GAAGGUGGGCCACUCCAUCCGG-3′ and 5′ -CCGGAUGGAGUGGCCC 
ACCUUC-3′ (PAM underlined)  spanning nucleotides 174–195 of the human PARP1 
ORF, and used the 59-base  synthetic oligonucleotides (PARP1-4F: 5 ′ - T TT CT TG G
C TT TA TA TA TC TT GT GG AA AG GA CG AA AC AC C GA AGGTGGGCCACTCC 
ATC-3′ a n d PARP1-4R: 5 ′ -GACTAGCCTTATTTTAACTTGCTATTTCTA 
GCTCTAAAACGATGGAGTGGCCCACCTTC-3′ ) encoding the 19 bp Tru-guide 
versions of the guide (underlined) minus the PAM.
The relevant oligonucleotide guide pairs were annealed and extended into 
a 98-base oligonucleotide duplexes using Phusion polymerase (NEB) and then 
subcloned into the guide RNA vector (Addgene 41824)23 using Gibson Assembly 
(NEB). hTERT RPE-1 cells were co-transfected with the relevant guide construct/s 
separately (XRCC1−/−, PARP1−/−) or together (XRCC1−/−/PARP1−/−) and with 
the Cas9 expression construct Addgene 41815 (ref. 23) using a NEON Transfection 
System (Invitrogen). Twenty-four hours later, the transfected cells were selected 
in medium containing 0.5 mg/ml G418 for 5 days and subcloned into 96-well 
plates. Once at sufficient cell density, the subclones were analysed for expression 
of the relevant protein/s by indirect immunofluorescence. Absence of the relevant 
protein/s in selected clones was then confirmed by western blotting. For 
XRCC1−/−, PARP1−/−, and XRCC1−/−/PARP1−/− RPE-1 cells, we selected clones 3, 
G7, and D1 for further work, respectively.
Complementation of XRCC1-patient cells with recombinant XRCC1 protein. 
Recombinant human XRCC1 harbouring a carboxy (C)-terminal decahisitidine 
tag (denoted XRCC1-His) was expressed in Escherichia coli from pET16b-XH and 
purified by metal-chelate affinity chromatography and gel filtration6. Control BSA 
(1 or 2 μ g) or purified XRCC1-His was electroporated into 1 × 105 XRCC1-patient 
fibroblasts using a NEON Transfection System (Invitrogen) according to the 
manufacturer’s protocol. Eighteen hours later the cells were treated with CPT 
for 45 min, fixed, and immunostained for levels of XRCC1 and ADP-ribose as 
 indicated.
RNA extraction, cDNA synthesis, and qPCR analysis. LCLs were treated with 
either 100 μ g/ml cycloheximide (Sigma) or vehicle alone for 4 h and total RNA 
extracted with RNAeasy Kit (Qiagen) essentially as described by the manufac-
turer but with an additional 15 min DNase I (Promega) digest of the samples 
on the column. 1 μ g total RNA was annealed to oligodT(15) primer and reverse 
transcribed using M-MuLV RT (NEB) for 2 h at 42 °C. After RNase A digest, the 
cDNA was purified using PCR purification kit (Qiagen) and 1/40 of the eluate 
used per reaction. Three replicate qPCR reactions using ABsolute qPCR SYBR 
Low ROX (Thermo) were performed per experiment in a MX3005P (Agilent) 
thermocycler and analysed using MxPro software (Agilent). The fold change 
was calculated from cycle threshold (Δ Ct) values relative to actin and Δ Δ Ct 
values relative to WT untreated for three independent experiments. Primers 
were as follows: XRCC1 exon10 forward, CAACACCCCCAAGTACAGC; 
XRCC1 exon 10 reverse, AGTCCAGCACCCACTCCTTAC; XRCC1 
exon11 forward, TCCAGCAGTGAGGAGGATG; XRCC1 intron11 
reverse, AGGCAAGAGTGGGAAGTTTG; XRCC1 exon 12 reverse, 
AGTGGGCTTGGTTTTGGTC; actin forward, CTCGTCATACTCCTGCTTGC; 
actin reverse, GAAGTGTGACGTGGACATCC.
XRCC1 cDNA cloning. cDNA prepared as above from patient cells treated 
with cycloheximide was used for Phusion polymerase (NEB) amplification of 
full-length XRCC1 transcripts using primers ATGCCGGAGATCCGCCTCCG 
and GGCTTGCGGCACCACCCCAT. PCR products were purified using Gel 
 extraction kit (Qiagen), cloned using TOPO cloning kit (Thermo Fischer Scientific) 
and plasmids originating from single colonies purified using Miniprep kit (Qiagen) 
and sequenced by Sanger sequencing (Beckman Coulter).
siRNA. WT and patient primary fibroblasts were reverse-transfected with 
Lipofectamine RNA iMAX (Life Technologies) as indicated by the  manufacturer, 
using non-targeting siRNA (ON-TARGETplus, Dharmacon) and siXRCC1 
SMARTpool (Dharmacon).
Western blotting. PBS-washed cells were lysed in Laemmli buffer, heated for 
10 min at 95 °C, and sonicated for 30 s using Bioruptor Pico (Diagenode). Protein 
concentrations were determined using the BCA assay (Pierce). Samples were 
subjected to SDS–PAGE, proteins transferred onto nitrocellulose membrane 
and detected by immunoblotting using the relevant primary and horseradish 
 peroxidase-conjugated secondary antibodies. Peroxidase activity was detected by 
ECL reagent (GE Healthcare) and Amersham Hyperfilm ECL (GE Healthcare). 
Non-saturated film exposures were digitalized using an EPSONperfection 2400 
photo scanner and quantified using ImageJ software.
Immunofluorescence and microscopy. Cells cultured on glass coverslips were 
fixed in 4% paraformaldehyde for 10 min at room temperature,  permeabilized in 
methanol/acetone solution (1:1), blocked in 10% fetal calf serum, and  incubated 
with primary antibodies for 60 min at room temperature. Following rinsing in 
PBS, coverslips were incubated with secondary antibodies at room  temperature 
for 60 min. Finally, after washing in PBS, nuclei were counterstained with DAPI 
(Sigma) and coverslips mounted using anti-fading mounting reagent (Vectashield, 
Vector Laboratories). To measure chromatin retention of proteins, cells were 
pre-extracted in cold 0.2% Triton X-100 for 2 min on ice before fixation as 
above. High-resolution microscopy of fixed samples was performed on a Zeiss 
AxioObserver.Z1 microscope, equipped with oil immersion objectives (Plan-
Apochromat 63× /1.4 and 100× /1.4), Hamamatsu ORCA-Flash4.0 LT camera and 
ZEN 2 core imaging software. Automated wide-field microscopy was  performed 
on an Olympus ScanR system (motorized IX83 microscope) with ScanR Image 
Acquisition and Analysis Software, 20×/0.45 (LUCPLFLN 20× PH) and 40× /0.6 
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primers. Both Xrcc1 and Cre PCR products were amplified using the following 
PCR conditions: initial denaturation for 5 min at 94 °C followed by 35 cycles of 
94 °C for 30 s, 59 °C for 45 s and 72 °C for 45 s.
Nissl staining of paraffin-embedded sections. Brains were removed at the 
 indicated times and placed in 10% neutral buffered formalin (3.7% formaldehyde, 
3.5 g/l NaH2PO4, 6.5 g/l Na2HPO4) for 24 h and then transferred to PBS. Paraffin 
embedding, sagittal sectioning and Nissl staining were performed by Propath UK 
(Hereford, UK) and UCL IQPath (Institute of Neurology, London, UK). Briefly, 
deparaffinized sections were stained in 0.1% cresyl violet solution (0.1% cresyl 
violet, 0.3% glacial acetic acid) for 3–10 min, rinsed in water, then 95% ethanol 
for 30 s to 5 min, 100% ethanol for 2 × 5 min, and xylene for 2 × 5 min before 
 mounting. Nissl-positive interneurons were counted within three randomly 
selected 16,875 μ m2 regions of each molecular layer, and the number of cells per 
square micrometre was calculated.
Rotarod analysis. To evaluate motor coordination/cerebellar ataxia, an  accelerating 
Panlab Rotarod (Harvard Apparatus, UK) was used. The apparatus was  composed 
of a rod with a diameter of 30 mm divided into five opaque  methacrylate arnite 
barriers, separating the rod into five 50 mm sections. Mice were trained for 
three successive attempts on the day before assessment. For assessment, mice 
were  positioned on the rod facing away from the experimenter while the rod was 
 stationary. Once activated, the rod accelerated at 0–40 r.p.m. at an acceleration rate 
of 5 r.p.m. per minute. Mice were rested for 15 min between each of the three trials 
and then positioned back on the rod for the next assessment. The time spent on 
the rod was recorded for each mouse and the mean time was calculated from the 
three independent trials.
Purkinje cell recordings. Vermis parasagittal slices (200 μ m) were taken from 
P13–P17 mice using a vibroslicer (VT1200S, Leica Microsystems, Germany) in 
ice-cold artificial cerebrospinal fluid containing (in mM): 125 NaCl, 2.5 KCl, 25 
glucose, 1.25 NaH2PO4, 26 NaHCO3, 1 MgCl2, 2 CaCl2 (bubbled with 95% O2 and 
5% CO2, pH 7.3). Slices were maintained in artificial cerebrospinal fluid at 34–35 °C 
for 45 min and then at 23–25 °C for electrophysiology. Voltage-clamp recordings 
of Purkinje cells were performed in cell-attached mode using a Multiclamp 700A 
amplifier (Molecular Devices) with pipettes (5–7 MΩ ) containing 150 mM NaCl. 
Signals were filtered at 10 kHz and digitized at 50 kHz, and analysis of spike activity 
performed offline using Clampfit (Molecular Devices).
Data analysis and statistics. The number of experimental repeats and  statistical 
tests (conducted in Microsoft Excel or GraphPad) are indicated in the relevant 
 figure legends. The means of population averages from multiple independent 
experiments (± s.d. or s.e.m.) are indicated. Where appropriate, power 
 calculations were conducted using online statistical resources. The experiments 
were not  randomized. Samples were not blinded but the collection and analysis of 
 microscopic data were automated and free of user bias. No animals/samples were 
omitted from data points/data analyses.
Data availability. The data sets generated during and/or analysed during the 
 current study are available from the corresponding authors on reasonable request.
(LUCPLFLN 40× PH) dry objectives and Hamamatsu ORCA-R2 digital CCD 
camera C10600.
ADP-ribosylation. Levels of ADP-ribosylation were measured in the indicated cell 
lines by indirect immunofluorescence using Anti-pan-ADP-ribose binding reagent 
(Millipore). Cells were treated where indicated with 150 μ M H2O2 for 10 min and 
then incubated in drug-free medium for 60 min to allow DNA repair or were incu-
bated with 30 μ M CPT for 45 min. ADP-ribose levels were quantified by Olympus 
ScanR imaging and plotted relative to the ADP-ribose level in untreated cells. 
For cerebellar sections, postnatal day ((P)17–P23) mice were anaesthetized using 
0.2 mg/g Euthanal (Vetoquinol UK) and perfused transcardially with PBS followed 
by 4% paraformaldehyde. Brains were postfixed in 4% paraformaldehyde for 48 h 
and stored in 25% sucrose/PBS until moulding and freezing. Sagittal sections 
(7 μ m) were prepared using a cryostat (Leica CM1850) and immunohistochemistry 
was conducted essentially as described7. Briefly, slides were washed in PBS 
and heated until boiling in antigen retrieval buffer (Nacalai Tesque, Histo VT 
One). Endogenous peroxidase was blocked by incubating slides in 0.6% H2O2 in 
methanol. After incubating in blocking solution (5% goat serum, 1% BSA, 0.4% 
Triton-X-100 in PBS) rabbit anti-poly(ADP-ribose) primary antibody (Trevigen) 
was applied overnight. Anti-rabbit Biotin-SP-conjugated AffiniPure Goat 
secondary antibody (JacksonImmuno Research, 1:500) was incubated on the slides 
for 1 h followed by ABC reagent (Vectastain Elite ABC kit, Vector Laboratories) 
according to the manufacturer’s instructions. The chromogen was developed using 
VIP reagent (Vector VIP peroxide substrate kit, Vector Laboratories; SK-4600). 
Images were obtained using a Nikon Eclipse E400 mounted with Electronic Digital 
Eyepiece Camera CMOS (C-mount UK).
Sister chromatid exchanges. Lymphoblastoid cell lines were incubated in medium 
containing 8 μ M chlorodeoxyuridine, 32 μ M thymidine, 10 μ M fluorodeoxyuridine, 
and 200 μ M cytidine (such that 20% of incorporated thymidine was replaced with 
chlorodeoxyuridine)11,24 for 20 h, washed twice in media, and then allowed to grow 
for another 20 h in medium containing 10 μ M thymidine. Cells were treated with 
100 ng/ml colcemid for 1 h, swollen in 75 mM KCl for 5 min at 37 °C, and fixed in 
Carnoy’s fixative before preparation of metaphase spreads. Slides were allowed to 
dry in air, rehydrated in PBS, incubated in 2 M HCl for 30 min, washed twice in 
100 mM borate buffer pH 8.5 for 10 min, and blocked in 10% fetal calf serum in PBS 
for 30 min. Further immunofluorescence and imaging was performed as above.
Single- and double-strand break assays. Alkaline comet assays were performed 
essentially as described25 and DNA breaks induced with 50 μ M H2O2 (RPE-1 
cells) or 25 μ M H2O2 (primary fibroblasts) for 10 min on ice. Data are plotted 
as the average comet tail moment (an arbitrary-unit measure of DNA strand 
breaks) of 100 cells per sample and are the mean (± s.e.m.) of three independent 
 experiments. For double-strand break repair assays, cells were irradiated with 2 Gy 
using a Gammacell 1000 machine, and γ -H2AX quantified at the indicated times, 
afterwards. Data are the average number of γ -H2AX foci per cell from about 1,000 
cells per sample, scored by Olympus ScanR software, and are the mean (±  1 s.d.) 
of three independent experiments.
Mouse maintenance and analysis. Animals were maintained and used under 
the auspices of UK Home Office project licence number 70/8300. The generation 
of Parp1−/− and Xrcc1Nes-Cre mice have been reported previously7,26. Intercrosses 
between Parp1−/− and Xrcc1+/loxp mice were maintained in a mixed C57/Bl6 × S129 
strain and housed on a 12 h light/dark cycle with lights on at 7:00. Temperature and 
humidity were maintained at 21 °C (± 2 °C) and 50% (± 10%), respectively. All 
experiments were performed under the UK Animal (Experimental Procedures) 
Act, 1986. Genomic DNA was extracted from biopsied tail using the REDExtract-
N-Amp Tissue PCR Kit in accordance to the manufacturer’s instructions (Sigma). 
For Parp1, the following primers were used: Parp1 F1 (5′ -GTT GTG AAC GAC 
CTT CTG GG-3′ ), Parp1 R1 (5′ -CCT TCC AGA AGC AGG AGA AG-3′ ), and 
Parp1 R2 (5′ -GCT TCA GTG ACA ACG TCG AG-3′ ). PCR products were 
 generated by an initial denaturation step at 94 °C for 2 min followed by 35 cycles 
of 94 °C for 30 s, 54 °C for 40 s, and 72 °C for 180 s. Xrcc1 was amplified using the 
forward PC1 (5′ -TAT GCT TGC TGT ACA GGG ATT GGG-3′ ) and reverse PC2 
(5′ -TGG ACC ATG AAA AAG CTG TGT GC-3′ ) primers. A 400 bp cre PCR 
product was generated using the forward Cre-3 (5′ -CTG CCA CGA CCA AGT 
GAC AGC-3′ ) and reverse Cre-4 (5′ -ACC TGC GGT GCT AAC CAG CG-3′ ) 
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